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PERSONNEL ROSTER
*Current CAP, -Previous CAP, + Minority
Name, Degree

Department

ABU-HASABALLAH, KHAMIS, PHD

Psychiatry

ADAMS, NANCY, MD

Medicine/Nephrology

AFFLECK, GLENN, PHD

Community Medicine

ALBERT, DAVID, PHD

Psychiatry

ALBERTSEN, PETER, MD

Surgery

ALESSI, SHEILA, PHD

Psychiatry

ALLEN, HOLLY, MD

PEDIATRIC ENDOCRINOLOGY

ARIAS, ALBERT, MD

Psychiatry

ARMELI, STEPHEN, PHD

Non-Host Institution: State,
Country

BAYSTATE MEDICAL CENTER:
MA, USA
PACE UNIVERSITY: NY, USA

ARNOLD, ANDREW, MD

Medicine

ASTUR, ROBERT, PHD

OLIN CENTER

AZIZ, KHALID, MD

Medicine

BABOR, THOMAS, PHD

Community Medicine

BAUER, LANCE, PHD

Psychiatry

BENMAMOUN, CHOUKRI, MD

Microbial Pathology

BONA, ROBERT, MD

Medicine/Hem-Onc

BONKOVSKY, HERBERT, MD

Medicine/Gasteroenterology

BOXER, REBECCA, MD

Medicine/Geriatrics

BRUNO, RICHARD, PHD,RD

NUTRITIONAL SCIENCES

BURKI, NAUSHERWAN K, MD

Medicine/Pulmonary Medicin

BURLESON, JOSEPH, PHD

Behavioral Sciences

CABRAL, CYNTHIA, BS

Dental-Students

CALHOUN, VINCE, MD

PSYCHIATRY

CAMPBELL, WINSTON, MD

Obstetrics/Gynecology

CAPRIGLIONE, ANTOINETTE, MD

OB/GYN

NEW BRITAIN GENERAL
HOSPITAL: CT, USA

CARROLL, CHRISTOPHER, MD

PEDIATRICS

CONNECTICUT CHILDREN'S
MEDICAL: CT, USA

CARROLL, KATHLEEN, PHD

PSYCHIATRY

YALE UNIVERSITY: CT, USA

CHAKRABORTY, NITYA G, PHD

Medicine

CHERNIACK, MARTIN, MD

Occupational/Environmental

CILLESSEN, ANTONIUS, PHD

PSYCHOLOGY

CLARK, ROBERT, MD

Immunology

CLOUTIER, MICHELLE, MD

Pediatrics

COBB, RICHARD, MD

Diagnostic Imaging

CONNER, TAMLIN, PHD

Psychiatry

CONWAY, JUDITH, ARNP

CANCER CENTER

COONEY, JUDITH, PHD

PSYCHIATRY

YALE UNIVERSITY: CT, USA

COONEY, NED, PHD

PSYCHIATRY

YALE UNIVERSITY: CT, USA

COVAULT, JONATHAN, MD,PHD

Psychiatry

CRANFORD, JAMES, PHD

SUBSTANCE ABUSE RESEARCH

DAMATO, KATHRYN L, MS

Oral Diagnosis

DANNENBERG, ANDREW J, MD

GASTROENTEROLOGY/HEPATOLOG

CORNELL UNIVERSITY: NY, USA

DAVENPORT, MARSHA, MD

PEDIATRICS

UNIVERSITY OF NORTH
CAROLINA: NC, USA

DECKERS, PETER, MD

Surgery

DEHART, TRACY, PHD

PSYCHOLOGY

DEMARTINIS, NICHOLAS, MD

Psychiatry

DIECKHAUS, KEVIN, MD

Medicine/Infectious Diseas

DIPASQUALE, CHRIS, PHD

KINESIOLOGY

DONGARI-BAGTZOGLOU, ANNA,
DDS,PHD

Periodontology

DORSKY, DAVID, MD

Infectious Disease

6/27/2008 9:32:04AM

HARTFORD HOSPITAL: CT, USA

UCONN STORRS: CT, USA
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USA

LOYOLA: IL, USA
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DOUGLAS, KARA R, BS

GCRC

DOWSETT, ROBERT J, MD

Radiation Oncology

DRAZINIC, CAROLYN, MD

Psychiatry

DUCK, KIM, PHD

Surgery

DUFFY, VALERIE, PHD

ALLIED HEALTH SCIENCES

ELSHEICKA, HANY, MD

Center for Microbial Patho

ESAYAG-TENDLER, BEATRICE, MD

Medicine

ESTRADA, ELIZABETH, MD

PEDIATRICS

FANG, MIN, MD,PHD

Genetics & Dev. Biology

FEDER, HENRY, MD

Medicine/Family Medicine

FEINN, RICHARD, PHD

Psychiatry

FISHER, JEFFREY D, PHD

PSYCHOLOGY

FORD, JULIAN, PHD

Psychiatry

FORMAKER, BRADLEY, PHD

Oral Health & Diagnostics

FORTINSKY, RICHARD, BA

Center on Aging

FRANK, MARION, DMD

Oral Diagnosis

FREILICH, MARTIN A, DDS

Prosthodontics

FRESTON, JAMES, MD

Medicine

FRIEDLAND, GERALD, MD

PSYCHIATRY

YALE UNIVERSITY: CT, USA

GELERNTER, JOEL, MD

PSYCHIATRY

YALE UNIVERSITY: CT, USA

GOLDBERG, JON, PHD

Biomaterials

GRAVELEY, BRENTON, PHD

Genetics and Developmental

GREENSTEIN, ROBERT, MD

Pediatrics/Genetics

GRILLE, MICHAEL, BS

GCRC

GUNTHERT, KATHLEEN, PHD

PSYCHOLOGY

AMERICAN UNIVERSITY: DC, USA

GUTMAN, CHARLES, MD

CNTR FOR NEUROLOGICAL IMG

BRIGHAM & WOMENS HOSPITAL:
MA, USA

HAGER, DAVID, MD

Medicine/Cardio-Pulmonary

HEGDE, UPENDRA, MD

Medicine

HERMAN, AREY, BA

Psychiatry

HERNANDEZ-AVILA, CARLOS, MD

Psychiatry

HESSELBROCK, VICTOR, PHD

Psychiatry

HETTINGER, THOMAS, PHD

Oral Health & Diagnostic

HULL, DAVID, MD

SURGERY

HUSSAIN, NAVEED, MD

Pediatrics

IOANNIDOU, EFFIE, DDS

Periodontology

ISOGNA, KARL, MD

INTERNAL MEDICINE

JOSEPH, CHERIAN, MD

Medicine/Geriatrics

KADDEN, RONALD M, PHD

Psychiatry

KAMINER, YIFRAH, PHD

Psychiatry

KAPLAN, RICHARD, PHD

Psychiatry

KAPTUCH, JUSTIN, BS

GCRC

KELLY, JOHN R, DDS,DSC

Oral Rehab, Biomaterials

KENNY, ANNE, MD

Center on Aging

KERSTETTER, JANE, PHD

NUTRITION

UCONN - STORRS: CT, USA

KING, ANDREA, PHD

DEPT OF PSYCHIATRY

UNIVERSITY OF CHICAGO: IL,
USA

KINGSBURY, JEFFREY, DDS,MD

Oral & Maxillofacial Surge

KNOX, ISABELLA, MD

Pediatrics

KOZLAK, SCOTT, BS

GCRC

KRANZLER, HENRY, MD

Psychiatry

KRAUSE, PETER, MD

Pediatrics

KREUTZER, DONALD L, PHD

Pathology

KUCHEL, GEORGE, MD

Center on Aging

KURTZMAN, SCOTT, MD

Surgery

LALANDE, MARC, MD

Genetics & Develop Biology

LALLA, RAJESH, BDS,PHD

Oral Diagnosis

LAMBRECHT, RICHARD, PHD

Pharmacology & Toxicology

LAMMI, KEEFE, PHD

NUTRITION
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LEVINE, JOEL, MD

Medicine

LEWIS, COURTLAND, MD

Orthopedics

LI, ZIHAI, MD,PHD

Ctr for Immunotherapy

LITT, MARK, PHD

Behavioral Sci & Comm Hlth

LORENZO, JOSEPH, MD

Medicine

MADEJ, OLGA, BA

GCRC

MALCHOFF, CARL, MD,PHD

Medicine/Endocrinology

MALCHOFF, DIANA, PHD

Medicine

MANSOOR, GEORGE, MD

Medicine/Hypertension

MARKS, LAWRENCE, PHD

GENERAL MEDICINE

MARTIN, ISHMAEL, MD

Pulmonary

MAYER, BRUCE, PHD

Genetics & Dev. Biology

MCELHANEY, JANET, MD

Immunology

MEIERS, JONATHAN, DDS

Prosthodonics

MENZOIAN, JAMES, MD

CTR FOR CLIN CARE IMPROV

MEYER, JOHN, MD,PHD

Occupational Medicine

MIRZA, FARYAL, MD

Medicine

MOFFITT, KATHIE H, PHD

Psychiatry

MOHLER, WILLIAM, PHD

Genetics & Dev. Biology

MOYO, VICTOR, MD

Medicine/Oncology

MUKHERJI, BIJAY, MD

Medicine

NELLISSERY, MAGGIE, MD

Psychiatry

NICHOLS, FRANK, PHD

Oral Health & Diag Science

NICHOLS, GINGER, MS

Human Genetics

O'CAMPO, PATRICIA, PHD

MATERNAL/CHILD HEALTH

ONCKEN, CHERYL, MD

Medicine

ONYIUKE, HILARY, MD

Neurosurgery

PACHTER, LEE, MD

PEDIATRICS

PANZER, VICTORIA, MD

Neurology

PAPPAGALLO, MARIANN, MD

Pediatrics

PARHAM, KOUROSH, MD

Surgery

PEARLSON, GODFREY, MD

PSYCHIATRY

PENDRYS, DAVID, DDS,PHD

Behavioral Sci & Comm Hlth

PETERSON, DOUGLAS, DMD,PHD

Oral Diagnostics

PETRY, NANCY, PHD

Psychiatry

PHULWANI, PRIYA, MD

MEDICINE/ENDOCRINOLOGY

PIERUCCI, AMIRA, PHD

Psychiatry

PILBEAM, CAROL, MD,PHD

Medicine

PRESTWOOD, KAREN, MD

Medicine

PROTIVA, PETR, MD

GASTEROENTEROLOGY

RADOLF, JUSTIN, MD

Microbial Pathogenesis

RAISZ, LAWRENCE G, MD

Medicine/Endocrinology

RAJAN, THIRUCHANDURAI V, MD,PHD

Pathology

REICHENBERGER, ERNST, PHD

Biostructure and Function

REYNOLDS, JENNIFER, MD

Center for Microbial Patho

REZAIE, TAYEBEH, PHD

Surgery

ROPER, NITIN, BS

GCRC

ROSENKRANTZ, TED S, MD

Pediatrics

ROSSON, ROBERT, MD

Medicine

ROUNSAVILLE, BRUCE, MD

PSYCHIATRY

YALE UNIVERSITY: CT, USA

RUBIN, KAREN, MD

PEDIATRICS

CONNECTICT CHILDREN'S
MEDICAL: CT, USA

SALAZAR, JUAN, MD

Pediatrics

SALERMO, EDWARD, MD

Medicine/Pulmonary

SANDERS, MARILYN, MD

Pediatrics

SARFARAZI, MANSOOR, PHD

Surgery

SCHRAMM, CRAIG, MD

Pediatric Pulmonary

SCOTT, DENISE, BS

GENETICS

6/27/2008 9:32:04AM

PIERCE FOUNDATION
LABORATORY: CT, USA

U OF TORONTO, CANADA

INSTITUTE OF LIVING: CT, USA

INSTITUTE OF LIVING: CT, USA

CONNECTICUT CHILDREN'S
MEDICAL: CT, USA

HOWARD UNIVERSITY: DC, USA
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SECOR, ERIC, MD

Immunology

SEIP, RICHARD, PHD

PREVENTIVE CARDIOLOGY

SHAFER, DAVID, DMD

Behavioral Sci & Comm Hlth

SILVERMAN, DAVID I, MD

Medicine

SMARADOTTIR, AGNES, MD

Medicine/Hem-Onc

SMILOWITZ, HENRY, MD

Diagnostic Imaging & Thera

SMITH, JOANNE, MD

Medicine

SONIS, STEPHEN T, DMD,DMSC

ORAL & MAXILLOFACIAL SURGE

SPIRO, JEFFREY, MD

Surgery

SPORN, JONATHAN, MD

CANCER CENTER

SQUIER, RACHEL, DSC,DMD

Prosthodontics

STEINBERG, KAREN, PHD

Psychiatry

STEVENS, MICHAEL, PHD

OLIN CENTER

STEVENS, RICHARD G, PHD

Community Medicine

SULLIVAN, BRIDGET, MD

ALLIED HEALTH SCIENCES

UCONN - STORRS: CT, USA

SULLIVAN, TAMI, PHD

FAMILY VIOLENCE RESEARCH A

YALE UNIVERSITY: CT, USA

SWEDE, HELEN, PHD

Community Medicine

TANEV, KALOYAN, MD

Psychiatry

TANNENBAUM, SUSAN, MD

Medicine/Hem-Onc

TAXEL, PAMELA, MD

Medicine

TAYLOR, ROBERT, MD

PHARMACOLOGY

TENNEN, HOWARD, PHD

Community Medicine

THAPAR, MANISH, MD

Internal Medicine

THOMPSON, PAUL, MD

PREVENTIVE CARDIOLOGY

THRALL, ROGER, PHD

Medicine/Pulmonary

TROJIAN, THOMAS, MD

MEDICINE/FAMILY MEDICINE

ST. FRANCIS HOSPITAL: CT, USA

TURNER, GARY, MD

OB/GYN

NEW BRITAIN GENERAL
HOSPITAL: CT, USA

VIDWANS, ANIRUDDHA, MD

Pediatrics

WAGNER, JULIE, PHD

Behavioral Sci & Comm Hlth

WALSH, KEVIN, BA

GCRC

WALSH, STEPHEN J, SCD

Ctr for Biostatistics

WARFIELD, SIMON, PHD

RADIOLOGY

WARREN, NICHOLAS, PHD

Occupational Medicine

WAYNIK, ILANA, MD

Pediatrics

WEIGERT, JEAN, MD

RADIOLOGY

WOMEN'S IMAGING: CT, USA

WEINER, SCOTT, MD

OB/GYN

NEW BRITAIN GENERAL
HOSPITAL: CT, USA

WHALEN, GILES F, MD

Surgery

WHITAKER, CHARLES, MD

Medicine/Neurology

WHITE, WILLIAM, MD

Medicine/Hypertension

WIKEL, STEPHEN, PHD

Microbial Pathogenesis

WILLIAMS, CARLA, PHD

MEDICINE

WINOKUR, ANDREW, MD

Psychiatry

WOLFSON, LESLIE, MD

Medicine/Neurology

YIGIT, SEVKET, MD

PEDIATRICS

ZAKKO, LIAM, BA

GCRC

ZARFOS, KRISTEN, MD

Surgery

ZUCKER, AARON, MD

PEDIATRICS

6/27/2008 9:32:04AM

HARTFORD HOSPITAL: CT, USA

DANA FARBER CANCER
INSTITUTE: MA, USA
ST. FRANCIS HOSPITAL: CT, USA

HARTFORD HOSPITAL: CT, USA

HOWARD UNIVERSITY: DC, USA

HARTFORD HOSPITAL: CT, USA

BRIGHAM & WOMEN'S
HOSPITAL: MA, USA

HOWARD UNIVERSITY: DC, USA

CONNECTICUT CHILDREN'S
MEDICAL: CT, USA

CONNECTICUT CHILDREN'S
MEDICAL: CT, USA
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SUBPROJECT DESCRIPTIONS
SPID:

0051

51

PROTOCOL:

TYPE: RESEARCH

SHORT TITLE:
LONG TITLE:

COGA
Collaborative Study on the Genetics of Alcoholism

AIDS:

N

START DATE:

TOTALS

9/1/1993

Total # pts expected for entire study:

3,175

Inpatient

A
0

B
0

D
0

Scatter Bed

0

0

0

Outpatient

21

0

0

Scatter RN Hours

0

0

0

Offsite Visits

0

0

0

RESEARCH BIONUTRITION

N

MULTICENTER STUDY

Y

INFORMATICS CORE

Y

CLINICAL TRIAL

N

BIOSTATISTICIAN

N

CORE LAB

Y

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

HESSELBROCK, VICTOR PHD

Psychiatry

BAUER, LANCE PHD

Psychiatry

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The primary goal of the Collaborative Study on the Genetics of Alcoholism (COGA) is the elucidation of the genes responsible
for susceptibility to alcohol dependence. The COGA project, initiated in 1987, is a large scale family study of alcoholism being
conducted at six sites nationwide. The initial clinical assessment has been completed on over 1800 probands and their biological
relatives (total N= 12,800) and a five-year follow-up is underway.
SUBPROJECT PROGRESS:

This report covers the period from April 1, 2007 to March 31, 2008 for the Collaborative Study on the Genetics of Alcoholism
(COGA) Participating Center at the University of Connecticut School of Medicine, Department of Psychiatry. This report covers
the period of time devoted to completing activities related to data collection and phenotyping/data analyses.
Specific Aims for the current grant period include:
• To identify additional susceptibility and protective genes for alcohol dependence and related phenotypes within regions that
provides evidence for linkage.
• To localize regions of linkage with newly generated, novel intermediate phenotypes related to behavioral impulsivity.
• To test in a prospective study of adolescents and young adults whether a variety of genes, including genes currently identified
(such as Gamma-Aminobutyric Acid A receptor Alpha 2 (GABRA2) and Alcohol Dehydrogenase (ADH)), contribute to the risk for
alcohol dependence and related disorders and predict the onset of psychopathology in adolescents and young adults.
• To develop multivariate phenotypes, based upon data collected across domains of data, for use in genetic analyses.
• To examine new statistical methods for use in developing typologies of alcohol dependence.
• To provide cross-sectional and longitudinal characterization of probands and family members in relation to different phenotypes,
including an examination of the stability of diagnoses and phenotype stability over time.
Data Collection and Phenotyping Studies / Results
Personnel - Some staff changes have occurred over the past year. Phlebotomy services continued to be provided by Ms. Pam
Ferzacca, who also performs the necessary laboratory/sample preparation work. Backup assistance, when necessary, continues to be
provided by staff from the General Clinical Research Center (GCRC) of the School of Medicine.
Ms. Carmel Bourgoin provides secretarial support to the project and Ms. Shirley Crall continued as the study's administrative
assistant. Data entry and data management duties over the past year remain the responsibility of the research technician's
[Kathryn Hayden, James Plouffe, and Jesse Wagner]. During the past year, Ms. Kathryn Hayden and Jesse Wagner served as the
UConn site's interviewers. Ms. Cheryl McCarter was also available on an 'as needed' basis.
Each person is fully trained on the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA-II), C-SSAGAs, and
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neuropsychological testing protocols. Ms Hayden and McCarter served as the primary SSAGA/C-SSAGA editors.
James Plouffe served as the site's ERP technician and will continue in that capacity. Jesse Wagner, who was hired during this grant
year, will also serve as a backup Enterprise Resource Planning (ERP) technician.
Dr. Lance Bauer continues as the investigator responsible for the electrophysiological portion of the study protocol.
Dr. Victor Hesselbrock continues as the site principal investigator.
Michie Hesselbrock, Ph.D. continues on the project part-time to assist with data analyses and other COGA related activities at the
UConn COGA site. She is knowledgeable regarding multivariate analyses and assists with the development of conceptual and
statistical phenotypes described in the renewal application.
Dr. M. Hesselbrock recently retired as a Professor at the University of Connecticut School of Social Work. Christine Ohannessian,
Ph.D. is an associate professor in the Department of Human Development, University of Delaware will continue to assist with the
data analysis of the child and adolescent data sets. Her particular interests are in peer relations and family relations as mediators
and moderators of the susceptibility for developing alcoholism among offspring at high risk for alcohol use disorders. She will focus
on developing structural equation models (SEM) of 'risk' as proposed in the renewal application.
Dr. Ohannessian currently is supported by a NIAAA-funded K01 career development award that began Sept 1, 2005; part of her
activities involves SEM analyses of the COGA adolescent data sets.
The scope of work proposed for FY19 was completed. During the past year, the UCONN site devoted much of its efforts to
recruitment of 13-22 year old subjects from previously assessed families for a baseline assessment as proposed in the new grant. As
in the past, productivity from the UCONN site has been very good; with 365 subjects having completed the new assessment
battery. Data entry still lags somewhat, given the project was one FTE short staffed fro much of the year; that vacancy was filled
by Jesse Wagner. We will catch up with the recruitment of subjects now that Mr Wagner is fully trained.
As of May 11, 2007, across all three previous waves of data collection, the UConn site had conducted 3078 adult SSAGA wave I-III
interviews, 742 child and adolescent interviews, 1723 DNAs, 1515 cell lines, and 1481 ERPs representing 245 families. This
sample includes 46.3% males and 53.7% females; 67.92% are Caucasian (no Hispanic), 26.95% are African-American, 3.2% are
Hispanic, and 0.5%% belong to other ethnic groups, rates similar to the population prevalence rates of the greater Hartford
metropolitan area. UConn has contributed 964 biochemistries, 569 neuropsychological test batteries, and 1513 personality tests to
the Masterfile (#153). Data entry with respect to the SSAGA, C-SSAGA, and FHAM for waves I-III is now complete.
Study Findings/Novel Clinical Phenotypes - Specific Aims of the Novel Phenotype component include: 1). To identify and test
both conceptual and multivariate phenotypes of alcohol dependence susceptibility among all available offspring (12-25 year olds)
in the COGA sample and at regular two year follow-up intervals thereafter. 2). To test and develop models of "Risk" for
susceptibility to heavier drinking and alcohol-related problems including alcohol dependence among 12-22 year old COGA subjects.
3.) To provide a cross-sectional and longitudinal phenotypic characterization of alcohol dependence among adult probands and
their adult biological family members using the clinical assessment and neurophysiologic data to examine factors related to the
onset and maintenance of drinking, recovery from alcohol dependence, and other aspects of the course of illness. During the
current year, our efforts have continued to focus on phenotype development in both the adult and in the child/adolescent data sets.
The analysis of clinical phenotypes of African - Americans in the sample has continued in collaboration with Drs. Denise Scott,
Robert Taylor and colleagues at Howard University School of Medicine. It is well known that patterns of alcohol use, abuse and
dependence are often found to vary widely among ethnic groups. Using information from samples obtained at Howard University,
the sequence and progression of alcohol related life events were investigated in this sample of African Americans and compared
with findings from the predominantly caucasian COGA sample. The sequence and mean age of appearance of alcohol-related life
events were similar for this sample of 224 African-American men and women. Arguments while drinking was the first alcohol
related event to emerge at about 20 years of age. Using alcohol in larger amounts than intended developed next, followed by
interference with functioning in multiple life areas such as problems with work or school. The onset of alcohol dependence
occurred about 26 years of age, and persistent or recurrent physical or psychological problems emerged around age 27 years. The
first initiation of seeking help from a health professional occurred at about 31 years of age. While there were similarities in the
progression of alcohol related life problems between the African American and the Caucasian samples, the frequency of symptom
endorsement for most problems was significantly higher in the Caucasian sample. Work has also continued to examine several
possible intermediate outcomes related to the development of alcohol dependence in both the COGA adult and adolescent samples.
Recent literature has suggested that age of initiation of alcohol use, intoxication and binge drinking may be important predictors of
alcohol use problems in adolescence and young adulthood. Adult Binge Drinking and Alcohol Dependence - In the adult SSAGA,
there is not a question that directly corresponds to the current definition of "binge drinking", ie 5 or more drinks per occasion etc.
Since the SSAGA was initially developed in 1989, it contains the older definition of binge drinking - the question reads "Have you
ever gone on binges or bender when you kept on drinking for 2 days or more without sobering up except for sleeping?". It is not
the same as asking 'have you ever had 5+ drinks in a 24 hr period'. When this SSAGA question is used from the wave II data set, we
find that N=1039 persons with a lifetime DSM-IV diagnosis of alcohol dependence answered this question positively. For 56% of
this N=1039, binge drinking first occurred about the same time or after the onset of DSM-IV alcohol dependence For the 44%
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(n=457) whose binge drinking preceded the onset of alcohol dependence, 303 (66%) had an onset of alcohol dependence within 5
years of first binging and 23% had an onset of alcohol dependence within 10 years of onset of binging. Adolescent Alcohol Use,
including Binging - About 65% (736/1130) of the COGA teens in wave II have tried alcohol (including a sip), with a wide range of
ages for this first experience, ranging from 1 - 17 years old. The modal age of first use is 13, with the median of 12-13 years old.
Only 42.5% of the sample (480/1130) have ever had a whole standard drink of alcohol. In the wave II adolescent sample, the
C-SSAGA-A did not have a question that specifically asks 'have you ever consumed 5+ drinks in one occasion, etc." Instead we
asked several different questions about what is the largest number of drinks consumed at one time for each grade in school
beginning in the sixth grade and going through the 12th grade. The C-SSAGA-A also asked how often this maximum amount was
consumed during that year in school. The C-SSAGA-A also asked the adult SSAGA MAX drinks question, a question about how
many times that the person had at least 3+ drinks in a 24 hr period and the age at which this first occurred. Since COGA was
surveying adolescents as young as 12, setting the bar at 3+ drinks per occasion seemed appropriate. Only 5 twelve year old subjects
reported having ever consumed 5+ drinks in a 24 hr period at any time in their life and only 1 reported doing this more than once.
The largest number of drinks ever consumed in a 24 hour period and the lifetime frequency of occurrence of this maximum
consumption was examined by age. Only 7/278 (2.5%) thirteen year olds reported ever having consumed 5+ drinks in a 24 hr
period; of this number, 3 consumed this amount only 1-2 times in their lifetime. Only 17/221 (7.7%) fourteen year olds reported
having ever consumed drinking 5+ in a 24hr period. Of this number 11 did so on only 1-2 occasions. At age 15, 60/238 (25%)
subjects reported a history of consuming 5+ drinks in a 24 hr period. Of this number, only 11 reported doing so on 1-2 occasions.
At age 16, 74/224 (33%) subjects reported a history of consuming 5+ drinks in a 24 hr period. Only 12 reported doing so on one or
more occasions. At age 17, 111/219 (51%) subjects reported drinking 5+ drinks in a 24 hr period. Only 7 reported doing so on 1-2
occasions. Thus, the data seem to show that the number of teens binge drinking (5+ drinks in 24 hr period) increases with age
across the adolescent years along with the frequency of occasions of binge drinking. An initial analysis indicates that the best
predictors of 'binge drinking' are beginning regular alcohol use before age 13 and a history of conduct disorder or oppositional
defiant disorder. Parental alcoholism [either one or both parents] does not add to the prediction. Adolescent Binging and Alcohol
Dependence - Among the COGA adolescents aged 13-17 years old, alcohol dependence is rare. The prevalence of DSM-III-R
alcohol dependence is 5.2% (N=59; 59/1130); DSM-IV alcohol dependence is even more rare with a prevalence rate of 2.5% (28;
28/1130). For those 28 adolescents with a DSM-IV diagnosis of alcohol dependence, 18 (64%) experienced their first binge and the
onset of alcohol dependence with one year or less of each other. For the remainder, the time between first binge and onset of
alcohol dependence was either 2 yrs (7.1%), 3 yrs (10.7%, 4 years (7.1%) or 5 years (10.7%).
Significance
The present study provides a fertile database for the identification of clinical and genetic factors related to the risk and
development of alcohol dependence. Both association and linkage studies continue to be performed. The influence of age at
interview, gender, ethnic/socio-demographic factors, and clinical characteristics on the transmission of alcoholism continue to be
examined in this large cross-national database, including an emphasis on externalizing behavior/disinhibition. Further, the database
has shown itself to be an excellent resource for studying the development of alcohol-related problems among individuals at high
genetic risk for alcohol dependence. A multiwave data set has been obtained on children (ages 7-12 yrs.) and adolescents (ages
13-17 yrs.) at baseline and at five-year intervals. The data collected in waves I-III and the wave IV data to be collected will provide
very fertile databases for the identification of personal, genetic, and environmental factors and their interaction related to the
vulnerability for and development of alcohol dependence. The clinical assessment battery to be used in this next wave of data
collection has been almost totally automated using CATI and electronic or web-based methods for data collection. The adolescent
and young adult COGA subjects to be assessed in the new grant period have been identified and their assessment continues on
schedule, with a good follow-up rate. The follow-up data will provide useful information on the characterization of the disorder
over time, including studies of gene-gene interaction and gene - environment interplay. In the coming year, we will continue to
examine the influence of certain psychosocial mediator/moderator variables that affect the initiation and maintenance alcohol use
in the adolescent sample, with some emphasis on the role of peer and family relations on the initiation of drinking behavior among
young adolescents. Genetic association and linkage studies will be performed, using the initial, follow-up, and combined databases.
Phenotypes based upon standardized diagnostic systems and novel phenotypes developed from information taken from all aspects
of the clinical assessment battery are being used in the search for alcohol dependence susceptibility genes.
Plans for 2008-2009
Personnel - The UConn site anticipates no vacancies in staffing and no personnel changes are anticipated for the coming year.
Subject recruitment - The UConn site will actively pursue recruiting for the wave IV assessment period. During the current year,
UCONN staff has been aggressively locating subjects from the current UCONN sample for this wave of data collection, and many
subjects have been scheduled for testing. These efforts are likely to leave the UCONN site on schedule to meet its revised
recruitment goals.
Phenotyping analyses - In the coming year, an emphasis will continue to be placed on the examination of certain psychosocial
mediator/moderator variables that affect alcohol use in the adolescent sample, with some emphasis on the role of psychological
and environmental factors as predictors of the initiation of drinking behavior among young adolescents [with Drs. Ohannessian and
M Hesselbrock]. In addition, genetic association and linkage studies will be performed [in conjunction with the COGA Genetic
Analysis committee], using the initial, follow-up, and combined databases with a focus on both qualitative and quantitative
externalizing behavior phenotypes. Our initial genetic findings in the adult sample will continue to be examined using more refined
phenotypes associated with adolescent drinking behavior (versus alcohol diagnoses such as abuse or dependence). We will also
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continue our efforts in relation to examining gene-environment interplay. Specific genes of interest that may have etiological
relevance include GABRA2, CHRM2 and the taste receptor gene, TAS16. The adult / parent sample has just undergone a genome
wide association study (GWAS) through the NIH's Center for Inherited Diseases Research (CIDR). In the coming year, as
examination of these findings increase, there are likely to be more candidate genes and SNPs identified as possible susceptibility
genes for alcohol dependence and related conditions that can be explored in the offspring sample described above now being
examined prospectively.
Human Subjects - There have been no changes in the study protocol since last submission. No subjects have been withdrawn due to
untoward consequences of participating in the COGA protocol. In order to comply with the new Health Insurance Portability and
Accountablity Act (HIPAA) regulations, a HIPPA Authorization form has been developed and put into place and the Informed
Consent Form (ICF) modified accordingly. Both the HIPAA Authorization form and the ICF have been approved for use by the
UConn Institutional Review Board (IRB), and all UCONN site staff and investigators have up-to-date IRB certifications.
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Primary Cortisol Resistance

AIDS:

N

START DATE:

Final
TYPE: RESEARCH

TOTALS

2/27/1998

Total # pts expected for entire study:

50

Inpatient

A
0

B
0

D
0

Scatter Bed

0

0

0

Outpatient

0

0

0

Scatter RN Hours

0

0

0

Offsite Visits

0

0

0

RESEARCH BIONUTRITION

N

MULTICENTER STUDY

N

INFORMATICS CORE

Y

CLINICAL TRIAL

N

BIOSTATISTICIAN

N

CORE LAB

N

ANCILLARIES ONLY

N

INVESTIGATOR
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MALCHOFF, CARL MD, PHD

Medicine/Endocrinology

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

It is our general hypothesis that primary cortisol resistance is a treatable cause of sexual precocity, hypertension, and in women,
hirsutism and menstrual irregularities. There are two specific hypotheses of the studies proposed here. First, we predict that
selected clinical, biochemical, and ligand binding measurements are sensitive and specific markers for primary cortisol resistance.
Second, we predict that the sexual precocity of primary cortisol resistance can be successfully and safely treated with
dexamethasone. Once we understand in detail the clinical and biochemical presentations of this disorder, then we will be able to
efficiently screen larger potentially affected populations to determine the frequency of cortisol resistance and to identify
potentially treatable individuals.
SUBPROJECT PROGRESS:

There is a total of 19 subjects enrolled since initiation of this study. For the current report period, no new subjects have been
enrolled.
There are no proposed changes in recruitment plans at this time. In addition, there are no unexpected safety concerns concerns to
report. This study closed in the General Clinical Research Center (GCRC) on 09/06/2007.
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MALCHOFF, DIANA PHD

Medicine

SARFARAZI, MANSOOR PHD

Surgery

WHALEN, GILES F MD

Surgery

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Identification of genes that cause human tumors provides important insight into the mechanisms of tumorogenesis. Inherited
malignancies provide an opportunity to identify these pathogenetic genes, since powerful positional cloning methodologies will
identify the gene of interest. Because there are relatively few multigeneration familial papillary thyroid carcinoma (fPTC)
kindreds, genetic linkage methodologies with positional cloning have not yet been used to investigate fPTC. The purpose of
this proposal is to use linkage analysis as the first step in positional cloning of the fPTC susceptibility gene.
SUBPROJECT PROGRESS:

The long term goal is identification of the gene(s) causing familial papillary thyroid carcinoma. We are currently sequencing gaps
in the human genome project within the minimal region of the 1q21 containing the gene and sequencing candidate genes. Large
new families are being categorized as to linkage region.
In the last year we have added 14 new subjects for a total of 96 subjects in all.
No changes in recruitment, no unexpected safety concerns, no new interim data, no changes in protocol.
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CAMPBELL, WINSTON MD

Obstetrics/Gynecology

KRANZLER, HENRY MD

Psychiatry

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The aim of this study is to evaluate the effects of maternal smoking on measures of fetal well-being and to determine whether
smoking cessation with nicotine replacement can lessen these effects.
SUBPROJECT PROGRESS:

A paper of the final results of this study was submitted to Obstetrics and Gynecology this last year but rejected. We are
resubmitting the paper to Journal of Maternal-Fetal medicine within the next month.
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Complication of Hemophilia and Serum Testing and Storage
Universal Data and Serum Specimen Collection System for Hemophilia.
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BONA, ROBERT MD

Medicine/Hem-Onc

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The primary congenital bleeding disorders are hemophilia A and B, which affect approximately 1 in 5,000 males and von
Willebrand's Disease which affects 1 in 100 men and women. Several plasma proteins called factors are necessary for normal
blood clotting. Persons with hemophilia are either missing a particular factor in their blood that is essential to the clotting
process or the protein is present but does not work. Without this factor, bleeding into muscles, joints, and internal organs often
occurs without any noticeable trauma. The treatment of a bleeding episode involves the replacement of the missing protein
through intravenous administration of factor concentrate which is derived from, or contains components of human blood. The
frequent bleeding and the necessary intravenous administration of blood products to control the bleeding are responsible for the
two most severe complications of hemophilia: 1) development of chronic joint disease from repeated bleeding into major joints;
and 2) infection with viral, blood-borne disease such as hepatitis and human immunodeficiency virus (HIV).
About three-fourths of all persons with hemophilia in the US receive some of their treatment from federally-sponsored,
specialized hemophilia treatment centers (HTCs). The Center for Disease Control and Prevention (CDC) provides support to
these treatment centers for programs designed to prevent complications of hemophilia.
The Universal Data and Serum Specimen Collection System will extend CDC's collaboration with the HTCs by assisting with the
analysis of a uniform set of clinical data which are used to monitor the extent of complications in congenital bleeding disorders
in the US. Specific measurements will be used to evaluate the degree of joint disease. In addition, serum will be tested for the
presence of blood borne pathogens. The remainder of each serum specimen will be used by the CDC to establish a serum bank
for possible future use in evaluating the safety of blood products. Information from this system will be used to assess the safety
of the blood supply and to develop and monitor the effectiveness of interventions designed to address the mandate from
congress which is to reduce or prevent the complications of hemophilia.
SUBPROJECT PROGRESS:

Number of subjects enrolling during the report period and since initiation of the study:
During the above report period, (1) one new study subject was enrolled as a participant, (2) one pediatric study patient had an
annual follow-up visit and (3) 4 adult study subjects had an annual follow-up visit. For CCMC study participants: the General
Clinical Research Center (GCRC) processes the blood specimens and sends out the specimens. For adult patients: GCRC will draw
the blood specimens, process the specimens and send them to the study site laboratory.
Study subjects are enrolled as participants or refusals. The study is being conducted at University of Connecticut Health Center
(UCHC) and the Connecticut Children's Medical Center (CCMC). When the patients/subjects come in for a scheduled visits, they
are invited to participate in the study. If a patient is already in the study, they are invited to continue to participate or refuse to
participate in the study at their annual visit.
Any changes in recruitment plans that might be needed: None
Unexpected safety concerns and their resolution: None
Interim data and outcomes if appropriate: The study is ongoing.
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Any proposed changes made or anticipated in the protocol. None at this time.
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NSABP Treatment B21
NSABP B21 Node Negative Clinical Occult Breast Cancer - Tamoxifen/Radiation
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NON-HOST INSTITUTION: STATE,
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SUBPROJECT DESCRIPTION:

Patients eligible for this study must have had a lumpectomy with tumor-free specimen margins and axillary node dissection with
pathologically-negative axillary nodes. The largest tumor diameter, by pathological examination of the resected specimen,
must be < 1 cm. If the pathologic tumor size is indeterminable from the report, then the maximum clinical and mammographic
tumor sizes must both be < 1 cm. If a tumor pathologically consists of both an invasive component and an intraductal
component, then the maximum diameter of both components when measured together must be < 1 cm. Finally, patients are
eligible if a carcinoma pathologically < 1 cm in size is detected in association with a benign lesion of any size. Patients in this
study will be randomly assigned to one of three groups: lumpectomy and breast radiation plus placebo, lumpectomy and breast
radiation plus tamoxifen, or lumpectomy, tamoxifen and no breast radiation.
SUBPROJECT PROGRESS:

This study was terminated here at the University of Connecticut Health Center on 06-20-2007.
There were no changes to protocol, no safety concerns, no publications
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NSABP BI-65 NSABP BI-65
NSABP BI-65 Menstrual Cycle in Surgical Treatment of Breast Cancer
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NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The purpose of this study is to evaluate whether the timing of breast cancer surgery during a woman's menstrual cycle affects
her ultimate outcome- namely, the likelihood of recurrence or death. While some reports have indicated that women operated
on during certain times of their menstrual period are at higher risk of recurrence of breast cancer, most studies have not found
any difference in results regardless of when breast cancer surgery is performed. Thus, it remains standard procedure to perform
breast cancer surgery as soon as a woman has been informed of her options and she is ready to proceed.
SUBPROJECT PROGRESS:

There is one subject on long term follow up for this study, one patient is deceased as of 04/03/2007. There have been no safety
concerns, no publications, there have been no changes to the protocol. This study remains closed to accrual, there is no
recruitment plan.
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NSABP B-27
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Surgery

Phase III

NON-HOST INSTITUTION: STATE,
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SUBPROJECT DESCRIPTION:

The primary aim of this study is to determine whether four cycles of preoperative or postoperative Taxotene given after for
cycles of preoperative Adriamycin; (A) and cyclophosphamide (C) (AC) will more effectively prolong disease-free survival
(DFS) and survival (S) than do four cycles of preoperative AC alone. The study will also evaluate the effect of the
administration of preoperative Taxotene after preoperative AC with respect to clinical and pathologic loco-regional tumor
response and conservation. Women with palpable, operable carcinoma of the breast diagnosed by age, clinical tumor size, and
clinical nodal status, then randomized to one of three groups. Group I will receive four cycles of preoperative A and C given at
60 mg/m2 and 500 mg/m2, respectively, every 21 days followed by surgery (lumpectomy and exillary node dissection, or
modified radical mastectomy). Group II will receive four cycles of preoperative AC as in group I, followed by four cycles of
preoperative Taxotere at 100 mg/m2 as a 1-hour infusion every 21 days followed by surgery. Group III will receive four cycles
as AC as in groups I and II, followed by surgery and by four cycles of postoperative Taxotere, as in group II. Beginning on the
first day of administration of their assigned chemotherapy, all three groups will receive tamoxifen at 20 mg p.o. once daily for
5 years. In all three groups, tumor measurements will be obtained after each cycle of preoperative chemotherapy. Assessment
of response will be performed after completion of all preoperative chemotherapy and before surgery. For patients in group II,
an additional assessment of response will be performed after completion of AC chemotherapy. Patients in groups I and II who
undergo lumpectomy will receive postoperative radiotherapy after their recovery from surgery. Patients in group III who
undergo lumpectomy will receive postoperative radiotherapy after their recovery from the fourth cycle of postoperative
Taxotere.
SUBPROJECT PROGRESS:

3 patients are in long term follow-up and have no evidence of disease, no Adverse Events, no new primaries and begin seen
annually for follow up. 4 patients have expired due to progression of disease. Please note that The Hospital of Central
Connecticut is not under our Institutional Review Board umbrella for this study. There have been no unexpected safety concerns.
There have been no publications that have cited the General Clinical Research Center.
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NSABP P-2: STAR
NSABP P-2: Study of Tamoxifen and Raloxifene (STAR) for the prevention of breast cancer.
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SPORN, JONATHAN MD

CANCER CENTER

Phase III-IV

NON-HOST INSTITUTION: STATE,
COUNTRY

ST. FRANCIS HOSPITAL, CT USA

SUBPROJECT DESCRIPTION:

In the P-1 study, tamoxifen was shown to prevent the development of invasive and in situ breast cancer. Raloxifene has shown
to be an effective drug for the prevention of osteoporosis. It was observed in the Multiple Outcomes of Raloxifene Evaluation
(MORE) trial that there were fewer breast cancers in the group of patients that had taken raloxifene compared to the controls.
This study will determine if raloxifene is either more or less effective than tamoxifen in reducing the incidence of invasive
breast cancer in postmenopausal women who are at increased risk for the disease. A secondary goal is to determine whether
raloxifene reduces the endometrial cancer rate compared to tamoxifen.
SUBPROJECT PROGRESS:

No new participants were enrolled this past year. study is closed to enrollment -58 women were randomized to STAR at the
University of Connecticut Health Center (UCHC)
-no changes in recruitment plan
-no unexpected safety concerns
-unblinded -amendment was passed to allow women to change from open label tamoxifen to open label raloxifene; 1 participant
chose to crossover
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Microbial Pathogenesis

SALAZAR, JUAN MD

Pediatrics

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Venereal syphilis is a chronic inflammatory disorder driven by the persistence of its etiologic agent Treponema pallidum.
Though the immune/inflammatory response at sites of local treponemal infection may ultimately underlie the development of
both protective immunity and clinical manifestations, these local cellular processes have yet to be characterized in humans using
the tools of contemporary cellular and molecular immunology. The components of T. pallidum that induce these potentially
deleterious inflammatory processes also remain poorly characterized. Our understanding of cellular immunity in syphilis is
further compromised by our currently limited knowledge concerning the interactions between syphilis and human
immunodeficiency virus (HIV) infection. Accordingly, the proposed research has three Specific Aims. In Specific Aim 1, we will
perform immunocytochemical analysis of skin biopsies and flow cytometry analysis of leukocytes in suction blisters to
characterize cutaneous cellular immune processes in HIV- and HIV+ patients with secondary syphilis. Data from these studies
will be correlated with our in vitro research involving immune effector cell activation by T. pallidum and treponemal
lipoproteins. In Specific Aim 2, we will use the same immunocytochemical and flow cytometric approaches to characterize the
cutaneous inflammatory response to synthetic analogs (lipopeptides) of T. pallidum lipoproteins. These experiments are an
outgrowth of our hypothesis that T. pallidum lipoproteins are major inflammatory mediators during syphilitic infection.
Building upon our observation that T. pallidum lipoprotein analogs induce HIV gene expression in vitro, the experiments in
Specific Aim 3 will elucidate the mechanisms which underlie this phenomenon. A principal long-term objective of this research
is to elucidate the immune/inflammatory events during syphilitic infection which engender both clinical manifestations and
protective immunity. An equally important objective is to obtain cellular and molecular data which will complement our
emerging understanding of the interactions between syphilis and HIV infection, including the potential for syphilis to serve as a
co-factor for HIV transmission and for HIV infection to alter the clinical course of syphilis.
SUBPROJECT PROGRESS:

The number of subjects enrolled during the reporting period is 34.
The number of subjects enrolled since the initiation of the study is 372.
There have been no unexpected safety concerns during this reporting period
Specific Aim One. To further characterize the innate immune responses elicited by treponemal lipoproteins in human skin
(already completed and closed enrollment).
Specific Aim Two. To further characterize the cutaneous immune response to T. pallidum in secondary syphilis lesions (already
completed and published).
Specific Aim Three. To elucidate immune cell responses to T. pallidum and B. burgdorferi or its constituents (manuscript in
preparation)
Specific Aim Four. To study how T. pallidum and B. burgdorferi or its constituents activate macrophages following uptake into
phagosomal vacuoles (ongoing using blood samples from healthy volunteers).
Studies related to Specific Aim and Two are now completed and have been published. Work on Specific Aim Two is also completed
and has been accepted for publication. Given our successes at the Cali site and the unanticipated wealth of new information
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obtained from combined analysis of blood and skin blister fluids, Dr. Salazar has expanded the scope of this work and has obtained
independent funding and Institutional Review Board (IRB) approval to continue his research activities in Cali. Studies for Specific
Aims Three and Four will continue at the University of Connecticut Health Center (UCHC) and will use the isolated peripheral
blood mononuclear cells (PBMC) system to assess monocyte, T cell, and dendritic cell responses to live spirochetes and spirochetal
components. to elucidate the mechanisms and signaling pathways elicited during uptake by macrophages of Borrelia burgdorferi and
opsonized T. pallidum.
No changes in the protocol are anticipated.
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The effects of nicotine on bone turnover in older women
The effects of nicotine on bone turnover in older women
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NON-HOST INSTITUTION: STATE,
COUNTRY

YALE UNIVERSITY, CT USA

SUBPROJECT DESCRIPTION:

This study will enroll 150 subjects (smokers, postmenopausal women)to evaluate the effects of smoking cessation with either
nicotine replacement or placebo on markers of bone resorption and formation.
SUBPROJECT PROGRESS:

Two papers have been published off this data set. We are analyzing the body composition data and hope to have another paper
submitted this year.
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Circadian Blood Pressure Profile
The circadian blood pressure profile, its reproducibility and its relationship to sympathetic nervous system
activity, circadian physical activity, sleep quality and novel markers of hypertensive organ damage.
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WHITE, WILLIAM MD

Medicine/Hypertension

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

About 20-30% of essential hypertensive patients will have less than the normal (15-20% of awake blood pressure) decline in
blood pressure during sleep. This higher than normal sleep blood pressure has been observed during ambulatory blood pressure
monitoring and such patients have been termed "non-dippers" to distinguish them from patients with a normal sleep blood
pressure decline, "dippers". Patients with nondipping sleep blood pressure are continuously exposed to higher blood pressure
levels. This persistent hypertension is likely to be injurious to the endothelium and other organs susceptible to the ill effects of
hypertension. Indeed, preliminary studies indicate that nondipper hypertensives have more evidence of hypertensive organ
damage. The present study will therefore examine some important issues regarding the criteria for dipper and nondipper
categories of blood pressure, the reproducibility of such categorization and the effects of daytime and sleep activity on the
decline of blood pressure during sleep. The study will also compare sympathetic nervous system activity, salt sensitivity, and
insulin resistance measures in relation to the extent of sleep blood pressure reduction. Finally, endothelial function, retinal
vascular structure and left ventricular mass will be compared in dippers and non-dippers.
The project will recruit 150 newly diagnosed and untreated hypertensive subjects to eliminate the effects of drug treatment on
blood pressure profiles. After an initial 2-week period when the presence of hypertension will be confirmed by clinic blood
pressure readings, patients will undergo 2 separate 24-hour ambulatory blood pressure and electronic activity monitoring sessions
about 1-2 weeks apart. During these two periods, awake and sleep sympathetic nervous system activity will be evaluated using
plasma and urinary catecholamines. Sleep quality will be measured using a questionnaire and actigraphy derived indices of sleep
quality. During the next two weeks and while remaining untreated, all patients will undergo endothelial function studies (B-mode
ultrasound), retinal vascular structure assessment (high-resolution retinal photography), and left ventricular mass estimation
(echocardiography). In the latter two years of the project, salt sensitivity and its relation to dipper and nondipper blood
pressure profiles will be studied.
The reproducibility of the dipper and nondipper categorization will be examined in relation to the effects of sleep and daytime
activity, sleep quality, and sympathetic nervous system activity. Direct comparisons between dipper and nondipper groups will
be made in salt sensitivity, insulin resistance, and sympathetic nervous system activity. This study will provide information that
will be important if clinical trials targeting nocturnal blood pressure are to be designed.
SUBPROJECT PROGRESS:

The study did not recruit any new patients during the reporting period, as recruitment was completed in June of '05. There have
been no safety concerns. The study closed in the General Clinical Research Center (GCRC) on 06/05/2007.
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Dendritic Type APC-Based Vaccine for Prostate Cancer
Dendritic Type Antigen Presenting Cell (APC) -Based Vaccine for Prostate Cancer
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MUKHERJI, BIJAY MD

Medicine

TAXEL, PAMELA MD

Medicine

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The overall goal of this study is to develop an effective form of active specific immunotherapy for prostate cancer based on the
fundamental principles of T lymphocyte activation and molecular mechanism of antigen processing and presentation. The
project is based upon the hypothesis that antigen presenting cells (APC) grown from prostate cancer patients will be able to
successfully present the prostate specific membrane antigen derived peptides to cytotoxic T lymphocyte (CTL) precursors to
induce a specific CTL response in in vitro co-cultures. The idea is to develop an in vitro model system consisting of prostate
cancer patients who are human leukocyte antigen (HLA) A2+ and who have very high levels of serum prostate specific antigen
(PSA). The question is whether or not it is possible to induce a peptide specific CTL response in vitro, by presenting one of
four PSA gene derived epitopes, exhibiting binding motif for HLA A2 molecules, on autologous APC.
SUBPROJECT PROGRESS:

It was not possible to enroll any subjects during the reporting period due to some questions raised by the Institutional Review Board
(IRB) about our recruitment procedure. We have recently got the final approval from IRB, which is valid until May 15 2009.
Although there are no safety concerns, the IRB needed some clarification of the protocol too. In between we were able to do
cytokine enzyme linked immunosorbent assay (ELISA) with some frozen culture medium collected from a previous study's case
samples. These will help us for our (near) future publication.
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ACSOG-Z0010
ACSOG-Z0010 A Prognostic Study of Sentinel Node and Bone Marrow Micro-metastases in Women with
Clinical T1 or T2 N0M0 Breast Cancer
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NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Prior to the development of this new procedure, sentinel lymph node dissection (SLND), the only way to identify if the tumor
had spread to the nodes in the armpit was to remove all the lymph nodes from the armpit. Numerous studies have shown that
removing all of the lymph nodes does not affect survival even though the cancer may come back under the arm. It is possible
that removal of the lymph nodes from the middle and lower areas of the armpit (Level I and II) is no better than removing just
the sentinel lymph node(s). In 1995, Giuliano et al. conducted a study comparing a SLND with immunohistochemistry (IHC) to
routine axillary lymph node dissection (ALND). SLND detected nodal metastases in 42% of all patients, and of these, 45% had
micrometastases. The main objectives of this study are: 1) to estimate the prevalence and to evaluate the prognostic
significance of sentinel node micrometastases detected by IHC, 2) to estimate the prevalence and to evaluate the prognostic
significance of bone marrow micrometastasis detected by immunocytochemistry (ICC) for the first 3600 women, 3) to evaluate
the hazard rate for regional recurrence in women whose sentinel nodes are negative by hematoxylin and eosin (H&E) staining,
and 4) to provide a mechanism for identifying women whose sentinel nodes contain metastases detected by H&E so that these
women can be considered candidates for Study Z001. Women with clinical T1 or T2 NO MO breast cancer will undergo
breast-conserving therapy (BCT), bilateral iliac crest bone marrow aspirations, and sentinel lymph node dissection (SLND).
When a sentinel node is not identified during the SLND, an ALND is performed. Patients who have no sentinel lymph node
metastasis by H&E will not have an ALND. Patients with evidence of metastatic disease in the sentinel node may be eligible for
registration and randomization to Study Z0011.
SUBPROJECT PROGRESS:

The 9 patients enrolled at the University of Connecticut Health Center (UCHC) are all alive and disease free. They are in the long
term follow-up. There have been no safety concerns, no unanticipated problems, no changes to protocol.
This study is closed to accrual; there is no longer a recruitment plan. There are no unexpected safety concerns and no anticipated
changes to the protocol. There have been no publications that have cited the General Clinical Research Center (GCRC).
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Fiber-Reinforced Composites in Dental Implants
The use of fiber-reinforced composites in implant dentistry
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Behavioral Sci & Comm Hlth

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Prostheses placed over dental implants are generally made with a metal substructure supporting either a ceramic veneer or resin
with artificial plastic teeth. The use of fiber composite technology in the creation of a metal-free implant prosthesis may solve
many of the problems associated with this metal alloy substructure such as corrosion, toxicity, complexity of fabrication, high
cost and esthetic deficiencies.
Glass fiber-reinforced composites (FRCs) have been developed which have the potential to make an esthetic implant prosthesis
substructure utilizing a simple, time-efficient technique. Laboratory and clinical research evaluating FRC prostheses used to
restore and replace teeth have shown that these materials exhibit excellent mechanical properties and can form a chemical bond
to resin-based veneer materials. Additionally, these FRC materials have the potential to be used to make a single visit,
chairside-fabricated provisional tooth replacement bonded to an adjacent anterior tooth prior to implant loading.
SUBPROJECT PROGRESS:

No participants were enrolled for study A & B during the above time period. There have been seven 2 year follow up visits and
sixteen 3 year follow up visits for studies A & B.
No participants have been enrolled or have had follow up visits for study C during the above time period.
There have been no unexpected safety concerns and no changes made to the protocol.
There have been no publications during the above-mentioned time period.
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Genetics of Cocaine Dependence
Genetics of Cocaine Dependence
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Psychiatry
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NON-HOST INSTITUTION: STATE,
COUNTRY

YALE UNIVERSITY, CT USA

YALE UNIVERSITY, CT USA

SUBPROJECT DESCRIPTION:

Cocaine dependence (CD) has been shown in twin and family studies to have a genetic contribution. This is a multi-center study
recruiting affected sibling pairs and other nuclear family members. A genome scan will make it possible to identify regions
containing genes that influence risk of CD.
SUBPROJECT PROGRESS:

We recruited 265 participants for this study between 4/1/07 and 3/31/08. We have recruited 940 total subjects in the study since its
initiation. We continue to recruit probands and controls in addition to our previous recruitment of sibling pairs and family trios.
A Certificate of Confidentiality was issued for the period 6/1/06 to 3/31/11 (Certificate No. DA-06-186 is on file with
Institutional Review Board (IRB)). We were previously covered under a certificate that was awarded to Yale University for the
original study involving sibling pairs. A waiver/alteration of informed consent for phone screening phase only; phone script was
changed to reflect change in payment from $75 to $100.
Breath alcohol readings are now done to ensure that participants are able to give informed consent. Following an extensive trial
period with Solutions in Surveys(SIS), the company we had hired to aid in our control recruitment, we decided to terminate our
relationship with SIS. We have continued control recruitment on our own.
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Psychiatry
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PSYCHIATRY

NON-HOST INSTITUTION: STATE,
COUNTRY

YALE UNIVERSITY, CT USA

YALE UNIVERSITY, CT USA

SUBPROJECT DESCRIPTION:

Opioid dependence (OD) risk has been shown by both twin and family studies to have a genetic component. This study is being
conducted at UConn and Yale, where small nuclear families (SNFs) containing affected sibling pairs are being recruited. A
genome scan will make it possible to identify chromosomal regions containing genes that influence risk of OD.
SUBPROJECT PROGRESS:

We recruited 184 participants for this study between 4/1/07 and 3/31/08. We have recruited 767 subjects in the study since its
initiation. Subject payment has changed from $75 to $100 for cases and from $50 to $75 for control subjects. We continue to
recruit cases and controls in addition to our previous recruitment of sibling pairs and family trios.
A waiver to consent for the phone screening phase only was approved as well as minor changes to the phone screen itself. Breath
alcohol reading is also now evaluated to ensure that participants are able to give informed consent. The protocol has been changed
so that control subjects are now being recruited as matches to the affected subjects as opposed to simply recruiting a control sample
of convenience.
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Contingency Management for Marijuana Dependence
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NON-HOST INSTITUTION: STATE,
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SUBPROJECT DESCRIPTION:

The overall goal of this research is to improve treatment outcome for marijuana-dependent individuals. The study will attempt
to enhance abstinence over the levels obtained in prior research by combining contingency management with Motivational
Enhancement Therapy and Cognitive Behavior Therapy (MET/CBT), providing voucher-based reinforcement for abstinence.
This combined intervention will be compared to three other interventions: MET/CBT-only, contingency-management-only,
and a control group that receives supportive case management only. Recruitment of 260 marijuana-dependent participants will
occur over a three-year period. They will be randomly assigned to one of the four interventions. All treatments will be
individual, manualized, and provided on an outpatient basis for 9-sessions. Pretreatment assessments will provide baseline data
against which to compare treatment outcomes. Follow-up assessments, at three-month intervals for one year following
treatment, will evaluate marijuana and other drug/alcohol use, and psychosocial functioning in several domains. It is anticipated
that the intervention combining contingency management and MET/CBT will result in the best outcomes, and that the
contingency management and MET/CBT interventions by themselves will each be superior to supportive case management.
SUBPROJECT PROGRESS:

-

Number of subjects enrolling during the report period and since initiation of the study
During the report period: 67
Since initiation of the original study: 330 (MTP2=250 + MTP3=80)
- Any changes in recruitment plans that might be needed None
- Unexpected safety concerns and their resolution
None
- Interim data and outcomes if appropriate
None at this stage
- Any proposed changes made or anticipated in the protocol
The following modifications were reviewed and approved by the IRB on 6/6/07:
Revisions to protocol, informed consent form, and Treatment Manual to extend reinforcement-for-attendance from 2 weeks to 3
weeks in the group that is to eventually receive reinforcement for marijuana-free urine specimens.
No other changes to the protocol are anticipated at this time.

A competitive-renewal application for this project was funded in September 2006, and General Clinical Research Center (GCRC)
support for the renewal period was approved in October 2006. After a start-up period for development of the Research and
Treatment manuals, for programming the Interactive Voice Response (IVR) system, and for therapist training and treatment of
training cases, the first Main Phase cases were recruited in March 2007. In the current reporting period a total of 67 participants
were recruited and randomized to the three treatment conditions.
After a slow start, recruitment rates have recently averaged somewhat greater than 1.5 subjects per week, which puts us on track to
recruit the projected number of 75 in the coming project-year. Thus far, 38 participants have completed the treatment phase of
the project, and follow-up assessments have begun at the 5-, 8-, and 11-month follow-up points. There are no safety concerns,
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and no outcomes to report at this early stage of the competitive-renewal project.
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Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Selenium and Vitamin E Cancer Prevention Trial (SELECT)
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NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

SELECT is a Phase III, double blind, placebo-controlled clinical trial designed to assess the effect of selenium and vitamin E
(individually and in combination) on the incidence of prostate cancer as determined by routine clinical management. The
accrual goal is 32,400 healthy men nationwide who are 55 years old or older (age 50 years or older for African-American men).
Study duration will be twelve years with a five-year uniform accrual period. Participants will receive study supplements from the
time of their randomization until the end of the trial period, between seven and twelve years depending upon when the
participant was randomized.
SUBPROJECT PROGRESS:

No new participants were enrolled in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) in the report period. Two
participants moved out of the area and transferred out to other SELECT sites.
# since initiation of trial: 60
Any changes in recruitment plans that might be needed: N/A, enrollment to the study is closed
Unexpected safety concerns and their resolution: In the report period, the Southwest Oncology Group (SWOG) sent us a prepared
Fact Sheet regarding a new finding of risks associated with excessive multivitamin use. The Fact Sheet was submitted to the IRB
and subsequent to approval was distributed to enrolled participants, who signed a document acknowledging receipt and who were
given a copy of the document.
Interim data and outcomes if appropriate: N/A - study is in data collection phase
Any proposed changes made or anticipated in the protocol: None known
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NSABP B-31
NSABP B-31: A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and
Cyclophosphamide Followed by Taxol (AC ·T) to That of Adriamycin and Cyclophosphamide Followed by
Taxol plus Herceptin (AC · T+H) in Node-Positive Breast Cancer Patie
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NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The primary aims of the study are 1) to compare the cardiotoxicity of four cycles of Adriamycin and Cyclophosphamide (AC)
followed by four cycles of Taxol, with that of the same chemotherapy regimen plus Herceptin, in patients with operable,
histologically node-positive breast cancer which overexpresses the HER2 protein; and 2)to determine whether, in this patient
population, four cycles of AC followed by four cycles of Taxol and weekly Herceptin for one year is more effective in
prolonging survival than four cycles of AC followed by four cycles of Taxol.
SUBPROJECT PROGRESS:

All have completed study and are in long term follow-up only.
The Hospital of Central Connecticut (THOCC): Four patients were enrolled at this site. Three are alive and well without adverse
events (AEs), new primaries, or recurrence. The fourth patient had new lung cancer primary in 03/12/07 and is being treated
accordingly. The patient did not have AEs or recurrence related to breast cancer.
The University of Connecticut Health Center (UCHC): Five patients were enrolled at this site. One patient expired due to
metastatic disease. One other patient moved to Washington DC and has been lost to follow-up. The other patient with metastatic
disease to the brain had surgery on 8/31/07 for a left cerebellar tumor and is now in follow-up. The last two patients are alive and
well without AEs, new primaries, or recurrence.

6/27/2008 9:32:04AM

31

5M01RR006192-14
SPID:

REPORT PD: 04/01/2007-03/31/2008

0374

374

PROTOCOL:

Final
TYPE: RESEARCH

SHORT TITLE:
LONG TITLE:

NSABP CO-7
NSABP CO-7: A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus leucovorin (LV) and Oxaliplatin with
5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients with Stages II and III Carcinoma of the Colon
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SUBPROJECT DESCRIPTION:

The primary aim of this study is to compare the relative efficacy of Fluorouracil (5-FU) + Leucovorin (LV) + Oxaliplatin
(FLOX) with that of 5-FU + LV in prolonging disease-free survival among patients who have undergone a potentially curative
resection of a stage II or III carcinoma of the colon. The secondary aim of the study is to compare the relative efficacy of
FLOX with that of FL in prolonging Survival (S).
SUBPROJECT PROGRESS:

Local Report:
University of Connecticut Health Center (UCHC): As of 2/13/08 One patient is alive with 3rd recurrence for which the patient is
receiving non-study treatment. No long-term toxicity noted.
The Hospital of Central Connecticut (THOCC): As of 2/13/08, 5 patients are alive and well with no adverse events (AE's), no new
primaries and no recurrence of disease.
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Study of the Human Malaria Parasite Plasmodium Falciparum
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SUBPROJECT DESCRIPTION:

Malaria is by far the world's most important tropical parasitic disease. It causes clinical illness in 300 million to 500 million
people, 1.5 million to 2.7 million of whom die. Sub-saharian Africa remains the most malarious region in the world with ninety
percent of cases and deaths, mostly among children, In this region, about 30% of outpatient consultations and up to 20%
hospital admissions are due to malaria. This causes major disturbance in economic and social development. Malaria cases in the
United States are linked to international tourism with about one thousand cases diagnosed and treated each year. Since the
mid-1950's malaria prophylaxis has relied mostly on chloroquine because of its effectiveness and, notably its low cost.
Chloroquine resistance has become widespread in different parts of the world. Mefloquine and quinine have been used
extensively in areas of resistance to chloroquine, and proguanil for prophylaxis and treatment, but resistance to these drugs is
becoming a substantial problem. The need for more efficacious and less toxic agents, particularly rational drugs that exploit
pathways and targets unique to the parasite, is therefore acute.
Plasmodium falciparum is an important intraerythrocytic protozoan pathogen, responsible for the most severe form of human
malaria. The parasite undergoes a number of developmental stages in the human host and multiplies asexually in the red blood
cell to effect its clinical symptoms and lethal outcome.
Research in my laboratory focuses on how the malaria parasite responds to changing environmental conditions. Maintaining
the parasite in culture is an essential step in our research toward understanding the basic biology of this parasite and future
development of a vaccine or new antimalarial drugs. The GCRC supports the study by by drawing blood and transporting the
sample to the research lab.
SUBPROJECT PROGRESS:

1. Number of Subjects enrolled during the reported period: 8 subjects (15 blood draws)
2. Number of Subjects enrolled since intiation of the study: 35 subjects (144 blood draws)
3. Any changes in recruitment plans that might be needed: No
4. Unexpected safety concerns and their resolution: None
5.Interim data and outcomes if appropriate: None
6.Any proposed changes made or anticipated in the protocol. Enrollment was increased from 10 to 35 and was approved on
4/19/07.
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NSABP B33 Randomized, Placebo-Controlled Double Blind Trial Evaluating the Effect of Exemestane in
Clinical Stage T1-2, NO-1, MO Postmenopausal Breast Cancer Patients Completing at Least Five Years of
Tamoxifen Therapy
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SUBPROJECT DESCRIPTION:

Currently, patients whose primary breast cancer demonstrated estrogen receptors, receive five years of anti-estrogen treatment
with tamoxifen. This has been standard care for many years. There is no data supporting more than five years of tamoxifen
use, in fact at least one study showed worse results with more than five years of tamoxifen. There is no treatment offered to
patients beyond this other than close observation. Exemestane is a new aromatase inhibitor, i.e. a drug that interferes with the
metabolism of steroid hormones. The primary aim of this randomized, placebo-controlled, double-blind clinical trial is to
determine whether oral administration of exemestane, for 2 years, in postmenopausal patients with estrogen-receptor-positive
(ER+) and/or progesterone-receptor-positive (PgR+) breast cancer (CT 1-3 cNO-1 MO) who have completed 5 years of
tamoxifen therapy, will prolong disease-free survival and overall survival when compared with placebo. To be eligible, patients
must have completed approximately 5 years of adjuvant tamoxifen therapy (either 10 mg po twice a day or 20 mg po daily), be
disease free, and have been resected by lumpectomy and axillary node dissection or by modified radical mastectomy. Eligible
patients may have received either adjuvant or neoadjuvant chemotherapy at the time of their breast cancer diagnosis.
Following stratification by nodal status, patients will be randomized to receive either exemestane 25 mg po daily or placebo, for
2 years. Another aim of this study is to evaluate the effect of tamoxifen withdrawal on bone and to determine if exemestane
has any additional effects on the rate of bone loss resulting from tamoxifen withdrawal. Data for fractures, height, and total
serum alkaline phosphatase will be collected on the entire study population.
SUBPROJECT PROGRESS:

University of Connecticut Health Center (UCHC) - 3 patients were enrolled into this study. All 3 patients are doing well. 2
patients are off study, one continues with Long Term Follow Up only. At last follow up (11-12-2007) patient was seen by Dr. Ann
Waitzman and is alive and well.
The Hospital of Central Connecticut (THOCC) report: 2 patients enrolled since initiation of trial.
One patient is deceased as of April 2006.
One patient was last seen 5/17/07 by Dr. Fallon, is still on treatment, no adverse events (AEs), recurrence, or new primaries. (Dr.
Fallon). Receiving Exemestane (as approved by the Food and Drug Administration (FDA) on October 5, 2005); not receiving any
experimental treatment.
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NSABP B34 A Clinical Trial Comparing Adjuvant Clodronate Therapy vs. Placebo in Early Stage Breast
Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen of No Therapy
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SUBPROJECT DESCRIPTION:

This phase III prospective randomized, double-blind, placebo-controlled trial in women with early-stage breast cancer that will
evaluate the worth of clodronate, a second-generation bisphosphonate. Bisphosphonates have been shown to block the
breakdown of bones, and in one small open label study, had a beneficial effect on bone metastases in patients with breast cancer.
This study's primary aim is to determine whether 1600 mg/day of clodronate administered for 3 years, whether alone or in
addition to adjuvant chemotherapy and/or hormonal therapy will improve disease-free survival. This study will also evaluate
whether adjuvant clodronate results in a reduction in the incidence of skeletal metastasis, skeletal-related morbidity,
non-skeletal metastases, and an improvement in relapse-free survival and overall survival. To qualify for this trial, women must
have undergone either a total mastectomy or a lumpectomy with either an axillary dissection or sentinel node biopsy. Patients
will be stratified according to age, nodal status and estrogen receptor (ER) and or progesterone receptor (PgR) receptor status.
Patients must have no evidence of metastatic disease. The administration of adjuvant chemotherapy and/or tamoxifen will be at
the discretion of the investigator. The exact regimen, dose and duration will be at the discretion of the investigator and is not
part of the study. It is the addition of either clodronate or placebo that is the subject of this study.
SUBPROJECT PROGRESS:

Locally: the University of Connecticut Health Center (UCHC) accrued 3 patients. All are alive and well and have not had
recurrence. The Hospital of Central Connecticut (THOCC) accrued 2 patients. One is alive and well. The other patient is deceased
as of 11/27/2007.
There have been 3 unexpected safety concerns with this study; however, they involved patients who were not enrolled in the
National Surgical Adjuvant Breast and Bowel Project (NSABP) B34 study. There are no proposed changes to the protocol at this
time. The Institutional Review Board (IRB) adverse event (AE) computer system reference numbers are: 3000, 3001, 3002.
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Testosterone Effects on Bone and Frailty in Men with Osteoporosis
Testosterone Effects on Bone and Frailty in Men with Osteoporosis
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SUBPROJECT DESCRIPTION:

Attention to osteoporosis has largely emphasized women's health, and little attention has focused on the diagnosis and
prevention of osteoporotic fractures in men. And yet the disease is also an important problem in men. Testosterone levels
decline with advancing age, and severe testosterone deficiency is associated with low bone mass and fracture. Several
epidemiologic studies suggest that low testosterone is associated with low bone mass in older men, but this finding is not
consistent. Men with hip fracture are found to be testosterone deficient more often than control subjects. Among men over age
70 with testosterone levels below the young normal range, we found differences in bioavailable testosterone accounted for 20%
of the variance in femoral neck bone mineral density (FN BMD) values. Additional predictors of FN BMD in this population
included body mass index and physical activity, two described parameters of frailty.
Based on these data, testosterone supplementation may be important for bone health and frailty in older men. We will test the
hypothesis that testosterone supplementation can increase bone mineral density in older men with hip fracture. We will also
evaluate the effects of testosterone on physical health and frailty.
SUBPROJECT PROGRESS:

The study is closed to recruitment. We are in the data analysis phase. We require continued support while preparing manuscripts.
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The Effect of Risedronate on Bone Turnover and Bone Mass in Older Men Receiving
The Effect of Risedronate on Bone Turnover and Bone Mass in Older Men Receiving Neoadjuvant Therapy
for Prostate Cancer
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SUBPROJECT DESCRIPTION:

This proposal will examine a therapeutic intervention with risedronate in a population of men at high risk for bone loss.
Carcinoma of the prostate gland is the most commonly diagnosed cancer in U.S. men, and is the second leading cause of cancer
death. Over the last decade, more and more men are being treated with hormonal suppression therapy for locally advanced
disease. Recent studies have shown that such hormonal suppression with Luteinizing Hormone Releasing Hormone (LHRH)
agonists leads to rapid bone loss and increased risk of osteoporotic fractures (1). The increased incidence of hip fractures and
other fragility fractures in older men is a major public health issue. Hip fractures are costly, increase mortality and significantly
compromise the independence and quality of life of the survivors. The potential for compounding this problem in men treated
with hormonal suppression for locally advanced prostate carcinoma is the rationale for this study.
SUBPROJECT PROGRESS:

There were 6 more subjects enrolled in the above time period. We closed the study for recruitment in the above time period. The
data is currently being analyzed by a statistician and manuscript preparation is underway.
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Transdermal vs Oral Estrogen Therapy on Adolescents with Turner's Syndrome
Effect of transdermal vs oral estrogen therapy on achieving near final adult height and near peak bone mass
in growth hormone treated adolescents with Turner Syndrome
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YIGIT, SEVKET MD

PEDIATRICS

CONNECTICUT CHILDREN'S MEDICAL,
CT USA

ALLEN, HOLLY MD

PEDIATRIC ENDOCRINOLOGY

BAYSTATE MEDICAL CENTER, MA USA
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PEDIATRICS

UNIVERSITY OF NORTH CAROLINA, NC
USA

RUBIN, KAREN MD

PEDIATRICS

CONNECTICT CHILDREN'S MEDICAL, CT
USA

SUBPROJECT DESCRIPTION:

Estrogen replacement in Turner Syndrome (TS) is accomplished most commonly using estrogen preparations. Based on
preliminary data we hypothesize that transdermal vs. oral estradiol will have more favorable effect on near final adult height
(FAH) and near peak bone mass (PBM) in growth hormone (GH) treated adolescents with TS. The aim of the study is to
evaluate the effect of transdermal vs. oral estrogen on growth and bone mass and their correlation with growth factor levels,
markers of bone turnover and sex steroid levels. This 2 year selectively randomized prospective study involves two treatment
groups: equivalent doses of oral vs. transdermal estradiol in combination with standard growth hormone therapy. The TS
adolescents ages 12-15 years will be selectively randomized to each group by bone age. Estrogen dose will be gradually increased
every 6 months over the two years in both groups mimicking normal puberty. With a sample size of 12 in each group and test
significance level of 0.05, we will have an 80% power to detect a 25% difference in growth of two groups. There is no
preliminary data in terms of bone mass to evaluate sample size estimation for signigicant difference between two groups.
Statistical analysis of outcome measures will be done with repeated measures analysis of variance.
SUBPROJECT PROGRESS:

4 subjects were enrolled in the study. There was no study activity in the reporting period. The study was terminated in the General
Clinical Research Center (GCRC) on 12/25/07.
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The SMART Study
A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (SMART)
for Human Immunodeficiency Virus (HIV) Positive Patients
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YALE UNIVERSITY, CT USA

SUBPROJECT DESCRIPTION:

The purpose of this study is to compare the long-term clinical consequences of two strategies of antiretroviral (AR)
management for the Human Immunodeficiency Virus (HIV): (1) the drug conservation (DC) strategy, a strategy aimed at
conserving drugs through episodic use of antiretroviral treatment for the minimum time to maintain CD4+cell count x 250
cells/mm^3 -versus- (2) the viral suppression (VS) strategy, a strategy aimed at suppressing viral load as much as possible,
immediately following randomization and throughout follow-up, irrespective of CD4+cell count.
The primary objective is to compare the DC group with the VS group for the following:
-Survival
-Incidence of major cardiovascular and metabolic complications
-Incidence of serious disease progression events
-Combined endpoint of clinical disease progression, major cardiovascular and metabolic complications, or death
-Grade 4 adverse events
-Self-reported changes in body appearance
-Prevalence at selected time points of multi-drug resistant (MDR) HIV, and rate of developing MDR HIV
-Adherence to antiretroviral treatment, averaged over follow-up
-Disease progression, death, and other outcomes
SUBPROJECT PROGRESS:

Seven subjects were enrolled, none within this reporting period. The study closed on July 11,2007. No further follow-up is planned.
Data from the trial has been presented and published. A final paper was published in the New England Journal of Medicine
355:2283-2296, 2006, which was reported in last year's annual report.
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NSABP B-31.1: Cardiac Function and Patient Characteristic Correlation
NSABP B-31.1: A Study to Determine the Correlation of Cardiac Function with Patient Characteristics and
Blood Markers in Women Enrolled in NSABP B-31
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SUBPROJECT DESCRIPTION:

This is a companion study to NSABP B31. This study, NSABP B-31.1, is designed to determine the usefulness of echo
cardiography (ECHO) in addition to multi gated acquisition (MUGA) scan in the monitoring of patients' cardiac function. This
study offers an excellent opportunity to assess more subtle effects of Herceptin on cardiac function and serum markers. More
sensitive and precise measures of Herceptin's cardiac effects may provide important information for early detection and risk
stratification of a patient's cardiac characteristics, which in turn may allow the application of preventive measures.
The primary aim of this companion study is to evaluate Herceptin-associated abnormalities via echo cardiographic ally
obtained parameters that indicate diastolic dysfunction and correlate these abnormalities with baseline patient characteristics to
determine whether such correlations predict which patients are at greatest risk of developing cardiac dysfunction when treated
with Adriamycin and cyclophosphamide (AC), followed by Taxol plus Herceptin as part of NSABP B-31.
The secondary aim of this companion study is to determine whether abnormal levels of brain natriuretic peptide (BNP),
troponin- T (TnT), troponin-I (TnI), tumor necrosis factor-alpha (TNF- cx), interleukin-1 beta (IL-1fJ), or interleukin-6
(IL-6) correlate with echocardiographic abnormalities that reflect myocardial damage in patients receiving AC followed by
Taxol with Herceptin and whether any of these blood markers can serve as early predictors of cardiac dysfunction in this
adjuvant setting.
The tertiary aim of this companion study is to evaluate the concordance of left ventricular ejection fraction (L VEF) results
measured by MUGA and by ECHO.
The changes in echocardiographic parameters and blood markers will be compared longitudinally in B-31 group 2 patients who
will receive Herceptin as well as compared laterally with group 1 patients who will not receive Herceptin. Because this research
is exploratory in nature, none of the results obtained from a patient's ECHOs or blood markers will be made known to the
patient or her investigator. The data analysis will be descriptive and numerous possible relationships will be considered. A total
of 220 B-31 patients will be enrolled. Patients enrolled in B-31.1 are subject to all eligibility criteria defined in NSABP B-31.
SUBPROJECT PROGRESS:

1 patient was accrued at The Hospital of Central Connecticut (THOCC). She is alive and well, no recurrences, Adverse Events
(AE's) or new primaries.
The progress notes for this reporting period remain the same as those from the last: 1 patient enrolled, who is in long term
follow-up and doing well. This study is closed to accrual therefore there is no recruitment plan at this time. There are no
anticipated changes to the protocol and no unexpected safety concerns.
There are no publications that have cited the General Clinical Research Center (GCRC).
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Dendritic Cells (DC) Crosstalk
DC-Th Crosstalk in Cytotoxic T Lymphocytes (CTL) Responses to Mart-1

AIDS:

N

START DATE:

Final

TOTALS

4/25/2002

Total # pts expected for entire study:

12

Inpatient

A
0

B
0

D
0

Scatter Bed

0

0

0

Outpatient

0

0

0

Scatter RN Hours

0

0

0

Offsite Visits

0

0

0

RESEARCH BIONUTRITION

N

MULTICENTER STUDY

N

INFORMATICS CORE

Y

CLINICAL TRIAL

N

BIOSTATISTICIAN

N

CORE LAB

N

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

MUKHERJI, BIJAY MD

Medicine

CHAKRABORTY, NITYA G PHD

Medicine

HEGDE, UPENDRA MD

Medicine

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The major goal of this proposal is to test the hypothesis that Crosstalk in Cytotoxic T Lymphocytes (CTL) response against
human thioacetamide acid (TAA) induced by Dendritic Cells (DC)-based stimulation is subject to regulation by DC-Th
cross-talks. A better understanding of the rules of the engagement of DC-Th cross-talks that govern the generation and the
control of anti-TAA CTL response will have a major impact in DC-based vaccine design.
SUBPROJECT PROGRESS:

This study is in the process of competitive renewal. We did not recruit any subject in the last year. We were conducting analysis
and going through renewal preparation.
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The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C)
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SUBPROJECT DESCRIPTION:

The purpose of this study is to conduct a randomized, controlled trial to determine if long-term interferon therapy can
reasonably reduce the risk of histologic progression to cirrhosis, decompensated liver disease and/or hepatocellular carcinoma in
patients with chronic hepatitis C and advanced fibrosis or cirrhosis who failed to respond to previous interferon therapy.
Specific aims: 1) To determine if 4 years of interferon therapy will prevent progression of advanced fibrosis to cirrhosis in
patients with chronic hepatitis C who failed previous interferon treatment; 2) to determine if 4 years of interferon therapy, in
patients with cirrhosis secondary to chronic hepatitis C who failed previous interferon treatment, will a) reduce the risk of
developing hepatic decompensation; b) reduce the need for hepatic transplantation; c) reduce the risk of developing
hepatoceullar carcinoma; and 3) To determine if 4 years of interferon therapy will improve the quality of life in patients with
advanced fibrosis or cirrhosis secondary to chronic hepatitis C who failed previous interferon treatment.
Approximately 1200 patients (at all centers) who meet the inclusion/exclusion criteria will be entered into a Lead-in
Phase. They will be treated with a combination of Peginterferon alfa-2a and ribavirin for a period of 24 weeks. Patients who
have no detectable Hepatitis C Virus (HCV)Ribonucleic Acid (RNA) at week 20 will continue on combination therapy until week
48. Patients who do not clear virus will be randomized 50:50 at week 24 to receive either Peginterferon alfa-2a alone or no
further therapy for the next three and a half years. Both randomized groups will be monitored quarterly during these 42 months
and biopsies will be obtained at 24 and 48 months after the start of the Lead-in Phase. An estimated 800 patients will be
evaluable at the conclusion of the trial.
SUBPROJECT PROGRESS:

Enrollment closed in 2003. We enrolled 37 patients. The target for enrollment was exceeded and nationally there were 1382
patients enrolled in the study. The Halt-C Trial was extended until October 2009 to add an observational period of time in which
to gather further data on the natural history of hepatitis C. All patients finished study drug as of January 2007 and most are now in
the Halt-C extension/observational part of the trial. The Data Safety Monitoring Board (DSMB) last met in June, 2007, and voted
unanimously to continue the Halt-C Trial. There were no safety concerns identified. A total of 11 patients continue to be seen
every six months at the University of Connecticut Health Center's (UCHC) General Clinical Research Center (GCRC). Other
patients have died or been transplanted, have moved away, have elected to leave the study, or have elected to have continuing
follow-up performed at another clinical center.
The main results of the Trial are that long-term, low-dose pegylated interferon is NOT of benefit in patients with advanced
chronic hepatitis C. Rather, it is important for us to find better ways of treating and curing the chronic viral infection. This result
was presented in Nov, 2007, at the annual meeting of the American Association for the Study of Liver Diseases, and the full paper
describing the results has been submitted to The New England Journal of Medicine. We anticipate final acceptance of a revised
version, but this cannot yet be guaranteed. There have been a number of publications that have appeared or been accepted during
2007--2008, all of which have cited the University of CT Health Center's GCRC, and all of which have already been transmitted to
the Administrative Office of the GCRC [Lisa Godin and Lesley Mancini].
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Feasibility of SH2 Domain Profiling
Feasibility of Src Homology 2 (SH2) Domain Profiling as a Molecular Diagnostic Tool for Patients
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SUBPROJECT DESCRIPTION:

There is a need for molecular diagnostic tools that will allow the classification of tumors beyond what is currently possible using
standard techniques. Ideally markers will be identified that will have prognostic value (correlate with response to particular
treatments, for example). Expression profiling using cDNA microarrays is now being tested for this purpose, but is at present
cumbersome, costly, and is unlikely to give any information about the molecular defects in the tumor cell. We are developing a
novel molecular diagnostic technique based on the profile of proteins in a tumor sample that bind to certain protein domains
known to play an important role in signal transduction. In preliminary experiments this technique can identify different
binding profiles in hematological malignancies, suggesting it may be a valuable molecular diagnostic tool. The resulting profiles
may also be informative about the molecular defects in a particular tumor. To date we have not tested the method on solid
tumor samples. We propose to test this technique on samples of breast cancers available at the UCHC to establish the
feasibility of implementation on a larger scale. Ultimately, if the technique is sufficiently robust and reproducible, we will
correlate profiling data with patient information to determine whether the interaction profiling provides information with
prognostic value.
SUBPROJECT PROGRESS:

No new patients were enrolled in this study in the past year. Because of ongoing difficulties in recruiting subjects, and changing
research priorities, this study was officially closed on 3/31/08.
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Soy and Isoflavones
The Effect of Soy Protein and Isoflavones on Bone on Older Women
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Center on Aging
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NON-HOST INSTITUTION: STATE,
COUNTRY

UCONN - STORRS, CT USA

SUBPROJECT DESCRIPTION:

Osteoporosis is a disease that primarily affects older women in the United States. Epidemiological studies report decreased hip
fracture incidence in Asian countries where the population ingests larger amounts of soy than is contained in the average US
diet. Recent data suggest that soy intake is correlated with bone mineral density in Asian women. Soy foods are rich sources of
isoflavones and these compounds may be responsible for the health benefits of soy. Although epidemiological and preliminary
cross-sectional data suggest that soy may be beneficial to bone (1,2), few well-controlled clinical trials have been completed to
adequately test this theory. Many women in the United States are demanding more 'natural' treatments for chronic diseases and
a substantial proportion of women are already consuming more soy products or using isoflavone supplements. However, it is
unclear if these practices are beneficial to postmenopausal women. We hypothesize that isoflavones and soy protein will have a
beneficial effect on bone in older women compared to control protein. Further, we hypothesize that there will be an additional
benefit to bone in women who receive soy protein plus isoflavones compared to control protein or soy protein alone. In order
to test these hypotheses we propose an 1-year nutrition intervention study in women over age 65 years in which the main
outcome measures will be biochemical markers of bone turnover, quality of life, bone mineral density.
SUBPROJECT PROGRESS:

The study was completed in August 2005. 99 women completed. Presently we are analyzing data and preparing manuscripts. There
were no safety concerns. There is no interim data. We will still need General Clinical Research Center (GCRC) support for ongoing
laboratory analysis and statistical assistance.
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Pilot Study of the Relationship Between Diabetes, History of Depression, and Coronary Heart Disease
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WAGNER, JULIE PHD

Behavioral Sci & Comm Hlth

SEIP, RICHARD PHD

PREVENTIVE CARDIOLOGY

HARTFORD HOSPITAL, CT USA

THOMPSON, PAUL MD

PREVENTIVE CARDIOLOGY

HARTFORD HOSPITAL, CT USA

SUBPROJECT DESCRIPTION:

Diabetes and depression both independently put women at increased risk for coronary heart disease (CHD). Thus, a better
understanding of how these risk factors interact is crucial to our understanding of heart disease in women. One hypothesized
mechanism for the depression-diabetes-CHD relationship is the Hypothalamic-Pituitary-Adrenal (HPA) axis and cortisol
production. Currently, no data have been published that look at these variables in concert. Thus, it is unclear if they each
convey an individual risk that becomes additive when combined, or if they interact to convey multiplicative risk.
The study being proposed is a cross sectional study of depression, diabetes, and CHD risk in women. The research design is a
2X2 factorial design. The sample will consist of 80 age-matched postmenopausal women. The independent variables are 1)
presence of a history of depression (yes or no), and 2) T2DM status (yes or no). The dependent variables are salivary cortisol
levels, lipids (total cholesterol, HDL subfractions, and triglycerides), waist-to-hip ratio, brachial artery flow mediated dilation,
hemostatic indicator (vWF), inflammatory marker (c-reactive protein), microalbuminuria, and blood pressure. Variables that
will be controlled for include BMI (Bone Mass Index), lipid lowering agents, beta blockers, ACE inhibitors, antihypertensive
agents, and history of smoking, physical activity, and alcohol use.
Three hypotheses will be tested: 1) There will be a main effect for diabetes, such that participants with diabetes will show higher
WHR, blood pressure, vWf, C-Reactive Protein (CRP), dyslipidemia, microalbuminuria, and more impaired endothelium
dependent brachial reactivity (EDBR) than those without diabetes; 2) There will be a main effect for history of depression, such
that participants a positive history will show higher WHR, blood pressure, vWf, CRP, microalbuminuria, more impaired EDBR,
and a flatter cortisol pulsatile circadian rhythm than those with a negative history; 3) there will be an interaction between
history of depression and diabetes, such that participants with both diabetes and positive history of depression will show higher
WHR, blood pressure, vWf, CRP, and more impaired EDBR, than those with only history of depression or diabetes.
SUBPROJECT PROGRESS:

From 4/1/2007 until 3/31/2008, 18 women enrolled. One was found to be ineligible during the first visit and excluded from
participation, for a total of 17 eligible participants during this period. Since initiation of the study, 150 subjects have enrolled and
122 have been eligible and able to fully participate (25 women were excluded from the study after an Informed Consent Form (ICF)
was collected and during first visit data collection). This was because it was discovered during first visit that they did not meet set
criteria to complete the study. Three withdrew from the study due to health reasons (unrelated to the study).
Modifications to the project approved by IRB this year include: 1) Hartford Hospital (HH) was removed as a collaborator on this
study due to changes in their staff and inability to run subjects. All references to HH were removed. Dr. Paul Thompson was
removed as a co-investigator. 2) Dr. Mallareddy completed her fellowship and is no longer employed by the University of
Connecticut Health Center (UCHC). Dr. White (currently a co-investigator) took over her study responsibilities, 3) A change in
protocol adding a mental stress challenge, additional flow mediated dilation assessments, and additional blood samples, 4) Change in
Protocol for subset of participants for an Expressive Writing Intervention***the General Clinical Research Center (GCRC) HAS
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THIS UNDER A SEPARATE STUDY NUMBER 657, 5) Changes have been made to the ICF and protocol to reflect the above
modifications. A separate ICF, Part B has been submitted for the Expressive Writing Intervention. This ICF is part of GCRC study
657. There were no unexpected safety concerns for this study
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Inhaled Nitric Oxide for the Prevention of Chronic Lung Disease
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SUBPROJECT DESCRIPTION:

Inhaled nitric oxide (iNO) therapy is a safe and effective treatment for term newborns with persistent pulmonary hypertension
of the newborn and hypoxemic respiratory failure. However, little is known about the potential role of iNO in premature
newborns with respiratory failure. The premature newborn is particularly susceptible to the adverse effects of ventilator-induced
lung injury, oxygen toxicity, and lung inflammation which contribute to the development of chronic lung disease (CLD).
Despite treatment with exogenous surfactant and steroids, CLD remains a major cause of morbidity and mortality in premature
newborns. Moreover, there is increasing evidence that steroid treatment causes long-term adverse neurodevelopmental and
cardiopulmonary sequelae.
Early clinical observations suggest that low-dose iNO improves oxygenation and decreases the need for mechanical ventilator
support in the premature infant. In addition to its effects on gas exchange, recent laboratory and clinical observations suggest
that iNO may also act as a lung-specific anti-inflammatory treatment and reduce the contribution of lung inflammation to the
evolution of acute and chronic lung injury in premature infants.
SUBPROJECT PROGRESS:

There were a total of six patients enrolled at this site since initiation of this study. It is a multi-center study. Enrollment is
complete and the study is now in the follow-up phase. One patient was lost to follow-up so we are following a total of five patients.
During the report period, we will see the infants at their age three visits. One final visit will be done as part of the study at age four
and one half. There are no changes anticipated to the protocol nor have there been any unexpected safety concerns identified.
No interim data available. There have been no publications submitted from this site. There have been publications from the
primary site referencing the study.
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Effects of Oral Estradiol Therapy on Osteoclastogenesis
The Acute Effects of Oral Estradiol Therapy on Osteoclastogenesis in Hypogonadal Older Men and
Women: A Pilot Study
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SUBPROJECT DESCRIPTION:

Our understanding of the mechanisms by which estrogens regulate bone cells are incomplete. This process is important because
estrogen loss by women after menopause and probably in hypogonadal men produces a relatively rapid decrease in bone mass
and predisposes susceptible individuals to the development of the disease osteoporosis. This translational project is the result of
a collaboration between basic and clinical scientists at the University of Connecticut Health Center (UCHC) whose work focuses
on the identification of the mechanisms by which human beings develop the disease osteoporosis. Our specific goal in this pilot
project is to examine the differences in cellular and molecular changes that occur in the bone marrow of sex steroid-replete and
deficient older men and postmenopausal women in response to estrogen, as preliminary data in mice demonstrates the
importance of this hormone.
In preliminary work we have found that ovariectomy in mice is rapidly followed by an increase in the ability of bone marrow
cells to differentiate into osteoclasts, the cells that mediate bone resorption. This finding suggests that regulates the ability of
hematopoietic precursor cells to differentiate into osteoclasts, a process that has not been adequately examined. Since increased
rates of bone resorption appear to be the earliest known effects of estrogen withdrawal on the human skeleton, a better
understanding of this process may lead to more effective therapies for the treatment of osteoporosis in both men and women.
Specific Aim 1:Examine the osteoclastogenic potential of each of these three groups of older men by evaluation of bone
marrow aspirates both before and after treatment with Estrogen (E2).
Specific Aim 2: Examine parameters of B-lymphocyte lineage development and osteoclast formation in cells from bone marrow
including markers of B-lymphocyte lineage development, and the percentage of early and mature B-lymphocytes in the bone
marrow before and after E2 treatment. These studies will also evaluate the ability of fractionated (CD19+ and CD19-) bone
marrow cells to form osteoclasts-like cells in vitro with and without treatment with receptor activator of NF-kappa B-ligand
(RANKL) and monocyte- colony stimulating factor (M-CSF).
Specific Aim 3: Examine the expression in the bone marrow of factors known to influence osteoclast formation including
messenger ribonucleic acid (RNA) for RANKL, receptor activator of NF-kappa B (RANK), osteoprotegerin (OPG), M-CSF and
the M-CSF receptor (c-Fms). We will also measure protein levels of RANK and c-Fms by flow cytometry.
SUBPROJECT PROGRESS:

Study is not actively recruiting
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SUBPROJECT DESCRIPTION:

Although medications are first-line treatment for smoking cessation in adults (1), and 30-40% of obstetricians prescribe or
recommend over-the-counter nicotine replacement therapies for smoking cessation during pregnancy (2,3), little information
on the efficacy or safety of these products is available for pregnant smokers. We propose a randomized, placebo-controlled,
clinical trial to assess the utility of nicotine gum for smoking cessation during pregnancy. Subjects for this trial will be recruited
from a large prenatal clinic in Hartford, Connecticut. This clinic serves an indigent population with a smoking rate of 29%. In
addition to testing the efficacy and safety of the intervention, we will examine predictors of response among the women and we
will conduct an analysis of maternal genetic factors that can augment the adverse effects of smoking on the fetus.
The specific aims of this study are: to compare the efficacy of nicotine gum or a matching placebo for smoking cessation
among pregnant smokers. To examine whether nicotine versus placebo gum reduces the number of cigarettes smoked per day
by pregnant smoker; to evaluate the safety of nicotine gum for smoking cessation during pregnancy. Specifically, we will
compare nicotine gum with placebo on overall nicotine exposure (as measured by salivary cotinine), overall tobacco exposure
(as measured by exhaled carbon monoxide and urinary alkaloids), and birth weight at the time of delivery; to identify factors
that determine which subjects benefit the most from the use of nicotine replacement therapy for smoking cessation during
pregnancy; and to examine the interaction between maternal smoking and allelic variation at two genetic loci (CYP1A1 and
GSTT1) on birth weight in a racially diverse sample of pregnant smokers. As an exploratory aim we will also evaluate the
interaction between smoking cessation and allele variations of other selected phase I and II genes of drug metabolism on birth
weight.
SUBPROJECT PROGRESS:

Since the initiation of the study we have had approximately 33 subjects enrolled in the pilot study and have randomized
approximately 194 subjects enrolled in the randomized trial. A paper has been written and sent to Obstetrics and Gynecology for
publication. We are awaiting a review.
The genetics substudy continues to run. We have recruited approximately 380 smokers and 200 never smokers. We also received
de-identified samples from Duke University (about 140 new id's) depending on how many of these deoxyribonucleic acid (DNA)
samples are useable, we are getting close to the goal of 565 pregnant smokers. We plan to recruit until Jan 2008 and conduct
follow-ups until July 2009.
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SUBPROJECT DESCRIPTION:

Adolescent smoking rates are higher than among adults. High teenage smoking rates are due to increased smoking initiation
rates in young persons and low success rates of adolescent smoking treatment programs. Low success rates may result from
treatments focusing on the long-term health risks of smoking, and adolescents being less concerned about these risks. In order
to optimize smoking treatment in adolescents, the Centers for Disease Control recommends that programs emphasize the
immediate health benefits of smoking cessation (i.e., improved lung function, whiter teeth, better smelling breath).
Unfortunately, these health benefits may not be meaningful enough for adolescents to quit smoking. Other potentially
persuasive benefits of smoking cessation, such as the effects of smoking cessation on bone remodeling, have yet to be fully
explored. This information holds promise to be beneficial for smoking treatment (especially in adolescent boys) if it can be
presented in terms of maximal bone strength and height potential. It also may provide useful information on the effects of
smoking cessation for osteoporosis prevention and treatment, which may motivate the public health community to invest more
dollars to combat the epidemic of teenage smoking. The specific aims of this study are to determine the effects of smoking
cessation on biochemical markers of bone turnover in adolescents and to elucidate the potential mechanisms by which smoking
could affect bone turnover by measuring plasma cotinine concentrations and hormone profiles.
SUBPROJECT PROGRESS:

All subjects have been enrolled. There have been no new subjects enrolled in the report period. We plan to analyze the data this
year. No unexpected safety concerns--this is a low risk study. No publications to date.
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SUBPROJECT DESCRIPTION:

The only specific genes known to affect risk for alcohol dependence (AD) are some of those coding enzymes important for
ethanol metabolism. Promising linkage regions have been identified in two genome scans, but for genetically heterogeneous
disorders (like AD), strategies that rely purely on linkage in the absence of disequilibrium for gene localization are likely to be
insufficient for gene discovery. Linkage disequilibrium (LD) studies, using methods such as the transmission-disequilibrium test
(TDT) (Spielman et al., 1993), provide a possible solution, and delineation of the properties of these methods has been the
subject of many recent studies. These methods address the gene localization shortcomings of linkage designs.
LD studies are complementary to conventional linkage approaches, but to be applied, they require specialized clinical materials,
collected under rigorous ascertainment conditions. Our proposed sample will be recruited through affected probands and not
conditioned on affection of more than one family member (although making use of multiple affecteds when available), and will
be more representative of alcoholism in the target population than samples recruited based on multiple affecteds in each family.
We will increase our chance of success by applying a novel approach to sample collection: we will specifically target the
African-American (AA) population, a recently admixed population.
Extensive regions of LD in AA populations have been demonstrated by Lautenberger et al. (2000); our data support LD to >7
cM in AAs recruited in Connecticut. While most project resources will be allocated to sample collection, we will also study a
series of markers mapped to regions showing statistically significant linkage to AD in prior studies, and we will seek new markers
in these regions and candidate loci.
SUBPROJECT PROGRESS:

We recruited 3 participants for this study between 3/31/07 and 4/1/08. We recruited a total of 967 subjects (261 control and 706
affected individuals) in the study since its initiation. The study was closed to enrollment 4/2007. Data anaysis still continues and
we are in the process of applying for renewal.
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Lower-Cost (Human Immunodeficiency Virus) HIV Contingency Management in a Group Setting

AIDS:

Y

START DATE:

TOTALS

10/24/2002

Total # pts expected for entire study:

172

Inpatient

A
0

B
0

D
0

Scatter Bed

0

0

0

Outpatient

4

0

0

Scatter RN Hours

0

0

0

84

0

0

Offsite Visits

RESEARCH BIONUTRITION

N

MULTICENTER STUDY

N

INFORMATICS CORE

Y

CLINICAL TRIAL

N

BIOSTATISTICIAN

N

CORE LAB

N

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

PETRY, NANCY PHD

Psychiatry

CARROLL, KATHLEEN PHD

PSYCHIATRY

DIECKHAUS, KEVIN MD

Medicine/Infectious Diseas

NON-HOST INSTITUTION: STATE,
COUNTRY

YALE UNIVERSITY, CT USA

SUBPROJECT DESCRIPTION:

Voucher contingency management (CM) interventions are efficacious in enhancing retention in treatment and reducing drug
use, but they have not been implemented widely in community-based programs. A lower-cost CM procedure, that provides
opportunities to win prizes ranging in value from $1 to $100, shows efficacy in retaining substance abusers in an HIV drop-in
center (Petry et al., 2001), as well as in reducing substance use in traditional, community-based treatment programs (Petry et
al., 2000; Petry & Martin, in press).
The purpose of this study is to evaluate the efficacy of this CM technique in enhancing attendance, reducing drug use, and
improving health among clients attending (Human Immunodeficiency Virus) HIV drop-in centers. Specifically, 172 clients will
be randomly assigned to one of two 6-month treatment conditions: standard 12-step oriented group treatment, or CM group
treatment. In the CM group, clients earn the chance to win prizes for submitting clean urine specimens and for complying with
steps toward their treatment goals. Activities related to improving health will be emphasized, such as attending medical
appointments, recording daily medication consumption, getting prescriptions filled, and attending medication adherence support
groups. Group attendance, drug use, medical problems and services received, and risky drug use and sexual behaviors will be
measured pre-treatment, at months 3 and 6, and at 9- and 12-month follow-up evaluations.
Compared to the control condition, we expect that those assigned to the CM condition will show greater retention in treatment,
reductions in drug use, improvements in health, and decreases in risk behaviors. This study represents an important extension
of our previous and ongoing work in low-cost CM in that it involves a specific population of substance abusers (HIV-positive),
expands our work to non-traditional, community-based settings (drop-in centers), and implements the CM approach in a group
(rather than individual) format.
SUBPROJECT PROGRESS:

Total Enrollment: 172
Past Year Enrollment: 0
No changes in recruitment plans are needed (enrollment is complete).
•
No unexpected safety concerns have occurred.
•
Interim data and outcomes are not available.
•
No changes were made to the protocol and none are anticipated.
•
Results not yet published as study is ongoing.
Do you wish to continue to receive GCRC resources for the period April 1, 2008 through March 31, 2009? No, study is completed
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Mu-Opioid Receptor Polymorphism and HPA
Examination of the Dose Effect of a Functional Polymorphism at the Mu-Opioid Receptor Locus
(OPRM1) and Hypothalamic-Pituitary-Adrenal (HPA) Axis Activation
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COVAULT, JONATHAN MD, PHD

Psychiatry

DEMARTINIS, NICHOLAS MD

Psychiatry

KRANZLER, HENRY MD

Psychiatry

Phase II-III

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Individuals with the variant form of the A118G (Asn40Asp) polymorphism in exon 1 of the m-opioid receptor gene (genetic
locus OPRM1) appear to have a greater cortisol response to opioid blockade after naloxone administration. This study will
examine whether there is a dose-effect relationship between the presence of the variant Asp40 allele and HPA axis activation
by opioid blockade. Additionally, we will examine the relationship between Asn40Asp alleles and measures of anxiety, distress,
and cardiovascular reactivity following the naloxone challenge.
METHODS: The study will employ a balanced, within-subject design involving two test days over a period of 3-7 days to
examine cortisol response to intravenous naloxone (125 mcg/kg) or placebo in 36 healthy subjects (12 subjects in each of the
three genotypic groups: Asn40 homozygotes, heterozygotes and Asp40 homozygotes). Deoxyribonucleic acid (DNA), isolated
from whole blood will be POlymerase chain reaction (PCR)-amplified and genotyped using artificial restriction sites, restriction
enzyme digestion and agarose gel size fractionation. Plasma cortisol will be measured at 15-minute intervals over 120 minutes
post infusion.
SUBPROJECT PROGRESS:

1) Number of subjects enrolled during the report period: none. Since initiation of study: 43.
2) Planned changes in recruitment plans: The study has been closed for enrollment since November 2005, the last subject ended
participation in December 2005.
3) Unexpected safety concerns and their resolution: None occurred.
4) Interim data: The OPRM1 Asn40Asp was unexpectedly found to associate with cortisol reponse only in subjects of
European-American heritage. Large differences in genetic background may have large effects even on biologically functional
genetic variants such as the Asn40Asp coding polymorphism. The results of this analysis have been published during the past year.
5) Proposed changes made or anticipated in the protocol: None.
6) Continued GCRC support requested - We request the GCRC protocol remain active with the potential request for additional
genotyping of the study participants at additional candidate loci related to regulation of the Hypothalamic-pituitary-adrenal (HPA)
axis.
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Discovery and Assessment of Genetic and Environment
Discovery and Assessment of Genetic and Environmental Factors that Influence Severity and Progression
of Hepato-Biliary Pancreatic Disease and Cancerµ-Opioid Receptor Polymorphism and
Hypothalamic-Pituitary-Adrenal (HPA) Axis Activation
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Psychiatry

COVAULT, JONATHAN MD, PHD

Psychiatry

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Host genetic, acquired factors and environmental influences affect the development, severity, progression, and outcome of
many chronic diseases, including hepato-biliary-pancreatic diseases. To facilitate the discovery of new genetic factors that
influence development or progression of chronic diseases, we need to develop tissue and Deoxyribonucleic acid (DNA) banks and
correlate results of polymorphisms and mutational analyses (genotypes) with patient and clinical characteristics (phenotypes).
To provide the necessary databases for such studies, we need to build-up clinical databases and tissue and DNA banks. This
project is designed to accomplish this for patients with hepato-biliary diseases seen at UConn who will be undergoing liver
biopsies for reasons unrelated to this study. We expect the database and specimen repository thus developed will allow us to
perform important and informative new analyses, and will form the basis for new grant and contract applications in the future.
It will serve as a paradigm for other studies in other diseases and disorders. The potential is great for studies of the kind. We
need support from the GCRC cores in order to get these initiatives off to a successful start.
SUBPROJECT PROGRESS:

There were no subjects enrolled during the report period. There are a total of 142 subjects enrolled. There are no changes to
recruitment at this time there are no unexpected safety concerns at this time there have been no publications at this time
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SH2 Profiling
Feasibility of Src Homology 2 (SH2) Profiling as a Molecular Diagnostic Tool for Patients with
Hematological Malignancies
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MAYER, BRUCE PHD

Genetics & Dev. Biology

BONA, ROBERT MD

Medicine/Hem-Onc

LI, ZIHAI MD, PHD

Ctr for Immunotherapy

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

There is a need for molecular diagnostic tools that will allow the classification of tumors beyond what is currently possible using
standard techniques. Ideally, markers will be identified that will have prognostic value (correlate with response to particular
treatments, for example). Expression profiling using Complementary Deoxyribonucleic acid (cDNA) microarrays is now being
tested for this purpose, but is at present cumbersome, costly, and is unlikely to give any information about the molecular defects
in the tumor cell. We are developing a novel molecular diagnostic technique based on the profile of proteins in a tumor sample
that bind to certain protein domains known to play an important role in signal transduction. In preliminary experiments this
technique can identify different binding profiles in similar tumor types, suggesting it may be a valuable molecular diagnostic tool.
The resulting profiles may also be informative about the molecular defects in a particular tumor. We propose to test this
technique on samples from hematopoietic malignancies available at the UConn Health Center to establish the feasibility of
implementation on a larger scale. Ultimately, if the technique is sufficiently robust and reproducible, we will correlate profiling
data with patient information to determine whether the interaction profiling provides information with prognostic value.
SUBPROJECT PROGRESS:

No patients were enrolled in the past year, and a total of 57 have been enrolled over the course of the study to date. In
consultation with General Clinical Research Center (GCRC) staff and leadership, we have decided to transfer coordination of this
study to the Neag Cancer Center. This will make more sense in terms of logistics, as Cancer Center staff and nurses are on the
appropriate wards continuously and can identify and consent subjects more easily.
This study was closed in the GCRC as of 3/31/08.
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Iron
The Role of Iron, Hemochromatosis Gene (HFE) Mutations, and Polymorphisms of other Genes in Chronic
Hepatitis C (CHC)
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LAMBRECHT, RICHARD PHD

Pharmacology & Toxicology

WALSH, STEPHEN J SCD

Ctr for Biostatistics

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The success of the human genome project provides the promise of a new era in understanding and modifying human disease. It
seems both likely and feasible that, during the next generation, we will identify the major host genes and their genetic
variations, which modulate susceptibility to and severity of disease and responsiveness to medical therapies. To translate this
promise into reality will require careful clinical characterizations of different patient phenotypes, coupled with determination of
genotypes (genetic variations), gene expression information Messenger Ribonucleic Acid (mRNA's by microarrays, etc.), and
information about translation of mRNA's into proteins (proteomics). A few studies have already identified genotypes that
predict with greatly improved accuracy susceptibility to chronic vascular or neoplastic diseases and/or severity and outcome of
these diseases. This project will take full advantage of the samples and clinical data obtained through the landmark HALT-C
Trial, in order to develop a similar body of knowledge for chronic hepatitis C (CHC).
The long-term goal of this program is to ascertain the major genetic variations that predispose patients to develop advanced
CHC and/or lack of responsiveness to (Interferon) IFN-based treatment. We will concentrate our efforts on variations in
selected genes, which in previous smaller studies, have been shown to predict severity of CHC and/or responsiveness to IFN
treatment. Specifically, we will delineate the role of iron, HFE gene mutations, and/or polymorphisms in other selected genes
or gene promoters on the production and progression of CHC. Our major hypotheses are that hepatic iron, mutations of the
HFE gene associated with human leukocyte antigen (HLA)-linked hereditary hemochromatosis (HHC), and/or selected
polymorphisms in other genes, are important host factors that influence the progression of chronic hepatitis C to cirrhosis,
decompensation, and hepatocellular carcinoma and/or the response of CHC to IFN-based therapies.
The specific aims of this project are:
To determine whether there is a direct correlation between progression of chronic hepatitis C (i.e., the major endpoints of the
HALT-C Trial) and hepatic or total body iron content and/or the presence of the HFE gene mutations (C282Y, H63D, S65C)
associated with HHC;
To determine whether there are correlations between progression of chronic hepatitis C and polymorphisms of the
angiotensinogen promoter (Ang-P), apolipoprotein E (apo-E) genotype, the interleukin-I0 promoter (IL-10-P), microsomal
epoxide hydrolase (mEH), transforming growth factor-beta (TGF), or the tumor necrosis factor-alpha promoter (TNF-P);
To explore whether there are significant interactions among mutations of HFE, polymorphisms of other genes, and patients'
responses to therapy or long-term outcomes; and
To determine whether the frequencies of these genetic variations differ significantly among subjects in the HALT-C Trial vs
other subjects with less advanced CHC, or control subjects without CHC, matched for age, sex, and ethnicity.
SUBPROJECT PROGRESS:

There were no subjects enrolled during the current report period. There were 282 subjects enrolled since initiation.
There are no changes in recruitment plans that might be needed or unexpected safety concerns at this time.
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Data analysis going on currently.
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Radiation-Induced Oral Mucositis
Cyclooxygenase-2 (Cox2) Inhibition in Radiation-Induced Oral Mucositis

AIDS:

N

START DATE:

Final

TOTALS

1/16/2003

Total # pts expected for entire study:

10

Inpatient

A
0

B
0

D
0

Scatter Bed

0

0

0

Outpatient

0

211

0

Scatter RN Hours

0

0

0

Offsite Visits

0

0

0

RESEARCH BIONUTRITION

N

MULTICENTER STUDY

N

INFORMATICS CORE

Y

CLINICAL TRIAL

N

BIOSTATISTICIAN

N

CORE LAB

Y

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

LALLA, RAJESH BDS, PHD

Oral Diagnosis

DAMATO, KATHRYN L MS

Oral Diagnosis

DANNENBERG, ANDREW J MD

GASTROENTEROLOGY/HEPATO
LOG

DOWSETT, ROBERT J MD

Radiation Oncology

HEGDE, UPENDRA MD

Medicine

PETERSON, DOUGLAS DMD, PHD

Oral Diagnostics

SONIS, STEPHEN T DMD, DMSC

ORAL & MAXILLOFACIAL
SURGE

NON-HOST INSTITUTION: STATE,
COUNTRY

CORNELL UNIVERSITY, NY USA

DANA FARBER CANCER INSTITUTE, MA
USA

SUBPROJECT DESCRIPTION:

Oral mucositis refers to inflammatory, erythematous, erosive or ulcerative lesions of the oral mucosa seen in 60-90% of
patients undergoing radiation therapy for head and neck cancer to fields involving the oral cavity. These lesions are painful,
compromise nutrition and become secondarily infected. Hospitalization is required for pain control and nutritional support in
approximately 15% of cases. Further, severe oral mucositis can necessitate interruptions in radiation therapy thus
compromising cancer therapy. No agent is currently available to prevent oral mucositis or reduce its severity.
Available evidence implicates inflammatory responses to radiation therapy and to products of colonizing microorganisms in the
pathogenesis of oral mucositis. The use of anti-inflammatory agents in oral mucositis has not been well-studied. However, the
limited available data using non-steroidal anti-inflammatory drugs (NSAIDS) indicates that this is a promising approach. The use
of celecoxib, a selective Cyclooxygenase-2 (COX-2) inhibitor, in radiation-induced oral mucositis has not been previously
studied. Celecoxib offers several potential advantages in this setting as compared to conventional NSAIDS.
This pilot study is intended to generate preliminary data in preparation for submission to extramural funding sources. This
randomized, double-blind, placebo-controlled pilot study will evaluate celecoxib in ten subjects at high risk for developing
radiation-induced oral mucositis. Subjects will be randomized to 200 mg bid celecoxib or placebo (both by mouth) in a 1:1 ratio.
They will be asked to use the study medication daily starting 5 days before the first day of radiation therapy until 3 days after
the end of radiation therapy. The primary endpoint will be the investigator's evaluation of severity of oral mucositis using the
Oral Mucositis Assessment Scale (OMAS). OMAS scores will be compared between the two groups to assess the impact of
celecoxib on mucosal injury. The secondary endpoint will be evaluation of pain severity using the severity subscale of the Brief
Pain Inventory. Additional assessments will include evaluation of 1. medications used for pain management 2. normalcy of diet
3. type, dose, duration and fields of radiation therapy and 4. mucosal injury using the World Health Organization (WHO) and
Common Toxicity Criteria (CTC) mucositis scales.
Further, 2 mm punch biopsies of the oral mucosa will be obtained from consenting subjects in both groups at four time-points.
Levels of selected enzymes, prostanoids and receptors involved in the cyclooxygenase pathway will be measured. In addition, a
10 ml blood sample will be obtained from subjects in both groups at four time-points. These blood samples will be used to
measure levels of selected prostanoids generated via the cyclooxygenase pathway and of selected cytokines that induce COX-2
expression. Comparison between the two groups will allow assessment of the role of the cyclooxygenase pathway in radiation
mucositis and the impact of celecoxib. Correlations will be examined between levels of prostaglandins whose synthesis is
mediated by COX-2 and mucosal injury and pain in radiation-induced oral mucositis.
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This line of research could lead to the development of an agent to prevent or reduce the severity of oral mucositis. This would
substantially decrease morbidity in these patients. In addition, it may also improve patient prognosis by avoiding breaks in
cancer therapy.
SUBPROJECT PROGRESS:

Number of subjects enrolling during the report period: 3 and since initiation of the study: 10
Any changes in recruitment plans that might be needed: None
Unexpected safety concerns and their resolution: None
Interim data and outcomes if appropriate: None
Any proposed changes made or anticipated in the protocol: Currently, only patients who receive head and neck radiation therapy
with concurrent chemotherapy are eligible for the study. We have submitted a protocol modification request to the Institutional
Review Board (IRB) to allow patients who are receiving head and neck radiation therapy without concurrent chemotherapy to also
be eligible for the study.
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Keloid Formation
Molecular Mechanisms for Keloid Formation

AIDS:

N

START DATE:

Final

TOTALS

7/9/2003

Total # pts expected for entire study:

50

Inpatient

A
0

B
0

D
0

Scatter Bed

0

0

0

Outpatient

76

0

0

0

0

0

53

0

0

Scatter RN Hours
Offsite Visits

RESEARCH BIONUTRITION

N

MULTICENTER STUDY

Y

INFORMATICS CORE

Y

CLINICAL TRIAL

N

BIOSTATISTICIAN

N

CORE LAB

Y

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

REICHENBERGER, ERNST PHD

Biostructure and Function

GREENSTEIN, ROBERT MD

Pediatrics/Genetics

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The long-term goal of this study is to understand the molecular mechanisms of neoformation of dermal tissue in fibrotic
diseases. To achieve this goal we study hereditary keloid formation. Keloids are benign tumors of the skin or cornea caused by
overactivity of fibroblasts during abnormal wound repair. The relatively large number of familial cases of keloid formation
makes it possible to propose a genetic approach for the identification of a gene responsible for increased cell proliferation and
extracellular matrix expression. We perform genome wide screening and linkage analysis of suitably large families afflicted with
the autosomal dominant form of hereditary keloid formation. Subsequently we identify and analyze the chromosomal loci. We
have identified possible disease gene loci and are now in the process of establishing high resolution maps of the keloid loci.
Additional families need to be identified and recruited to verify and further characterize the loci. These families will be tested for
co-localization. Suitable families that do not co-localize to an existing locus will be used for genome wide screening.
SUBPROJECT PROGRESS:

Total number of patients enrolled as of 3/31/2008: 685
Current Year Enrollment: 124
Changes in recruitment plans: No changes needed.
Unexpected safety concerns and their resolution: None
Interim data and outcomes:
-We have enrolled 124 subjects during the reporting period.
-The General Clinical Research Center (GCRC)-sponsored pilot project for recruitment in Nigeria is highly successful.
-Preliminary mapping has been performed with a pilot grant from the GCRC.
Proposed changes made or anticipated in the protocol:
- We tested the families for consistency using Combined DNA Index System(CODIS) markers and for exclusion or linkage to
published keloid loci on chromosomes 7 and 2.
-Hepatocyte Growth Factor (HGF) was tested for mutations.
We will need to test more families for consistency in the coming period.
Publications: None
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Open Angle Glaucoma
Molecular Screening of Optineurin Gene in Patients with Adult-Onset Primary Open Angle Glaucoma
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SUBPROJECT DESCRIPTION:

Glaucoma is an optic neuropathy that affects over 67 million people worldwide. This condition has broad clinical manifestation,
possibly resulting from a significant genetic heterogeneity that exists within this group. Glaucoma is divided into many clinical
subtypes, ranging from onset at birth to very late in life. The most common form, Primary Open Angle Glaucoma (POAG) has
a prevalence of about 1% of a predominantly white population over 40 years of age. Several genetic loci have been identified
for POAG but so far only mutations in Myocilin gene are predominantly reported in juvenile-onset and certain other
adult-onset cases.
Recently, we identified a gene that is primarily involved in a subgroup of Adult-Onset POAG, commonly known as Normal
Tension Glaucoma (NTG). This gene that we named Optineurin (for "Optic Neuropathy Inducing" protein; OPTN) is mutated
in 16.7% of our hereditary NTG families. This gene maps to the GLC1E locus on 10p14 and has 13 coding exons that encodes
for a protein with 577 amino acids (~66-kDa). Our OPTN protein studies showed co-localization with Golgi, secretion into
aqueous humor and expression in many ocular and non-ocular tissues. Cloning of both mouse and monkey genes showed very
similar patterns of Messenger Ribonucleic Acid (mRNA) and protein expression to human OPTN. It has also been shown by
other investigators that OPTN interacts with Ad E3-14.7K, Huntington, TFIIIA, RAB8 and 2 other unknown kinases.
Although existing evidence suggests that OPTN, through its interaction with other proteins may be utilizing TNF-á or
Fas-Ligand pathways to mediate apoptosis, inflammation or vasoconstriction, as yet there is no clear indication on how OPTN
mutations lead to either NTG or POAG. Therefore, as an initial step towards understanding the function of this gene and its
protein products we propose to do the following: 1)-Screen a large number of glaucoma patients for OPTN mutations by
SSCP/DHPLC and Automated Deoxyribonucleic acid (DNA) sequencing to establish a firm genotype/phenotype correlation.
This specific aim will be done as a main part of this GCRC protocol. In a complementary study we plan to: 2)-Identify
promoter, its transcription start points, binding sites, regulatory elements and to study its activity and expression patterns; 3)
-Use OPTN as "bait" and search for new interacting proteins by a Yeast Two Hybrid System and to search for protein motifs
that are important for OPTN function; 4)-Determine ultracellular localization of OPTN in normal and glaucomatous eyes by
immunogold labeling; 5)-Study specific sites of localization of OPTN in normal and glaucomatous eyes by
immunohistochemistry and to determine its potential differential expression patterns; and 6)-Use In Situ hybridization to study
developmental expression patterns of OPTN in mouse embryos.
At the conclusion of this investigation, it is anticipated that our study will provide essential information that one day may
contribute to the design of innovative drug intervention in this group of optic neuropathies.
SUBPROJECT PROGRESS:

During the last year a total of 180 blood samples were processed by the General Clinical Research Center (GCRC) Molecular Core
Laboratory for Deoxyribonucleic Acid (DNA) extraction. Most of these were re-extraction of samples from patients that recruited
into the study in the prior years.
The number of participating patients has generally been much less than expected. There have been no changes to our active
recruitment of these patients for this study. However, despite the fact that our clinical collaborators are still actively recruiting
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patients for this study, the numbers of patients that volunteered for this study have been limited. There has been no safety concern
on any of the patients recruited during this time. The samples obtained and processed during the prior years will be analyzed
together with other samples that have been processed in our laboratory. We have not made any changes to our protocols and
anticipate that no changes are necessary to our current protocol for the upcoming year of this study.
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Targeted Naltrexone for Problem Drinkers
Targeted Naltrexone for Problem Drinkers

AIDS:

N

START DATE:

Final

TOTALS

1/16/2003

Total # pts expected for entire study:

200

Inpatient

A
0

B
0

D
0

Scatter Bed

0

0

0

109

0

0

Scatter RN Hours

0

0

0

Offsite Visits

0

0

0

Outpatient

RESEARCH BIONUTRITION

N

MULTICENTER STUDY

N

INFORMATICS CORE

Y

CLINICAL TRIAL

N

BIOSTATISTICIAN

N

CORE LAB

Y

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

KRANZLER, HENRY MD

Psychiatry

ARMELI, STEPHEN PHD

NON-HOST INSTITUTION: STATE,
COUNTRY

PACE UNIVERSITY, NY USA
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Community Medicine
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SUBPROJECT DESCRIPTION:

In the US, heavy drinking occurs commonly and is associated with a variety of alcohol-related problems. Available treatments
for problem drinking have limited efficacy. This proposal is for a 12-week, placebo-controlled trial of naltrexone (50 mg
orally) in 200 problem drinkers. Problem drinkers are those individuals whose drinking puts them at risk of a variety of
psychosocial and medical problems, including alcohol dependence, but who are not physically dependent on alcohol. They are
estimated to comprise up to 20% of the general population. The study will employ a factorial design in which the effects of
medication (naltrexone vs. placebo), schedule of medication administration (i.e., daily vs. targeted), and the interaction of these
factors on drinking behavior will be examined. Targeted administration refers to the use of medication to cope with anticipated
high-risk drinking situations. The primary outcome measures will be drinking days and heavy drinking days. Secondary
outcomes will include alcohol-related problems and biological measures of alcohol consumption (i.e., serum Gamma glutamyl
transpeptidase (GGTP) and Carbohydrate-Deficient Transferrin CDT).
The study will extend the results of a recently completed 8-week trial of targeted naltrexone in early problem drinkers. That
study showed a significant advantage of naltrexone over placebo on heavy drinking days and for targeted administration on daily
drinking. The effects of targeted administration diminished substantially over time, apparently due to the schedule that was used
for targeted medication administration.
In the proposed study, the targeted medication schedule has been modified, the sample size increased, the duration of treatment
lengthened and a pharmacogenetic analysis added to examine the effect of allelic variation at candidate loci on the response to
naltrexone. The daily monitoring of mood, desire to drink, perceived self-efficacy, and drinking behavior will make it possible
to examine in depth the processes by which the study variables exert their effects.
Daily monitoring will be performed using automated telephone interviews, with in-person follow-up evaluations conducted at 3
and 6 months post-treatment to provide a measure of the durability of treatment effects. A pharmacogenetic analysis based on
preliminary evidence showing that a functional polymorphism in the gene encoding the mu-opiate receptor (OPRM1) affects
response to naltrexone will serve to explore an important source of variation in the response to naltrexone treatment.
Exploratory analyses involving other the gene encoding the delta opioid receptor (OPRD1) will also be conducted. Careful
evaluation of the study hypotheses will provide important information on the efficacy and mechanism of the effects of targeted
naltrexone in problem drinkers. This study will allow us to model effects across multiple levels of analysis in an effort to apply
novel genetic findings to understanding the psychopharmacological mechanisms underlying the therapeutic effects of
naltrexone in problem drinkers.
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SUBPROJECT PROGRESS:

A total of 8 subjects were enrolled during the report period (a total of 192 since initiation of the study). Subject enrollment began
in January 2003 and was completed in May 2007. Of the 192 subjects enrolled, 29 subjects were excluded and were not randomized
to receive study drug (due to meeting exclusionary criteria, having out-of-range bloodwork results, or deciding not to participate).
A total of 163 subjects were randomly assigned to receive either naltrexone or placebo, administered on either a daily or a targeted
basis. Of the 163 subjects randomized to study treatment, 138 (85%) completed treatment and 25 (15%) withdrew early (5 due to
medication side effects, 7 due to lack of efficacy, and 13 due to other issues unrelated to study medication). The last treatment was
delivered in August 2007 and the last follow-up assessment was completed in March 2008.
Follow-up data at 3 and 6 months post-treatment are available for 142 (87%) and 138 (85%) of patients, respectively There were
no unexpected safety concerns associated with this study. This study used interactive voice response technology (IVR) for daily
data collection, with support from the General Clinical Research Center (GCRC). Compliance with the daily reporting of moods,
events, drinking, and medication usage approached 90% of days for subjects while in the study, and was about 80% for all possible
days, suggesting that data analysis will be able to proceed as planned.
Changes made in the protocol during the report period include the following: 1) addition of a statistician co-investigator (Grace
Chan);
2) due to a letter from the Office of Human Research Protections (OHRP), the study protocol was reviewed and modified (where
necessary) to cover the Deoxyribonucleic Acid (DNA)/genetic testing aspects of the study (including: an explanation of the
purpose of the DNA testing aspects of this research study and a description of the DNA tests to be run on the collected samples; a
description of any foreseeable risks and discomforts to the subjects regarding DNA testing; a description of any benefits to the
subject or others that may reasonably be expected from the DNA testing; and a statement describing the extent to which the
confidentiality of these records/samples identifying the subject will be maintained;
3) the protocol was modified to explain that DNA samples and phenotypic datasets will be de-identified before any examination of
genetic markers for risk of alcohol dependence is resumed (and a notification will be sent to the IRB once all DNA samples and
phenotypic data are completely de-identified);
4) protocol language was modified to reflect that women who become pregnant are withdrawn from the study;
5) removal of a co-investigator (Carlos Hernandez-Avila). There have been no recent publications associated with this study since
data analysis is ongoing.
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Recurrent Lyme Disease: Incidence, Pathogenesis and Clinical Outcome
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SUBPROJECT DESCRIPTION:

Lyme disease is the most frequently reported tick-borne infection in the United States. People who live in areas that are
endemic for Lyme disease are often repeatedly exposed to bites of uninfected as well as infected Ixodes ticks and recurrent
episodes of this infection have been reported. We found that about 14% of people experiencing Lyme disease on Block Island,
Rhode Island suffered recurrent infection and that subsequent episodes of infection were associated with fewer symptoms than
the initial infection. It is unclear whether a similar rate of recurrence and a milder clinical outcome during recurrent episodes
occur at endemic mainland sites. It is also unclear what prevents the majority of people from experiencing either initial
infection or recurrent infection when they are repeatedly exposed to Borrelia burgdorferi-infected ticks. Although immunity
against the causative pathogen probably helps limit recurrence, immune responses directed against the tick vector also may help
prevent initial and repeated infections. Our first two objectives are to compare frequency and clinical outcomes of recurrent
Lyme disease on Block Island and at mainland sites in southern New England and New York. Our third objective is to examine
relationships among immune responses to I. scapularis salivary gland proteins and protection against the development of
primary and recurrent B. burgdorferi infections. In particular, we propose three specific aims.
1. Determine whether the frequencies of primary and recurrent Lyme disease differ among residents of Block Island, RI and of
southern New England and New York.
2. Determine whether the acute symptoms of repeated episodes of Lyme disease are less severe than the initial episode of Lyme
disease.
3. Determine whether immune factors directed against the tick Ixodes scapularis are protective against B. burgdorferi
transmission and whether they correlate inversely with the incidence of primary and recurrent Lyme disease.
This proposed body of work will provide a basis for understanding the frequency and clinical outcome of recurrent Lyme disease
and how immune factors directed against the tick vector may limit the incidence of recurrent Lyme disease and other tick-borne
infections.
SUBPROJECT PROGRESS:

1. The number of subjects enrolled during the report period was 290.
2. The number of subjects enrolled since initiation of the study has been 2587.
3. No changes in recruitment plans have been needed.
4. There have been no unexpected safety concerns.
5. Interim data and outcomes have been summarized in the papers and regional/national talks listed below.
6. There were no proposed changes to the protocol during the reporting period; however, we are planning to submit National
Institute of Health (NIH) grants for babesiosis and Lyme disease diagnostic studies and a babesia immunity study during the next
reporting period. These will be collaborative studies with investigators from other universities. We plan to initiate pilot studies as
part of these studies this summer.
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Brief Focused Treatment for Temporomandibular Joint Dysfunction: Mechanisms of Action (TMD)
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SUBPROJECT DESCRIPTION:

Temporomandibular joint dysfunction (TMD)is a widespread chronic pain condition. A number of psychosocial treatments for
TMD have been developed that have been successful for a majority of patients. The mechanisms by which these treatments
achieve their effects, however, are not well specified. The general goal of the current study is to evaluate the cognitive,
behavioral, and physiological mechanisms of treatment to discover what accounts for treatment gains in this disorder. To do
this we will deliver to patients a brief cognitive-behavioral treatment designed to maximize adaptive cognitions and behaviors,
while periodically monitoring their pain, thoughts, feelings, and coping behaviors using an experience sampling paradigm.
Specifically the aims are as follows:
1. To evaluate the effects on TMD patients' pain and psychosocial functioning of a brief treatment that combines a standard
splint therapy with a focused cognitive-behavioral program (STD+CBT) intended to maximize coping self-efficacy and
minimize catastrophization in response to specific pain-related circumstances.
H1. It is hypothesized that patients exposed to the brief cognitive behavior treatment will have better outcomes than will a
group of patients given a standard conservative treatment based on splint therapy without cognitive-behavioral treatment.
2. To determine what situational factors and dispositional factors are predictive of general adaptation and pain perception
following TMD treatment.
H2. It is expected that both dispositional factors, and situational factors measured four times daily, will play a role in
predicting adaptation and pain following treatment.
3. To determine specifically what moods, cognitions and coping behaviors are changed as a result of treatment.
H3. It is predicted that patients in the STD+CBT treatment will exhibit increased numbers of specific coping behaviors,
improved mood, higher self-efficacy for pain control, and decreased frequency and intensity of catastrophization as measured in
real time, as compared to STD patients, and that these changes will be associated with treatment outcome.
4. To determine what effects treatment per se may have on measures of physiological stress and cell-mediated immunity.
H4. It is expected that, at the follow-up points, subjects in the STD+CBT group will have lower levels of plasma cortisol and
lower levels of proinflammatory cytokines than will the STD subjects.
5. To determine whether changes in treatment-related situational process variables such as self-efficacy are associated with
changes in cortisol and cytokine levels, suggesting that psychosocial treatments act partly by altering HPA axis and
cell-mediated inflammatory processes.
H5. It is hypothesized that changes in number of coping behaviors used and changes in situational self-efficacy and
catastrophization will be correlated with changes in cortisol and cytokine levels from pre-to post-treatment.
The results may indicate what classes of variables need to be addressed to enhance treatment for TMD sufferers, and start to
pinpoint the true active mechanisms accounting for improvement in TMD treatment. If these mechanisms can be successfully
identified it would have implications for the development of more effective treatment programs for TMD and for related
disorders.
SUBPROJECT PROGRESS:
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100 subjects have been enrolled, 12 since last progress report. Enrollment is now completed. 87% have provided posttreatment
data, 80% have provided 6-month data, and 87% have provided 9-month data. There are no safety concerns. There are no
interim data or outcomes available at this time. No publications have been prepared to date, but two are in preparation. One
scientific presentation was made in March 2008. The General Clinical Research Center (GCRC) was cited as a contributor to this
talk.

6/27/2008 9:32:04AM

67

5M01RR006192-14
SPID:

REPORT PD: 04/01/2007-03/31/2008

0500

500

PROTOCOL:

Final
TYPE: RESEARCH

SHORT TITLE:
LONG TITLE:

PACTG 390
Pediatric AIDS Clinical Trial Group (PACTG) 390: A Phase II/III randomized, Open-Label Study of
Combination Antiretroviral Regimens and Treatment-Switching Strategies in HIV Antiretroviral Naïve
Children >30 Days and <18 Years of Age
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SUBPROJECT DESCRIPTION:

The primary objectives of this study are: to compare the combination of 2 NRTIs plus a protease inhibitor (PI) versus 2
Nucleoside Reverse Transcriptase (NRTIs) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI) as initial therapy,
followed by second-line therapy if failure occurs, in terms of their effects on a long-term virologic endpoint and to compare two
different viral load criteria for switching from first-line to second-line therapy in HIV Antiretroviral Naive Children > 30 Days
and < 18 years of age.
SUBPROJECT PROGRESS:

Pediatric Acquired Immune Deficiency Syndrome (AIDS) Clinical Trial Group (PACTG) 390 (Version 3.0) has had a total
enrollment of two subjects at the Connecticut Children's Medical Center since the initiation of the study. Both of these subjects
have discontinued study participation as of Nov. 2007 due to the overall PACTG Site closure at Connecticut Children's Medical
Center. The closing was due to non-refunding of the site.
This study has been closed to accrual.
There have been no unexpected safety concerns reported by The PACTG 390 team.
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NSABP B-35: A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with
Ductal Carcinoma in situ (DCIS) Undergoing Lumpectomy with Radiation Therapy
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SUBPROJECT DESCRIPTION:

This Phase III randomized, double-blind study will evaluate the effectiveness of anastrozole compared to tamoxifen in
preventing the subsequent occurrence of breast cancer (local, regional and distant recurrences, and contralateral breast cancer) in
postmenopausal women with primary ductal carcinoma in situ (DCIS) treated with lumpectomy and breast radiation. In
addition, this study will compare adjuvant anastrozole to tamoxifen in terms of time to invasive breast cancer, ipsilateral
recurrence, contralateral breast cancer, other non-breast second primary cancers, osteoporotic fractures, disease-free survival,
and overall survival. Also, B-35 will ascertain the effects of anastrozole on patients' symptoms and quality of life as compared
to tamoxifen. Analysis will include an endpoint based on survival time adjusted for the quality of life experienced.
SUBPROJECT PROGRESS:

Local Report:
University of Connecticut Health Center (UCHC): 5 patients were enrolled. Four patients are receiving study medication and are
doing well with no evidence of disease. One patient discontinued study drug because of the side effects she was experiencing but did
not withdraw her consent and is continuing with the quality of life questionnaire. This patient is alive and doing well.
The Hope Clinic: 2 patients were enrolled: One patient is still receiving study and doing well, was last seen on 04/21/2008. One
patient drug was discontinued because she developed tuberculosis, which was unrelated to the study medication. This patient is also
doing well
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Muscle Biopsy Frail vs Non-frail
Correlation of clinical outcome measures with high resolution muscle imaging in frail versus non-frail older
individuals
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SUBPROJECT DESCRIPTION:

Although frailty has been difficult to define, Fried and her colleagues have established criteria for frailty based on physical ad
psychological characteristics. These characteristics include unintentional weight loss (10 or more pounds per year),
self-reported exhaustion, weakness as measured by grip strength, slow walking speed, and low physical activity (Fried et al.,
2001). With a framework to examine frailty, we propose to explore more fully the pathophysiology of sarcopenia in frail and
non-frail older individuals. In Frontera et al. 2000 and Balagopal et al. 1997, the authors hypothesized that sarcopenia largely
results from the decreased ability for the replacement of dysfunctional contractile proteins within the myofilament lattice.
Exploiting the signal in Second Harmonic Imagine Microscopy (SHIM), which is derived from and sensitive to the local density
and alignment of contractile proteins within muscle sarcomeres, this new mode of non-linear laser-scanning microscopy will
allow quantitative analysis of both the histology and molecular structure of completely native, intact muscle tissue. Thus far,
few studies to date have provided extensive and quantitative ultrastructural examination of muscle from very old individuals
(Frontera et al. 2000). Fiatarone Singh and colleagues, reported data outlining aspects of muscle damage in frail elders using
electron microscopy, which has limitations in comparison to SHIM.
SUBPROJECT PROGRESS:

The study to assess the differences in high resolution muscle imaging in frail and non-frail individuals and correlate the changes to
clinical outcomes is ongoing. Preliminary data suggest that there may be measurable differences in muscle morphology in frail and
non-frail adults or at least correlations with physical performance measures. We have worked in the last year to better objectively
quantify the output from the high resolution imaging. We now believe we should compare samples from young and old adults. We
have recruited 6 subjects (3 M, 3F) within the last year. The samples and data has been analyzed and we are again working out
methodology issues with the SHG. We may need to recruit another 6 individuals once this methodology issue has been resolved. We
have had no unexpected safety concerns. No further changes in protocol have been made. There have been no publications from
the work but preliminary data was presented at the 2004 meeting (May) of the American Geriatrics Society in Washington, DC.
We request further General Clinical Research Center (GCRC) support for the project while we continue to work through the
laboratory methods and prepare to biopsy a final 6 subjects.
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Anabolic and Catabolic State of Adults with Congestive Heart Failure (CHF) According to Level of Frailty
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SUBPROJECT DESCRIPTION:

Background: Congestive heart failure (CHF) is common in those defined as frail. CHF may increase bone and muscle loss, due to
either pathophysiology or treatment. In this study we set out to evaluate bone mineral density (BMD), and muscle mass in an
older population with congestive heart failure compared with healthy aged matched controls.
Methods: Subjects were recruited from a university CHF clinic if ejection fraction (EF) was 40%. Healthy controls were recruited
from the community. Participants were assessed for level of frailty with the 5-step frailty phenotype(1) including self reported
weight loss, grip strength, energy level, walk time, and physical activity. Lean tissue masses, appendicular skeletal muscle
mass/height2 (ASM/Ht2) and bone mineral density were assessed by dual x-ray absorptiometry.
Results: There were 83 subjects; 60 with CHF (43M,17W), 23 (15M,8W) healthy age matched controls. The mean age of CHF
men was 76.5+8.9 and women 77.7+12.2, control men 76.8+9.0, control women 78.1+10.6. NYHA classification was class I
and II n=35; III and IV n= 25 and mean EF was 28.9+8.0. Frailty phenotype score for CHF was 28.3% (n=17) not frail, 45%
(n=27) pre-frail, and 26.7% (n= 16) frail compared to controls 47.8% (n=11) not frail, 52.1% (n=15) pre-frail, and 0% frail.
Sarcopenia was present in 12.5% women and 20.9% men with CHF, and 12.5% women and 26.7% men of controls. In separate
regression models of femoral neck (fnBMD) and ASM/Ht2, the variables of age and gender were significant (age p=0.007;
p<0.00) and gender p=0.031, p<0.001) but the diagnosis of CHF was not. Regressions of fnBMD and ASM/Ht2, controlling for
age and sex, showed a significant relationship with frailty score (p= 0.02) and EF (p=0.03) for fnBMD. There was no
relationship with frailty score or EF with ASM/Ht2.
Conclusion: Older age, female gender, frailty score and ejection fraction all predict low fnBMD although the diagnosis of CHF
does not. Age and female gender were also related to ASM/Ht2, but frailty and EF were not. This work suggests that CHF
severity may affect BMD and that individuals with CHF and frailty should be evaluated for osteoporosis. In this cohort of older
adults, with CHF, sarcopenia was not related to CHF or frailty status.
SUBPROJECT PROGRESS:

The study recruited 83 individuals, 23 controls and 60 individuals with heart failure. No safety concerns were noted during the
active phase of the trial. We are presently closed for recruitment but are actively analyzing data. We continue to use the services
of the General Clinical Research Center (GCRC) statisticians for the project. Three manuscript preparations have been published
from this work.
One manuscript in Osteoporosis International. Kenny AM, Boxer R‡, Walsh S, Hager HD, Raisz LG. Femoral Bone Mineral
Density in Patients with Heart Failure.Osteoporos Int. 2006;17(9):1420-7. Epub 2006 Jun 13. American Journal of Geriatric
Cardiology Boxer R,Walsh S, Wang Z, Hager WD, Kenny AM Use of the Frailty Phenotype and 6-Minute Walk Test to Define a
Syndrome of Pre-Frailty in Older Adults with Heart Failure. Journal of Cardiac Failure Boxer R,Walsh S, Wang Z, Hager WD,
Kenny AM The Association of Vitamin D and Inflammation with the 6-Minute Walk and Frailty in Patients with Heart Failure
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Due to critiques from one of the papers, we will be extending the project to identify whether participants are alive and for those
living, to reassess frailty status. This project received Institutional Review Board (IRB) approval and will begin data collection this
summer.
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SUBPROJECT DESCRIPTION:

Craniometaphyseal dysplasia (CMD) is a monogenic craniotubular bone disorder, which is characterized by deposition of highly
mineralized bone matrix in the cranium and face, whereas long bones exhibit flared metaphyses of decreased bone density.
Diaphyses appear normal. Cherubism is a disorder of excessive bone degradation which affects only maxillar and mandibular
bones. Excessive bone resorption occurs first in the cyst-like cavities of the mandible. Bone in the cavities is replaced by soft
fibrous tissue. Jaw bones progressively resorb until in more severe cases only an outer shell of cortical bone remains. The soft
stromal tissue proliferates and causes characteristic facial features. Isolated aplasia cutis congenita (ACC) manifests in congenital
skin defects which are typically on the scalp, and the underlying cranial bone can be absent. Patients with trichodentoosseous
syndrome (TDO) present with curled hair, enamel hypoplasia and hypocalcification of teeth, increased bone density of the skull
and subtle undertubulation of long bones.
All of the above disorders occur as autosomal dominant (AD) traits, but also sporadically, and in the case of CMD, ACC, and
cherubism also in an autosomal recessive (AR) fashion. Disease genes for the AD form of the disorders have been identified.
However, there are a number of patients who did not have mutations in the known disease genes. The AD form of CMD is
caused by mutations in ANK (Reichenberger et al., 2001), AD cherubism by mutations in SH3BP2 (Ueki et al., 2001), and TDO
by a deletion in DLX3 (Price et al., 1998).
Our goal is to identify additional mutations in these genes which could help to explain the mode of action of the mutations
during pathogenesis. We also attempt to identify and recruit families which do not map to the known loci and perform
genome-wide screening, especially for cherubism and ACC.
SUBPROJECT PROGRESS:

Total number of patients enrolled as of 3/31/2008: 382
Current Year Enrollment: 12
Changes in recruitment plans that might be needed: None
Unexpected safety concerns and their resolution: None
Interim data and outcomes: Research in the past year was directed on the analysis of mouse models for the human disorders
Cherubism and Craniometaphyseal Dysplasia. Recruitment of human subjects is still ongoing. We will test human specimen for
results which we gained from studies in an animal system. Deoxyribonucleic Acid (DNA) samples from ACC patients will be
subjected to genome-wide screening and linkage analysis. Recruitment efforts will be increasing in the future.
Proposed changes made or anticipated in the protocol:
We used Luminex instrument to test samples for Tumor Necrosis Factoy-alpha (TNFalpha). In the future we would like to test
more samples for TNF-alpha and Interleukin 6 (IL-6). Supplies will be provided by Reichenberger laboratory.
Publications (with mention of the General Clinical Research Center): None
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SUBPROJECT DESCRIPTION:

In our research evaluating contingency management (CM) that provides opportunities to win prizes, we have noted that the
efficacy of CM may be dependent on the status of the individual as they initiate treatment. Patients who begin treatment with a
cocaine-positive urinalysis result tend to drop out of treatment prematurely and to continue using while in treatment. CM
interventions have been efficacious in reducing drug use in this subgroup, and the effects were magnitude dependent. However,
we have thus far only tested up to a maximum of $250 in prizes, and larger magnitudes may further improve outcomes. One
purpose of this proposal is to examine the efficacy of an enhanced CM procedure, in which increased frequencies of prize
winnings are provided during initial periods of abstinence. Cocaine-dependent patients beginning treatment with a
cocaine-positive urine sample (N=120) will be randomly assigned to one of three conditions: (a) standard, non-CM treatment,
(b) standard treatment plus CM with an expected probability of winning about $250 in prizes, or (c) standard treatment plus
CM with an expected probability of winning about $560 in prizes.
We have also found that patients who present to treatment with cocaine-negative samples generally remit negative samples
throughout their time in treatment, regardless of whether they received a non-CM or a CM treatment contingent upon
abstinence. Thus, we will also conduct a parallel study that will assess whether simply reinforcing attendance at treatment
enhances retention and improves long-term outcomes in this subgroup. Cocaine-dependent patients (N=330) initiating
treatment with a cocaine-negative urine sample will be randomly assigned to one of three conditions: (a) standard treatment
without CM or (b) standard treatment plus CM with an expected probability of winning about $250 worth of prizes contingent
upon cocaine abstinence, or (d) standard treatment plus CM with an expected probability of winning about $250 worth of prizes
contingent upon treatment attendance. Together, these studies will address the conditions under which lower and higher cost
prize CM procedures may improve outcomes of cocaine-dependent patients
SUBPROJECT PROGRESS:

Total Enrollment: 437
Past Year Enrollment: 63
•
No changes in recruitment plans are needed.
•
No unexpected safety concerns have occurred.
•
Interim data and outcomes are not available.
•
No changes were made to the protocol and none are anticipated.
•
Results not yet published as study is ongoing.
Do you wish to continue to receive General Clinical Research Center (GCRC) resources for the period April 1, 2008 through March
31, 2009? Yes
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SUBPROJECT DESCRIPTION:

Fracture risk as measured by low Bone Mineral Density (BMD), is found to be genetically determined. Family history of hip
fracture predicts osteoporotic fracture independently from bone mass. It is unclear whether many genes, each with small effects
or small number of genes with somewhat larger effects are responsible for the genetic contribution determining BMD.
Inheritance of BMD at the hip has been estimated to be between 70-85%. Nevertheless, many factors play a role in predicting
the development of a fracture including bone mass, as well as the quality, and geometry of the bone architecture.
Potential candidate genes, which may contribute to the development of osteoporosis include genes coding for bone matrix
proteins, adhesion molecules and ligands, hormones and their receptors, as well as enzymatic pathways (e.g. Aromatase, Matrix
Metalloproteinases (MMPs)). Although many genetic studies have already been done, further work needs to be done looking for
a candidate gene with major effect on molecular or cellular mechanism underlying osteoporosis.
Research Hypothesis: We propose that individuals with a higher mean CATT (cytosine, adenine, thymine,thymine)repeats in
the Mif gene will have lower bone mineral density than individuals with lower mean CATT repeats.
SUBPROJECT PROGRESS:

The study is now closed to recruitment. There were no changes to recruitment plans. There were no reported adverse effects or
safety concerns. Analysis and work to obtain access to a national database to obtain adequate sample size is ongoing.
Preliminary analysis follows: The distribution of Macrophage Migration Inhibitory Factor (Mif) genotype are as follows: 5,5
genotype were 5/86 (5.81%); 5,non 5 genotype present in 26 (30.2%); and non 5, non 5 present in 55 (63.9%) participants. The
mean femoral neck Bone Mineral Density (BMD) for those with any 5 allele (low expressing genotype) was 0.89 ± SD 0.13 and for
group with no 5 allele (high expressing genotype) was 0.84 ± SD 0.13 difference of 0.06 in bone density. (p= 0.063). There was no
significant contribution of CATT genotype to femoral neck bone density (F 1.64, P=0.204.) when adjusted for age, gender, and
Body Mass Index.
Conclusions: In this preliminary pilot study, no difference was seen in femoral neck bone density between individuals with low- and
high-expressing Mif alleles once potentially confounding variables were controlled. A larger sample cohort will be required to
adequately address the study hypothesis. The data was presented at the 2004 annual meeting of the Society for Bone and Mineral
Research. No publications from the data are available to date. We are presently attempting to expand the work with collaborators
in Europe to assess similar issues in a large population based study. If this can be accomplished, manuscript preparation will begin.
Continuing General Clinical Research Center (GCRC) resources are required for continued data analysis and manuscript preparation.
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SUBPROJECT DESCRIPTION:

Aging causes a decline in cell-mediated immunity (CMI) and is associated with a tremendous increase in the late-life morbidity
from influenza infections. Vaccination can prevent influenza illness but current vaccines are only 50-60% effective in the over
65 population (versus 90% in younger adults). Even with this limited efficacy, influenza vaccination is a cost-saving
intervention due to the reduction in hospitalization for acute respiratory illness and congestive heart failure (CHF). This
proposal outlines a strategy to advance the basic science of influenza learned from studies in the aged mouse model, to
application in a very high-risk population of older adults with CHF. Identifying age and CHF-related changes in the innate and
adaptive immune responses to influenza and influenza vaccination, is imperative to the development of new vaccines or
adjuvant therapies for improved prophylaxis in older people.
The long-range goal of this project is to use translational methodology to determine the mechanism by which age and
disease-related factors increase the risk of influenza and diminish vaccine efficacy. The objective of this application is to
characterize protective immunologic responses, compare the level of immunity in different risk groups, and finally define the
level of laboratory measures that predict outcomes of illness in older people. In the process, clinical and laboratory measures
will be developed as individual and population indicators of how risk for influenza illness is altered by vaccination and including
clinical trials of new vaccines.
The central hypothesis of the application is that the level of granzyme B (Grz B) in influenza-specific cytotoxic T
lymphocytes (CTL) predicts risk for influenza illness. Grz B levels decrease with advancing age and functional decline due to a
dysregulation of T-cell function that is not reversed by vaccination with killed influenza virus. The rationale for the proposal is
that older adults with CHF have a very high-risk for serious complications of influenza and suggests that the senescent immune
response to influenza is further compromised in the presence of CHF. Influenza attack rates are higher and vaccine efficacy is
lower in this population. CHF in older adults thus provides a model for studying immunologic responsiveness that can be linked
to clinical outcomes. Very high-risk groups of older adults who continue to suffer disabling consequences of influenza due to
poor responses to current killed-virus vaccines can then be targeted for new prophylaxis strategies. Recent studies have
highlighted the role of Toll-like receptors (TLR) in the transition from innate to adaptive immune responses. TLR recognize
pathogen-associated molecular patterns (PAMP) and stimulate cytokine production by a number of cells including Th type 1
(Th1), creating the necessary microenvironment to stimulate effector mechanisms such as CTL. In viral infections, it is
critical that the transition from the innate to adaptive immune response activates cytotoxic T-lymphocytes (CTL) to kill
virus-infected host cells. The methodology derived from this work will be critical for screening new vaccines for immunologic
responsiveness prior to expensive, large clinical trials. In the interim, it will be possible to combine vaccination with the use of
antiviral drugs in those very high-risk groups with poor responses to current vaccines.
SUBPROJECT PROGRESS:

Total number of subjects enrolled: 585
Number of subjects enrolled since last reporting period: 158
Changes in recruitment plan: no changes in recruitment plan at this time

6/27/2008 9:32:04AM

76

5M01RR006192-14

REPORT PD: 04/01/2007-03/31/2008

Final

Unexpected safety concerns and their resolution: no unexpected safety concerns occurred this past year
The study in question has three aims:
1) Establish causal relationships between changes in T-cell function and outcomes of influenza illness through a prospective study
of older adults including those with congestive heart failure (CHF) and acute coronary syndromes (ACS). The hypothesis is that
granzyme B (Grz B) is a key mediator of protection against influenza illness and is stimulated by a Th1 response to vaccination.
With a defined threshold level of protection for GrzB and demonstrated low Th1 response (IFN-gamma:IL-10 ratio) to influenza,
the next step is to determine the effect of different chemokines and cytokines on the response to influenza. The analysis is
designed to produce a model of influenza risk based on prospectively measured GrzB and cytokine levels and the effect of clinical
factors.
2) Elucidate mechanisms that alter the immune response to influenza and are associated with increased risk of influenza. The
hypothesis is that influenza risk increases with the loss of the costimulatory molecule, CD28, and Grz B in influenza virus-specific
CTL. A new hypothesis is that CD4+CD8+ T-cells become the reservoir for influenza-specific memory CTL with aging. FACS
analysis will identify the cellular determinants that correspond to protection versus vaccine failure using the threshold level of
GrzB as a correlate of protection following influenza vaccination. Similarly, microarray analysis will characterize the differences in
gene expression with a protective vs. failed response to vaccination. The hypothesis that activation-induced cell death (AICD)
determines the Th1:Th2 response has been abandoned due to recent evidence that T-cells must be conditioned in vitro to exhibit
AICD. Thus, the effect of AICD is not a testable hypothesis under the ex vivo conditions of our assays.
3) Aim 3 has been modified to an alternate approach to enhancing the CTL response to influenza in older adults using
costimulatory molecules. Our previous results suggest that efficacy in older adults may be improved with vaccines targeted to the
CTL response. The hypothesis is that costimulatory molecules, 4-1BB ligand and CD70, will specifically increase the response to
influenza-peptide CTL epitopes in older adults. FACS analysis will evaluate the virus-specific CTL frequency in virus or
peptide-stimulated PBMC. Testing of heat shock proteins as potential vaccine adjuvants has been deferred until testing of
co-stimulatory molecules has been completed.
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SUBPROJECT DESCRIPTION:

Oral candidiasis is perhaps the most frequent opportunistic infection associated with an immunocompromised host. The most
important immune cell type in the defense against Candida is the neutrophil (PMN). Although these cells are considered
important in the resistance to and eradication of fungi, expression of these functions requires activation by soluble proteins
known as cytokines. In the immunocompromised host these molecules are more likely to be derived from cells of non-immune
origin, such as epithelial cells. The purpose of this study is to test the activation of neutrophil anti-fungal functions in response
to cytokines secreted by oral epithelial cells.
SUBPROJECT PROGRESS:

Since the initiation of the study we enrolled 18 subjects. During the last report period, we did not recruit any subjects. Recruited
human subjects at the General Clinical Research Center (GCRC) provide the blood/neutrophils used in in vitro experiments. We
expect to recruit 10-15 subjects during the next year of funding by the National Institute of Health (NIH) (RO1 was just renewed).
There are no unexpected concerns or changes in the protocol. There were no publications related to human subjects during the last
period.
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SUBPROJECT DESCRIPTION:

The Fabry Registry is an ongoing, observational database that tracks the natural history and outcomes of patients with Fabry
disease. Participation is open to all physicians managing patients with Fabry disease. Physicians are encouraged to collaborate,
share observations, and generate hypotheses for evaluation, as well as assist in the collection of clinical data in an effort to guide
and assess future therapeutic interventions.
SUBPROJECT PROGRESS:

The Fabry Registry was not discontinued as noted in the prior report, but was transferred to a new principal investigator Nancy
Day Adams, MD in September 2007. She completed the Institutional Review Board (IRB) renewal with the help of the General
Clinical Research Center (GCRC) staff and was officially accepted by Genzyme as a Registry physician in November 2007.
Registry visits have been performed in the GCRC and also during routine clinical follow-up nephrology visits, with data entry via
the GCRC computers. A single new patient has been enrolled in the Registry during the above time frame, and two additional
patients identified by 3/31/08. Anticipated enrollment of these two will occur in the current study period. They have affected
relatives who may participate. Activity during this current year should be greater than in 07-08.
No local publications have resulted from the registry to date. The International Registry has published two studies during this
period.
Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM,
Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP. Females with Fabry disease frequently have
major organ involvement: Lessons from the Fabry Registry. Mol Genet Metab. 2008 Feb;93 (2):112-28. 2007 Nov 26.
Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C; on behalf of the Fabry Registry. Nephropathy in males
and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
Nephrol Dial Transplant. 2008 Jan 9 [Epub ahead of print].
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SUBPROJECT DESCRIPTION:

The Gaucher Registry is an ongoing, post-marketing, observational database that tracks outcomes of routine clinical practice for
patients with Gaucher disease. Not all patients in the Registry are on Enzyme Replacement Therapy (ERT). All physicians
participating in the Registry are considered members of the International Collaborative Gaucher Group (ICGG). Data collected
from ICGG physicians will represent Gaucher disease practice patterns under common clinical conditions. Thus, the data
collected by this international, collaborative Registry will provide information to better characterize the natural history and
progression of Gaucher disease, as well as the clinical responses of patients whose physicians have prescribed ERT.
SUBPROJECT PROGRESS:

Since our last report on this project, there have been no new subjects enrolled. We continue to collect Registry data on 19 subjects.
There are no changes in recruitment plans. There were no unexpected safety concerns and no major adverse events. There is no
interim data to report nor outcomes to report. The participation of the principal investigator will end 6/30/07 and the funding is
completed as of 12/31/06 with a no cost extension through 6/30/07.
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SUBPROJECT DESCRIPTION:

Cutaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the two most common cancers in the U.S.. While
they both arise from the epidermis, these cancers differ dramatically in biological behavior and their underlying gene expression
patterns have not been compared. We thus examined Messenger Ribonucleic Acid (mRNA) transcript levels in these
malignancies as well as in psoriasis, a benign epidermal hyperplasia. Transcript expression patterns distinguish these disorders
and identify differentially expressed genes. Among these is Egr-1, whose epidermal expression is consistently decreased in BCC
and SCC but is elevated in psoriasis. Our preliminary data indicated that Egr-1 inhibits accelerated growth of benign and
malignant epidermal cells in association with suppression of Cdc25A expression. We would like to confirm this finding and
further investigate whether the phosphorylation status and kinase activity of Cdk2, a downstream target of Cdc25A, are
affected. We hypothesize that gene expression profiling can differentiate epidermal hyperproliferative diseases and identify a
role for Egr-1 in preventing uncontrolled epidermal growth.
SUBPROJECT PROGRESS:

Number of subjects enrolled during the report period and since initiation of the study TOTAL NUMBER OF PATIENTS
ENROLLED:15
Current Year Enrollment: 0
Any changes in recruitment plans that might be needed No Unexpected safety concerns and their resolution No Interim data and
outcomes if appropriate Interim findings: Sequence analysis has shown mutations in samples from patients with Gleevec resistance.
The hypothesis remains sound and continuation of the investigation is justified by the data obtained so far. However, the system
stopped working for unclear reasons. The core lab has trouble amplifiying products for sequencing. Still trouble shooting. Any
proposed changes made or anticipated in the protocol No Publications N/A
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SUBPROJECT DESCRIPTION:

During the past decade, the pharmacotherapy of alcoholism has received increasing attention both from National Institute on
Alcohol Abuse and Alcoholism (NIAAA)and the pharmaceutical industry. However, despite the Federal Drug Administration
(FDA)approval of naltrexone for relapse prevention, medications are still not widely used to treat the disorder. This contrasts
sharply with the treatment of nicotine dependence, for example, as well as other psychiatric disorders. In an effort to broaden
the options for pharmacotherapy of alcoholism, this proposal will examine the effects of sertraline, a selective serotonin
reuptake inhibitor (SSRI), for the treatment of alcohol dependence. The study is based on evidence that, although SSRI therapy
is not appropriate for all alcoholics (Kranzler et al. 1996a, Pettinati et al. 2000), there exists a substantial subgroup with the
disorder (i.e., Type A or later-onset alcoholics) for whom SSRI's appear to exert a clinically important effect. Since sertraline is
well tolerated and among the most widely prescribed psychotropic medications in the world, a prospective demonstration of its
efficacy could have a broad influence on the treatment of alcohol dependence. Consequently, this study will examine the safety
and efficacy of sertraline, the mechanism and duration of those effects and the best method for subtyping alcoholics to identify
individuals for whom the medication is most likely to produce a clinically important reduction in drinking behavior.
SUBPROJECT PROGRESS:

A total of 30 subjects were enrolled during the report period (a total of 123 since initiation of the study). As of 3/31/08, a total of
112 subjects had been randomized to receive treatment with either sertraline or placebo. We plan to run a recruitment ad
specifically targeting individuals with early onset alcohol dependence, due to a difficulty in recruiting individuals in that group.
There have been no unexpected safety concerns associated with this study. Interim outcomes data are not available at this time.
This study uses interactive voice response technology (IVR) for daily data collection, with support from the General Clinical
Research Center (GCRC). The overall completion rate for IVR calls exceeds 87% among subjects while in treatment and 68% for
all subject days. There have been no recent publications associated with this study since data collection is ongoing. Changes made in
the protocol during the report period were: 1) Removal of a co-investigator (Carlos Hernandez-Avila) and addition of a new
co-investigator (Carolyn Drazinic); 2) due to a letter from the Office of Human Research Protections (OHRP), the study protocol
and consent form were reviewed and modified (where necessary) to cover the Deoxyribonucleic Acid (DNA)/genetic testing aspects
of the research study (including: an explanation of the purpose of the DNA testing aspects of this research study and a description
of the DNA tests to be run on the collected samples; a description of any foreseeable risks and discomforts to the subjects regarding
DNA testing; a description of any benefits to the subject or others that may reasonably be expected from the DNA testing; a
statement describing the extent to which the confidentiality of records/samples identifying the subject will be maintained); 3) the
protocol and consent form were modified to explain that DNA samples will be kept in the laboratory until the study ends and that
samples will then be de-identified (Due to the protocol and consent form modifications made for items #2 and 3, subjects who were
active in the treatment phase of the study were re-consented at their next regularly scheduled appointment with the revised
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consent form once it was IRB-approved. Prior to that, the research nurse reviewed the information regarding the DNA aspects of
the study with active subjects and documented the discussion and date of discussion in subject's progress notes. Subjects were then
asked to sign the revised consent form at their next visit once it was IRB-approved); 4) The IRB-approved consent form has
always stated (since this study was originally IRB-approved), "My DNA will be studied to identify specific genetic markers that
might influence my risk of alcohol dependence or my response to sertraline treatment." For consistency with the IRB-approved
consent form, the protocol was updated to mention this specific aim of the study.
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SUBPROJECT DESCRIPTION:

Anterior cruciate ligament (ACL) tears are a major health risk for female athletes. Early degenerative arthritis of the knee is
more likely to develop in women with ACL tears as compared to their uninjured counterparts. ACL tears normally produce 6 12 months of disability after the injury. The National Collegiate Athletic Association Injury Surveillance Survey data identifies
that female college athletes have a 3 - 8 times higher rate of ACL tears compared to males. ACL tears produce immediate and
delayed disability in women.
Little is known about modifiable risk factors in the prevention of ACL tears. Discovering these factors has been identified as a
major goal by the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS) and the Office of Research on
Women's Health. There are a number of proposed risk factors for instance a proposed association between ACL tears and the
menstrual cycle. Over the menstrual cycle, changes are seen in the ACL measurements. The fluctuation of estrogen levels are
proposed to be the cause of the changes in the ACL properties. Muscle-tendons complexes, including the Achilles tendon (AT),
provide additional stability to the knee joint. These secondary restraints play an important role in the stability of the knee.
Estrogen and progesterone affect the collagen content of tendons and ligaments (like the ACL and AT). Some investigators
have recommended oral contraceptives, which prevents the estrogen spike, in order to prevent injury. These recommendations
are premature since ACL risk factors have not been thoroughly studied and any current recommendations for the use of oral
contraceptives are from retrospective studies with small sample sizes.
Further, prospective, adequately powered, studies are needed to define the affects of supplemental hormones such as oral
contraceptives (OCP) on the stretch and strain properties of the ACL. Previous studies quantifying the change in ACL laxity
measurements across the menstrual cycle while a woman is on OCPs do not exist.
The specific aims of the proposed research project are first, to identify the affects of a monophasic OCPs on ACL
measurements across the menstrual cycle. The secondary aim of the proposed research project is to identify the affects of
monophasic OCPs on tendon extensibility across the menstrual cycle. Lastly, the proposed project will be used as preliminary
data for a cross-over study investigating the change in ACL measurements with and without OCPs in an RO3 or RO1
application to NIAMS, which will carry out a more comprehensive evaluation on the risk factors for ACL tears.
SUBPROJECT PROGRESS:

We are near completion of the study and we will soon start analysis of blood samples. The Institutional Review Board (IRB) has
approved the study through January 2009.
We have 17 total completed subjects with 6 new since 4/1/2007. We have tried newspaper, broadcast e-mail, and other methods of
recruitment but only get responses from the Broadcast E-mail message. There have been no unexpected safety concerns. No injury
to participants has occurred. We have no interim data since the blood work is being batched analysized at end of study. We will
need to request an extension to the time frame. We have recruited 18 but 17 completed. One stopped due to time commitment.
We are planning to have the lab analyze the bloods. No publications from this study have occurred, yet.
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SUBPROJECT DESCRIPTION:

A. 1. Specific Aims:
To study the effect of aripiprazole on behavioral effects (i.e., sedative/hypnotic, anxiolytic, stress-reducing properties) and
physiological effects (i.e., blood pressure, heart rate, psychomotor task performance) of a moderate dose of alcohol in 20
healthy subjects with no history of alcohol abuse or dependence. Genetic analysis will also provide preliminary information on
allelic association both to alcohol response in healthy individuals and as control data for studies of individuals affected with
alcohol and/or drug dependence.
2. Hypothesis:
Aripiprazole is a new atypical antipsychotic with a unique receptor binding profile that combines partial agonist activity at D2
and 5-HT1A receptors and potent antagonism at 5-HT2A receptors. Based on this profile of activity, we hypothesize that
aripiprazole will reduce the pleasurable, stimulating, and anxiolytic effects of alcohol, but not its effects on blood pressure and
heart rate. An evaluation of this hypothesis may help to elucidate the neuropsychopharmacology of alcohol and may suggest a
novel approach to the pharmacotherapy of alcohol dependence.
SUBPROJECT PROGRESS:

A total of 49 subjects were enrolled since the initiation of the study. This study has been closed to enrollment since December
2006 and is currently under secondary data analysis. Due to enrollment closure, there have not been any changes in recruitment
plans. Further, there have not been any unexpected safety concerns within this report period.
During the report period, a protocol modification to address Deoxyribonucleic Acid (DNA) testing and DNA sample storage was
Institutional Review Board (IRB) approved on 12/10/07. In response to a recent letter from office for human research protections
(OHRP), the study protocol was modified to address the DNA/genetic testing aspects of the study. Therefore, the following
elements were fully addressed in the protocol:
'b7 An explanation of the purpose of the DNA testing aspects of this research study and a description of the DNA test to be run
on the collected samples
'b7 A description of any foreseeable risks and discomforts to the subjects regarding DNA testing
'b7 A description of any benefits to the subject or others that may reasonably be expected from the DNA testing
'b7 A statement describing the extent, if any, to which the confidentiality of these records/samples identifying the subject will be
maintained.
The protocol was also modified to explain that all DNA samples and data sets will be completely de-identified in order to conduct
the genetic analysis as planned. Genetic analyses will not be conducted with the samples until the de-identification is complete. A
notification will be sent to the IRB once all DNA samples and phenotypic data are completely de-identified.
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Additional genotyping is anticipated (use of the General Clinical Research Center (GCRC) Core lab), suggesting 28 samples with 10
markers each.
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SUBPROJECT DESCRIPTION:

Studies using aromatase inhibitors (AI) have recently demonstrated improved disease free survival after five years of tamoxifen
therapy for early stage breast cancer in postmenopausal women. AI are a class of compounds that inhibit the synthesis of
estrogens from androgens by blocking aromatase, a cytochrome P450 enzyme, which catalyzes the peripheral conversion of
androgens to estrogens, thereby reducing the tissue and plasma concentration of estradiol to below castrate levels.
We hypothesize that with suppression of estradiol, letrozole, the most potent aromatase inhibitor, will cause a significant
increase in markers of bone resorption and bone formation, along with an increase in baseline blood pressure and loss of
nocturnal dipping of blood pressure. The following specific aims will be studied:
To determine the effects of letrozole on sex hormone levels and the relationship of change in sex hormone levels to the change
in bone markers.
To determine the change in markers of bone resorption and formation.
To examine the effects of letrozole on 24 hr ambulatory blood pressure monitoring and office blood pressure.
To determine change in parameters of neurocognitive function with letrozole therapy.
This will be a 12 week, open label pilot study evaluating women with primary breast cancer, who have completed five years of
tamoxifen treatment and are opting to choose letrozole as treatment in consultation with their oncologist. The patients will
serve as their own controls.
SUBPROJECT PROGRESS:

There are 12 subjects enrolled so far since initiation of the study. 2 subjects did not complete the study and one withdrew due to the
time commitment involved.
There were no subjects enrolled during the period of 4/1/07 to 3/31/08, although 2 of the subjects previously enrolled were active
during the above study period.
A significant increase in the blood pressures as measured by 24 hour ambulatory blood pressure monitoring has been seen in the 8
subjects who have completed the study.
Measurement of the hormones of the renin angiotensin system including measurement of serum aldosterone, renin levels,
angiotensin converting enzyme level and angiotensin 1 levels are anticipated to be added to the protocol to help understand the
pathogenesis of the increase in blood pressure with aromatase inhibitor therapy.
An oral abstract has been accepted for presentation at the Endocrine Society Annual meeting in San Francisco in June 2008. The
General Clinical Research Center (GCRC) has been cited in the abstract.
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SUBPROJECT DESCRIPTION:

In a pilot study from our previous granting period, we demonstrated the efficacy of a relatively low-cost contingency
management (CM) procedure for retaining alcohol-dependent patients in treatment and reducing alcohol as well as other drug
use (Petry et al., 2000). This study will extend use of these procedures to chronic recidivist alcohol-dependent patients and
evaluate their efficacy for reducing in-patient detoxification services. Specifically, 116 alcohol-dependent patients who have
received 4 or more alcohol detoxifications in a calendar year will be randomly assigned to one of two 6-month treatment
conditions: standard case management treatment, or standard case management treatment plus CM. In the CM condition,
patients earn the chance to win prizes by submitting negative breath samples and by complying with steps toward treatment
goals, such as attending outpatient substance abuse treatment services, attending appointments with low income housing
programs, or complying with outpatient psychiatric treatment. Treatment services received, alcohol and drug use, psychosocial
functioning, and Human Immunodeficiency Virus (HIV) risk behaviors will be measured pre-treatment and at months 1, 3, and 6
(post-treatment), and at follow-ups scheduled for 9, 12, and 18 months after intake.
Compared to standard case management treatment, we expect that those assigned to the CM condition will decrease alcohol
consumption and present for fewer inpatient detoxifications, while showing greater engagement and retention in outpatient
treatment. We also anticipate improvements in psychosocial functioning and decreases in HIV risk behaviors in the CM group.
Patient characteristics that may be associated with a positive response to treatment will be assessed. We will also evaluate the
cost-effectiveness of this CM intervention in relation to standard case management services.
SUBPROJECT PROGRESS:

Total Enrollment: 104
Past Year Enrollment: 2
•
No changes in recruitment plans are needed (enrollment is complete).
•
No unexpected safety concerns have occurred.
•
Interim data and outcomes are not available.
•
Changes to protocol: 1) Added to the protocol a new recruitment site, Connecticut Renaissance West in Waterbury, CT. 2)
Clarified the timing of the follow-up interviews in the Informed Consent Form and protocol by stating that the interviews will
occur "about 1, 3, 6, 9, 12 and 18 months" from intake. 3) Added new recruitment poster.
•
Results not yet published as study is ongoing.
Do you wish to continue to receive General Clinical Research Center (GCRC) resources for the period April 1, 2008 through March
31, 2009? No, study enrollment is completed
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SUBPROJECT DESCRIPTION:

Alcohol dependence is a highly prevalent disorder that is associated with serious morbidity and mortality. Alcohol dependence
has a significant heritable component estimated to account for 50-60% of risk. We have recently used a Connecticut sample of
258 Caucasian alcohol dependent and 335 screened controls to confirm an association of alcohol dependence with the GABRA2
gene reported in an abstract at the Research Society on Alcoholism in 2003. We found a 7% excess frequency (44% vs. 37%)
of a seven-marker haplotype extending 98,000 bp over the 3'-half of the GABRA2 gene for subjects with alcohol dependence.
We are now proposing to extend our case control association investigations of the GABRA2 gene and alcoholism by examining
a more diverse multi-center sample of 1100 alcoholic subjects collected in project MATCH (a multi-center alcoholism
treatment trial) with a collection of 1100 control subjects. We will use this sample to extend our observations in several ways:
i) to test for the association in a larger and more geographically diverse sample, ii) to use additional markers to better define the
3'-endpoint of association, iii) potentially focus the area of association by use of a larger and more genetically diverse sample
iii) to examine for association with subtypes of alcohol dependent phenotype and co-morbid conditions. We will use the Duffy
antigen as an initial screen for differences in Caucasian versus Black chromosome admixture in the MATCH versus control
sample from the NYC Cancer Project. If significant differences are detected we will plan to collaborate with Dr. Joel Gelernter
at Yale whose laboratory has developed techniques using a panel of racially informative markers to allow statistical correction
case-control genetic associations.
A second aim will be to examine human GABRA2 Carrier Deoxyribonucleic Acid (cDNA) clones for splice or coding sequence
changes in linkage with a known exon 4 synonomous Single nucleotide polymorphism (SNP) present at higher frequency in
alcoholics in our initial sample.
SUBPROJECT PROGRESS:

1) Number of subjects enrolled during the report period: N/A since initiation of study: N/A (this study uses blood samples
collected from subjects enrolled in a multicenter National Institute of Health (NIH) alcohol treatment study 'Project Matching
Alcoholism Treatments to Client Heterogeneity (MATCH)' several years ago as well as cases and controls collected at the
University of Connecticut Health Center (UCHC) as part of other studies of alcohol dependence)
2) Planned changes in recruitment plans: n/a
3) Unexpected safety concerns and their resolution: None occurred.
4) Interim data: Single Nucleotide Polymorphisms (SNP) genotyping has been completed on 800 project MATCH together with
600 control and 600 alcoholic cases from central Connecticut at 8 SNPs in the GABRA2 gene, 4 SNPs in the adjacent GABRG1
gene and 3 SNPs in the intergenic region. Results from indicate the markers in these two genes are both associated with diagnosis
of alcohol dependence, but with greater effect size for markers in the Gamma-Aminobutyric Acid A Receptor, Gamma 1
(GABRG1) gene. The results are not explained linkage disequilibrium between markers in the two genes, although there is moderate
linkage between the two haplotype blocks in the two genes. In a more recently completed analysis, we found that that the risk
allele for both GABRA2 and GABRG1 genes was associated with a poorer response to psychological treatment in project MATCH.
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5) Proposed changes made or anticipated in the protocol: None
6) We request the General Clinical Research Center (GCRC) protocol remain active with the potential request for additional
genotyping of the study sample.
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SUBPROJECT DESCRIPTION:

Background and Rationale: Drug induced liver injury (DILI) is the single most common reason for regulatory actions
concerning drugs, including failure to gain approval for marketing, removal from the market place, and restriction of prescribing
indications. DILI is also a significant cause of morbidity and mortality in many patient populations. To stimulate and facilitate
research into DILI, the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) has recently established the
Drug-Induced Liver Injury Network (DILIN). One of the initial projects to be conducted by the network is to retrospectively
establish a nationwide registry of patients who have suffered severe idiosyncratic liver injury associated with drugs (ILIAD), and
to collect, immortalize and store serum, Deoxyribonucleic acid (DNA), and lymphocytes from these patients (hereafter referred
to as the "ILIAD protocol"). This ILIAD protocol will serve as a resource for subsequent mechanistic investigations of the
basis for susceptibility to severe idiosyncratic DILI.
Specific Aims and Objectives: The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of
individuals who have experienced severe DILI caused by four specific drugs, and the relevant clinical data concerning the episode
of DILI; and, (b) to create a bank of biological specimens obtained from these individuals. Corresponding information from
control subjects will also be collected. These biological specimens will be DNA, plasma, and immortalized lymphocytes.
Immortalized lymphocytes will provide unlimited amounts of genomic DNA for study as well as living immune cells for
phenotyping studies. A secondary goal of the ILIAD protocol is to maintain a registry of cases in the ILIAD database so that
they may be recontacted in the future. It is expected that this will facilitate additional studies exploring the mechanisms of
DILI.
Targeted Drugs: The initial drugs to be targeted in the ILIAD protocol are isoniazid (INH), phenytoin, clavulanic acid /
amoxicillin (Augmentin and valproic acid. For INH, phenytoin, or clavulanic acid / amoxicillin, severe liver injury is defined as
a documented serum total bilirubin > 2.5 mg/dl; for valproic acid, the criteria are compatible symptomatic clinical presentation
that is severe enough to prompt hospitalization and evidence of liver dysfunction International normalized ratio (INR) > 1.5 or
Alanine transaminase (ALT) > 3 X Upper Limit of Normal (ULN), and/or characteristic liver biopsy). The target drugs were
chosen because they cause severe DILI at a high rate compared with other drugs, making our target enrollment for each drug (n
= 50-100) attainable. In addition, these drugs are frequently administered to reasonably healthy patients not concurrently
receiving other drugs more likely to be hepatotoxic, facilitating causation assessment.
Basic Study Design: The five DILIN clinical centers will identify and contact patients at their own and affiliated institutions who
may have suffered a liver injury due to one of the targeted drugs. They will also contact gastroenterologists, hepatologists, and
other health care professionals most likely to have treated DILI cases. In the latter case, an information packet will be sent by
the treating physician to the potential subject, and interested subjects will be requested to contact one of the five clinical sites.
In either case, the subject will be given a brief description of the study's purpose and procedures, and when further interest in the
study is expressed, s/he will be mailed provided with an information packet including the informed consent document, The
Health Insurance Portability and Accountability Act (HIPAA) authorization and release of medical record forms. Once these
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documents have been received reviewed by the subject, study staff will contact the potential subject by telephone a second time.
This follow-up contact will either occur by telephone or in person at the subject's convenience. Informed consent will be
obtained, and if this occurs over the telephone, it will be witnessed by a third party on the line. Then, requisite information will
be collected using a telephone or personal interview format. Prior to ending this phone call the end of the second contact, the
subject will be asked to sign the consent, HIPAA authorization, and release of medical information forms and return provide
them to the DILIN clinical site. Arrangements for blood drawing will be made. The blood sample will be shipped to the Rutgers
University Cell and DNA Repository (RUCDR) where DNA will be extracted and lymphocytes will be immortalized. DNA,
plasma and immortalized lymphocytes will be frozen and stored for future studies. Once the signed documents have been
received, medical records and charts will also be retrieved from the appropriate health care provider(s). Detailed clinical
information concerning the DILI event will be abstracted from the charts and entered onto case report forms. This
information will then be reviewed by the DILIN Causality Committee, and it will make the final determination on whether the
patient was a true DILI case.
SUBPROJECT PROGRESS:

There are a total of eight subjects enrolled into this study. There was no new enrollment during the current report period. There
are no changes in recruitment plans at this time. In addition, there are no unexpected safety concerns to report. At this time, there
only publication that has resulted from this study is: Etiology of New-Onset Jaundice: How Often Is It Caused By Idiosyncratic
Drug-Induced Liver Injury In The United States? (pdf) American Journal of Gastroenterology, Oct. 2006, © 2006 by Am. Coll. of
Gastroenterology, however the GCRC was not cited on this publication.
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SUBPROJECT DESCRIPTION:

Bone and muscle loss in microgravity have been identified by National Aeronautics and Space Administration (NASA) as key
barriers to successful long-term space flight. Further, the potential importance of balance effects of flight were highlighted by
the disequilibrium findings in John Glenn following his return from a space shuttle flight and the initiative of NASA to assess
longitudinally balance in cooperation with the Baltimore Longitudinal Aging Study. The bone and muscle loss in microgravity
are not completely understood. There are several changes that occur during space travel that may influence changes in bone
and muscle including weightlessness, hormone changes, nutritional changes, stress response, and protein metabolism (1, 2, 3).
Many changes that occur with space travel are also seen with aging and culminate in a syndrome described as frailty (4,5,6).
Changes with aging include increases in cortisol and insulin levels, decreases in sex hormones, poor nutritional intake and
anorexia contributing to bone, muscle and balance loss. Study of interventions that may mitigate the effects of aging on frail,
older individuals, may provide insights into countermeasures and strategies for minimizing bone, muscle and balance loss in
space.
Most geriatricians agree that frailty is a syndrome of decreased reserve and resistance to stressors, resulting in cumulative
declines across multiple physiologic systems, resulting in increased vulnerability to adverse outcomes ( 4,5,6). Physical markers
of frailty include declines in lean body mass, strength, endurance, balance, walking performance, low activity and some include
osteopenia (4,5,6,7). Many of the components of frailty are interrelated and all are associated with declining reserve. Since
multiple of these components must be present clinically to constitute frailty, a physical continuum of robust to prefrail to frail
can be envisioned. Fried et al. has proposed a phenotype of frailty, highlighting 5 characteristics from the physical markers of
frailty, and used the phenotype to assess the contribution of baseline frailty status to the incidence of health outcomes during 3
and 7 years of follow-up (8). For this phenotype, frailty is defined as having 3 of the 5 characteristics and prefrailty has having
1 or 2 of the 5 characteristics. Frailty and prefrailty are associated with increased risk of death, hospitalization, falls, worsening
Activities of Daily Living (ADL) disability and worsening mobility (8).
Dehydroepiandosterone (DHEAS) and yoga may mitigate or reverse the effects of aging and frailty on bone, muscle and balance
loss. The mechanism of the effects may be direct - working through androgen or estrogen receptors in bone, muscle or brain.
Or the effects may be indirect, countering effects of the stress response.
Hypotheses: Muscle strength and balance will improve in women with frailty selected for dehydroepiandosterone sulfate
(DHEAS) levels below 305 ng/dl treated with DHEAS supplementation and Hatha yoga. The effects of both treatments will
improve outcomes more than either treatment alone and may be additive. In addition, lean body mass, skeletal muscle mass,
markers of bone turnover and physical performance will improve following treatment with DHEA and/or yoga.
SUBPROJECT PROGRESS:

The study is closed to recruitment and study visits were to complete classes and data collection by July 2006. There have been no
safety concerns There are no interim data or publications to date but we are currently working with statisiticians to complete
analysis and prepare manuscripts

6/27/2008 9:32:04AM

94

5M01RR006192-14
SPID:

REPORT PD: 04/01/2007-03/31/2008

0558

558

PROTOCOL:

Final
TYPE: RESEARCH

SHORT TITLE:
LONG TITLE:

Clinical Behavior of Lithium Disilicate, Single-Unit, CAD/CAM Crowns
Clinical Behavior of Lithium Disilicate, Single-Unit, Computer-aided Design/Computer-aided Machining
(CAD/CAM) Crowns

AIDS:

N

START DATE:

8/5/2004

TOTALS

A
0

B
0

D
0

Scatter Bed

0

0

0

Outpatient

24

0

0

Scatter RN Hours

0

0

0

Offsite Visits

0

0

0

Inpatient
Total # pts expected for entire study:

40

RESEARCH BIONUTRITION

N

MULTICENTER STUDY

N

INFORMATICS CORE

Y

CLINICAL TRIAL

Y

BIOSTATISTICIAN

N

CORE LAB

N

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

KELLY, JOHN R DDS, DSC

Oral Rehab, Biomaterials

SQUIER, RACHEL DMD, DSC

Prosthodontics

Phase III

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

This trial will examine the performance of 40 single unit crowns (25 posterior and 15 anterior) for a period of at least 2 years.
Crowns will be fabricated from a lithium disilicate glass-ceramic using a computer-aided design/computer-aided machining
(CAD/CAM) process. Both the material and the processing equipment have FDA 510-K clearance for this clinical application.
The principal investigator (PI) initiated this trial at UConn as an important complement to ongoing laboratory efforts to better
understand clinical behavior and aid ongoing research into the development of validated laboratory tests of ceramic-ceramic
compatibility and bulk fracture.
SUBPROJECT PROGRESS:

This study was closed to enrollment for the reporting period. All 2 year recalls were finished and a final report was submitted to the
sponsor.
There were two additional bulk crown failures this year, no unexpected safety concerns and no changes to protocol. Scanning
electron microscopy and EDAX chemical analysis were used on four failed crowns to identify a likely failure mechanism.
Nothing related to this research has yet been published.
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PACE UNIVERSITY, NY USA

CILLESSEN, ANTONIUS PHD
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COVAULT, JONATHAN MD, PHD
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DEHART, TRACY PHD

PSYCHOLOGY

LOYOLA, IL USA
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ALLIED HEALTH SCIENCES
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PSYCHOLOGY

HERMAN, AREY BA

Psychiatry

KRANZLER, HENRY MD

Psychiatry

AMERICAN UNIVERSITY, DC USA

SUBPROJECT DESCRIPTION:

The proposed study is an addendum to an existing Alcohol Research Center longitudinal study of college students' daily alcohol
consumption employing a daily report methodology to study the linkage of daily life events and students' health-related and
school related behaviors. The 574 students currently enrolled in this study will be offered the opportunity to enroll in this
genetics addendum which will (a) examine the influence of a functional polymorphism, 5-HTTLPR, in the promoter region of
the serotonin transporter gene, and an alcohol dependence associated halplotype of the GABRA2 gene encoding the
benzodiazapine receptor subunit GABRA a-2, on the use of alcohol by college students (b) evaluate the interaction of
5HTTLPR and GABRA2 genotypes with daily life stressors, positive experiences, social interactions/peer influences, and
positive or negative mood states on the use of alcohol by college students. In an exploratory aim we will also examine the
effects of variation in two other genes influencing serotonin signaling: i) TpH2 which encodes the brain specific form of
trypthophan hydroxylase, the rate limiting enzyme in serotonin synthesis, and ii) MAOA encoding monoamine oxidase, a key
enzyme involved in metabolic inactivation of synaptic serotonin (as well as norepinepherine and dopamine).
SUBPROJECT PROGRESS:

1) Number of subjects enrolled during the report period: none since initiation of study: 410
2) Planned changes in recruitment plans: none
3) Unexpected safety concerns and their resolution: None occurred.
4) Interim data: Polymorphisms in several genes have been examined. Results for two genes (SLC6A4 and HTR1B) have shown
significant associations with clinically relevant behavioral phenotypes (stress related alcohol use, daily anxiety reactivity, and
aggressive behaviors). Results from this work have been published in the past year. Results for two other genes (TPH1 and TPH2)
did not show hypothesized association with alcohol use, the results of this analysis have been recently accepted for publication
(Gacek et al).
5) Proposed changes made or anticipated in the protocol: None.
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6) Continued GCRC support requested - We request the GCRC protocol remain active with the potential request for additional
genotyping of the study sample.
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SUBPROJECT DESCRIPTION:

Background and Rationale: Liver injury due to prescription and non-prescription medication use is a medical, scientific, and
public health problem of increasing frequency and importance in the United States. Indeed, drug-induced liver injury (DILI) is
the most common reason for nonapproval, withdrawal, limitation in use, and clinical monitoring by the Food and Drug
Administration (FDA). However, detection of signals for liver injury frequently relies upon the reporting of cases by
practitioners to health authorities in post-marketing surveillance. Under-reporting of cases, lack of mandatory reporting
systems, and difficulties in establishing a diagnosis make the current system sub-optimal. Moreover, with the growing use of
complementary and alternative medications (CAM), there have also been increasing reports of liver toxicity due to various
non-prescription herbal, dietary, and food additive supplements. Because the manufacturing, dispensing, and testing of these
products is not regulated, the hepatotoxic potential of these formulations is poorly characterized or completely unknown. As a
result, there is a great need to develop an improved means of detecting, defining, and studying DILI in the United States.
The DILIN prospective study is a multi-center study designed to gather clinical information and biological specimens on cases
of suspected liver injury due to drugs and CAM. The goals of this study include the earlier recognition of DILI, especially due to
newer drugs, development of standardized instruments and terminology to help identify cases of DILI, investigating clinical and
genetic risk factors that predict DILI, and performing a careful longitudinal follow-up of DILI subjects. The biological samples
collected will be used in future studies of the mechanisms and genetics of DILI.
Specific Aims and Objectives: The primary objective of this study is to prospectively identify bona fide cases of liver injury due
to drugs and complementary and alternative medications within 6 months of presentation. Secondary objectives include
collecting clinical data and biological specimens including blood, DNA, urine, and liver tissue from affected patients and matched
controls for future mechanistic and genetic studies. We will also investigate the clinical, immunological, and environmental risk
factors of drug-mediated hepatotoxicity by comparing DILI cases to matched controls with a similar drug exposure history but
no evidence of clinically significant liver injury. The natural history of drug- and CAM-induced DILI will be tracked for at least
6 months following enrollment, with longer follow-up for those in whom there is evidence of chronic liver injury at 6 months.
We will also develop and test causality assessment instruments for drug and CAM-induced liver injury that are sensitive, specific,
and reproducible.
Basic Study Design: The DILIN Prospective Study is a multi-center, prospective, epidemiological study. Patients who are
referred to one of the DILIN clinical sites and who, in the opinion of a gastroenterologist / hepatologist, experienced a
drug-induced liver injury will be enrolled. Detailed clinical data and biological specimens will be collected. Clinical data will be
reviewed by the DILIN Causality Committee, and it will make the final determination of whether the subject qualifies as a bona
fide DILI case. Up to three matched controls will be individually matched to each index case. They will be matched by age,
duration of exposure to the implicated medication, and from the same clinical site. DILI cases (only) will be followed for at
least 6 months to derive the longitudinal profile of drug- and CAM-induced liver injury. Detailed clinical data and biological
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specimens will be collected at this time point. Patients who satisfy the definition of chronic DILI will be evaluated at 12
months and yearly thereafter.
SUBPROJECT PROGRESS:

A total of 62 subjects have consented to this study, 58 of whom were deemed eligible after the baseline visit. During the current
reporting period, 11 eligible subjects have been enrolled. In our New England-Northeastern Consortium, we are establishing satellite
sites to help identify and enroll suitable subjects throughout the northeastern quadrant of the USA. Out of four previously approved
sites: SUNY, Syracuse (PI: R. Levine); University of Rochester - Strong Memorial Hospital (PI: B. Maliakkal); Hartford Hospital
(PI: R. Rosson); and Hebrew Health Care Inc. of Hartford, two sites: Hartford Hospital and Hebrew Health Care Inc. of Hartford,
were closed. SUNY has screened 15 and enrolled 12 subjects. University of Rochester has screened 7 and enrolled 4 subjects.
Hartford Hospital has screened 4, enrolled one subject and referred 11 subjects 7 of which have been enrolled at the University of
Connecticut Health Center (UCHC). Hebrew Health Care has screened 1 subject. Dartmouth-Hitchcock Medical Center (PI: D. van
Leeuwen) has been a good source of subject referrals, 6 of whom have enrolled at UCHC.
There are no safety concerns to report. Because this is an observational study, primarily to develop a registry of subjects, there is
minimal risk for subjects to take part, and we do not expect any significant adverse events. During the past year, the only
modifications submitted to the IRB were administrative modifications; Dr. Bonkovsky's role in the study changed from principal
investigator to co- investigator, now Dr. Petr Protiva serves as principal investigator, Dr Michael Grupka, Dr Paul Appleton,
Kathleen Curley, and Thomas Kiely were added to the study stuff, Laura Glynn was removed from the study. Due to a difficulty in
the recruitment and enrollment of the study subject Hartford Hospital and Hebrew Health Care Inc. of Hartford, were closed as
study satellite sites.
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KING, ANDREA PHD

DEPT OF PSYCHIATRY

UNIVERSITY OF CHICAGO, IL USA

SUBPROJECT DESCRIPTION:

The goal of this investigation is to compare unique behavioral and physiological responses to alcohol and their associations in
light and heavy social alcohol drinkers. We plan to specify their objective, performance, and subjective alcohol response in a
preclinical laboratory study. Measures will be obtained during both rising and declining blood alcohol concentrations in order to
better understand potential factors involved in the earlier stages of heavy alcohol use. We also plan to follow-up on study
participants for several years after the preclinical phase of the study to examine whether acute alcohol response factors are
significantly associated with future drinking patterns and alcohol consequences.
SUBPROJECT PROGRESS:

For recruitment purposes, this protocol is commonly referred to as The Chicago Social Drinking Project (CSDP).
Number of Enrolled Subjects: Enrollment for the CSDP ceased in July 2006. Our final total for the study was 198 enrolled subjects.
Of these 198 subjects, 190 completed all three required experimental sessions. At this time, two subjects have withdrawn from the
study (1 subject for unstated reasons in 2/06 and another who passed away following her 2-Year Follow-Up interview) leaving 188
subjects currently engaged in the longitudinal follow-up portion of the study.
Changes in Recruitment Plan: The CSDP is no longer recruiting new subjects; thus, no changes in the recruitment plan are
warranted.
Unexpected Safety Concerns and Their Resolution: No unexpected safety concerns occurred during this reporting period.
Interim Data and Outcome: During this period, the CSDP utilized the interactive voice recording (IVR) phone system provided by
the University of Connecticut to complete quarterly follow-up data collection (at 3, 6, 9, 15, 18, and 21 months following the
final in-lab experimental session). Data obtained from these follow-up interviews provide information regarding changes in the
subject's alcohol consumption and cigarette smoking behavior as well as moods and significant life events. From 4/1/07 to 3/31/08,
the CSDP successfully completed 171 of 171 of these interviews. In addition, at 12 and 24 months, subjects completed a more
extensive annual follow-up, consisting of demographic and substance use updates and psychosocial measures completed via online
survey as well as a brief diagnostic interview completed during a brief phone conversation. During this period, the CSDP completed
97 of 97 of these interviews. Overall, the CSDP reports a 100% follow-up rate during this reporting period and an impressive
99.05% follow-up rate for the duration of the entire study.
Proposed Changes to Protocol: No changes are proposed for this protocol
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SUBPROJECT DESCRIPTION:

The hypothesis for this study is that chemotherapy itself induces thrombophilic state in cancer patients by causing endothelial
damage and therefore is able to activate the coagulation system. It is our aim to show that markers of endothelial damage and
activation of the coagulation cascade is induced when patients receive chemotherapy. Each patient will serve as his/her own
control.
SUBPROJECT PROGRESS:

This study closed in the General Clinical Research Center (GCRC) as of April 30, 2007.
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SUBPROJECT DESCRIPTION:

The study is a randomized clinical trial comparing two psychotherapy interventions with an active comparison condition to
determine their efficacy in addressing behavioral, cognitive, affective, and interpersonal substrates of a core problem in complex
Post Tramatic Stress Disorder (PTSD) that often occurs for persons living in adverse socioeconomic circumstances and in
violent families and communities. One goal of the study is to reduce the severity of or produce remission from PTSD and
associated anxiety, mood, and addictive disorders, in order to reduce impulsivity, aggression, dissociation, and isolation by
high-risk or previously incarcerated women. The long-term goal, which will be assessed in subsequent studies over time is to
reduce the likelihood of their or their children becoming involved in, or victimized by other persons' involvement in, illegal
activities. Children will not be involved in the present study, only women who are the mothers of young children.
Aim #1: To test the efficacy of Target Affect Regulation Guide for Education and Therapy (TARGET) and Present Centered
Therapy (PCT). TARGET (Frisman, Ford, & Lin, 2004) and PCT (McDonagh-Coyle, Friedman, McHugo, Ford et al., in press)
have demonstrated efficacy in randomized trial studies, but have not been tested specifically with mothers of young children.
The study will assess outcomes that are of potential importance not only for the well being of the participating women but for
their ability to develop secure attachments with their child which are protective against exposure to violence, crime, and
victimization and associated with positive psychosocial development by children. Outcome measures reflect self-regulatory
capacities compromised by trauma which are essential for effective caregiving by adults.
Aim #2: To compare the efficacy of TARGET and PCT on theory-based differential outcomes. TARGET and PCT use similar
but different therapeutic strategies. Each teaches skills for managing negative emotions and critical symptoms (e.g., inhibiting
impulsivity). TARGET teaches a skill sequence for affect regulation and social/interoceptive information processing, while PCT
teaches a skill sequence for recognizing and solving problems in relationships. We expect that TARGET and PCT will reduce
stress-related avoidance and depression and enhance active coping with current stressors. TARGET should be superior to PCT in
enhancing the ability to cope with trauma memories, stress reactivity, and anxiety, and therefore, physical well-being and
ability to remain free from illegal activities or future or further involvement with criminal justice systems. PCT should be
superior to TARGET in enhancing the participant's overall social adjustment.
SUBPROJECT PROGRESS:

The study has been closed for recruitment during this reporting time. A total of 174 participants have been enrolled. All
participants have completed study procedures including the daily phone calls to the interactive voice response system (IVR)
operated by the General Clinical Research Center (GCRC). There have been no unexpected safety concerns and no modifications
were submitted. Data analyses are currently being prepared. No publications have been completed at this time.
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HARTFORD HOSPITAL, CT USA

SUBPROJECT DESCRIPTION:

Chronic periodontitis and oral candidiasis are the most frequent opportunistic oral infections associated with
immunosuppression caused by disease or treatment. These oral infections are frequently asymptomatic and therefore can remain
undiagnosed and untreated. Solid organ transplant recipients represent a growing population of chronically immunosuppressed
patients whose oral health status has been largely uncharacterized. Because recent studies have shown that chronic oral infection
can trigger low grade systemic inflammation which may contribute to vascular disease and because chronic graft vasculitis can
lead to transplant rejection, studies characterizing the oral and systemic inflammatory status in this patient population are
urgently needed. Serum interleukin-6 (IL-6) and C-reactive protein (CRP) are well established, sensitive markers of systemic
inflammation which have been shown to be elevated in chronic periodontitis patients and are also good diagnostic indicators for
transplant rejection. In this proposal we hypothesize that in transplant patients with Candida stomatitis or chronic
periodontitis, chronic elevation of serum IL-6 may directly or indirectly (via induction of CRP) be associated with chronic graft
allograft failure.
To begin to explore a potential relationship between chronic oral opportunistic infection and chronic transplant rejection we
propose to a) study the prevalence of oral candidiasis and chronic periodontitis in their patients population; b) collect
preliminary data on a possible association between the presence of these oral opportunistic infections and a history of chronic
rejection; and c) determine the levels of IL-6 and CRP in the serum of transplant patients and study their relationship with i)
the presence of oral infection; and ii) the levels of oral mucosal IL-6 expression in situ. The pilot work proposed herein will
provide the framework for the design of a larger scale prospective clinical study which will conclusively address the role of oral
opportunistic infections in systemic inflammation and chronic transplant rejection in this special needs patient population.
SUBPROJECT PROGRESS:

We have enrolled more than 115 transplant patients at Hartford Hospital and more than 70 healthy subjects at the University of
Connecticut Health Center (UCHC) since initiation of the study, none during the last report period. This study continues to be
closed to recruitment. There were no unexpected concerns or changes in plans/protocol. The following abstracts were accepted for
presentation: Ioannidou E*, Hull D, Burleson J, Dongari-Bagtzoglou AI. Relationship between chronic periodontitis and chronic
organ transplant rejection". 2007 IADR meeting (Continental European and Israeli Divisions). Ioannidou E*, Hull D, Burleson J,
Dongari-Bagtzoglou AI. "Periodontitis is an independent predictor for elevated serum CRP levels in solid organ transplant
recipient". 2007 AAP meeting.
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SUBPROJECT DESCRIPTION:

1. Resting minute ventilation (Ve) is increased in normocapnic patients with COPD.
2. The ratio of CO2 production (VCO2) to resting Ve, is decreased in COPD
3. Whilst the relationship VCO2/arterial PCO2 in COPD is similar to normals, the relationship Ve/arterial PCO2 is decreased.
4. VCO2 is similar in normocapnic and hypercapnic COPD, but Ve/VCO2 is decreased in
hypercapnic vs normocapnic COPD.
5. In contrast to normal subjects, both normocapnic and hypercapnic COPD patients respond to an added respiratory resistive
load with a decrease in Ve and increase in end-tidal PCO2.
SPECIFIC AIMS
1. In patients with normocapnic COPD, and in healthy normal subjects, measure resting Ve, VCO2, end-tidal CO2 and anatomic
deadspace (Vdan) and alveolar deadspace (Vdalv) and examine the relationship amongst these parameters and in relationship to
arterial PCO2 (PaCO2).
2. In patients with hypercapnic COPD, measure resting Ve, VCO2, end-tidal CO2, PaCO2, Vdan and Vdalv and examine the
relationship amongst these parameters, and compare the results to normocapnic COPD patients.
3. In normocapnic and hypercapnic COPD patients, and in healthy normal subjects, examine the effects of an added resistive
load on Ve, VCO2, and end-tidal CO2 to approximate the effects of acute exacerbations of COPD on these parameters.
Ventilatory failure is associated with an increased arterial PCO2 (PaCO2). Arterial PaCO2 is determined by the balance between
CO2 production and excretion from the body (VCO2). CO2 production is known to be increased in obesity (1), during exercise
(2), fever, and with high carbohydrate diets (3, 4).
The critical importance of CO2 has been recognized for a very long time: Were it not for the peculiar properties of carbon
dioxide - a very weak acid and a gas - our bodies would be unable to survive in their present state" (5). A great deal is known
about the production of CO2 (VCO2) by the human body as a natural physiologic process: CO2 is produced in muscle as a
product of metabolism, diffuses rapidly into blood where it is transported to the lungs and excreted.
The production of CO2 is dependent on three factors: metabolism, blood carriage mechanisms (acid/base, buffering
mechanisms), and pulmonary excretion.
Dietary factors which alter CO2 production are due to the differences between carbohydrates and fat: in glycolysis, 1 mol of
CO2 is produced in regenerating 6 mol of ATP, whereas in non-esterified fatty acid metabolism 1 mol of CO2 is produced for 8
mol of ATP. Thus CO2 production is dependent on the balance between fat and glycogen oxidation, and can be influenced by
dietary changes (3, 4).
CO2 is carried in the blood as dissolved CO2 and [HCO3-] and is affected by the acid -base state. The excretion of CO2 by the
lungs is considered primarily a function of ventilation, and complete equilibration is assumed between the PCO2 of capillary
blood and the alveoli (2). However, under stress, such as during exercise, a disequilibrium occurs, related to the breathing cycle
and blood flow. In healthy normal subjects there is a direct, curvilinear relationship between alveolar ventilation (VA) and
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arterial PCO2.
SUBPROJECT PROGRESS:

We are currently continuing to study both normal (>60 years age) and COPD patients. We have completed studies in an additional
5 normal subjects, and 3 COPD patients. The data have not been analysed yet.
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Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer

AIDS:

N

START DATE:

4/28/2005

TOTALS

Total # pts expected for entire study:

10

Inpatient

A
0

B
0

D
0

Scatter Bed

0

0

0

Outpatient

0

0

0

Scatter RN Hours

0

0

0

Offsite Visits

0

0

0

RESEARCH BIONUTRITION

N

MULTICENTER STUDY

Y

INFORMATICS CORE

Y

CLINICAL TRIAL

N

BIOSTATISTICIAN

N

CORE LAB

N

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

KURTZMAN, SCOTT MD

Surgery

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Breast conserving therapy (BCT) has become an accepted option in the treatment of most patients with Stage 1 and 2 breast
cancer. The major advantages of BCT are superior cosmetic results and reduced psychological and emotional trauma compared
to mastectomy. However, BCT also has disadvantages. The technique is more complex and prolonged treatment regimen
requiring approximately 5-7 weeks to complete. For patients who are elderly or whom live a distance from treatment centers,
logistical problems can prove to be prohibitive. In addition, with the more frequent use of adjuvant chemotherapy in patients
with both node negative and node positive breast cancer, delays can occur prior to the initiation of radiation therapy or
hormonal therapy. Despite the advantages of BCT, only 10-40% of patients who are candidates for BCT actually receive it.
Most of the logistical problems associated with BCT relate to the protracted course of external beam radiation to the whole
breast. Standard therapy generally includes 5 weeks of radiation to the whole breast followed by a boost to the tumor bed with
either additional 8-10 fractions of external beam radiation or 2-3 day interstitial implant. Studies have shown that it appears
radiation therapy after tumor excision exerts its maximal effect upon reducing breast cancer recurrence at or near the tumor
site.
The primary aim of the study is to determine whether partial breast irradiation (PBI) limited to the region of the tumor bed
following lumpectomy provides equivalent local tumor control in the breast compared to conventional whole breast irradiation
(WBI) in the local management of early stage breast cancer. The secondary aims are 1) to compared overall survival,
recurrence-free survival, and distance disease-free survival between women receiving PBI vs. WBI; 2) to determine whether PBI
delivered on 5 treatment days over a period of 5-10 days can provide a comparable cosmetic result to WBI; 3) to determine if
PBI produces less fatigue and treatment-related symptoms compared to WBI; 4) to determine if perceived convenience of care
is greater for women receiving PBI compared to women receiving WBI; and 5) to compare acute and late toxicities between the
radiation therapy regimens.
SUBPROJECT PROGRESS:

There have been 0 patients accrued to this study. This study was closed here at UCHC as of 05-14-2008. There have been no
safety concerns, no publications.
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SUBPROJECT DESCRIPTION:

Rectal cancer remains a significant oncologic problem, with approximately 34,700 new cases diagnosed each year with an
expected overall 5-year survival of 50%. Surgical resection is the primary therapy, which unfortunately often requires creation
of permanent colostomy. Due to high recurrence rate with surgery alone, adjuvant chemoradiation has become standard
practice for the treatment of advanced rectal cancer. However, the optimal treatment schedule remains unknown. This
protocol will examine if preoperative radiotherapy plus capecitabine is similar to preoperative radiotherapy (XRT) plus
continuous intravenous infusion (CVI) of 5-FU in achieving durable local-regional disease control. Because studies using
postoperative chemotherapy and radiotherapy did not improve disease free survival or overall survival, more recent trials have
been looking at preoperative radiotherapy. A trial conduced in Sweden, using preoperative radiotherapy reports a significant
increase in survival and similar trials conducted by the Dutch has shown a decrease in local recurrence. The clinical usefulness of
capecitabine has been demonstrated in 2 large phase 3 studies comparing 5-FU to capecitabine in untreated colorectal patients.
The studies have shown that oral administration of capecitabine results in higher response rate that 5-FU. Also, capecitabine
has certain characteristics that make it a potentially useful radiosensitizer. The primary aim is to compare the rate of
local-regional relapse in patients receiving preoperative oral capecitabine with XRT to CVI 5-RU and XRT. The secondary
aims are to downstage the primary tumor, increase the number of patients undergoing sphincter-saving surgery, correlate genetic
patterns and the presence of absence of specific tissue biomarkers with response and prognosis, compare capecitabine and CVI
5-FU in the setting of preoperative XRT for rectal cancer, examine the differences in toxicity and burden of care for the 2
chemotherapy treatment regimens, and to describe the impact of the type of surgical management of rectal cancer on QOL at 1
year after surgical treatment.
Study Design
Patients must have histological diagnosed adenocarcinoma of the rectum, be amenable to surgical resection and tumor must be
located < 12cm from the anal verge. Patients will then be stratified by gender, tumor stage, and intent for surgery. Following
stratification they are randomized to receive either CVI 5-FU and XRT or capecitabine and XRT. The chemotherapy ends with
the last XRT dose. This is followed by surgery.
SUBPROJECT PROGRESS:

2 enrolled at The Hospital of Central Connecticut (THOCC) for which the University of Connecticut Health Center (UCHC) is the
operating Institutional Review Board (IRB). There are no unexpected safety concerns and no anticipated changes to the protocol.
The General Clinical Research Center (GCRC) is not cited in any publications.
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SUBPROJECT DESCRIPTION:

Recently, oncologists have begun treating breast cancer patients with dose dense (DD) regimens. This means that the patients
receive the chemotherapy drugs over a much shorter period of time. Surprisingly, the overall toxicities
experienced by the patients is no worse and the efficacy equal if not superior. Studies have shown that women with breast cancer
treated with Docetaexel/Doxorubicin/Cyclophosphamide (TAC) (Arm I) or ddose-dense. Doxorubicin/Cyclophosphamide
followed by DD Paclitaxel (DD AC-P) (Arm II) have improved treatment outcome compared to previously used chemotherapy
regimens. Unfortunately some women still develop local, regional, and systemic disease recurrence. This reality provides a
compelling reason to continue efforts to further improve therapy for node-positive breast cancer. To date there has not been a
study to directly compare TAC to DD AC-P and this trial will
provide that comparison. Another potential advantage of DD AC-P is that it's reported toxicity profile provides opportunity
for incorporating a fourth chemotherapy agent into the program. The anti-metabolite gemcitabine has shown promise in
combination with paclitaxel for treatment of mestastatic breast cancer arguing for its potential use in the adjuvant setting. A
phase 2 study of gemcitabine in combination with paclitaxel as a third-line therapy showed a response rate of 55% with a
manageable toxicity profile. On the basis of the activity of the gemcitabine/paclitaxel combination
demonstrated in these trials, coupled with the favorable toxicity profile of the dose-dense schedule, they propose to determine
whether sequential dose-dense AC followed by DD AC-PG (Arm III) can further improve the outcome provided by both TAC
and DD AC-P.
The primary aims of this study are to determine whether the DD AC-PG regimen is superior to the TAC and the DD AC-P
regimens in improving DFS and to compare the relative DFS of TAC and DD AC-P. Secondary
aims are to determine whether DD AC-PG is superior to TAC and DD AC-P in improving overall survival, compare survival of
the TAC and DD AC-P regimens Alone, and to compare the toxicities of the 3 regimens.
Study Design: The study will be conducted in women with operable, invasive carcinoma of the breast with histologically positive
axillary nodes. Patients will be stratified by number of positive nodes, hormone receptor status, and type of surgery and planned
radiotherapy. Following stratification, patients wi11 be randomized to 1 of the 3 chemotherapy regimens. Women with ER
positive and/or PR positive tumors should receive hormonal therapy for a minimum of 5 years following completion of
chemotherapy. All women who have had a lumpectomy wi11 have whole breast irradiation. Chest wall and regional nodal
irradiation will be prospectively determined at the discretion of the investigator and will be used as a stratification factor. The
study will enroll 4800 patients.
SUBPROJECT PROGRESS:

University of Connecticut Health Center (UCHC): 6 patients were enrolled: all 6 patients completed their therapy without
complications and are currently in the follow-up phase. All of the patients are doing well and have no evidence of disease.
The Hospital of Central Connecticut (THOCC): 4 patients were enrolled: 1 deceased beginning of March 2007; 3 finished
treatment and are in follow-up phase. Patients are doing well otherwise.
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SUBPROJECT DESCRIPTION:

The primary aim of this phase III trial are to determine whether a regimen of 6 cycles of 5-fluorouracil (5-FU), epirubicin and
cyclophosphamide (FEC-100) is superior to 4 cycles of Adriamycin and cyclophosphamide (AC) in prolonging disease-free
survival (DFS) in patients with node-negative breast cancer. Chemotherapy (AC or FEC-100) plus celecoxib is superior to
chemotherapy along in prolonging DFS in women with node-negative breast cancer.
SUBPROJECT PROGRESS:

There have been 0 patients accrued to this study. This study was closed here at the University of Connecticut Health Center
(UCHC) as of 05-14-2008. There have been no safety concerns, no publications.
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Medicine/Infectious Diseas

SUBPROJECT DESCRIPTION:

Antiretroviral therapy (ART) has enormous promise for reducing Human Immunodeficiency Virus (HIV)-related morbidity and
mortality, but ART regimens are often complex, prone to side effects, and expensive, and ART adherence is often extremely
poor. The individual and public health consequences of suboptimal ART adherence are significant and include treatment failure,
viral load increase, immune compromise, development of multidrug resistant (MDR) HIV, and potential transmission of drug
resistant HIV to uninfected others. Although the consequences of suboptimal ART adherence are well-recognized, ART
adherence promotion efforts in clinical settings are typically intermittent and ad hoc. When adherence promotion
interventions are systematically implemented in clinical care settings, they almost always involve exceedingly time-, cost-, and
labor-intensive one-on-one counseling procedures that cannot be widely deployed to assist substantial numbers of HIV+ patients
to adhere to ART over time. Moreover, to date, relatively few theoryART adherence promotion interventions have been
conducted, rigorously evaluated, and found to be effective in increasing ART adherence. The present research employs a
well-validated conceptualization of health behavior change, the Information-Motivation-Behavioral Skills (IMB) model (J.
Fisher & Fisher, 1992, 2000, 2002; W. Fisher & Fisher, 1993, 1999; W. Fisher et al., in press), as a basis for the design and
implementation of a cost-, time- and labor-efficient, completely individualized and engaging, computer-assisted ART adherence
promotion intervention. The intervention we propose will be employed on an ongoing basis in the context of routine clinical
care, to teach adherence enhancement strategies to HIV+ patients about to begin ART, and to increase adherence and
maintenance of adherence among HIV+ patients currently on ART.
The proposed research has four specific aims:
1. We will conduct elicitation research with HIV+ patients in clinical care and with HIV care clinicians, to explore the dynamics
of ART nonadherence in the HIV+ clinical population, and to identify the optimal structure and content of a theory-based,
computer-assisted ART adherence intervention linked to clinical care visits. Elicitation research findings will be systematically
integrated to guide the development of the intervention and to increase its ecological validity by adapting it to the dynamics of
ART nonadherence among clinic patients, and to the realities of real-life clinical settings.
2. Based on elicitation research findings, guided by the IMB model, and employing motivational interviewing (MI) techniques as
an intervention delivery system, we will design, pilot test, refine, and fully implement a theory-based, computer-assisted ART
adherence intervention that is linked to naturally occurring HIV clinical care.
3. We will conduct rigorous intervention outcome research comparing the effects of the ART adherence intervention with an
appropriate standard-of-care control group with respect to multiple measures of adherence collected over 18 months. Rates of
adherence, estimated by three types of indicators (self-reports of adherence to medication, pharmacy refill records, and viral
load assessments) will be collected over an 18 month period and will serve as the major outcomes of interest. We hypothesize
that participants in the intervention condition will demonstrate better adherence, as defined by greater gains in absolute values
of the adherence indicators noted above and by a larger proportion of participants who experience success in achieving and
sustaining clinically optimal levels of adherence (e.g., ¡Ý 95%), compared to those in the control condition. Additionally, we
predict that individuals who use the intervention¡ training arm component before beginning ART will demonstrate better initial
degrees of adherence, compared to controls. Finally, we predict that changes in adherence as a result of the intervention will be
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mediated by intervention effects on ART adherence information, motivation, and behavioral skills.
4. We will use the standard-of-care control group from the intervention outcome research as a no-cost cohort for a longitudinal
natural history study of ART adherence in HIV+ patients. We will test putative proximal determinants of adherence to therapy,
including levels of adherence-related information, motivation, and behavioral skills. We will also test the influence on adherence
of subjective and objective health status, substance use, depressed mental health functioning, changing ART regimens,
development of new drugs, and other historical events that may occur over the course of the study. We hypothesize that ART
adherence will be predicted longitudinally by ART adherence related information, motivation, and behavioral skills. We also
hypothesize that longitudinal trends in adherence will be influenced by factors such as substance use, mental health functioning,
and historical events.
SUBPROJECT PROGRESS:

At this time, the study is no longer recruiting participants nor is the study running LifeWindows sessions in clinic. The study is in
the data analysis stage.
A total of 138 participants were recruited for the LifeWindows Study at the University of Connecticut Heath Center (CHIP). Two
Participants transferred within study clinics, and 11 participants were screened-out leaving 125 participants at UCHC to completed
baseline.
Baseline Information
Study wide, 594 [125] active participants completed baseline measures. Condition assignment was 290 treatment arm [59] and 304
control arm [66].
Of these, 61% (361) [60%, 75] were male, 39% (229) [40%,50] female, and .7% (4) [0%, 0] were transgendered or intersexed.
26% (156) [26%, 32] were Latino, and in response to self-report items, 44% (262) [32%, 40] reported being Black, 24% (141)
[34%, 42] White, 7% (40) [9%, 11] reported other or multiple races, and 25% (151) [26%, 32] reported solely Latino.
Routes of HIV infection varied, with the most common being heterosexual sex (39%, 232 [37%, 46]), followed by IDU (21%, 126
[14%, 18]) and MSM (14%, 85 [22%, 28]), while estimated date of diagnosis with HIV ranged from 1981 to 2006 within and
across all clinics.
Participants, according to self-report, were predominantly heterosexual (73%, 431 [66%, 82]), with fewer reporting gay (19%,
112 [27%, 34]) or bisexual (7%, 39 [4%, 5]).
Over a quarter of the participants were employed at baseline (39%, 233 [42%,53]), with a small number finding medications hard
or very hard to afford (7%, 42 [5%, 6]). Housing was fairly stable within this population, with 91% (538 [96%, 120]) reporting a
relatively stable place to live. A small number were on a self-prescribed break from all or some of their medications at baseline
(7%, 43 [3%, 4]), and almost half reported consistent use of a pillbox as a strategy to take medications (46%, 270 [40%, 50]).
Finally, active injection drug use (in the past month) was reported by 6% of participants (38 [3%, 4]) at baseline. In terms of
overall functioning, the sample was generally comparable to other HIV-positive sample in functioning slightly below the national
average in physical and mental health measures (SF8 = ~46 (sd=10) and ~43 (sd=12), respectively [45.8(sd=10.59) and
43.4(sd=12.54)].
Average adherence (across all individual HIV medications prescribed) at baseline was generally high, with 89% (sd= .25) of
prescribed HIV medication pills taken per day averaged over the previous 3-days (90%, sd=23%), 86% (sd= .27) of prescribed HIV
medications taken within the prescribed time-frame over the last 3-days (88%, sd=26%), and across participants the average for
Visual Analog Scale reports of adherence at baseline was 88% (sd= 21% [92%, sd=17% ]). It is important to note that all
continuous adherence measures at baseline were kurtotic and non-normally distributed. Determining the most representative metric
and appropriate analyses for these outcomes is the focus of our first phase of data analyses.
In terms of barriers to adherence, across all sessions, an average of 12 (sd=6 [11, sd=5.49]) IMB-model based adherence-deficit
areas were triggered by participant responses. For those in the treatment arm, the software program then would offer an
opportunity to work on any of these individually triggered potential problem areas, and the average amount of time spent
specifically within intervention activities within the selected area for improvement was 11 minutes at baseline session (sd=6 [9.30,
sd=5.54 ]).
The total time commitment for completing a baseline LifeWindows session ranged between 24 minutes (sd=10.10 [7.20, sd=2.92 ])
for those in the control arm to 39 (sd= 14.58 [31, sd=9.16 ]) minutes for those in the treatment arm. Time commitments
decreased from baseline to average 13 [21] minutes for control sessions (sd= 4.46 [sd=6.99 ]) and 25 [20] minutes for treatment
arm sessions (sd= 8.39 [sd=4.85 ]), with about 9 [12] minutes (sd= 3.79 [sd=2.6 ]) spent specifically engaging in intervention
activities.
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The only change made to our study protocol during this Progress Report timeframe was the addition of adherence study nurses for
the purpose of collecting Resistance data. No other changes were made during this time period.
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SUBPROJECT DESCRIPTION:

Mobility is a critical component of independence and the quality of life of older persons. A significant number of older persons
with mobility impairment demonstrate ischemic lesions in brain white matter (WM).
We hypothesize that: Students with a high level of vascular disease risk factors, will have a larger initial volume and higher
accrual rate of white matter signal abnormality (WMSA); impaired mobility is caused by site-specific WMSA damaging
fronto-parietal periventricular WM and WMSA accrual rate is stable allowing predication of Ss at risk" for large WMSA
increases. The link between ischemic WM lesions, which appear on MRI as WM signal abnormality (WMSA), and vascular
disease risk factors (VDRF), as a cause, requires better definition. We propose to link VDRF to mobility impairment associated
with WMSA and then determine if the risk factors predict incident cases. This will allow us to assess the magnitude of the
VDRF as a cause of mobility impairment in order to plan new treatment strategies.
We will use quantitative Magnetic Resonance Imaging (MRI) and quantitative measures of mobility to link WMSA to mobility
disorders. In preliminary studies, we separated older persons into groups with normal and impaired mobility. Automated
quantitative segmentation of the MR images showed an accrual of WMSA is related to a disease process. Site-specific
periventricular WMSA involving frontal and parieto-occipital regions were present in Students with impaired mobility.
Follow-up MRIs on 14 Students, 20 months after the initial scan, showed WMSA accrual was related to WMSA volume at
baseline suggesting a continuous process and that the volume of WMSA increased at a five-fold greater rate in mobility impaired
compared to normal Students. We have recently determined that the quantitative measures of mobility are reliable. To move
beyond correlation, we are proposing a 5-year project with 2 components: a cross-sectional analysis of 99 Students 70 years
and older stratified by mobility, followed by a 4 year longitudinal follow-up.
The cross-sectional component will determine the relationship of VDRF, WMSA volume, WMSA location, use diffusion tensor
imaging to identify/quantify damage to WM pathways and quantitative measures of mobility. Using the same measures, the
longitudinal component will: 1) establish the link between VDRF and mobility impairment; 2) establish clinical predictive value
of imaging; 3) evaluate the causal relationship of WMSA to mobility; 4) refine our understanding of the anatomic substrate of
mobility impairment; and 5) define the progression of this disorder.
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SUBPROJECT PROGRESS:

Data collected for the cohort in our sub-study have included standardized clinical blood pressures (BP), 24-hour ambulatory BPs,
and the following vascular plasma biomarkers: C-reactive protein, lipoproteins, fibrinogen, plasminogen-activator inhibitor-1,
glucose/insulin concentrations. We have been evaluating the relations among the various BP components and white matter lesion
(WML) volume and ultrasound-derived carotid intimal-medial thicknesses.
Initial cross-sectional analyses have demonstrated that approximately 15% of the total sample had elevated WML volumes; no
significant correlations between the clinic nor 24-hour BP values and WML volumes have been observed. However, there are
moderate and statistically significant positive relations among both 24-hour mean and sleep systolic BP and carotid intimal-medial
thickness. Follow-up ambulatory BP and vascular biomarkers have been obtained in approximately half of the original cohort at 2
years. Analyses of the relations among these parameters and the brain and vascular target organ involvement are pending
completion of the cohort at this time period.
Mobility baseline data analysis is complete and 24 month data analysis has been progressing as data is collected. A manuscript is
in preparation detailing the sensitivity and specificity of the baseline data based upon the measurement variables selected. A frailty
measure has been developed and will be applied to all data analyses. Analyses of the relationships between mobility variables and
MRI, Cognitive, Cardiovascular and other measures await completion of the respective preliminary data analyses in those areas.
We found significant inverse correlations between lesion burden in these WM regions and outcome measures of mobility.
Logistic regression analysis indicated lesion burden in the SCC as the most significant regional predictor of low mobility
performance. Another significant predictor was the body mass index. Voxel-based group analysis showed that independently of
mobility status the most frequent WM damage occurred in periventricular areas within the anterior and posterior aspects of the
corona radiata.
White matter hyperintensities (WMHs) on T2 weighted and FLAIR sequences are ubiquitous in older persons and although
initially a nuisance, population-based studies have linked them with vascular disease risk factors, most notably hypertension.
Limited pathologic data indicate that WMHs correspond to areas of poor white matter integrity with spongiosis, demyelation and
glial proliferation. This description suggests non-specific tissue damage consistent with ischemia/infarction. Logic leads one to
infer microvascular disease as the causative agent with ischemia/infarction of small areas of white matter resulting in the WMHs.
The anatomy of the blood supply to deep hemispheric white matter supports this as it is derived from end arterioles, distal in the
vascular tree and thus vulnerable to disruption. What makes this important is the increasing link of WMHs to the major geriatric
syndromes including cognitive and mobility impairment and well as urinary dysfunction. Our analysis of lesion burden and mobility
indicate that damage to motor pathways plays an important role in mobility impairment of elderly individuals. We believe that
this indicates that for a significant fraction of older persons these lesions are playing a role in limiting their mobility. Furthermore
we have comparable data for urinary function which is compromised by lesion burden in frontal white matter tracts. We are
currently analyzing the effects of regional lesion burden on cognition but have already demonstrated that total white matter lesion
burden is associated with diminished speed of executive function. Thus we have demonstrated that WMHs play a role in impaired
mobility, urinary dysfunction and diminished cognitive power by limiting brain connectivity. Our approach differs from others in
that we are utilizing the regional specificity of the lesions to characterize their effects on the functional capacity of older persons.
We have also shown that vascular disease risk factors are related to carotid artery intima-media thickness but not to brain WMH
burden.
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BENMAMOUN, CHOUKRI MD

Microbial Pathology

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Malaria, a disease caused by protozaon parasites of the genus Plasmodium, is one of the most dangerous infectious disease
affecting human populations. The purpose of this research is to determine the conditions that help the multiplication of the
parasite in human red blood cells. The scientific information received from this study may help understand the disease and
identify new drugs or a vaccine against malaria. Research in the Lab will focus on how the Human Malaria Parasite develops
within human red blood cells. Our goal is to characterize, at the molecular level, the pathways essential for the parasites survival
with an eye toward future drug development
SUBPROJECT PROGRESS:

1. Number of Subjects enrolled during the reported period: 0
2. Number of Subjects enrolled since initiation of the study: 18 subjects (26 blood draws)
3. Any changes in recruitment plans that might be needed: No
4. Unexpected safety concerns and their resolution: None
5.Interim data and outcomes if appropriate: None
6.Any proposed changes made or anticipated in the protocol.
Study was closed on 1/23/2008
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SUBPROJECT DESCRIPTION:

Malaria, a disease caused by protozaon parasites of the genus Plasmodium, is one of the most dangerous infectious disease
affecting human populations. The purpose of this research is to determine the conditions that help the multiplication of the
parasite in human red blood cells. The scientific information received from this study may help understand the disease and
identify new drugs or a vaccine against malaria. Research in the Lab will focus on how the Human Malaria Parasite develops
within human red blood cells. Our goal is to characterize, at the molecular level, the pathways essential for the parasite survival
with an eye toward future drug development.
SUBPROJECT PROGRESS:

1. Number of Subjects enrolled during the reported period: 6 subjects (7 blood draws)
2. Number of Subjects enrolled since intiation of the study: 20 subjects (40 blood draws)
3. Any changes in recruitment plans that might be needed: No
4. Unexpected safety concerns and their resolution: None
5.Interim data and outcomes if appropriate: None
6.Any proposed changes made or anticipated in the protocol. Enrollment was increased from 10 to 35 and was approved on
4/19/07.
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NON-HOST INSTITUTION: STATE,
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SUBPROJECT DESCRIPTION:

Little research has been done to assess the level of osteoporosis evaluation or diagnosis, bone mass measurement or contributors
to bone loss and fall risk in residents of assisted living communities. Hypotheses and Specific Aims 1)Individuals residing in
assisted living will have a low rate of osteoporosis evaluation or diagnosis relative to community dwelling elders. We will survey
individual for history and evaluation of osteoporosis in assisted living and compare to a group of age and gender matched
community dwelling adults 2)Individuals residing in assisted living will have low bone mass, measured by heel ultrasound,
compared to community dwelling elders. Quantitative ultrasound will be used to assess bone mass. 3)The stiffness index T score
will correlate with calciotropic hormones (directly with 25OHD and inversely with parathyroid hormone (PTH)) and directly to
physical performance measures (hand grip, walking speed and physical activity). Study Design: Cross-sectional analysis of 79
residents of assisted living with a comparison to 79 age and gender-matched community dwelling adults. Research volunteers
will undergo bone assessment using heel ultrasound, questionnaires to assess fracture history and previous osteoporosis
evaluation, falls in previous 6 months, dietary intake of calcium, vitamin D and protein, and will have physical performance
measures including hand grip strength and walking speed. In a previous study of 55 community dwelling older men (mean age
73 + 8 y), correlations were found between stiffness index T score and physical activity score (r=.30,p=.043), walking speed (r=
-.37, p=.006) and a trend with handgrip (r=.24, p=.07). Based on this previous work, we calculate that we will need to assess 158
subjects. The proportion of underserved individuals in the assisted-living, elderly population will be contrasted with that in the
healthy, non-assisted-living, older population using contingency table methods. The frequency of osteoporosis detected by heel
ultrasound will be calculated and compared to established, national, age-adjusted, prevalence estimates. Correlation analysis will
be used to evaluate associations between heel ultrasound, bone mineral density, vitamin-D levels, parathyroid hormone levels,
and frailty measures. For the contrast of proportions, samples of 79 assisted-living subjects and 79 non-assisted-living subjects
will provide 80% power to detect odds ratios of 3.0 or more when testing at the 5% level of significance. When combined,
those samples will also provide 80% power to detect correlation coefficients greater than +0.22 or smaller than -0.22. pard
SUBPROJECT PROGRESS:

We have begun data analysis and submitted one paper for publication thus far. The paper is under review and the General Clinical
Research Center (GCRC) has been cited. We plan further analysis and will continue to require biostatistical support.
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NON-HOST INSTITUTION: STATE,
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YALE UNIVERSITY, CT USA

SUBPROJECT DESCRIPTION:

Despite the popularity of Cognitive-Behavioral Treatment (CBT) in substance use disorders, recent findings have indicated that
CBT may be no more effective than other, less theoretically driven, treatments, and that CBT treatments often fail to result in
coping skills acquisition. In order to explore the possibility that current manual-driven modes of CBT delivery may not be
adequate to successfully teach coping skills, we are proposing a pilot project for the development of an individualized assessment
and cognitive-behavioral treatment program (IATP) for alcohol-dependent persons, in which experience sampling conducted
via random calls to cell-phones is used to provide data to create individualized treatment plans. Data collected during
experience sampling will include momentary assessments of patients cognitions, affects, and coping behaviors with respect to
drinking.
Participants will be 112 men and women meeting criteria for alcohol dependence or alcohol abuse, who will be randomly
assigned to either a standard packaged manual-driven cognitive-behavioral treatment program (PCBT) like that used in Project
MATCH, or to IATP. Patients in both treatments will be asked to engage in experience sampling for two weeks prior to
treatment, and for another two weeks after treatment has ended, in order to compare in-vivo measures of coping skills
utilization, pre- and post-treatment, between the two groups. Therapy will be conducted over 12 sessions in both treatments.
In IATP, the information gathered from experience sampling will form the basis of a functional analysis of patients' drinking
and drinking urges during the monitoring period. Cognitive appraisals, moods and coping responses will be evaluated as
antecedents and consequences of drinking behavior. Therapists will use the information to address specific cognitions, affects,
and behaviors that are adaptive and maladaptive, and will work with the patient to substitute adaptive coping tactics instead.
In PCBT the experience sampling data will not be specifically used in therapy, but will still provide in-vivo measures of drinking
and coping skills. It is hypothesized that IATP will yield significantly better coping skills acquisition than will PCBT, and that
change in coping skills will predict better post treatment outcomes for IATP. These results would have implications for our
delivery of treatment, and for the validity of coping skills training for alcohol addiction.
Specific Aims are as follows:
1. To determine whether an Individualized Assessment and Treatment Program (IATP) results in greater acquisition of coping
skills than does a standard Packaged Cognitive-Behavioral Treatment (PCBT).
H1: It is hypothesized that IATP will result in significantly greater increases in reported use of coping skills from pre- to
post-treatment relative to PCBT.
2. To determine if coping skills acquisition in IATP accounts for treatment outcome over and above the contribution made by
pretreatment individual differences (i.e., motivation and self-efficacy).
H2: It is hypothesized that pre- to post-treatment increases in coping skills in the IATP condition will account for more
variance in drinking outcomes at post-treatment than will pretreatment individual difference variables.
3. To determine whether IATP, based on functional analysis of in-vivo patient monitoring, will yield better outcomes at
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post-treatment than will PCBT
H3: It is hypothesized that IATP will yield better drinking outcomes at post-treatment than will the standard packaged CB
approach. Drinking outcomes will include proportion days abstinent, and proportion heavy drinking days during the treatment
period.
SUBPROJECT PROGRESS:

110 patients enrolled in the study thus far, 16 in this study period. Enrollment is complete. Follow-up rate is 87%.No changes in
recruitment plans needed. No safety concerns. No interim data available as yet. No changes in protocol made or anticipated. No
publications available at this time.
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COUNTRY

U OF TORONTO, CANADA

SUBPROJECT DESCRIPTION:

Evidence suggests that some groups of pregnant workers may be at risk for premature delivery or small-for-gestational-age
(SGA) births as a consequence of workplace psychosocial stressors. Clear associations between occupational stressors and
adverse pregnancy outcomes have been difficult to draw. Factors including study design, retrospective assessment of exposure,
and choice of exposure measurement may be partially obscuring any association between work-related stress and pregnancy
outcomes.
The overall goals of this proposed developmental and planning grant are to obtain preliminary data assessing two models of
occupational stress during pregnancy, in particular measuring repeatedly and longitudinally across the course of pregnancy to
evaluate the possibility that these may change across pregnancy. This proposal aims also to evaluate the use of the
effort-reward imbalance (ERI) model, which has not been tested in pregnant workers or used in studies of pregnancy outcomes.
Using a sample of 200 pregnant working women, this study proposes repeated, longitudinal measures of occupational stress at
four different times across the course of pregnancy.
Principal aims of the study are:
1) To explore the use of newer instruments measuring occupational psychosocial stressors in pregnant women; specifically using
the Effort-Reward Imbalance (ERI) model, with comparison to, and possible combination of features with, the Demand-Control
(DC) model.
2) To evaluate the psychometric properties of the ERI in pregnancy, including reliability, and content validity.
3) To evaluate the construct validity of the stress scales, to enable their use in measuring occupational psychosocial strain in
pregnancy.
4) To evaluate the possibility that occupational psychosocial stressor levels in working women change across the unique time
period represented by pregnancy, assessing the direction and magnitude of this change. Statistical methods for
repeated-measures and hierarchical data will be used to examine trajectories of occupational stressors as well as their possible
modification by other individual-level factors. Outcomes will be measured by subjects' measures of their stress, health, and
fatigue, as well as blood pressure measurements and salivary cortisol levels. The work proposed here represents a necessary first
step in the ability to test these hypothesized effects, and will assist in determining whether newer models of the psychosocial
parameters of stress in the workplace might be useful in measuring an association with adverse pregnancy outcomes.
As well, this work will represent an initial assessment of whether changes in measured parameters of stress, or distinct
trajectories over time, occur during the course of pregnancy. Once these aims are accomplished, the resultant exposure
measurements can be used in ongoing studies to recognize and target particular types of work that may be associated with
adverse birth outcomes. The exploratory work proposed here may enhance understanding of special populations at risk from
work stressors.
SUBPROJECT PROGRESS:

This study which effectively started in early 2006 began recruiting in the spring of 2006. 40 subjects were recruited in the first year
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and an additional 30 recruited and completed at least one interview in the current reporting period. Data are collected on scannable
questionnaire forms; initial data on the first 30 subjects has just been scanned and received. Analysis of data from the first 30
participants completing all four survey waves and for which data was scanned and entered into our database shows findings that are
consistent with the hypotheses of the study and already of statistical significance, which was unexpected at this stage, but positive
for the study.
Larger-than-expected changes in within-individual work effort (mean difference 2.2 units, p<0.01), work overcommitment (2.6
units, p<0.001) and a marginal difference in work rewards (1.6 units, P=0.18) from early pregnancy through to term or
near-delivery are already seen in our preliminary analyses, with >25% of subjects still to complete the full set of questionnaires.
Moreover, there are major significant differences by race/ethnicity in findings which are consistent with other work by the PI;
these show very strong differences in self-rated job control, which is lower in blacks than whites despite equivalent or better
educational attainment in blacks (from the initial questionnaires, for blacks, 8/8 in low control work vs 18/32 for whites; p = 0.012
by chi-sq. Very limited data is yet available for birthweight, since <50% of subjects have reported back, but based on few data
points this shows a high correlation with job control in blacks (r2 = 0.83) vs whites (0.06) which is also consistent with our data
from other studies. Cortisol measurements will be run en masse by the GCRC lab and are not yet available for analyses. Overall,
based on limited preliminary data we are seeing stronger evidence of changes in job characteristics across pregnancy than we had
anticipated, and substantial racial/ethnic differences.
There have been no unexpected safety concerns or problems during the performance of this study to date. No changes have been
made or are anticipated in the protocol. As the study remains in data collection and analysis stages, no publications have yet been
completed.
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SUBPROJECT DESCRIPTION:

Major depressive disorder is a well-established risk factor for incident coronary heart disease and women have higher rates of
major depressive disorder than their male counterparts. Endothelial functioning is impaired during current depressive episode.
However, it is unknown whether this impairment continues once the depressive episode resolves. The overarching question this
study asks is whether previous (but specifically not current) major depressive disorder is associated with endothelial dysfunction
in post-menopausal women.
This retrospective, controlled study will investigate the relationship between previous major depressive disorder and current
coronary heart disease risk in postmenopausal women who are matched for age and Bone Mass Index (BMI). The independent
variable is previous major depressive disorder. A reliable, valid, and widely used method for assessing previous behaviors, the
timeline follow back method, has been adapted for use with the gold standard diagnostic interview (SCID) to assess previous
major depressive disorder. The dependent variable is brachial artery flow mediated dilation. Specific aims are to:
1.
Determine whether currently nondepressed women who have experienced previous major depressive disorder have impaired
flow mediated dilation relative to their never depressed counterparts. We hypothesize that currently non-depressed women who
have experienced previous major depressive disorder will have impaired flow mediated dilation relative to their never depressed
counterparts.
2.
Determine whether there is a 'dose-response' relationship between number of depressive episodes over the lifespan and flow
mediated dilation. We hypothesize that more depressive episodes over the lifespan will be related to decreased flow mediated
dilation.
3.
Determine whether treatment for depression attenuates any deleterious effects that depression exerts on flow mediated
dilation. We hypothesize that previously depressed women whose depression was treated pharmacologically will have less
impaired flow mediated dilation than their counterparts whose depression was untreated.
SUBPROJECT PROGRESS:

From 4/1/2007 until 3/31/2008, 19 participants enrolled. Since initiation of the study, 39 women have enrolled, and 38 have been
fully eligible to participate. One woman was excluded from the study after ICF was obtained and during first visit data collection.
This was because it was discovered during first visit that they did not meet set criteria to complete the study. Modifications to the
project approved by IRB this year include: 1) Approval of a new recruitment add targeting women with a history of depression. At
this time, we have nearly completed enrollment of women without a history of depression, but still need approximately 40 women
with a history of depression. 2) Approval of a new HIPAA form in accord with IRB"s revision to language. 3) Removal of Dr.
Mallareddy from the study. She has completed her fellowship and is no longer affiliated with the University of Connecticut Health
Center (UCHC). Dr. White has assumed her responsibilities. 4) Approval of a Dr. Gina Abbott as Principal Investigator Back up.
5) Approval of new Informed Consent Form (ICF) incorporating changes in language regarding storage of samples (we will no
longer be storing samples beyond close of study), method of payment (The General Clinical Research Center (GCRC) requests
checks be made out to "cash", and the addition of the GCRC Research Subject Advocate's (RSA's) phone number. There are no
unexpected safety concerns.
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SUBPROJECT DESCRIPTION:

Recurrent aphthous stomatitis (RAS), also known as canker sores, is the most common soft tissue disease of the mouth in
humans in all geographic regions, including Connecticut. In a large study of over 10,000 young adults, 38.7% of men and 49.7%
of women reported two or more previous occurrences of RAS. These ulcerations are painful and affect the patient's ability to
eat and drink.
Further, they may also impact on oral hygiene practices and speech. Thus, RAS has a significant effect on the patient's quality
of life. There is currently no known method to prevent RAS. Topical and/or systemic steroids are sometimes used for the
treatment of this condition. However, because these drugs have significant side-effects, they are used only for the treatment of
the most severe cases. The vast majority of patients with RAS do not have any scientifically validated options for prevention
or treatment. Several studies have demonstrated that patients with RAS are more likely to have lower blood levels of vitamins,
such as B12 and folic acid, compared to healthy controls. More importantly, multiple studies have demonstrated that specific
replacement therapy to correct such deficiencies is effective in inducing improvement or remission of this disease.
A workshop convened by the National Institutes of Health (NIH) recommended complete hematologic screening of all patients
with RAS. However, testing for vitamin deficiencies is invasive and expensive. It is not feasible to take blood samples on every
patient with RAS and test for such deficiencies. Therefore, this is rarely done in practice and patients continue to suffer from
these lesions.
This study proposes an alternative approach: To prevent RAS using a multivitamin supplement that would correct any
deficiencies of factors known to commonly contribute to RAS. If successful, this would result in a simple, cost-effective
approach to reducing the morbidity of this prevalent disease.
We propose a double-blind, placebo-controlled clinical study in 120 subjects who suffer from RAS. Subjects will be randomly
assigned to either a multivitamin supplement or an inactive placebo, in a 1:1 ratio (60 in each group). The study medication will
be taken once a day for one year. We will document, in all subjects, the number of RAS episodes in one year and the duration of
episodes. These will be compared between the two groups to find out if the multivitamin supplement was effective in reducing
the number or duration of RAS episodes. We will also collect data on pain and normalcy of diet during RAS episodes to
determine if the multivitamin supplement had any effect on these variables.
To enhance subject compliance and retention, we will use Interactive Voice Response (IVR) technology that uses the telephone
to administer survey questions. A blood sample will be collected from all consenting subjects at baseline. This blood sample will
be used to measure the baseline levels of vitamins B12 and B9 (folic acid). These are the principal vitamins whose deficiency has
been associated with RAS. All subjects will be asked to complete a Diet History Questionnaire at the beginning and at the end of
the study. The purpose of this questionnaire is to estimate dietary intake of the vitamins being supplemented, at baseline and
over the one-year period of the study.
SUBPROJECT PROGRESS:

Number of subjects enrolling during the report period: 52, and since initiation of the study: 147. No changes in recruitment plans
are needed. There were no unexpected safety concerns. Interim data and outcomes: None. Proposed changes made or anticipated
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in the protocol: None.
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SUBPROJECT DESCRIPTION:

The effect of chlorhexidine on taste perception with whole-mouth stimulation is well established. The intensities of both salty
and bitter compounds are reduced after treatment with chlorhexidine, the active ingredient in mouth rinses used to control
periodontitis. This study addresses whether effects on salty and bitter are localized to distinct regions of the human tongue. The
hypothesis is that salty will be affected more on the front of the tongue, bitter on the back of the tongue. The hypothesis is
based on differential localization of specific taste qualities to distinct areas. For example, salt receptors are differentially located
to the front of the tongue; whereas, bitter receptors are located more to the back of the tongue. Subjects, who will be tested for
taster status with 6-n-propylthiouracil, will be 24 paid volunteers. Treatment rinses include 1.34 mM chlorhexidine gluconate,
the concentration in PeridexÒ, and a water control. Test stimuli are: 1.0 M NaCl, 32 mM citric acid, 1.0 M sucrose and 1.0 mM
quinine. Subjects will participate in 2 sessions, with one rinse condition per session (1.34 mM chlorhexidine or water) and at
least 2 days between sessions. Rinse condition for sessions will be randomly assigned. Following a 5-min waiting period after the
treatment rinse, stimuli will be applied with a cotton swab to 8 points on the tongue: The tip, lateral edge, dorsal rear and palate,
bilaterally; exactly as presented in the Taste and Smell Clinic Spatial Taste Test. Bilateral test stimuli will be presented at a pace
of 1 per min. The effect of chlorhexidine on different tongue regions will be analyzed using repeated measures Analysis of
Variance (ANOVA). Within subjects factors include time (before and after treatment rinse), chlorhexidine concentration (0,
1.34 mM), and stimulus compound (NaCl, citric acid, sucrose, quinine). Our predicted outcome is that chlorhexidine effects on
bitter taste will be more substantial on the tongue's lateral edge and dorsal rear sites than on the tongue tip and palate. The
chlorhexidine effects on the salty taste will be the opposite: more substantial on tongue tip and palate than on lateral edge and
dorsal rear tongue sites. An alternate outcome is that effects on salty and bitter tastes will be similar in all regions
SUBPROJECT PROGRESS:

This year we published one paper. The abstract follows.
Regional specificity of chlorhexidine effects on taste perception.
Grover R, Frank ME.
Chlorhexidine (CHX) gluconate, a bitter bis-biguanide antiseptic, reduces the intensity of the salty taste of NaCl and bitter taste of
quinine in humans.
This study addresses regional specificity of CHX's effects on taste. Perceptual intensity and quality were measured for separate taste
bud containing oral loci innervated either by afferent fibers of cranial nerve (CN) VII or CN IX. Measurements were obtained
following three 1-min oral rinses with either 1.34 mM CHX or water, the control rinse. CHX rinse reduced the intensity of NaCl
more at the tongue tip and palate than at posterior oral sites. Thus, fungiform and palatal salt-taste receptors may differ from
salt-taste receptors of the foliate and circumvallate taste papillae. The intensity of quinine.HCl was reduced equally by CHX at all
sites tested but was frequently tasteless on the less sensitive anterior sites, suggesting quinine receptor diversity. In rodents, a
portion of NaCl-taste receptors in the receptive field of CN VII is sensitive to the epithelial Na+ channel blocker amiloride and a
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portion is amiloride insensitive; all CN IX receptors are amiloride insensitive. The current results are the first to suggest that there
may also be distinct, regionally specific populations of NaCl-taste receptors in humans.
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SUBPROJECT DESCRIPTION:

Cigarette smoking is responsible for the greatest number of preventable poor outcomes among pregnant women. How tobacco
smoke harms developing fetuses is largely unknown. We propose to explore mechanisms that may explain how maternal
tobacco use leads to low birth weight among infants. This translational tobacco research project focuses on identifying new
biomarkers of prenatal tobacco exposure, which is important to understanding the effects of maternal smoking on infants and
children. Project 1 hypothesizes that tobacco smoke changes the chemical structure of genes in the placenta (i.e., DNA
methylation) and in the baby critical to fetal growth by altering Deoxyribonucleic acid (DNA) methylation. The ultimate effect
of these changes may be low birth weight. Cord and placental tissue will be obtained at the time of delivery from 15 smokers and
from 15 nonsmokers. Many of these samples will be obtained from subjects who are already participating in R01 "Nicotine
Replacement Treatment for Pregnant Smokers" that is being conducted at Hartford Hospital.
Maternal DNA will be extracted using our standard techniques. The DNA will be subjected to sodium bisulfite treatment that
converts unmethylated but not methylated cytidine to uracil. Sodium bisulfite treatment will be performed using standard
protocols. Ribonucleic acid (RNA) from umbilical cord, placenta, and maternal blood will be extracted utilizing Trizol protocol.
Measurement of Insulin-like growth factor 2 (IGF2) Messenger Ribonucleic Acid (mRNA) levels will be performed by standard
quantitative real-time polymerase chain reaction (RT-PCR) techniques.
SUBPROJECT PROGRESS:

We have enrolled 15 smokers and non-smokers to examine methylation of IGF2 gene in cord tissue. Of these subjects, IGF2
analyses has been analyzed by Dr. Lalandes, lab, but their were questions regarding validity of the data. The General Clinical
Research Center (GCRC) lab is now confirming this analyses. And finally, Hur data analyses is also underway. We hope to have this
completed by august of 2008. Thus, All subjects have been enrolled. We are currently analyzing the samples and hope to report the
data in a manuscript in the coming year.
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SUBPROJECT DESCRIPTION:

The general goal of the proposed work is to test a theory that links the Catechol-O-methyl transferase (COMT) and
gamma-aminobutyric acid A receptor, alpha 2 (GABRA2) genes to intermediate phenotypes, and, in turn, to the important
clinical problem of relapse to substance abuse. It will test whether genes that have been empirically linked to substance
dependence, and to measures of frontal brain function (viz., fast b power in the spontaneous electroencephalogram and frontal
P300a amplitude), also confer an increased risk for relapse to these disorders. The specific goals of the project are: (1) to
examine whether the genotypes of 100 cocaine-, heroin, or polydrug-dependent patients who return to substance use within 4
months after study enrollment are different from those of 100 patients who successfully maintain abstinence and 50
non-substance-dependent controls; (2) to replicate our previous findings of enhanced electroencephalographic (EEG) fast b
activity and reduced frontal P300a amplitude in patients who return to substance use in comparison to patients who maintain
abstinence and to healthy non-substance-dependent controls; (3) to determine if polymorphisms in GABRA2 and COMT genes
are respectively associated with phenotypic variation in EEG fast b power and frontal P300a amplitude; (4) to determine if
genetic markers improve the prediction of relapse beyond the predictive accuracy attained with EEG fast b power and frontal
P300a amplitude, in combination with other known risk factors, including severity/chronicity of dependence, age, type of
substance dependence, and Antisocial Personality Disorder.
SUBPROJECT PROGRESS:

This report describes progress during Year 3 of NIDA grant # R01 DA017666-01A2, "Genetic versus phenotypic markers of
relapse risk". As described in our progress report for Years 1 and 2, the recruitment and screening of study participants began on or
about February 1, 2006. As of March 13, 2008, we have successfully recruited and tested 96 patients. The current number of
recruits is slightly behind our projected goal. We are now (March 2008) in the 32nd month (i.e., approximate mid-point) of a 60
month project and are only 29 subjects shy of recruiting 50% of the sample. We are not concerned about this minor shortfall
because we are now beginning to recruit 50 subjects to fill a healthy group of non-drug-dependent subjects who will be
demographically matched to the patients. The subjects forming this group can be acquired and completed easily because they are
required to participate in one laboratory session only and are not followed over time (unlike the drug dependent groups). Thus, in a
relatively short period of time, our recruitment total can jump from 96 to 146. We anticipate no difficulties in attaining our final
recruitment goal.
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SUBPROJECT DESCRIPTION:

Tobacco smoke contains over 4000 chemicals and 60 carcinogens, thus the mechanisms by which maternal smoking causes fetal
and infant harm are likely to be multi-factorial. Studies suggest that infants born to smokers have altered auditory processing,
which has been correlated with deficits in reading and spelling in school-aged children. Nicotine exerts its effects mostly via
specific receptors in both neuronal and non-neuronal tissue which may, in turn modulate expression of cytokines, which act as
mediators. However the roles played by nicotinic receptors and cytokines in fetal development have not been well studied.
Objective:1.To determine if maternal smoking during pregnancy is associated with infant abnormalities in the auditory
component of the Brazelton Neonatal Behavioral Assessment Scale (BNBAS),a scale devised to test auditory function.2. To
determine if maternal smoking increases/alters nicotinic receptor (nAChR) expression in umbilical cord blood and cord tissue,a
non-neuronal tissue that is more readily available .3.To determine if maternal smoking causes an increased level of the
inflammatory cytokine interleukin-8(IL-8) in fetal circulation, which in turn may be related to neuronal injury and auditory
dysfunction in infants and in turn will serve as a potential biomarker to predict which babies are at risk.4. Differences in nAChR
expression and IL-8 production will be correlated with auditory functioning in newborn infants of smokers and non-smokers.
SUBPROJECT PROGRESS:

Study: 78 mothers were recruited, of which 44% were smokers (S) and 56% were non-smokers (NS).There was no difference in
groups with regards to ethnicity, race and sex of the baby but a difference was noted with respect to maternal age (less in
smokers-P= 0.02).The birth weight (BW) of babies in the S group(2.48 kg 0.40) was< the NS group (3.31 kg 0.40); p <0.0001.IL8
protein in cord blood/tissue was higher in S (125.03) vs NS (43.12)(F statistic = 0.0006) which correlated with poor scores on the
NBAS exam p<0.05.On logistic regression using NBAS scores and smoking status, controlling for birth weight, babies in the S group
had poor scores with regards to habituation items, with a worse performance in inanimate and animate auditory and visual
(social-interactive) items. Quality of alertness was poor in babies of S group, p = 0.01. Microarray analyses of cord tissue were done
to study differential regulation of growth related genes. Conclusions: The birth weight of babies born to smokers was < that of
non-smokers. The babies of mothers who smoked were found to have poor scores on the auditory and visual components of the
NBAS exam which when combined with high IL8 levels may help in identifying babies with neurodevelopmental problems in the
newborn period. (Abstract presented at the Society for Pediatric Research Meeting in Toronto Canada, May 6, 2007). The results
of microarray studies were presented at the Eastern Society of Pediatric Research meeting in Philadelphia (March 2008) A
manuscript based on the microarray findings in umbilical cord samples, was submitted to 'Pediatric Research' for publication. The
journal has accepted it for publication and we expect to see it in their August 2008 issue.
Another manuscript based on the Brazelton findings is in preparation.
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Placental cotinie levels have been analyzed and the data are being evaluated.
Further work is planned on studying the placental samples for genes of interest and collaborations with other researchers are being
sought.
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SUBPROJECT DESCRIPTION:

Fatigue is the most common and the most debilitating symptom of cancer and cancer treatments. In at least 50% of cancer
patients, the etiology of fatigue remains unidentified even after a comprehensive work-up. This idiopathic' cancer fatigue (iCF)
is highly prevalent in patients with breast cancer and prostate cancer. Despite its high prevalence and its devastating effect on
quality of life, very little evidence exists on pharmacological interventions for treatment of this incapacitating problem
affecting the lives of millions of cancer patients. Until we identify the precise mechanisms underlying the pathophysiology of
cancer fatigue, it is crucial that we evaluate and develop novel pharmacological interventions targeting the general hypoarousal
mechanisms. The analeptic properties of thyrotropin-releasing hormone (TRH) are well established in multiple animal models.
Intravenous TRH studies conducted in patients as a cognitive enhancer and an antidepressant, confirmed these analeptic actions
of TRH. Patients in these trials showed significant and persistent improvement in energy, motivation, cognition and
psychomotor retardation. This novel pilot study proposes a 4-week randomized double blind placebo-controlled cross-over trial
to evaluate the efficacy and safety of synthetic thyrotropin-releasing hormone (TRH) to treat cancer-related fatigue in breast
cancer and prostate cancer patients. In addition to assessing the impact of TRH administration on fatigue, we will also
investigate its impact on patients' depressive and anxiety symptoms, overall psychological status, overall quality of life and
global clinical status. We will also investigate the impact of TRH administration on immune and endocrine dysfunction
associated with the cancer-related fatigue. This pilot study is a proof-of-principle study and is a vital first step towards the future
development of TRH-based therapeutics including oral TRH analogs to treat cancer-related fatigue.
SUBPROJECT PROGRESS:

Number of subjects enrolled during the report period: 3
Number of subjects enrolled in the study altogether: 4
Any changes in recruitment plans that might be needed: As per the Progress Report from last year, we contacted Dr. Andrew
Salner, Director of the Radiation Oncology Program at Hartford Hospital, to obtain the assistance of his group in recruiting
subjects for this study, and we received Institutional Review Board (IRB) approval for adding this site. We are now communicating
with Dr. Kenneth Miller from the Cancer Center at Yale University School of Medicine to determine whether he and his radiation
oncology colleagues would be willing and able to assist us in subject recruitment. If we find that Dr. Miller and his colleagues are
willing to help with subject recruitment, we will seek and obtain the appropriate IRB approvals from Yale and the Uconn Health
Center IRB's.
Unexpected safety concerns and their resolution: None to report.
Interim data and outcomes if appropriate: No data to report at this time as we continue to remain blinded to study treatment
assignment.
Any proposed changes made or anticipated in the protocol. None
Publications: none
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SUBPROJECT DESCRIPTION:

Receptor agonists are the most important group of drugs used in the treatment of asthma. A number of studies have established
that genetic variations of the ß2-adrenergic receptor have important effects in modulating responses to therapy for asthma.
We propose to investigate the influence of a patient's ß2-adrenergic receptor genotype on the clinical response to b2-AR
agonist therapy during acute severe asthma exacerbation in children.
The overall objective is to assess the influence of a patient's ß2-adrenergic receptor (b2-AR) genotype on the clinical response
to ß2-AR agonist therapy. Our hypothesis is that children admitted with status asthmaticus who are homozygous for the Gly16
allele of the ß2-AR gene have a longer Intensive Care Unit (ICU) length of stays than children who are heterozygous at this
locus or homozygous for the Arg16 allele when treated with high-dose continuous ß2-AR agonists (both inhaled and
intravenous). Secondary aims are (1) to assess the rate of improvement in MPIS based on genotype and (2) to attempt to
correlate asthma phenotype with genotype by comparing demographic data and hospital course.
SUBPROJECT PROGRESS:

There are two arms to this trial, a prospective arm and a retrospective arm. The retrospective arm to this trial was added by
Institutional Review Board (IRB) addendum on February 28, 2006 and was approved by the General Clinical Research Center
(GCRC) Advisory Committee (GAC) on March 30th, 2006. Currently 74 children have enrolled in the prospective arm and 37
children have enrolled in the retrospective arm. The retrospective arm of this trial is completed and now closed. In the
prospective arm, we plan to enroll 90 children over a 3 year period. Enrollment in the prospective arm began on December 28th,
2005 and should complete enrollment in the Fall of 2008. The core laboratory at the General Clinical Research Center (GCRC)
has successfully able to obtain genotype results on all patients enrolled in the study.
There have been no safety concerns with this study. Nor are there any proposed changes or anticipated changes in the protocol or
in the recruitment plans.
In the retrospective arm, since the previous report, we have enrolled an additional 5 patients into this study (now n=37). The
addition of these subjects did not change the results of this study. Children with the Gly/Gly genotype had significantly shorter ICU
length of stay, duration of continuous albuterol therapy, and were significantly less likely to require IV ß2-AR therapy than
children with other ß2-AR genotypes. We concluded that a child's ß2-AR genotype significantly affected that child's response to
acute ß2-AR agonist therapy. An abstract summarizing these findings was presented at the American College of Chest Physicians
International Meeting in October 2007. Support and funding from the GCRC was been sited in this abstract. There have been no
safety concerns or adverse events associated with this study. There are no proposed changes to this study. Other than the abstract
submitted above, there have been no associated publications.
In the prospective arm, since the previous report, we have enrolled an additional 27 patients into this study (now n=74). This
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enrollment was slower than expected due to a milder than expected asthma season with less children requiring ICU admission.
However, we continue to plan on completing enrollment this Fall, following the Spring 2008 and Fall 2008 asthma seasons. At
interim analysis, genotyping data is available for 67 of these 74 children. Thus far, at amino acid position 16, fifteen (22%)
children had the Gly/Gly genotype, six (61%) children had the Arg/Arg genotype, and forty-one (61%) children were heterozygous
(Arg/Gly). There were also similar admission severity of illness between in these two groups of children as quantified by admission
MPIS. However, those children with the Gly/Gly genotype had significantly shorter ICU length of stay and duration of
supplemental oxygen therapy when compared to those with Arg/Gly or Arg/Arg genotypes. This supports the findings in the
retrospective arm of this trial.
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SUBPROJECT DESCRIPTION:

The study of adults with serious mental illness will evaluate two promising manualized therapeutic interventions for complex
post-traumatic stress disorder (PTSD): 1) Trauma Adaptive Recovery Group Education and Therapy (TARGET) and
Present-Centered Therapy (PCT), as proposed in the Principal Investigator's (PI's) National Institute of Mental Health
(NIMH) Career Development study grant. Both interventions will provide 16 one-to-one educational and therapeutic sessions
that teach coping skills and stress reduction techniques. The aims of the study are: Aim 1) To test how participation in
TARGET and PCT relates to clinically and statistically significant improvements will occur in PTSD symptoms, psychosocial
functioning, and emotion/impulse regulation; Aim 2) To compare the differential affects of TARGET and PCT on affect
regulation, social support, stress-related information processing and cognitive coping, and the reduction of serious mental illness
(SMI) symptoms; Aim 3) To identify changes in daily self-regulation after TARGET and PCT. A diverse sample (N=60) of
adults will be recruited in the UConn Department of Psychiatry Partial Hospital Program (PHP) and offered the opportunity to
receive 16 sessions of individualized counseling when they are discharged from PHP. After screening for eligibility and obtaining
valid signed consent forms, participants will be randomly assigned to one of the two experimental conditions. Psychometric
self-report and daily monitoring measures will be obtained at baseline, post-treatment, and 4-month follow-up assessments and
multivariate statistical techniques will be used for analysis of treatment effects. The study builds on findings by the PI and Co-I
Albert who have demonstrated that adults with SMI commonly have untreated PTSD.
SUBPROJECT PROGRESS:

One participant has been enrolled in this study since 4/1/07. A total of 20 participants have been enrolled since the start of the
study, and is currently closed to enrollment. All of the participants have completed treatment and follow-up interviews. The
interactive voice response system (IVR) component operated by the GCRC has also been completed by all study participants. The
UCHC IRB has approved the study until 11/10/08. At the next continuation, a request will be made for expedited review for data
analyses only.
There have been no unexpected safety concerns in the past year, however, there was one serious adverse event reported to the
UCHC IRB due to a study participant being hospitalized for psychiatric reasons. This was an expected event due to the population
that was included for enrollment.
There was an addendum included with the last continuation for approval of the John Dempsey release of information form to be
stamped by the IRB to allow for communication with staff from the partial hospital program (PHP). This allowed for
communication with the PHP staff regarding referring individuals for the study and to be able to communicate necessary
information without breaking confidentiality.
The data are currently being prepared for analyses. No outcomes are ready to be reported at this time. There have been no
publications, but hopefully this data will provide significant results that will facilitate future grants and enable us to further include
those that have mental illness and substance use issues and are also coping with past traumatic experiences to research and provide
treatment.
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Metformin on Cardio Markers
Effect of Metformin on Cardiovascular Markers in Obese Adolescents Pilot Study
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PREVENTIVE CARDIOLOGY
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SUBPROJECT DESCRIPTION:

Obesity has been linked to hyperinsulinemia due to insulin resistance. Insulin resistance is defined as the inability of insulin to
act at the level of its target tissues. It contributes to arterial endothelial dysfunction, which in turn is a marker for impending
cardiovascular disease. As the incidence of childhood obesity approaches epidemic proportions, there is a strong need to
decrease their cardiovascular risk in the long term. Metformin, an oral hypoglycemic agent, decreases insulin levels while
improving endothelial dysfunction and decreasing serum markers for heart disease, in obese adults.
Our hypothesis is that metformin will decrease cardiovascular risk factors in obese adolescents with hyperinsulinemia. Our
specific aims are: 1) to examine the effect of metformin on the following surrogate markers of cardiovascular disease: a)
Endothelial function via ultrasound to assess dilation of the brachial artery. b) Serum markers namely C-reactive protein, von
Willebrands factor, fibrinogen, homocysteine and a fasting lipid profile. 2) to study the correlation of these cardiovascular
markers on indices of insulin sensitivity, namely Homeostasis Model Assessment (HOMA-index) and Quantitative insulin
sensitivity check (QUICKI). Our plan is to conduct a double blinded, placebo controlled trial and measure the above at baseline
and at the end of sixteen weeks. We will enroll 15 adolescents in each group - metformin 850 mg twice a day and placebo. The
goal is an increase in dilation of the brachial artery of 5% in the metformin group and 1% in the placebo group; using a within
subject variability of 3-4%, two-tailed significance level of 0.05 and power of 80%.
SUBPROJECT PROGRESS:

No subjects were enrolled during the report period. 44 subjects were enrolled since the initiation of the study. There are no
unexpected safety concerns. Data analysis has ben completed.
We had baseline data on 44 subjects. 54% of subjects had an elevated Cardiac CRP, 77% of subjects had an elevated fibrinogen, 52%
of subjects had elevated brachial flow mediated dilation (FMD). Waist circumference correlated with area under the curve of glucose
(r=0.428). BMI correlated with systolic blood pressure (r=0.448) and with TSH (r=0.441). Triglycerides correlated with markers of
insulin {AUC-I (r=0.650), AUC-G (r=0.493), HOMA-R (r=0.487), QuickI (r=-0.482) and ISI (r=-0.602)}.
29 subjects completed the 16 week study. Metformin did not produce any changes when compared to placebo. Change in absolute
levels of 25 hydroxyvitamin D correlated positively with fibrinogen (r=0.705), positively with triglycerides (r=0.701), negatively
with peak FMD (r=-0.738) and negatively with HOMA-R (r=-0.576). The percentage change in AST from baseline correlated
negatively with the percentage change in CIR 30 (r=-0.544). (p<0.01 for all correlations).
Conclusions: Cardiometabolic abnormalities are common in obese hyperinsulinemic adolescents. We found correlations between
markers of obesity, insulin resistance, cardiovascular disease and non-alcoholic fatty liver disease. TSH correlated with BMI
suggesting that there may be some subclinical hypothyroidism in this group. An increase in Vitamin D levels was associated with a
decrease in insulin resistance but an increase in cardiovascular disease markers.
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There are no publications to date. The study is closed.
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Zonisamide versus Placebo in the Treatment of Alcohol Dependence
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SUBPROJECT DESCRIPTION:

This is a pilot study designed to examine the potential efficacy and tolerability of zonisamide for the treatment of alcoholism,
and to compare this to topiramate, a similar medicine with demonstrated efficacy in a randomized clinical trial. Zonisamide is
potentially better tolerated and easier to titrate in the outpatient setting than topiramate.
SUBPROJECT PROGRESS:

A total of 15 subjects were enrolled during the report period (a total of 24 since initiation of the study). As of 3/31/08, a total of
20 subjects had been randomized to receive treatment with either zonisamide or placebo.
We have not changed the recruitment plans, and are not planning any changes, although we did modify the advertisements in order
to clarify that counseling is offered as part of study participation. There have been no unexpected safety concerns associated with
this study.
Interim outcomes data are not available at this time. There have been no publications associated with this study since data
collection is ongoing.
Changes made in the protocol during the report period were: 1) addition of Dr. Carolyn Drazinic as a co-investigator (change made
to the Informed Consent Form (ICF) as well), 2) a revised Health Insurance Portability and Accountability Act (HIPAA) form was
added, 3) The protocol and ICF were modified to add the rare/uncommon (but expected) possible adverse effects of paresthesia and
taste perversion, 4) a new subject handout was added that illustrates standard drinking and educates the patients on non-hazardous
drinking. All of these modifications have been approved by the IRB.
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Topiramate alone or in combination with the nicotine patch for smoking cessation
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SUBPROJECT DESCRIPTION:

1. To obtain pilot data on 4-week continuous quit rates associated with either 12 weeks of treatment with topiramate alone or
topiramate in combination with 10 weeks of nicotine patch for smoking cessation.
2. To obtain pilot data on the effects of 12 weeks of topiramate alone or topiramate combined with 10 weeks of nicotine
patch, on nicotine withdrawal symptoms, smoking satisfaction, and adverse effects during smoking cessation.
3. To obtain pilot data on weight gain over 12 weeks with either topiramate alone or topiramate in combination with the
nicotine patch.
SUBPROJECT PROGRESS:

71 subjects screened and 53 subjects have been randomized to treatment. Our goal is 60 subjects randomized to treatment. We
have not analyzed any data.
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SUBPROJECT DESCRIPTION:

Alcohol abuse and dependence are important public health problems. Inherited (i.e., genetic) risk factors are thought to be
important in the development of alcohol use disorders. Recent family-based and case-control studies of genetic factors in
alcohol dependence indicate that variation in the GABA-A gene, GABRA2, is associated with alcohol dependence. Our
preliminary results from alcohol challenge studies in humans suggest that variation in GABRA2 also influences the subjective
effects of alcohol, suggesting a potential mechanism by which the gene may influence risk of alcohol dependence. Based on
these preliminary data, the aims of this study are to: 1) examine the effect of alcohol on multiple domains of the response to
acute alcohol administration in 30 social drinkers and to 2) examine the moderating effect of GABRA2 genotype on these
subjective measures in response to acute alcohol administration. We hypothesize that, during the ascending limb of the BrAC,
the stimulating and rewarding effects of alcohol will be moderated by GABRA2 genotype, such that individuals who are
homozygous for the A-allele at SNP rs279858 (an intronic marker in GABRA2) will show a greater response to the effects of
alcohol than will carriers of the alcohol-dependence-associated G-allele. In contrast, other effects of alcohol, such as sedation,
motor incoordination, and decreased cognitive performance (the latter two measured by static ataxia and working memory,
respectively), will not be influenced by GABRA2 genotype, as these effects are more likely to involve modulation of receptors
containing the GABA-A á-1 subunit. The identification of specific genetic determinants for variation in the quality or
magnitude of responses to alcohol may help in our understanding of why some individuals are vulnerable to, or protected from,
alcohol dependence.
SUBPROJECT PROGRESS:

1) Number of subjects enrolled during the report period: 90 Since initiation of study: 156.
2) Planned changes in recruitment plans: Study enrollment expected to be complete by end May 2008.
3) Unexpected safety concerns and their resolution: There have been no unexpected safety concerns associated with this study and
no serious adverse events. Approval was requested and received from the IRB for subject 612-086's to repeat 2nd lab session due to
an alcohol dosing error by the pharmacy (problem reported to the Institutional Review Board (IRB)).
4) Interim data: none to date, awaiting completion of study.
5) Proposed changes made past year or anticipated in the protocol: Cheryl Oncken and Grace Chen were added as co-investigators.
IRB approved Principal Investigators (PIs) request to increase in enrollment to 200 subjects on 8/13/07. Approval was requested to
conduct a brief pre-screening visit for initial medical eligibility and to obtain saliva for genetic inclusion testing. This could occur
off site (especially those at UCONN Storrs campus). IRB approved on 9/10/07. Approval was requested to add an additional
specific aim #3, investigation of genetic variation in other candidate genes beyond GABRA2 and between subject differences in
alcohol response. Several other genes are emerging from literature reports as being related to alcohol effects or alcohol
dependence. Protocol and ICF were modified to address this change. Protocol was also modified to correct the current IRB
approved enrollment number. IRB approved on 11/5/07. Request made to IRB and approved for increase in potential number of
study completers to 80 (from 60) in the event a larger than anticipated number of subjects complete all 3 monthly lab sessions.
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IRB approved January 2008 - A recruitment web site URL - www.uchcalcoholstudy.com (refer to study #1) - was added to all
recruitment materials for this study. The PI purchased a short easy to remember URL www.uchcalcoholstudy.com for a site that
we may use to link interested potential participants to our study brochure, ICF and contact information contained in a separate web
page.
6) Continued General Clinical Research Center (GCRC) support requested - We request the GCRC protocol remain active, resource
needs - GCRC clinic exam room for alcohol lab session, GCRC nursing/research assistant support for alcohol lab sessions, core lab
for DNA isolation and genotyping.
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Vouchers versus Prizes for Cocaine-Dependent Methadone Patients
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SUBPROJECT DESCRIPTION:

About 40-60% of methadone maintenance patients are also cocaine dependent. Cocaine dependence is associated with
significant morbidity and mortality, but few traditional therapies are efficacious in treating cocaine dependence in this difficult
patient population. Contingency management (CM) strategies that provide positive incentives upon direct evidence of cocaine
abstinence are promising interventions. Typically, vouchers, exchangeable for retail goods and services, are used as reinforcers.
When voucher amounts range from $1000 to $3000 over a 12-week treatment period, CM can reduce cocaine use in
methadone patients. We have data from cocaine-dependent patients treated in drug-free settings that suggest a novel
reinforcement system that provides the chance to win prizes, rather than vouchers, may also be efficacious in decreasing
cocaine use, at potentially lower costs. The purpose of the study is to evaluate the efficacy of voucher and prize CM in
cocaine-dependent methadone patients.
Cocaine-dependent methadone patients (n=240) will be randomly assigned to one of four conditions: standard treatment,
standard treatment plus usual magnitude prize CM ($300), standard treatment plus higher magnitude prize CM ($900), or
standard treatment plus voucher CM ($900). Urine samples will be screened 2-3 times weekly for 14 weeks, and follow-up data
will be collected throughout a 12-month period. We expect that CM will decrease cocaine use relative to standard treatment, the
efficacy of prize CM will be magnitude dependent, and $900 prize CM will be more efficacious than $900 voucher CM.
We will also examine patient characteristics and their association with treatment response. Further, we will obtain a detailed
analysis of relapse following CM treatment and evaluate the cost-effectiveness of CM. In sum, this study will provide a stringent
test of the relative efficacy and cost-effectiveness of voucher and prize CM, and it will address moderators of response to CM in
the treatment of cocaine-dependent methadone patients.
SUBPROJECT PROGRESS:

Total Enrollment: 131
Past Year Enrollment: 65
No changes in recruitment plans are needed.
•
No unexpected safety concerns have occurred.
•
Interim data and outcomes are not available.
•
Changes to protocol: 1) Removed Tressa Hanson as study coordinator and contact. Danielle Barry and Ellen Ciesielski were
added as study coordinator and study contact, respectively. Sean Sierra and Shanelle Carmichael were added as consenters and Todd
Olmstead was added as co-investigator. 2) Clarified description of when the Service Utilization questionnaire (SU) is administered
(at baseline and at each follow-up interview). 3) Expanded the description of the payment for urine samples submitted to include
other small items up to $3 in value (e.g., toiletries, snacks, bus tokens, etc.) in addition to gift certificates in the protocol and
Informed Consent Form (ICF). 4) Revised the description of standard treatment in the protocol because we have observed that
clinics vary on whether group therapy is mandated. 5) Clarified the form of payment for interviews by adding the words "in gift
certificates" for the baseline assessment and "check" for the follow-up assessments in the protocol. 6) Removed two outdated
references to the Substance Dependence Severity Scale (SDSS) in the protocol. 7) Clarified that FileMaker is used in conjunction
with Excel and SPSS for data in the protocol. 8) Added a Methadone Treatment History Questionnaire. 9) Three questions added to
the Addiction Severity Index regarding Medical Status and Drug/Alcohol Use. 10) A comments Box added to the bottom of page 2
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of the Brief Symptom Inventory to document any discussion regarding suicidal or homicidal ideation if needed for potential adverse
events records. 11) Additional codes and spaces were added to the Service Utilization in order to improve the accuracy of data
collection and questions regarding visits with parole officers were also added. 12) Removed outdated phone number from one
recruitment flyer.
•
Results not yet published as study is ongoing.
Do you wish to continue to receive GCRC resources for the period April 1, 2008 through March 31, 2009? Yes
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SUBPROJECT DESCRIPTION:

Our main goal is to improve the skeletal health of children with cerebral palsy (CP), a population with a high lifetime risk of
fractures. In this study we seek pilot funding to examine the prevalence of vitamin D (vit D)
insufficiency and deficiency in children with CP in the greater Hartford area. This is a necessary step before a planned
intervention trial of vit D in children with CP. Vit D sufficiency is a requirement for normal bone
mineralization, and plays roles in muscle strength, regulation of cell differentiation and immune function. Consequently, it is
desireable to prevent vit D insufficiency/deficiency in children in general. Children with CP
may be at higher risk for vit D deficiency because of limited exposure to unfiltered sunlight, impaired nutrition because of
swallowing dysfunction and use of anticonvulsants that increase vit D breakdown. In addition, vit
D deficiency is more prevalent in Northern latitudes, even among healthy children. In consequence, children with CP in the
greater Hartford area may be at particular risk for vit D insufficiency/deficiency. However, there are no prevalence data
concerning the sufficiency of vit D stores in children with CP in our geographical area. Our anecdotal clinical experience
indicates that children with CP frequently have reduced serum 25 (OH) vit D, an indicator of vit D reserves. Therefore, we
hypothesize that children with CP in the Hartford area have a higher prevalence of vit D deficiency than healthy children. To
test this hypothesis, we aim to measure serum 25 (OH) vit D in children with CP and their unaffected, healthy siblings living in
the same household. Seasonal differences will be examined, since vit D stores tend to decrease in colder, dimmer months. We
will invite children with CP who are followed at the Special Kids Support Center (SKSC) at the Connecticut Children's Medical
Center (CCMC) to participate. These children are well characterized clinically, including use of
anticonvulsants. Multiple clinical specialists will assess these children. Children with CP will have motor function assessment
during the study visit at SKSC and a clinical nutritionist will obtain data on calcium and vit D intake. The PI will exclude
primary and secondary bone diseases. Children with vit D deficiency will be treated with oral vit D. This screening study will
provide pilot data for a subsequent intervention trial that aims to find the optimal dose of enteral vit D to restore normal vit D
status in children wit CP. Timely identification and treatment of vit D deficiency will improve bone health in these fragile
individuals.
SUBPROJECT PROGRESS:

Total of 62 subjects were enrolled in the study since the initiation. There are no changes in the recruitment plan. There are no
unexpected safety concerns. There are no anticipated changes in the protocol. There are no publications based upon the current
study yet.
We analyzed the data of 62 subjects and submitted the findings as an abstract to the Annual Meeting of American Society for Bone
and Mineral research. The abstract including the available data is as follows:
Is Vitamin D deficiency more common in children with cerebral palsy than in healthy children?
S.Yigit , B. McKinney, J.Pedersen, B.Draheim, F.Sylvester
Children with cerebral palsy (CP) may be at higher risk for vitamin D(vit D) deficiency because of limited exposure to unfiltered
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sunlight, impaired nutrition because of swallowing dysfunction and use of anticonvulsants that increase vit D breakdown. In
addition, vit D deficiency is more prevalent in Northern latitudes, even among healthy children. Therefore, we hypothesized that
children with CP have a higher prevalence of vit D deficiency than their unaffected siblings. To test this hypothesis, we measured
serum 25 (OH) vit D (RIA, Immunodiagnostic Systems Ltd, Fountain Hills, AZ) levels in children with CP and their unaffected,
healthy siblings living in the same household. Seasonal differences were examined. Vit D deficiency was defined as serum level <15
ng/ml and vit D insufficiency as serum level < 20 ng/mL based on previously published pediatric studies. 31 children with CP and 31
healthy siblings as controls between ages of 6 -18 years were enrolled. 12.9 % of children with CP were vit D deficient while 29 %
of the siblings were deficient. Vit D insufficiency was found in 29 % of children with CP and 38.7 % of healthy siblings. Only 20 %
of the children with CP and 13 % of healthy siblings had 25 (OH) vit D level of more than 30 ng/ml, a level considered as optimal.
While the mean 25 (OH) vit D levels were low on both groups, healthy siblings had a significantly lower 25 (OH) vit D levels
compared to the children with CP (mean 25 (OH) vit D level for children with CP 24.5 ± 12.9, healthy siblings 19.6± 8.4,
p=0.04). Low vit D levels were more prevalent in healthy siblings during winter season (mean 25 (OH) vit D level for children with
CP 33.2 ± 16.5, healthy siblings 19.8± 8.8, p=0.01). 80 % of the healthy siblings were consuming < 1 serving of milk per day. 58.8
% of the children with CP who had sufficient vit D levels were on supplemental tube feedings. Only one CP patient with vit D
deficiency was on tube feedings but was on a ketogenic diet. None of the healthy siblings were taking vit D supplements while only
2 children with CP were on multivitamin supplements. Vit D deficiency/ insufficiency appear to be a prevalent public health care
problem in both children with CP and healthy children. Although children with CP have higher risk factors, healthy siblings seem
to have a higher prevalence of vit D deficiency/ insufficiency. Children with CP who are on tube feedings are less likely do develop
vit D deficiency/ insufficiency. Healthy children may need counseling for prevention.

6/27/2008 9:32:04AM

144

5M01RR006192-14
SPID:

REPORT PD: 04/01/2007-03/31/2008

0617

617

PROTOCOL:

Final
TYPE: RESEARCH

SHORT TITLE:
LONG TITLE:

Weight Reduction
Prevalence and Predictors of Weight Reduction Activities in Metabolic Syndrome

AIDS:

N

START DATE:

TOTALS

3/1/2006

Total # pts expected for entire study:

5,643

Inpatient

A
0

B
0

D
0

Scatter Bed

0

0

0

Outpatient

0

0

0

Scatter RN Hours

0

0

0

Offsite Visits

0

0

0

RESEARCH BIONUTRITION

N

MULTICENTER STUDY

N

INFORMATICS CORE

Y

CLINICAL TRIAL

N

BIOSTATISTICIAN

Y

CORE LAB

N

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

WALSH, STEPHEN J SCD

Ctr for Biostatistics

KENNY, ANNE MD

Center on Aging

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Metabolic syndrome is a major risk factor for cardiovascular disease (CVD). It involves the clustering of three or more of the
following conditions -obesity, hypercholesterolemia, hyperglyceridemia, hypertension, and hyperglycemia. Available
prevalence estimates suggest that 20-to-25 percent of the U.S. adult population currently have this syndrome. Numerous studies
demonstrate that weight loss via changes in diet and exercise can reduce the severity, and even the existence, of these
conditions. However, at the present time, no published investigation has reported on the frequency, circumstances, or success of
weight reduction activities among persons with metabolic syndrome. The broad objective of the research outlined in this
proposal is to address this gap in our understanding of metabolic syndrome and, thereby, to provide a basis for the formulation
of public health initiatives that might reduce its severity, prevalence, and evolution into CVD. Using data from the National
Health and Nutrition Examination Survey (NHANES) we will conduct statistical analyses to address the following questions:
1. Do individuals with metabolic syndrome perceive obesity and being overweight as a problem that needs to be addressed?
2. What nutritional and lifestyle changes are persons with metabolic syndrome undertaking in order to manage the condition
and its effect on levels of CVD risk?
3. What factors enhance and/or inhibit the initiation of weight loss activities among persons with metabolic syndrome?
4. Which types of weight loss activities hold the most potential for achieving weight loss in those with metabolic syndrome?
The project will utilize staff and expertise of the Biostatistics Core of the University of Connecticut General Clinical Research
Center (GCRC) and faculty clinicians. The proposed project will contribute to our understanding of the scope and, perhaps,
growth of the epidemic of metabolic syndrome in the U.S. population. It will also shed light on the simplest and most
economical factors through which that epidemic might be controlled.
SUBPROJECT PROGRESS:

This project utilizes the GCRC Biostatistics Core to analyze data from the 1999-2000, 2001-2002, and 2003-2004 waves of the
National Health and Nutrition Examination Survey (NHANES). Since the survey has already been administered by the National
Center for Health Statistics, the project does not involve enrollment of new subjects at the University of Connecticut Health
Center (UCHC) or within the GCRC. Because the project involves only the analysis of existing, publicly available data, the UCHC
Institutional Review Board has determined that it does not constitute human subjects research. Therefore, there are no issues
related to subject recruitment and no issues related patient safety.
By the end of Year 14 of GCRC funding, statistical analyses for this project were essentially complete (except for minor
refinements) and a manuscript was in preparation. Study findings include the following: 1. demonstration that increases in the
national prevalence of metabolic syndrome among adults in the United States continue to occur, having reached a level of
approximately 34% during the 1999-2004 period; 2. discovery that metabolic syndrome develops through two distinct patterns of
risk factors that appear to be determined substantially by age -one pattern that occurs primarily before age 40 and another that
occurs primarily after age 50; 3. determination that, on an annual basis, approximately 50% of persons with metabolic syndrome
who are overweight engage in some type of "weight loss" activity and that approximately 50% do not; 4. determination that, on
an annual basis, less than 20% of persons with metabolic syndrome who are overweight succeed in intentionally losing 10 pounds or
more; 5. demonstration that physician advice regarding overweight status, the presence of other metabolic syndrome components
(high blood pressure, high cholesterol, and diabetes), and the need for weight loss constitutes one of the strongest predictors both of
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the attempt to lose weight and of successful weight loss; 6. recognition that more than 40% of individuals with metabolic syndrome
who are overweight report that they have never been told by their doctors that they are overweight. Use of GCRC resources will
continue into Year 15 of GCRC funding, but the resources required (primarily, time from Biostatistics Core staff) will be minimal.

6/27/2008 9:32:04AM

146

5M01RR006192-14
SPID:

REPORT PD: 04/01/2007-03/31/2008

0618

618

PROTOCOL:

TYPE: RESEARCH

SHORT TITLE:
LONG TITLE:

Girls in Recovery
Girls in Recovery from Life Stress (GIRLS)
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N

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

FORD, JULIAN PHD

Psychiatry

ABU-HASABALLAH, KHAMIS PHD

Psychiatry

ASTUR, ROBERT PHD

OLIN CENTER

MOFFITT, KATHIE H PHD

Psychiatry

STEINBERG, KAREN PHD

Psychiatry

STEVENS, MICHAEL PHD

OLIN CENTER

TENNEN, HOWARD PHD

Community Medicine

NON-HOST INSTITUTION: STATE,
COUNTRY

HARTFORD HOSPITAL, CT USA

HARTFORD HOSPITAL, CT USA

SUBPROJECT DESCRIPTION:

The purpose of the GIRLS study is to provide counseling to adolescent girls in the juvenile justice system who are experiencing
Post Traumatic Stress Disorder (PTSD) to help them regulate their emotions, planning, decision-making, and actions/
interactions in ways that will reduce PTSD and enhance their safety, responsible civic involvement, learning, peer, family, and
adult relationships, and physical and psychological well-being.
The study will be the first randomized clinical trial of two promising manualized therapeutic interventions for complex
post-traumatic stress disorder (PTSD): 1) Trauma Adaptive Recovery Group Education and Therapy (TARGET; Frisman, Ford,
& Lin, 2004) and Life Skills/Life Story (LS/LS; Cloitre et al., 2002). Both interventions will provide 16 one-to-one educational
and therapeutic sessions that teach coping skills and stress reduction techniques.
The aims of the study are:
1) To test how participation in TARGET and LS/LS relates to clinically and statistically significant improvements will occur in
PTSD symptoms, psychosocial functioning, and emotion/impulse regulation;
2) To compare the differential affects of TARGET and LS/LS on affect regulation, social support, stress-related information
processing and cognitive coping, and the reduction of impulsive or aggressive thinking/behavior;
3) To identify changes in daily self-regulation after TARGET and LS/LS; and 4) To identify alterations in brain activity that
change after TARGET and LS/LS. An ethnically diverse sample (N=52) of juvenile justice-involved girls between 13 and 17
years of age will be recruited in clinic, community, detention, and residential programs. After screening for eligibility and
obtaining valid signed consent forms, participants will be randomly assigned to one of the two experimental conditions. Within
each condition, trained clinicians will administer 16 sessions of individualized counseling using manual for the specified
intervention. Psychometric self-report and daily monitoring measures will be obtained at baseline, post-treatment, and 4-month
follow-up assessments and multivariate statistical techniques will be used for analysis of treatment effects.
The research conducted highlights the need to address trauma among justice-involved youths. Most have experiences past
traumas and many exhibit risk behaviors (substance use and suicidal ideation) that jeopardize their wellbeing and reduce their
ability to engage in prosocial lifestyles. Contact with court-related services presents a critical window of opportunity. Juvenile
justice agencies have the chance to identify at-risk youths through early screening and assessment and referral to
age-appropriate and gender-sensitive treatment services.
SUBPROJECT PROGRESS:

Thirty three participants have been enrolled in the GIRLS study since 4/1/07. A total of 70 have been enrolled since the beginning
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of the study. Nine did not meet eligibility requirements at the time of the baseline interview. A total of 61 participants will be
included in the data analysis. The GIRLS study closed for recruitment at the end of February, 2008. Funding for the study is
provided by the Office of Juvenile Justice and Delinquency Prevention (OJJDP) through the end of August, 2008. This will provide
the study staff with completing follow-up interviews. Thirteen girls are currently receiving the counseling component of the study.
We expect a total of 15 girls to begin making their final round of phone calls to the interactive voice response (IVR) system
operated by the GCRC within the next 3 months.
Modifications that were approved in the past year included changes in study personnel, re-assenting of girls that would allow for the
GIRLS study staff to communicate with staff where the girls were recruited in order to help with scheduling appointments, the study
safety procedures were modified as requested by the Department of Children and Families (DCF) to allow for a streamlined protocol
in the event that a girl presents with suicidal ideation, the protocol for screening a participant was modified to include asking the
parent/guardian permission before screening was done, some of the study forms were updated and modified, one measure (traumatic
events screening inventory TESI) was modified to include specific ages of trauma occurrence, recruitment material was modified to
reflect new changes as was the consent form and protocol, the consent form was modified to reflect the reduction of follow-up
interviews from 3 to 2 if time point of the end date of the study did not allow for the final interview to be done, the treatment
completion window was extended to allow for clinician/participant vacations, illnesses, or other activities that may come up, a
reduction in the time period for the final follow-up interview was modified from 6 months to 4 to allow for all girls that were
consented to complete the 3 study interviews, and recently we submitted a modification to be able to complete the post-treatment
and follow-up interview in the participant's home. This will allow for increased number of interviews to be completed.
There have been no unexpected safety concerns in the past year, but there have been 10 adverse events concerning suicidal
ideation, one participant was arrested at her residential facility for assaulting a staff member, two girls were sent to detention from
their residential facility for aggressive behavior, and two girls went AWOL from their residential facility. A report to DCF was
made because a GIRLS study participant reported to a study clinician that her friend (also a GIRLS study participant) told her that
her stepfather was sexually abusing her. Five serious adverse events occurred regarding hospitalization for suicidal behavior. All of
these events were reported to the UCHC and DCF IRB, as well as to the review board for the Court Support Services Division
(CSSD).
The data are currently being prepared for analyses. No publications have been completed at this time.
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DA1c
Subjective and Physiological Effects of Alcohol: Role of Genetic Variation and Adrenal Hormones
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N
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COVAULT, JONATHAN MD, PHD

Psychiatry

ARIAS, ALBERT MD

Psychiatry

BAUER, LANCE PHD

Psychiatry

FEINN, RICHARD PHD

Psychiatry

KRANZLER, HENRY MD

Psychiatry
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Oral Health & Diag Science
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Psychiatry

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Alcohol has multiple pharmacological effects, though which of these effects relate to the risk of alcohol dependence is not
clear. Family-based and case-control genetic studies of alcohol dependence indicate that genetic variations of the GABAA gene,
GABRA2, influence the risk of developing alcohol dependence. Preliminary results from our alcohol laboratory studies in
humans suggest that variation in GABRA2 influences the subjective effects of alcohol. Animal studies indicate that the
neuroactive steroid allopregnanolone is an alcohol-modulated endogenous agonist at GABAA receptors and that genetic
variation in steroid 5ƒÑ-reductase type I gene which generates neuroactive steroids, may moderate alcohol effects. Studies in
humans have identified a functional ƒÝ-opioid receptor polymorphism (Asn40Asp) that moderates the feedback regulation of
the HPA axis and may be associated with variation in the neurosteroid response to acute alcohol. To better define the role of
GABRA2 gene variation, neuroactive steroids and genetic variants of 5ƒÑ-reductase and ƒÝ-opioid receptor genes on the acute
effects of alcohol in humans, we propose to conduct a laboratory study of non-alcohol dependent drinkers using a 4-session
design in which alcohol/placebo beverage is paired with dutasteride/placebo pretreatment. Dutasteride, an inhibitor of both type
I and type II 5ƒÑ-reductase enzymes, blocks the production of 5ƒÑ-reduced neuroactive steroids. This study will extend our
preliminary findings with finasteride by including a) a placebo control for alcohol, b) a more specific inhibitor of both
5ƒÑ-reductase isoenzymes, c) a larger group of subjects (including both light and heavy drinkers), d) quantitative tests of static
ataxia and response inhibition, e) plasma concentrations of neuroactive steroids and their adrenal steroid hormone precursors at
several time points following alcohol administration, and f) the effects of polymorphisms in steroid 5ƒÑ-reductase enzymes and
ƒÝ-opioid receptor genes on acute alcohol effects (including changes in levels of neuroactive steroids).
SUBPROJECT PROGRESS:

1) Number of subjects enrolled during the report period: 26 Since initiation of study: 26
2) Planned changes in recruitment plans: We will explore during the next year the feasibility of conducting the alcohol lab sessions
at the Storrs campus for the Spring 2009 semester.
3) Unexpected safety concerns and their resolution: There have been no unexpected safety concerns associated with this study and
no serious adverse events. Due to a pharmacy error in providing a lower dose of alcohol, one subject was asked and agreed to repeat
one of the lab sessions.
4) Interim data: Limited examination of data from first 15 completers currently underway. Dutasteride found to have expected
reduction in subjective responses to alcohol, but with greatest effect in 5 subjects who were classified as heavy drinkers.
5) Protocol changes made past year or anticipated:
IRB Approved on 4/12/2007: Question 13a was added to the phone screener to help determine subject's eligibility based upon
availability for completion of the study visits. Questions 27c and 27d were added to carefully screen for alcohol dependence, and
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questions 30a and 30b were added to carefully screen for drug abuse. Protocol was modified to add alcohol expectancies
questionnaire to baseline data collection. the Informed Consent Form (ICF) was modified to include the following description of
lab sessions: "In such an event, you would receive payment for that session but may or may not be invited back for any additional
drinking sessions based on decision of study investigator." ICF was modified to include the following description of time of
sessions: "This study requires a total of nine visits over a period of approximately 14-16 weeks: 1 screening visit, 4 lab sessions
(scheduled about 1 month apart), and 4 "pre-lab sessions" (which take place 2-4 days before the lab sessions)." Dr. Cheryl Oncken
was added as co-investigator. Certificate of Confidentiality (COC) was added to the study. Recruitment materials were modified to
further clarify study details concerning visits and consumption of alcohol and medication.
IRB Approved on 5/30/2007: The header for all recruitment materials was modified from "Recruiting Healthy Research
Volunteers" to a more specific header "Healthy Adult Men Needed for Alcohol Study". The study protocol was modified to include
an additional brief cognitive test - GMLT. This test adds 4-5 minutes to each assessment battery. We shortened the GoStop task
by 2 minutes making a net change of 2-3 minutes. The ICF was modified to include the name of Peter Snyder, PhD who developed
the GMLT as co-investigator of the study.
IRB Approved on 7/16/2007: Approval granted to offer subjects the opportunity to repeat the medication (or placebo)
administration followed by the alcohol lab session in the event they missed a particular lab session after they have completed the
entire set of 4 planned medication (placebo) administrations in order to make full use of the data from fully completed paired
medication and alcohol lab sessions for that subject. In other words, an additional pre-lab visit and matching lab session will be
offered to individuals who have completed 4 pre-lab visits and 3 matching lab visits (however, miss the 4th lab visit). The
additional pre-lab visit and matching lab session will be identical to the visits that the subject missed due to unforeseen events (ie
drug or placebo and alcohol or placebo drink). These visits will take place approximately one month after the subject finishes their
scheduled series of study visits. The subject will be asked to sign an additional consent form explaining these procedures & any
risks. The study phone script was modified to clarify and further explain certain details concerning the subject's involvement in the
study. A statement concerning duration of study visits and method of blood draws, at each lab session, through an IV catheter in
the arm, has been added to the phone script. The study quick reference criteria list for staff use was modified to add information
concerning the amount of blood that will be drawn at each of the visits, and it's method through an IV catheter. Questions #15a,
30, and 39-43 were added to the study phone screener and questions #20, 21, 21a, 21b, 26b, 30b, and 34 were modified to assist
with the careful screening of subjects for study eligibility.
IRB Approved on 10/18/2007: Approval granted to offer pre-screening brief visits, particularly for interested UConn Storrs
campus students or staff which would occur at the Storrs campus (Psychology Department interview room) to avoid participants
who screen out based on Body Mass Index (BMI), medical history or genetic inclusion criteria from needing to travel to UCHC.
We also offer this brief pre-screening visit at the UCHC clinical site for subjects who live nearby and would not be inconvenienced
to attend both a pre-screening visit and a baseline study screening visit should they meet study inclusion criteria at the
pre-screening visit. Approval granted for an additional ICF, ICF Form C, and Medical History form for the pre-screening visit.
Details of the pre-screening visit were added to the study phone script and study criteria list. Approval granted to include the
following forms as part of a nursing history packet (in addition to the previously IRB approved nursing history): Physician's Order
Sheet, Nursing Medical Administration Record, Medical and Alcohol Administration Sheet, EZ Screen, Physician's Sober exam,
Progress Notes, Physical Exam report, Medical Review of Systems, and Psychiatric Review of Systems. Approval granted to have
subject #619-006 repeat this lab session after his fourth lab session. In the contingency response letter of this review, a
typographical error was addressed to the approval of a repeat lab session for subject #619-006. The correct subject for the
repeated lab session was subject #619-004. Please note that the IRB approval letter was not modified to reflect the correction
made of subject #619-006 to subject #619-004.
IRB Approved on 11/9/07: Dr. Carolyn Drazinic was IRB approved as a co-investigator for this study to provide additional MD
cross-coverage if needed. ICF and protocol version dates were revised.
IRB approved at time of annual renewal January 2008:
We requested the removal of Amira Pierucci-Lagha, PhD as co-investigator for she is no longer employed at the UCHC nor
affiliated with this study. Please note that removal of Dr. Pierucci-Lagha was submitted on the 3/7/2007 IRB approved
continuation. However, her name still appears on all IRB approval cover letters & notices. We have modified the HIPAA
Authorization form, used for the pre-screening visit and screening visit, with the updated version/language now required by the IRB.
A recruitment web site URL - www.uchcalcoholstudy.com (refer to study #2) - was added to all recruitment materials for this study.
The PI purchased a short easy to remember URL www.uchcalcoholstudy.com for a site that we may use to link interested potential
participants to our study brochure, ICF and contact information contained in a separate web page. Currently, subjects are providing
timeline follow-back data on their alcohol and drug consumption. IRB approval given to contact subjects one month after
completion of their last visit (4th lab visit, or IRB approved repeat visit) to gather alcohol consumption data for the 30 days that
follow the last visit. On the day of the fourth laboratory visit, subjects will be given a pre-paid stamped envelope and a timeline
follow-back calendar, for the 30 days that follow the last visit. Subjects will be asked to complete the timeline follow-back calendar
with the number of alcohol beverages consumed within the past 30 days, and mail it back to the study staff at UCHC. Subjects will
be given a reminder call when the 30 days are soon to be due. If a subject fail to mail the timeline follow-back data after the 30
days, study staff will contact the subject to potentially collect the data over the phone. This information has been added to the
study protocol and ICF. This final 30-day reporting of alcohol use will provide additional information to monitor whether study
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participation including the pre-lab medication influences alcohol use outside of the study visit and to allow comparison of the 4 lab
study conditions on such alcohol use. Addressed IRB guidelines for deoyxribonucleic acid (DNA) testing in protocol: The study
protocol and ICF were modified to address the DNA/genetic testing aspects of this research study as recently requested by the IRB.
The following elements have been fully addressed in the protocol: An explanation of the purpose of the DNA testing aspects of
this research study and a description of the DNA test to be run on the collected samples.A description of any foreseeable risks and
discomforts to the subjects regarding DNA testing. A description of any benefits to the subject or others that may reasonably be
expected from the Deoxyribonucleic Acid (DNA) testing. A statement describing the extent, if any, to which the confidentiality
of these records/samples identifying the subject will be maintained. To responds to new IRB guidelines regarding DNA sample
storage: The protocol and ICF have also been modified to explain that all DNA samples and data sets will be completely
de-identified at the conclusion of subject enrollment and completion of the primary outcomes analysis. A notification will be sent
to the IRB once all DNA samples and phenotypic data are completely de-identified.
The protocol was updated to provide
information concerning the use of a Certificate of Confidentiality (CC) from the Food and Drug Administration (FDA) under the
Section 301(d) of the Public Health Service Act (42 U.S.C. 241 (d)) to protect the researchers from being forced, even by court
order or subpoena, to identify research subjects. (Please note that the CC was IRB approved on 4/12/2007).
All ICF's were
modified to include "DAlc" as an abbreviation to the studies name. This will help study staff distinguish and identify the informed
consents for this study.
6) Continued GCRC support requested - We request the GCRC protocol remain active, resource needs - GCRC clinic exam room for
alcohol lab sessions, GCRC nursing/research assistant support for alcohol lab sessions, ancillaries, core lab for hormone assays, DNA
isolation and genotyping.
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AIDS:

N

START DATE:

Final

TOTALS

3/23/2006

Total # pts expected for entire study:

40

Inpatient

A
0

B
0

D
0

Scatter Bed

0

0

0

Outpatient

0

0

0

Scatter RN Hours

0

0

0

Offsite Visits

0

0

0

RESEARCH BIONUTRITION

N

MULTICENTER STUDY

N

INFORMATICS CORE

Y

CLINICAL TRIAL

N

BIOSTATISTICIAN

N

CORE LAB

N

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

COVAULT, JONATHAN MD, PHD
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ARIAS, ALBERT MD

Psychiatry
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Psychiatry

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

To monitor the inhibition of 5a-reductase (5AR) enzyme activity at 1, 3, 7, 14, 21 and 28 days following administration of a
single dose of dutasteride (2, 3, or 4 mg) by measuring the change in blood levels of 3a-androstanediol glucuronide (3a-diolG) and
the ratio of dihydrotestosterone (DHT) to testosterone. To accomplish this aim, an open-label, between-subjects dose
comparison study design will be employed with subjects receiving a 2, 3, or 4 mg dosage. Subjects (up to n=40 enrolled to allow
a minimum of 24 completers) will be randomly assigned to one of the 3 dose levels. Results of this study will inform the dose
selection for a subsequent placebo-controlled, within-subject, crossover study of dutasteride on the effects of alcohol. A
secondary aim of this study is to examine the correlation of a genetic variation in the type I 5AR gene and baseline DHT/T
ratio and effect of dutasteride at day 3. A variation in this gene, whose product is one of the targets of dutasteride, has been
reported to be associated with higher baseline levels of DHT.
SUBPROJECT PROGRESS:

1) Number of subjects enrolled during the report period: none since initiation of study: 26
2) Planned changes in recruitment plans: The study is currently closed to enrollment. The last subject completed participation of
this study on 01/02/07.
3) Unexpected safety concerns and their resolution: There were no unexpected safety concerns associated with this study. No
subjects experienced serious adverse events. No subjects dropped out of the study due to adverse experiences related to the study
medication.
4) Interim data: With regard to the primary aim, as expected dutasteride reduced the concentration of 5-alpha reductase hormone
metabolites, this was evident in examination of either dihyrotestosterone or 3a-androstanediol glucuronide. The later metabolite
showed less variation between subjects and a more consistent pattern of change overtime. These results validate the future use of
3a-androstanediol glucuronide as a marker of dutatsteride in our GCRC protocol #619 study. Our results indicate that the 4 mg dose
provides more consistent inhibition (80%) of enzyme activity in the 3-7 day window during which we plan to study the effect of
dutasteride pre-treatment on alcohol responses in GCRC protocol 619. The inhibition was progressively reduced in the 2-4 week
interval and was reversed at all doses by 6 weeks. Study medication was well tolerated at the 2mg, 3mg, and 4mg dose.
During the past year we examined hormone data for association with 2 Single Nucleotide Polymorphisms (SNPs) in each of the two
isoforms of 5-alpha reductase. During the next year we will explore other candidates for pharmacogenetic effects as we observed
large between subject differences in hormone changes due to dutasteride.
5) Proposed changes made or anticipated in the protocol: The PI plans to conduct GC/MS analysis of the collected plasma samples
to more finely describe the nature of changes in 5a-reduced steroids following a single dose of dutasteride to better inform the
primary R01 funded GCRC protocol #619.
6) Continued GCRC support requested - We request the GCRC protocol remain active with the potential request for additional

6/27/2008 9:32:04AM

152

5M01RR006192-14

REPORT PD: 04/01/2007-03/31/2008

Final

genotyping of the study sample for pharmacogenetic purposes.
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FAMILY VIOLENCE RESEARCH
A

ABU-HASABALLAH, KHAMIS PHD

Psychiatry

NON-HOST INSTITUTION: STATE,
COUNTRY

YALE UNIVERSITY, CT USA

SUBPROJECT DESCRIPTION:

As evidenced by a number of current initiatives such as National Institute of Drug Abuse (NIDAs) initiative on stress and drug
abuse, Healthy People 2010, and the National Institute of Health (NIH) Agenda for Research on Women's Health for the 21st
Century, the relationship between substance abuse and violence has become a national priority. Moreover, although research
demonstrates associations between intimate partner violence (IPV) victimization and the development of substance use
disorders among women, this phenomenon has not been adequately examined (NIDA, 2003b; Wekerle & Wall, 2002). This is of
particular concern because women, by virtue of substantially higher risks of victimization (Dansky, Byrne, & Brady, 1999),
may be at increased risk to use substances to cope with their tension and stress. A gap exists in the literature in its ability to
explain this complex temporal relationship within a single episode and, across multiple episodes over time. This gap was the
catalyst for the current study which will gather information regarding the temporal relationships of IPV events to substance use
among a community sample of 180 abused women. Specific aims are; a) to gather pilot data on the temporal relationship of
substance use and IPV events, and b) to examine the effectiveness of three methods of data collection 1) paper diaries; 2)
monthly, retrospective, semi-structured interviews; and 3) telephone data collection methods. For each data collection
condition, feasibility will be assessed by a) compliance with the instructions, b) perceived safety in completing assessments, c)
reported honesty, d) reported ease, e) preference for methodology assigned, or alternate methodology, f) percent attrition by
methodology, and g) degree and pattern of missing data. *** The only participants to have contact with the GCRC would be
those participating in the telephone data collection condition (i.e., approximately 60 participants).
SUBPROJECT PROGRESS:

During this reporting period the study protocol was developed and programmed into the Interactive Voice Response (IVR) system.
Three participants pilot tested the protocol. Full implementation of the study began in December. Sixteen participants have been
enrolled in the study and 1 participant completed the study. The response rate for the IVR group (one of the three groups in the
study and the only group that has a connection to the GCRC) was 52.00%. No publications have been written about this study.
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PETRY, NANCY PHD

Psychiatry

ALESSI, SHEILA PHD

Psychiatry

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Contingency management (CM) interventions are highly efficacious in improving substance abuse treatment outcomes. These
interventions have been provided primarily in an individual format, but most therapy for substance abusers is delivered in the
context of groups. We have preliminary data suggesting that our prize-based CM, which is substantially less costly than
traditional voucher-based CM, can be administered in a group setting. This study will evaluate the efficacy of prize-based CM
when administered exclusively in groups. Substance dependent patients beginning intensive outpatient day treatment (N=360) at
one of three community-based programs will be randomly assigned to one of two conditions: (a) standard, non-CM treatment or
(b) standard treatment plus prize CM delivered in groups. In the CM condition, patients will earn the opportunity to win prizes
ranging from $1 to $100 in value for attending groups and submitting drug-free biological specimens. Substance use and
psychosocial problems will be measured at intake, month 1, month 3 (post treatment), and at 6-, 9-, and 12-month follow-up
evaluations.
We will also assess patient characteristics that may be associated with improved outcomes within and across conditions. We will
evaluate the cost-effectiveness of group-based CM by assessing receipt of psychosocial and medical services and criminal justice
system involvement throughout the treatment and follow-up periods.
SUBPROJECT PROGRESS:

Total Enrollment: 271
Past Year Enrollment: 79
No changes in recruitment plans are needed.
•
No unexpected safety concerns have occurred.
•
Interim data and outcomes are not available.
•
Changes to protocol: 1) Added Justyna Tymoszczuk and Shanelle Carmichael as consenters, Jeremiah Weinstock as study
coordinator and Ellen Ciesielski as study contact. 2) Revised study screening form to include a space for the research assistant to
initial this form. 3) Partial Consent Waiver to complete screening approved. 4) Added the Methadone Treatment History
Questionnaire. 5) Changed the timeframe in which study enrollment occurs from 48 hours to 1 week after treatment start for those
being recruited from outpatient programs in order to facilitate recruitment. 6) Deleted a phrase in the Inclusion Criteria section of
the protocol that refers to a recruitment site was approved to be removed from the protocol on 9/18/06. 7) Revised screener form
to facilitate study recruitment. The additional questions help to better determine preliminary eligibility based on basic
inclusion/exclusion criteria. 8) Added Dr. Jeremiah Weinstock as member of the DSM Committee for this study. 9) Three questions
added to the Addiction Severity Index regarding Medical Status and Drug/Alcohol Use. 10) A comments Box is added to the bottom
of page 2 of the Brief Symptom Inventory to document any discussion regarding suicidal or homicidal ideation if needed for
potential adverse events records. 11) Additional codes and spaces were added to the Service Utilization in order to improve the
accuracy of data collection and questions regarding visits with parole officers were also added. 12) Clarified that a modified version
of the SCID is used to measure antisocial personality disorder. 13) Removed Marcia DeSousa and added Trisha Feery as a consenter.
14) Added questions to the Addiction Severity Index (ASI) regarding HIV status and previous and current treatment. 15) Revised
Cigarette Smoking History questionnaire.
•
Results not yet published as study is ongoing.
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Do you wish to continue to receive GCRC resources for the period April 1, 2008 through
March 31, 2009? Yes
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Omega-3
Effects of Omega-3 Fatty Acids on Bone and Fragility

AIDS:

N

START DATE:

Final

TOTALS
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RESEARCH BIONUTRITION

N

MULTICENTER STUDY

N

INFORMATICS CORE

Y

CLINICAL TRIAL

N
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N

CORE LAB

Y

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

KENNY, ANNE MD

Center on Aging

LAMMI, KEEFE PHD

NUTRITION

PILBEAM, CAROL MD, PHD

Medicine

SECOR, ERIC MD

Immunology

THRALL, ROGER PHD

Medicine/Pulmonary

WALSH, STEPHEN J SCD

Ctr for Biostatistics

NON-HOST INSTITUTION: STATE,
COUNTRY

UCONN, STORRS, CT USA

SUBPROJECT DESCRIPTION:

Osteoporosis is a bone thinning disease that results in fractures that occur with minimal trauma. The direct health care costs
related to osteoporosis are estimated to be 14 billion dollars per year, comparable to costs in heart failure and asthma. Frailty
or poor physiologic reserve to deal with stressors, in the general population over age 65 is estimated to be 7%; frailty is
associated with an increase risk of falls and fracture. Both osteoporosis and frailty are thought to have inflammation as a
contributing factor. Omega-3 fatty acids found in fish oil [eicopentaenoic acid (EPA, 20:5n-3) and docohexaenoic acid (DHA,
22:6n-3)] have been shown to decrease markers of inflammation (cytokines) and decrease death due to heart disease. A number
of studies in animals suggest that fish oil (or EPA and DHA supplementation) inhibits bone break down, increases calcium
absorped from the diet and and enhances calcium in bone. Studies done in humans are few. The studies have used a mix of
essential fatty acids including n-6 and n-3 fatty acids. N-6 fatty acids are thought to increase inflammation while n-3 fatty acids
are thought to decrease inflammation. The effects of the fatty acids appear to depend on the level of n-6 to n-3. In one study,
investigators demonstrated that n-6/n-3 fatty acid mixture supplementation increased bone mineral density or bone thickness of
the spine and hip over 18 months in a group of older, nursing home residents with osteoporosis or low bone mass. As far as we
know, no study as evaluated the role of n-3 fatty acids in the frailty syndrome, characterized by sarcopenia or muscle loss,
inflammation, low estrogen, growth hormone and testosterone levels, poor nutrition and disability.
SUBPROJECT PROGRESS:

This study is actively underway. We have recruited 125 subjects, shy of the 150 we had hoped to recruit due to slow recruitment in
the beginning. We modified the inclusion criteria and resulted in markedly improved recruitment. We have had very few drop outs
(only 7) and all have been for minor complaints. No unexpected safety concerns have been noted. There are no interim outcomes
available at this time. No publications have occurred. The last subject will complete the study in the end of July and data analysis
will begin at that time.
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Androgen Receptor Polymorphisms in East Asian Men
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RAJAN, THIRUCHANDURAI V MD,
PHD

Pathology

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The specific aim is to examine androgen receptor polymorphisms that have been associated with increased risk of osteoporosis
and bone fracture. The hypothesis driving this proposal is that the androgen receptor genes of ethnic East Asian Indians will
encode a protein with larger numbers of glutamine residues than other groups.
SUBPROJECT PROGRESS:

During the reporting period in question we were provided the following services from the GCRC: Sample collection,
Deoxyribonucleic Acid (DNA) extraction, and genotyping on androgen receptor polymorphisms.
This study closed to enrollment in July of 2007 and is currently in data analysis. We hope to have publications based on this data
published within the next year.
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Genes, Home Allergens and Asthma in Puerto Rican Children
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CLOUTIER, MICHELLE MD

Pediatrics

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Asthma affects over 14 million people in the United States.1 The prevalence of asthma in the U.S. increased by 74.9% from
1980 to 1996; 1 ethnic minority populations such as Puerto Ricans are disproportionately represented in this trend of
increasing asthma morbidity. 2, 3 Puerto Ricans had the highest age-adjusted asthma mortality from 1990 to 1995 among U.S.
Hispanics in general and among Hispanics in the U.S. Northeast in particular. Although asthma is a major public health problem
among Puerto Ricans, little is known about the contribution of genetic and environmental factors to asthma in this population.
5 To date, results of genome-wide analyses for linkage to asthma phenotypes have been published by 11 groups in 13 distinct
populations. 6-17 None of these genome scans included Puerto Ricans. Because of the high prevalence of single-parent
households among Puerto Ricans in the U.S. mainland,18 family-based studies of genetic association would be difficult to
perform in this population. A population-based case-control study of genetic association for asthma and asthma-related
phenotypes among Puerto Ricans in the U.S mainland is feasible and would offer a unique opportunity to examine genetic and
environmental risk factors in a minority population with high asthma morbidity. We have recruited children with asthma in
Hartford (Connecticut) as part of a program to improve asthma management by physicians in this community.19 In these
children, we have shown that Puerto Rican ethnicity is associated with sensitization to specific allergens and increased asthma
severity.20, 21 Among school children in Hartford, we have collected data in a group of Puerto Rican children with asthma
(cases) and a group of Puerto Rican children without asthma (controls). We propose to conduct a case-control study of
association between selected genetic and environmental factors and asthma in Puerto Ricans. Between 75% and 94% of Puerto
Rican children with asthma are atopic (see C.4.c).22 In atopic children, production of cytokines (IL-4, IL-5, IL-9, and IL-13)
by T-helper (Th)2 cells promotes increased production of immunoglobulin E (IgE), eosinophilia, mast cell differentiation, and
long-term expression of allergen-specific immunity.23,24 Atopy and atopic asthma may result from lack of upregulation of
Th1 immune responses and/or inadequate downregulation of Th2 immune responses.25, 26 We hypothesize that single
nucleotide polymorphisms (SNPs) in genes that control the development and regulation of Th1 cells, Th2 cells, and regulatory
T cells (Tregs) are associated with asthma and/or intermediate phenotypes of asthma (asthma phenotypes") in Puerto Rican
children. We further hypothesize that parental report of exposure to pets in early life (during pregnancy and/or the first year of
life) is associated with reduced risks of asthma and atopy, and that current exposure to high levels of indoor allergens is
associated with a) increased asthma severity and abnormal lung function phenotypes (reduced FEV1 and FEV1/FVC, increased
airway responsiveness, and reduced bronchodilator responsiveness) in Puerto Rican children with asthma and b) atopy
phenotypes (e.g., increased serum total IgE) in Puerto Rican children with and without asthma. In addition, we hypothesize that
variants in genes that control the development and regulation of Th1 cells, Th2 cells, and Tregs interact with indoor allergen
exposures in influencing asthma and asthma severity in Puerto Rican children.
To test these hypotheses, we will pursue the following specific aims: 1. To recruit 500 Puerto Rican children with asthma
(cases) and 500 Puerto Rican children without asthma (control subjects). 2. To test for association between Single Nucleotide
Polymorphisms (SNPs) in 20 positional candidate genes and i) asthma (in all subjects), ii) lung function phenotypes (airway
responsiveness, FEV1, FEV1/FVC, and bronchodilator response)and atopy phenotypes (skin test reactivity to allergens, serum
total and allergen-specific IgE, and eosinophil count) separately in cases and in control subjects, and iii) asthma severity in
cases. 3a. To examine whether i) parental report of exposure to pets (dogs and/or cats) in early life is associated with reduced
risks of asthma (in all subjects) and atopy (separately in cases and in control subjects), and b) current exposure to indoor
allergens (dust mite, cockroach, dog, cat, mouse, and rat) is associated with increased asthma severity and abnormal lung
function phenotypes in cases, and with atopy phenotypes separately in cases and in control subjects. 3b. To examine
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interactions between exposure to the indoor allergens outlined in Specific Aim 3a and SNPs in the candidate genes selected in
Specific Aim 2.
SUBPROJECT PROGRESS:

During the time period from 4/01/07-3/31/08 we enrolled a total of 227 children into our genetic study. In total, to date, we have
enrolled 421 children. We continue to make good progress on this project. On average, our no show rate for the home visits is ~
43% while the no show rate for the hospital visits is ~38%. While these rates are significant, they are anticipated. In an effort to
address attendance to the home and hospital visits, we continue to place reminder calls to the families the day before the scheduled
visit as well as on the day of the visit. In addition, we also mail reminder letters that include magnets with the family's appointment
information and our office phone number.
Recruitment efforts continue to focus within Hartford public schools during the academic year (flyer distribution, attendance at
Open House, parent/teacher conferences, PTO meetings, and after school programs). When weather permits, we also conduct live
recruitment after school when parents typically go to the school to pick their child up. In addition, throughout the school year, we
make efforts to attend various health fairs in Hartford. As summer vacation approaches, we will be focusing our recruitment efforts
at the Boys and Girls Clubs in Hartford as well as other community agencies (i.e. Mi Casa, Hispanic Health Council, summer camps,
etc.).
To date, we have not experienced any unexpected safety issues while conducting recruitment or study visits and we do not
anticipate any safety concerns. However, study equipment was stolen from our office in January 2008 (one laptop and one KoKo
spirometer). Appropriate individuals were notified and replacement equipment was secured via Connecticut Children's Medical
Center (CCMC). Various CCMC IRB approved safety precautions have been identified and implemented; these were outlined and
approved by the CCMC IRB.
We continue to collaborate with our colleagues in Boston. No publications have resulted from this work to date, as it is too early.
Based on recent scientific evidence that vitamin D may influence the pathogenesis of asthma and asthma morbidity, our Boston
colleagues propose that we measure vitamin D levels in blood samples. Due to the impracticality of re-consenting existing
participants (addresses and phone numbers frequently change), we wish to do this by using the blood samples that we have already
collected on existing participants. We submitted a request to the CCMC IRB on 4/18/08, the IRB of record, requesting permission
to modify our consent form to indicate that blood collection will be used to measure vitamin D levels in addition to gene testing
(DNA) and allergy testing. We are awaiting approval.
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Discrimination Stress
Daily process pilot study of discrimination stress and diabetes outcomes in African American Women
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WAGNER, JULIE PHD

Behavioral Sci & Comm Hlth

TENNEN, HOWARD PHD

Community Medicine

WHITE, WILLIAM MD

Medicine/Hypertension

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Our group is investigating the influence of racial discrimination on diabetes outcomes among African American (AA)women.
Our next step is an National Institute of Health (R01) for a daily process study that will test the hypotheses that glycemia,
blood pressure, and health behaviors will be more affected by daily stress in women with high lifetime discrimination than their
low discrimination counterparts. The pilot project proposed here will collect data to support that R01 application regarding the
feasibility of the data collection , the acceptability of the protocol to participants, and the effect sizes among relationships.
Ten diabetic AA women will wear continuous glucose sensor and ambulatory blood pressure monitoring equipment for 3
consecutive days, and report health behaviors for 7 consecutive days. Twice daily, participants will provide data on daily
stressors using an interactive voice response telephone system. Information regarding recruitment, retainment, participant
burden, effect sizes, technical challenges with data collection, and modification of questionnaires for daily assessment will
increase the likelihood of a successful R01 application.
SUBPROJECT PROGRESS:

From 4/1/2007 until 3/31/2008, 6 women enrolled. Since the initiation of this pilot study, 9 woman enrolled and all have
completed the study. Modifications to the project approved by the Institutional Review Board (IRB) this year include: 1)
Approval of the Informed Consent Form (ICF) and Protocol revisions to reflect new IRB rules and language regarding storing of
samples. Samples will no longer be stored beyond completion of the study. 2) Approval the removal of Dr. Madhavi Mallareddy
as a co-investigator. Dr. Mallareddy has completed her fellowship and is not longer affiliated with UCHC. Dr. White has assumed
her responsibilities. 3) Approval of revised HIPAA; language changed to comply with new IRB guidelines dated 9/2007. 4) A
Principal Investigator (PI) back up form was approved naming study coordinator Dr. Gina Abbott as PI Back up.
There are no unexpected safety concerns.
Preliminary data shows support for the hypotheses, and feasibility of conducting this multi-faceted study. PI is submitting a larger
grant (RO1) based on this pilot data.
There are no publications at this time.
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Contingency Management Reinforcement for Adolescent Cannabis Abuse
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Psychiatry

BURLESON, JOSEPH PHD

Behavioral Sciences

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The specific hypotheses to be tested are 1) Implementation of Voucher Based Reinforcement Therapy (VBRT) for youth with
Cannabis Use Disorder is feasible and acceptable for both youths and therapists; 2) VBRT for youth produces a reduction of
cannabis use during and at the completion of treatment; and 3) VBRT reinforcement for youth enhances a superior reduction of
cannabis use relative to the non-reinforcement control condition. The proposed trial follows the guidelines for a preliminary
Stage I study developed by the National Institute of Drug Abuse (NIDA) (Rounsaville et al., 2001). The goals of a Stage I
project are 1) to determine whether or not a Stage II project is indicated for the therapy examined in a Stage I project, and 2) if
so, provide the necessary procedures, manuals, measures, and data needed to support a Stage II application (e.g., effect size
estimates). Decision on appropriateness of Stage II project implies that the data generated supports the feasibility and clinical
utility of the therapy examined for that condition, and/or behavior that it is designed to treat.
SUBPROJECT PROGRESS:

Number of subjects enrolled during the report period is 22 and since initiation of the study is 59. The study is now closed to
enrollment; therefore no changes in recruitment plans are needed. No safety concerns. No interim data and outcomes are
available at this juncture. No proposed changes made or anticipated in the protocol. No publications completed yet.
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Student Daily Life Experiences
Howard University Study of College Student Daily Life Experiences and the Interaction of Genetic
Variation
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INVESTIGATOR

DEPARTMENT

COVAULT, JONATHAN MD, PHD

Psychiatry

HERMAN, AREY BA

Psychiatry

KRANZLER, HENRY MD

Psychiatry

SCOTT, DENISE BS

GENETICS

HOWARD UNIVERSITY, DC USA

TAYLOR, ROBERT MD

PHARMACOLOGY

HOWARD UNIVERSITY, DC USA

TENNEN, HOWARD PHD

Community Medicine

WILLIAMS, CARLA PHD

MEDICINE

HOWARD UNIVERSITY, DC USA

SUBPROJECT DESCRIPTION:

This study is designed to evaluate the day-to-day associations among alcohol use, school-related behaviors, stressful events and
mood states over the course of a one month period. Specifically, this study uses a web-based daily report tool to focus on how
individuals cope with stressful daily events and negative mood states and, in turn, how coping efforts and mood affect alcohol
use. Additionally, this project will examine (a) the influence of a functional polymorphism, 5-HTTLPR, in the promoter
region of the serotonin transporter gene (as well as two other variations in this gene), and alcohol dependence associated
haplotypes of the GABRA2 and GABRG1 genes encoding the and ƒ×-1 subunits of the GABAA receptor on the use of alcohol
by college students, and (b) evaluate the interactive effects of genotypes with daily life stressors, positive experiences, social
interactions/peer influences, and positive or negative mood states on the use of alcohol by college students. In an exploratory
aim we will also examine the effects of variation in other neurotransmitter related genes including: i) Monoamine oxidases
(MAOA) which encodes monoamine oxidase, a key enzyme involved in metabolic inactivation of synaptic serotonin (as well as
norepinepherine and dopamine), ii) TpH2 which encodes the brain specific form of trypthophan hydroxylase, the rate limiting
enzyme in serotonin synthesis, iii) a functional promoter variant of the serotonin 5-HT1A presynaptic autoreceptor gene
HTR1A and iv) CB-1 which encodes the brain form of the cannabinoid receptor and is thought to be involved in the regulation
of appetitive and substance use behaviors.
This study will follow a protocol used in a parallel ongoing multi-year longitudinal study of college student daily life experiences
at the University of Connecticut (UConn), Storrs, CT. By comparing results from these two campuses we hope to compare and
contrast the influence of mood states, life events and genetic variation on alcohol use behaviors to identify shared and unique
characteristics for the two college student samples. This cross sectional study at Howard University will provide important
information about the feasibility of using methodologies developed at UCHC / Storrs sites at other college campuses to examine
the generalizability of findings from our current Alcohol Research Center / GCRC study at the Storrs campus.
SUBPROJECT PROGRESS:

1) Number of subjects enrolled during the report period: none; since initiation of study: 149
2) Planned changes in recruitment plans: Preliminary results from this and from GCRC#560 were used in support of a new grant
application which was recently funded to continue this project by enrolling a larger sample of Howard University college students
(approximately 150 students each semester for 6 semesters).
3) Unexpected safety concerns and their resolution: None occurred.
4) Interim data: Salivary Deoxyribonucleic Acid (DNA) has been prepared from the 149 participants to data and used to generate
genotype data at the 5HTTLPR locus and the HTR1B 3'UTR polymorphism. The sample is too at this time for genetic
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association studies of behavioral phenotypes.
5) Proposed changes made or anticipated in the protocol: The new R21 grant supporting subject recruitment at Howard
University includes specific aims to examine awakening salivary cortisol as a potential biological marker of recent stress or stress
reactivity. GCRC core lab assay of salivary cortisol from 4 samples collected on 4 occasions from each participant has been added
to the GCRC protocol. Interactive Voice Response (IVR) will be used to track subject compliance with collection parameters for
awakening salivary cortisol.
6) Continued GCRC support requested - core lab for salivary DNA, genotyping and salivary cortisol. Informatics support for IVR.
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Perceptions of Racism in Minority Children
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PACHTER, LEE MD

PEDIATRICS

INSTITUTE OF LIVING, CT USA

SUBPROJECT DESCRIPTION:

The objective of this project is 1)to gain an understanding of the ways children of different ethnic minority backgrounds
perceive, interpret, conceptualize, and process racism (racial discrimination and prejudice). 2)to utilize this information to
create valid and reliable instruments for measuring perceptions of racism in minority children which will be based on
developmental theory and which have saliency for children of different ethnicities, and 3)to use these instruments in studies
aimed at understanding the effects of perceived racism on a]the developmental competencies and behavioral health of minority
children, as well as b]disparities in health and health care outcomes seen in minority populations. Institutional Review Board
(IRB) approval is being sought for Objective 2: the creation and testing of instruments (questionnaires) aimed at measuring
perceptions of racism in minority children. A proto-questionnaire has been developed based on data gathered from
semi-structured interviews with minority youths. This questionnaire includes items that pertain to 1) whether a child has
experienced situations in which he/she perceived as being discriminated against based on ethnicity, skin color, accent, or culture.
2)the child's emotional response to the incident, and 3)the child's coping response.
The present study proposal is to administer this proto-questionnaire to a sample of minority youth between the ages of 8 and
18, and psychometrically analyze the response to determine validity and reliability of the instrument. In addition to the
Perceptions of Racism questionnaire, the Revised Children's Manifest Anxiety Scale and the Child Depression Inventory will be
administered (as measures to be used in the determination of construct validity). These analyses will likely result in refinement
of the proto-questionnaire, which can then be used in future studies to determine the effects of racism (as a psychosocial
stressor) on minority child behavioral health and development, as a contributory stressor in acute and chronic illness etiology,
as well as it's effects on health care and health services issues. Initial piloting of the proto-questionnaire will be conducted at the
Boys and Girls Club of Asylum Hill. Additional testing will be conducted in the Hartford Public School System (upon approval
from the Superintendent's Office of the Hartford Public School System). At the Boys and Girls Club, a convenience sample of
minority (i.e., African American, Puerto Rican, and West Indian/Caribbean) children attending summer camp will be recruited.
In the public school system, samples based on classroom assignment in middle and high schools will be procured. In both
settings, informed consent of the parent, as well as child assent will be obtained. Although general descriptive demographic
information such as age and ethnicity will be obtained, anonymity and confidentiality will be maintained; no personal identifiers
will be recorded. Data analyses will include factor analysis for subscale identification, item analyses, item-scale correlations,
determination of the internal consistency reliability (coefficient alpha), and construct validity determination through
correlation analyses.
SUBPROJECT PROGRESS:

During the present reporting period we have finished enrollment and enrolled 35 new participants into the study. This raises our
final total subject number to 277. We have begun data analysis during this report period as well. We are in the process of using the
data to develop and refine an instrument to measure perception of racism in children and youth, using traditional psychometric
analyses as well as structural equation modeling. We have also begun descriptive analyses of the occurrence of perceptions of
racism in this sample, vis-à-vis race/ethnicity, age, and gender. We are in the process of writing manuscripts for publication.

6/27/2008 9:32:04AM

165

5M01RR006192-14
SPID:

REPORT PD: 04/01/2007-03/31/2008

0634

634

PROTOCOL:

TYPE: RESEARCH

SHORT TITLE:
LONG TITLE:

Serotonin 1A
Serotonin 1A Receptor and Mood in Daily Life
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SUBPROJECT DESCRIPTION:

Recent evidence identifies variation in the gene encoding the serotonin 1A (5-HT1A) receptor (genetic locus HTR1A)as a
potential factor in the development of mood and anxiety disorders, with carriers of the G allele of the C(-1019)G single
nucleotide polymorphism (SNP) of HTR1A being more vulnerable to such disorders than non-carriers. We request funding to
examine this allelic variation and its relation to mood-related outcomes in two existing data sets--416 Deoxyribonucleic acid
(DNA) samples from college students taking part in an ongoing study of student life (IRB#03-128) and 1,510 DNA samples
from a large case-control sample collected by Dr. Kranzler as part of an ongoing study of the genetics of alcohol dependence
and co-morbid disorders (IRB# 96-156). The first primary aim will be to test whether variation in teh HTR1A SNP predicts
mood-related outcomes in the college student sample [measured by daily self-reported anxiety and other moods obtained across
multiple years of study participation] and the case-control sample [measured by participants' lifetime history of Diagnostic and
Statistical Manual (DSM) diagnosed major depression]. The second primary aim will be to test whether variation in HTR1A
interacts with variation in the 5-HTTLPR polymorphism of the serotonin transporter gene (obtained previously in all of
samples 1 and half of sample 2) to predict mood-related outcomes and lifetime history of depression. Results from primary
analyses will provide pilot and feasibility data for a National Institutes of Health (NIH) R03 grant application by the Principal
Investigator (PI) to examine the role of serotonin-related genetic predictors of mood-related experience. A secondary aim will
capitalize on existing data to determine whether variation in HTR1A and is possible interaction with 5-HTTLPR predicts
differences in alcohol use for the student sample and differences in alcohol dependency in the case-control sample. Results from
the secondary aim will provide pilot data for the Alcohol Research Center renewal grant to be submitted in December, 2006.
SUBPROJECT PROGRESS:

This archival study involved genotyping on archived saliva samples of 416 college students and examining single gene associations
with daily emotional outcomes. No additional subjects have enrolled since the start of this project on April 1, 2006 or since the
previous GCRC progress report. No changes in recruitment plans were needed and no unexpected safety concerns have arisen. All
genotyping and costs associated with the project was completed in 2007.
The primary hypotheses relating to the HTR1A polymorphism to daily mood states
were unsupported (reported in 2007 Progress Report); therefore, remaining funds were used to genotype snps in the tryptophan
hydroxylase-2 (TPH2) gene [G(-703)T snp (rs4570625) and the T(-473)A snp (rs11178997)], CRHR1 (rs1876831), and DRD4
(VNTR polymorphism in exon III). Furthermore, analyses were expanded to examine associations between these snps and daily
alcohol use.
FINAL OUTCOMES
1. Analyses of associations between TPH2 SNPs and alcohol use have resulted in
publication (Gacek, Conner, Tennen, Kranzler, & Covault, in press). Fingings
replicated prior research showing no association between the TPH2 rs4570625
snp and quantity and frequency of alcohol use in this non-clinical population. The GCRC is cited in the acknowledgement section
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of the paper. A final copy of the paper will be sent to the GCRC when it is published.
Gacek, P.*, Conner, T. S., Tennen, H., Kranzler, H. & Covault, J., (in press).
Tryptophan Hydroxylase 2 Gene and the alcohol use among college students.
Addiction Biology
*UCHC Master's in Public Health student Paul Gacek
2. Analyses of associations between TPH2 snps and daily mood states showed
significant results. Carriers of the riskier T allele of the G(-703)T snp reported more intense negative mood states in their daily
life, compared to those homozygous for the less risky G allele. This pattern occurred in women only. Genotype carrier status
accounted for 5% of the variance in negative mood levels for women in year 1, and 3% of the variance in negative mood levels for
women in year 2. These patterns were three times as strong as associations found with traditional retrospective survey measures.
Results will be written up for publication.
3. Statistical analyses of the CRHR1 and DRD4 snp data will be conducted over the 2008-2009 academic year. Results will be used
for publications and to inform decisions whether similar genotyping should be done in a larger genetic data set currently being
collected at UCHC (P.I., Howard Tennen).
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Hip Fracture Pilot
Feasibility of Multi-Component Training in Patients 2 Months Post Hip Fracture
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NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Over 325,000 hip fractures occur in the US each year, with the cost to patients, families and the health care system estimated
at between 14 and 20 billion dollars annually. (1-2) Despite improvements in medical management, significant residual disability
remains in older persons post hip fracture.(3) The current practice goal for discharge from medical management at 2-3 months
post surgery is independent, safe household ambulation.(4) Hip fracture-acquired dependency in functional activities of daily
living persists well beyond that point: 20% of patients need help putting on pants, 50% need assistance to walk, and 90% need
assistance to climb stairs 12 months after hip fracture.(5-6) These figures indicate that the current standard
Medicare-reimbursed rehabilitation therapy fails to return a large proportion of patients to pre-fracture levels of function. Thus,
while hip fractures are common and lead to extended disability under usual care management strategies, there is a paucity of
evidence to justify extending medical management beyond the current standard in persons post-fracture.
This pilot will evaluate a 16-week, supervised multi-component intervention that is introduced as soon as the patient completes
usual care (typically within two months of the fracture). The intervention has been designed to address four relevant precursors
to community ambulation using stress overload and specificity of training principles. The effect of the intervention on
impairments, functional limitations, and disability also will be examined.
SUBPROJECT PROGRESS:

The study has received Institutional Review Board (IRB) approval. We are working with orthopedic surgeons and local home care
agencies to identify potential participants. We have recruited 3 subjects into the study and have 2 more in the screening process.
We continue to work with orthopedic surgeons to identify subjects. We have had no safety concerns but one subject did fall and
sustain a broken pelvis (during usual activities, not during the intervention). No manuscripts have been prepared from the data yet.
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CRANFORD, JAMES PHD

SUBSTANCE ABUSE RESEARCH

UNIVERSITY OF MICHIGAN, MI USA

SUBPROJECT DESCRIPTION:

We are trying to determine if alcoholism leads husbands and wives to engage in more negative behaviors in marriage, and if
these behaviors in turn lead to higher levels of drinking, depressed mood, marital aggression, and divorce. This project is
designed to improve our understanding of several public health problems, including alcoholism, depression, marital aggression,
and divorce.
SUBPROJECT PROGRESS:

UCHC GCRC Progress Report Summary for Project 5R21 AA015105-02. The targeted enrollment for this project was n=50
alcoholic couples. In our previous progress report, we indicated that n=5 couples had completed the Time 1 (T1) interview and
marital interaction task. We also indicated that we had submitted a request for a second set of modifications to the research
protocol to the UCHC IRB on 04.13.07. These modifications, which included expansion of recruitment efforts, revisions to the
informed consent, and changes to the recruitment brochure, were approved by the University of Michigan (U of M) Medical
School IRB on 03.22.07 (Amendment eResearch ID: Ame00003772) and by the UCHC IRB on 05.21.07 (UCHC IRB Number:
07-035-3). Unfortunately, this expansion of recruitment efforts was not sufficient for us to meet our recruitment goals, and we
therefore submitted a request for a third set of modifications to the research protocol. These modifications involved further
expansion of recruitment efforts to include 1) unmarried heterosexual couples (18 or older) who have been living together in a
committed relationship for at least 6 months; 2) posting the study on the University of Michigan Clinical Outcomes and Research
Engine (M-Strides) and on public websites (e.g. Craig's list, Arborlist, etc.); and 3) distributing recruitment brochures to local bars
and churches in the Ann Arbor area. This third request was approved by the U of M IRB on 09.05.07 (Amendment eResearch ID:
Ame00005000), and by the UCHC IRB on 10.11.07 (UCHC IRB Number: 07-035-3). In addition, the first Scheduled Continuing
Review (SCR) of this project was approved by the U of M Medical School IRB on 04.28.07 (SCR eResearch ID: CR00003882) and
by the UCHC IRB on 09.10.07. The second SCR of this project was approved by the U of M Medical School IRB on 03.07.08
(SCR eResearch ID: CR00006849 <https://eresearch.umich.edu/eresearch?PageID=CR00006849>).
Expansion of recruitment efforts allowed us to exceed our targeted enrollment, and we were able to recruit n=54 alcoholic couples
into this study. Recruitment was closed on 01.15.08, and the final couple completed their T1 interview on 02.09.08. This final
couple completed their final call to the UCHC Interactive Voice Response (IVR) system on 03.11.08. Given that our final sample
size was N=54 couples, with each spouse asked to complete 14 daily reports on their drinking, marital interactions, and moods
every night for 14 consecutive nights using the UCHC IVR system, our IVR data set had a maximum of 54 × 2 × 14 = 1,512
observations or diary days. Participants in our study completed a total of 1,418 IVR reports. Thus, our total compliance rate was
1,418 / 1,512 = 93.8%.
Couples are also asked to complete telephone interviews at T2 (6 months after T1) and T3 (12 months after T1). As of today
(05.11.08), n=23 couples have completed the T2 interview and n=5 couples have complete the T3 interview. Due to recruitment
challenges, data collection will continue beyond the originally scheduled end date of May 31st, 2008. Accordingly, we submitted a
request for a 12-month No-Cost Extension (NCE) to NIH on 03.13.08. This request was approved by NIH on 03.31.08, and the
new end date for this project is now 05.31.09. No unexpected safety concerns have arisen and no further changes to the protocol
are anticipated. Because the final IVR data were collected only 2 months ago, we have not yet published any results from this
project. However, an abstract based on this project was recently accepted by the Research Society on Alcoholism. As indicated
below, this abstract cites the U of M and UCHC GCRCs.
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The DMAC Study
A Pilot study to assess the DNA Methylation patterns in Alcoholics and Controls-The DMAC Study
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COUNTRY

SUBPROJECT DESCRIPTION:

Deoxyribonucleic acid (DNA) methylation, which is thought to play an important role in carcinogenesis, is an emerging area of
epigenetic research. A recent Request For Applications (RFA) (AA-06-005) from the National Institutes of Health (NIH), to
which a multidisciplinary investigative group from UCHC responded (Drs. Bonkovsky, Hesselbrock, Lalande, and Lambrecht)
targeted epigenetic effects of alcohol and its metabolism as an important area of research. Alcohol has long been associated
with cancer and has recently been associated with increased DNA methylation levels. In this pilot study, we propose to
determine whether and how DNA methylation patterns in chronic alcoholics are different from suitable controls. This will be
the first step in finding out if DNA methylation patterns are altered in subjects with chronic alcohol dependence and provide
important pilot data for later, larger proposals to the NIH and other external funding agencies focused on mechanisms whereby
alcohol and its metabolites influence cancer risk and other epigenetic effects.
SUBPROJECT PROGRESS:

DNA methylation, which is thought to play an important role in carcinogenesis, is an emerging area of epigenetic research.
Consistent with NIH Roadmap initiatives, a multidisciplinary investigative group from UCHC responded (Drs. Bonkovsky,
Hesselbrock, Lalande, and Lambrecht) is examining the epigenetic effects of alcohol and its metabolism as an important area of
research. Alcohol has long been associated with cancer and has recently been associated with increased DNA methylation levels. In
this pilot study, we propose to determine whether and how DNA methylation patterns in chronic alcoholics are different from
suitable controls. This will be the first step in determining if DNA methylation patterns are altered in subjects with chronic alcohol
dependence and provide important pilot data for later, larger proposals to the NIH and other external funding agencies focused on
mechanisms whereby alcohol and its metabolites influence cancer risk and other epigenetic effects.
Specific Aims: This pilot study is designed to obtain preliminary data on the methylation patterns of DNA for genes known or
suspected of playing a role in cancer development. Aim 1: To assess global DNA methylation status in well-characterized chronic
alcoholics and to compare it to suitably matched non-alcoholic family members as controls. Hypothesis 1: There are clinically and
statistically significant differences in global DNA methylation and in patterns of DNA methylation in chronic alcoholics,
compared to matched non-alcoholic controls. Aim 2: To explore whether there are observable, meaningful differences in
methylation patterns between the two groups at different gene loci and whether there are relationships between life time alcohol
use and the degree or pattern of DNA methylation. Hypothesis 2: There are differences in methylation patterns between alcoholics
and controls, which correlate directly with dose and duration of alcohol use. To achieve these aims we proposed a pilot study to
examine the methylation pattern in DNA samples from 48 chronic alcoholics and 48 matched controls.
The field of epigenetics is the study of heritable differences related to changes in DNA expression, which are not due to differences
in the DNA sequences themselves. Although still in its infancy, epigenetics is expanding rapidly. DNA methylation is one of the
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three main types of epigenetic inheritance. It is involved in many physiological and pathophysiological conditions, including
regulation of gene expression and silencing of repeat elements in the genome. DNA methylation plays a role in many diseases, such
as multiple sclerosis, diabetes mellitus, schizophrenia, alcohol dependence, and cancer. It has been shown that global methylation
status in peripheral blood monocytes (PBM) is associated with plasma homocysteine levels in healthy individuals. Chronic
alcoholics commonly have elevated homocysteine levels. The importance of homocysteine to DNA methylation status stems
from the fact that homocysteine is a precursor of S-adenosyl methionine (SAM), which is the methyl donor when cytosine residues
in the dinucleotide sequence CpG are methylated by DNA methyltransferases (DNMT). Bonsch, et al., showed associations among
alcohol-associated elevated plasma homocysteine levels, the global methylation status, and the subsequent expression of DNMT
mRNAs in alcoholic patients compared to controls. These findings support the hypothesis that ethanol exposure increases DNA
methylation, and suggest that changes in DNA methylation status can be responsible for changes in expression of some of the
genes involved in this methylation process.
Further research will be needed to confirm this possible chain of alcohol-induced events. In all likelihood, many more genes (whose
levels of expression are partially controlled by the methylation status of the DNA in their promoters) are yet to be discovered.
Changes in DNA methylation are recognized as one of the most common forms of molecular alteration in human neoplasia.
Hypermethylation of CpG islands located in the promoter regions of tumor suppressor genes has been firmly established as a
frequent mechanism for gene inactivation in cancers.In contrast, global hypomethylation of genomic DNA17 and loss of IGF2
imprinting were observed in tumor cells and a correlation between hypomethylation and increased gene expression was reported for
many oncogenes.In addition, monitoring global changes in DNA methylation has been used for molecular classification of cancers.
Most recently, gene hypermethylation was associated with clinical risk groups for neuroblastoma,1 as well as with hormone
receptor status and response to tamoxifen in breast cancer. Therefore, it may be feasible to use methylation markers to classify
and predict cancer risk, different kinds or stages of cancer, cancer therapeutic outcomes, and patient survival.
Alcoholism and cancer risk: Chronic excessive alcohol consumption is the strongest risk factor for upper aerodigestive tract
(UADT) cancer (oral cavity, pharynx, hypopharynx, larynx, and esophagus). Chronic alcohol use also increases the risk for cancer
of the liver, colorectum and breast. Many epidemiological studies have demonstrated a correlation between alcohol ingestion and
the occurrence of cancer in these organs. Because the ingestion of all types of alcoholic beverages is associated with an increased
cancer risk, more likely than not, ethanol itself is the crucial compound that increases cancer risk. The exact mechanisms of
ethanol-associated carcinogenesis have remained obscure. Multiple mechanisms are believed to be involved in alcohol-associated
cancer development of the UADT, including the effect of acetaldehyde (AA), the first metabolite of ethanol oxidation, induction
of cytochrome P-4502E1 (CYP2E1) leading to the generation of reactive oxygen species (ROS), and enhanced procarcinogen
activation, modulation of cellular regeneration, and nutritional deficiencies. Folate deficiency, primarily the consequence of low
dietary intake and destruction by AA, is common in alcoholics and contributes to the inhibition of transmethylation, which is an
important factor in the regulation of genes involved in carcinogenesis. Acetaldehyde decreases DNA repair mechanisms and the
methylation of cytosine in DNA. However it has been shown recently that chronic alcoholics have significantly increased levels of
genomic DNA methylation. About 3.6% of all cases of cancer and a similar proportion of cancer deaths are attributable to
consumption of alcohol. These figures are higher in selected regions of the world, in particular in Central and Eastern Europe.
Among women, 60% of cancers attributable to alcohol occur in the breast. DNA Methylation: Methods for measurement of DNA
methylation include methylation-specific enzyme digestion, bisulfite DNA sequencing, methylation-specific PCR (MSP) and
MethyLight, methylation-sensitive single nucleotide primer extension (MS-SnuPE), MALDI mass spectrometry and differential
methylation hybridization (DMH). However, none of these methods combines access to specific sequences in the genome with high
throughput and low cost, which is needed for analyzing methylation profiles at high resolution in large sample sets. In addition,
many of these methods are insensitive to low levels of methylation changes in diseased tissues, for example, 10% or 20%
hypermethylation.
We propose using the recently validated adaptation of a high-throughput single nucleotide polymorphism (SNP) genotyping
system for DNA methylation detection, based on genotyping of bisulfite-converted genomic DNA. This technology combines a
miniaturized bead-based array platform, a high level of assay multiplexing, and scalable automation for sample handling and data
processing. We intend to use the technology developed by Illumina labs, including their methylation chip and bead array system.
The bead array system is presently available at UConn. Illumina expects to have a fully functional assay system in the second half
of this year. With use of this system, we will analyze methylation profiles of 1536 CpG sites from 371 genes. These genes were
selected based upon their relevance to carcinogenesis. This assay can resolve a 22% methylation difference between samples with
99% confidence and a 10% methylation difference with 95% confidence.
Resources available through the NIAAA-funded Alcohol Research Center were used to identify suitable alcohol-dependent subjects
and appropriate sibling controls. This information is available as part of the database of the long-standing Collaborative Study on
the Genetics of Alcoholism, (COGA). Alcohol dependent adult subjects along with their nonalcohol dependent siblings were drawn
from the COGA study sample. After being consented, 15 mL of peripheral blood was obtained and peripheral blood monocytes
(PBM) was separated for DNA extraction using the Progene DNA purification kit and the standard protocol currently in use at the
GCRC Core Lab. The plasma is being stored frozen (-80oC) in 1 mL aliquots for possible future use. The DNA samples, stored at
-80oC were processed by the Molecular Core Lab under the supervision of Dr. B. Graveley. The DNA methylation pattern has been
studied using the methylation chip from Illumina labs. We are continuing to analyze the results for differences in the methylation
patterns in the sibling pairs. GCRC resources have been used for recruitment and enrollment of subjects (Clinical core), for the
study visits (Nursing core and exam rooms, etc), for the processing of the blood samples, including the preparation of PBM and
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subsequent extraction of DNA (Core laboratory).
Subject recruitment was considerably slower than expected. To date only 29 sibling pairs, from a total of n=55 subjects, were
recruited and have also provided blood samples for DNA extraction. Following completion of this last subject pair, DNA
extraction was be completed on all samples and the DNA sent to Dr Gravely's lab to examine the DNA methylation pattern using
the recently available methylation chip obtained from Illumina labs.
An initial analysis of these pilot data revealed no clear methylation pattern attributable to chronic alcohol use, but more careful
analysis using other alcohol-related phenotypes -apart from a formal diagnosis - is underway. There have been no unexpected
safety concerns from this study; no publications or presentations have resulted from this work to date.
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Osteoporosis and Bone Augmentation/Implant Outcomes: An Observational Study
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SUBPROJECT DESCRIPTION:

Bone augmentation is frequently a necessary component of dental implant reconstruction. While in the future, tissue
engineering methods including cell transplantation and the release of cell signaling agents will be available for clinical use, the
current gold standard to increase bone volume is through autogenous grafting. Grafting tends to be successful in young healthy
patients, but there is evidence that success rates of grafting procedures markedly decrease with age and certain systemic
conditions, such as osteoporosis. In the US, there are roughly 10 million women over the age of 50 with osteoporosis and an
additional 34 million with low bone mass or osteopenia." It is estimated that 40-50% of women over the age of 50 will sustain
an osteoporotic fracture in their remaining lifetime. Given that a statistically significant correlation has been shown between
hip and mandible BMD, this large population may be at increased risk for complications and low success rates for bone
augmentation procedures compared to women with healthy bone. The relationship between this systemic health problem and
implant success is not well documented and additional research in this area is needed. Despite the suggestion of the negative
effect of low bone density/osteoporosis to bone graft success, no studies have been reported which carefully demonstrate this
relationship.
SUBPROJECT PROGRESS:

Forty-two patients have signed consent at a screening visit and of those, 11 cases screen failed, 7 cases need to be reviewed to
determine eligibility for the second of screening visits/Treatment planning visit, 24 have passed onto the second
screening/Treatment plan visit. Of those 24 cases, 2 withdrew, 4 have failed out, 4 cases need to be reviewed, 4 are pending surgery
and 10 have been baselined (i.e. received implants).
Changes in recruitment plans during the above-mentioned time period have included adding posters, brochures, and opening the
recruitment to the general public. No major scientific changes have been made to the protocol since the studies inception.
However addendums included the addition of a surgical consult appointment prior to bone augmentation/implant surgery
appointment in which the provider reviews the treatment plan with the patient and obtain standard consent for surgery. The
following changes were made to the inclusion and exclusion criteria are being made. Inclusion of those requiring a sinus elevation
procedure less than or equal to 2mm in combination with their dental implant placement was also added to the protocol.
No interim data or outcomes are available at this time. No publications have been produced as a result of this study as of yet.
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Pilot Study of Circulating Markers of Pulmonary Epithelial Effects of Hypoxic Exposure
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SUBPROJECT DESCRIPTION:

Increasing evidence from in vitro animal studies suggests that hypoxia has direct cellular effects on the alveolar epithelium and
the alveolocapillary membrane (1). Indirect evidence indicates that this is also likely to be true in man, but there are few studies
examining this. The alveolar epithelium and pulmonary vascular endothelium perform crucial functions critical to the overall
integrity of the lung, including transfer of fluid and proteins between the alveolar lumen and the interstitial and intravascular
spaces, mechanical stability of the lungs, and immune and anti-inflammatory functions. In man, hypoxia-induced damage to
some or all of these pulmonary functions can be inferred from some clinical syndromes, such as high altitude pulmonary edema
(HAPE), but the mechanism(s) of these actions of hypoxia are unclear (2). It is well established that removal of the hypoxic
stimulus relieves acute mountain sickness (3), and recent data indicate an additive effect of supplemental inhaled CO2 with the
oxygenation (4). The majority of studies on hypoxia in man have focused on ventilatory neural regulatory mechanisms
(5,6,7,8,9) and autonomic nervous control of the pulmonary circulation (2); studies of possible mechanisms of hypoxia-induced
lung damage in man have, of necessity been invasive, such as analysis of bronchoalveolar lavage fluid, which itself may alter the
milieu being studied (10) and invasive vascular studies (11). There have been no studies specifically evaluating the effects of
hypoxia on the pulmonary epithelium in man, partly because until recently there were no available, generally accepted
circulating biomarkers of pulmonary epithelial function. Clara cell protein (CC16) is expressed in pulmonary Clara cells and has
been shown in animal (12) and human studies (13) to be a sensitive marker of pulmonary epithelial function. Circulating levels
of CC16 are altered on exposure to ozone or other noxious stimuli (14, 15). In order to investigate the effects of hypoxia, we
performed studies on circulating markers of pulmonary epithelial and endothelial function in normal subjects exposed to
hypoxia at sea level and identified changes in circulating levels of these markers. Our hypothesis is that exposure to hypoxia in
normal human subjects directly affects pulmonary epithelial and endothelial cell function; in its severe form this may be
manifested as pulmonary edema. This effect of hypoxia may be modified by mucosal acidification as would occur with an
increase in alveolar CO2.
SUBPROJECT PROGRESS:

This study was approved by the General Clinical Research Center (GCRC) for 6 subjects which were enrolled. A manuscript is in
preparation.
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SUBPROJECT DESCRIPTION:

We hypothesize that 33% of the tonsillar squamous cell carcinoma tissue analyzed will have evidence of a virulent strain of
Human Papilloma Virus (HPV) (16, 18, 31, 33). Within this subgroup of subjects the response to therapy measured in 5 year
survival data will be greater then the remaining 2/3rd. We also expect that the tonsillar specimens of healthy non-cancerous
patients will be free of virulent strains of HPV. This would allow for a stronger argument of causation rather than association.
To look for an increase in HPV for those patients who have no other risk factors.
SUBPROJECT PROGRESS:

Adam Lubinguhl graduated from Uconn School of Medicine in May 2007 and is now an Otolaryngology resident in Philadelphia.
There has been no additional subject enrollment since the prior progress report. Follow-up was updated late in 2007 during
preparation of an abstract for submission to the upcoming (July 2008) International Conference on Head an Neck Cancer. The
study was accepted for a podium (oral) presentation at this upcoming meeting, and we plan on submitting a manuscript for
publication as well. The GCRC will be cited in both cases.
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SUBPROJECT DESCRIPTION:

Women begin to face their greatest fear when they have been told that their routine mammogram or breast exam is abnormal.
Women experience an array of symptoms throughout the course of their diagnosis, treatment and recovery from breast cancer.
Symptoms are perceived indicators of change in normal functioning as experienced by patients. Symptoms disrupt daily
functioning, most notably social function and communication. Symptom outcomes impact functional and emotional status,
health care service utilization, mortality/morbidity, financial status, and self-care/management. Research has demonstrated the
presence of significant associations between symptoms experienced by breast cancer survivors, suggesting a complex web of
symptom experience. The nature of the complex interactions between symptoms remains unclear. Patients with one symptom
are likely to have others, as well. Cancer-related fatigue, depressive-anxiety symptoms and sleep disturbances are the most
frequent symptoms experienced by women diagnosed with breast cancer. These symptoms can have a devastating impact on
their quality of life. Recent studies imply a correlation of these symptoms with selected markers of inflammation including
levels of proinflammatory cytokines.
Systemic Biomarkers: Biomarkers like carcinoembryonic antigen, CA-125 and prostate-specific antigen (PSA) are helpful in
monitoring and in some cases diagnosing cancer (41). Three new serum biomarkers derived from membrane proteins found on
breast cancer cells, Aminopeptidase N (CD13), membrane type 1-matrix metalloproteinase (MT1-MMP), and stromal derived
receptor-1 (SDR-1), are hopeful novel biomarkers that may prove useful in the diagnosis of breast cancer. Aminopeptidase N,
also known as CD13, is a membrane-bound, zinc-dependent peptidase that cleaves neutral amino acids from the N terminus of
oligopeptides. In addition to being expressed by a number of tissues, CD13 is aberrantly upregulated on both the tumor cells and
developing blood vessels of cancerous tissue. Accumulating evidence points to CD13 as a key regulator in this tissue of both
angiogenesis, or new blood vessel formation (42, 43), and the migration and invasion of tumor cells (44, 45). Interestingly,
although CD13 was first defined as a membrane bound protein, a soluble form was later detected in a variety of bodily fluids
including blood. Moreover, a number of studies have shown CD13 to be elevated in the serum of cancer patients, and to
correlate with larger tumor size (46, 47). To date, however, no studies have investigated CD13 serum activity as a prognostic
marker. Membrane type 1-matrix metalloproteinase (MT1-MMP) also shares similar characteristics as CD13. It is expressed as
an inactive cell surface proteinase which is induced under breast cancer progression and angiogenic responses (48-50).
Interestingly, the functional activation of MT1-MMP results in increased cell migration and invasion and has been shown to be
actively translocated to the cell surface in hypoxia, both in vitro and in human breast cancer (51). It has also been shown to be
shed from tumors as an active fragment which can be detected by MT1-MMP-specific fluorescent peptide substrates (52, 53).
The third biomarker is a novel cell surface protein which is over-expressed in human breast cancer and is selective for a highly
invasive ductal carcinoma; high expression predicts distant metastasis (54). This cell surface protein also depicts cleaved protein
isoforms in human breast tumor lysates indicating it may be shed in blood. This novel tumor antigen was identified from a breast
cancer patients sentinel lymph node and an antibody directed against it was synthesized. This unique antibody will be used in a
fluorescent-based assay on blood samples to determine whether it is a potential diagnostic marker.
SUBPROJECT PROGRESS:

Number of subjects enrolling (Correction to last year's stats)
Time Frame

Enrolled

6/27/2008 9:32:04AM

Screened

177
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4/1/06-3/31/07

7

16

4/1/07-3/31/08

30

53

4/1/08-6/09/08

4

7

Final

30 patients have been enrolled and 53 screened for the progress report period. There are no changes to recruitment plans. We
plan to continue until we meet the recruitment goal of 100 patients. There are no unexpected safety concerns. Interim data was
presented October 2007 to the Board of Directors of the CT Breast Health Initiative, Inc. (Please see attached slide). Jayesh
Kamath is presenting an abstract at the IPOS 10th World Congress of Psycho-Oncology in Madrid, Spain (Please see attached
PDF). There have been no changes made to the protocol within the reporting period. The slide presentation does include
reference to the GCRC.
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SUBPROJECT DESCRIPTION:

Pediatric Aids Clinical Trials Group (PACTG) 1047 is a phase II, double blind, placebo controlled study of the safety and
immunogenicity of Quadrivalant Human Papilloma virus (QHPV) vaccine in a population of Human Immunodeficiency Virus
(HIV)-1 infected boys and girls aged 7 years to under 12 years. The vaccine, also known as Gardasilwas developed by Merck Labs
with the target viral types being 6, 11, 16, and 18. The most common oncogenic Human Papillomavirus (HPV) types that
cause cervical dysplasia and cancer, in both HIV-infected and uninfected women, are HPV 16 and 18. The most common types
of HPV, causing genital warts, are types 6 and 11. On May 18, 2006, an advisory committee for the Federal Drug
Administration (FDA) reviewed Merck's application for licensure of Gardasil®. It is expected that the vaccine will receive
approval in early June, 2006. However, no HIV-infected children, or children with other immune compromising conditions,
have been enrolled or received monovalent or quadrivalent HPV vaccine in any clinical trials.
The incidence of cervical cancer in HIV-infected women increases as immune competence decreases with progression of HIV
disease. Cervical cancer is more extensive and more difficult to cure in HIV-infected women than in HIV-uninfected women and
the recurrence rate after standard clinical care is higher. In addition, HIV-infected individuals are at increased risk for penile and
anal cancer, including individuals who do not report prior anal intercourse. Because HPV is a sexually transmitted infection,
prevention in women will be enhanced by prevention in their partners as well. Thus, evaluation of a prophylactic vaccine,
which might protect HIV-infected girls and boys from infection with the most common HPV types that cause anogenital
dysplasia and external genital lesions, is an important scientific goal.
The study population will consist of 120 HIV-1 infected children recruited from multiple PACTG sites in the U.S. This protocol
will be undertaken in children > 7 to < 12 years of age because it is likely that this preventative vaccine will be used before
children become sexually active. It is expected that, in terms of safety, QHPV Vaccine will be generally well-tolerated in
HIV-infected children in this age group. The subjects will be randomly selected to receive the study vaccine or placebo, with
75% receiving the active vaccine and 25% receiving placebo during Stage I of the study. Since it is expected that children with
weaker immune status would respond differently from children with stronger immune systems, the population will be stratified
into three groups based on their CD4% history and current CD4%.
Stage I: After satisfying eligibility criteria including real-time pregnancy testing for menstruating females, the vaccine/placebo
is given intramuscularly 3 times (at entry, week 8 and week 24). Subsequent safety assessment consists of at least 30 minutes in
the clinic directly after immunization, a day 3 phone evaluation, study visits on week 4, 8, 12, 24, and 28. Subjects will also be
asked to keep a record of oral temperature and symptoms following the injections. (See attached Appendix IV, the Vaccination
Report Card) Subjects will be strongly encouraged to phone the study nurse or Dr. Salazar should any unusual or alarming
symptoms occur.
Stage II: At week 96, the groups will be unblinded. If the vaccine has been deemed safe and well tolerated, a fourth dose will be
given to those children who had received active QHPV. The placebo group would now begin the regimen of active QHPV and
follow up visits. For the group who receives the fourth dose of active QHPV, safety follow up will occur at weeks 97, 100 and
108. Those who begin active QHPV at 96 weeks will be followed in a likewise fashion until study week 124. (Please see attached
Appendix 1I A and IB.) Throughout the course of the study, immunogenicity will be evaluated via blood and saliva samples using
ELISPOT (anti-HPV CMI), HPV antibody cLIA (Competitive Luminex Immunoassay) and IgG and IgA anti-HPV testing.
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SUBPROJECT PROGRESS:

Pediatric Aids Clinical Trials Group (PACTG) 1047 (Version 1.0) has had one subject participating at the Connecticut Children's
Medical Center site since the opening of the study. Due to non-refunding of our site, this subject was discontinued from study
participation as of Nov 2007.
This study has been closed to accrual.
There have been no unexpected safety concerns reported by The PACTG 1047 team.
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SUBPROJECT DESCRIPTION:

This study compares two different approaches to combining workplace safety and health with personal health improvement.
The primary focus is on improvement of musculoskeletal health (mobility and fitness, preventing and controlling joint disease,
and workplace risk reduction), and the secondary focus is on depression and mental health. One approach relies on traditional
health promotion, where a management sponsored program offers an educational package and professional review of work
organization and ergonomics. The second approach involves developing groups within the workforce (Employee Sponsored
Groups or ESPs) that will determine and construct workplace health and safety and personal health programs. The study
involves a comparison of costs, measures of health status, and evaluation of the effectiveness of the workforce planning groups.
The direct involvement of the workers compensation insurance carrier in the study team is intended to produce realistic and
respected agreements about health program conduct and content between the workforce and management. There is a significant
economic and econometric component, which is designed to link health and process outcomes to rate structure.
SUBPROJECT PROGRESS:

Subjects: There are no subjects currently enrolled in this project.
Personnel: There were no changes in key personnel over the year. Professor Vicki Magley in the Department of Psychology at
UCONN-Storrs has formally joined the project as an investigator. Her background is in workplace violence. Her involvement and
the incorporation of HITEC and CPH-NEW fieldwork with the NIOSH-funded industrial psychology program at UCONN, has
brought 3 new graduate trainees into HITEC. Currently, 7 graduate students from UCONN Health Center and UCONN-Storrs are
engaged in the project as their field practicum or as part of their thesis work.
AIMS: HITEC has selected 2 matched sites, facilities with the State of Connecticut Department of Corrections. These currently
active study sites represent a departure from the original plan to use only Travelers clients, but reflected the strong interest on the
part of the State of Connecticut in the challenged health of corrections officers. Selection of the second pair of sites has not been
concluded, and is discussed under Site Selection. The original Aims are presented below. 1. Creation of semi-independent employee
sponsored participant (ESP) groups that will devise a program combining individual health promotion with a corresponding
worksite health and safety intervention. 2. Development of evaluation processes sufficient to compare outcomes from ESP
programs to a more traditional wellness and ergonomic programs: the standard of care (SOC). 3. Development of economic and
econometric models for assessing effectiveness, costs, and benefits of interventions, and providing a program evaluation model
that is understandable, reproducible, and acceptable to all participating parties, and in particular to insurers and financial
representatives. 4. Direct participation of the insurance carrier in quantifying costs and benefits, in developing a rate-based
incentive structure, in "institutionalizing" the employer's involvement, and in disseminating results. We have renamed the ESP
sites participatory sites and refer to the SOC sites as professional sites. AIM #1 remains in process. Practically, we have prepared
a series of operative scenarios based on participatory ergonomics to optimize the process. The evaluation process for site
comparison (AIM #2) is in place and has not changed in principle since last year. Because of security considerations at DOC,
environmental exposure evaluation has been modified. While the development of models (AIM #3) is an ongoing process, there
has been considerable progress in compiling practical data bases. AIM #4 requires an adjustment. Because the State of Connecticut
is self-insured, the model developed with Traveler's underwriters for pard assigning a cost threshold no longer applies. We have
adjusted by working with the Comptrollers Office (group health) and the Department of Administrative Services (DAS) both to
assure capital funding and to apply our cost-plus model to the public sector.
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Site Selection:
The DOC site selection process is described below. As noted in the Year I progress report, a sophisticated selection strategy
involving 1200 Traveler's clients was unsuccessful. We have followed up on reasons for company caution with a survey to key
personnel and to the responsible Traveler's account managers. Results have been presented (APA-NIOSH Work, Stress, and Health
Conference, 3/7/08), and publication is in progress. The reasons for refusal are being studied with Traveler's to look for
generalizable patterns.
We have continued to recruit through Travelers by holding Employer's Schools and have made solicitations outside of the
Traveler's network. The following 13 companies and sites were screened and directly solicited with site visits, PowerPoint
presentations and summaries of worker's compensation costs. The numbers conceal relatively different levels of recruitment
effort. Sites 5 and 6 extended over 4 months each with preliminary agreements and site materials prepared. In both cases, the
deteriorating economic climate and increased pressures from state regulators lead senior management to withdraw.

ID

Description

Traveler's Client

1.

Accounting and finance

Yes New York State

2.

Consumer warehousing

Yes Mid-west No* Travel Costs

3.

Global manufacturing

No

4.

Parts manufacturer

Yes Northern mid-west

5.

Utility

No

CT No

Poor financial climate

6.

Utility

No

CT and MA

7.

Precision manufacturer

8.

Drivers/DOT

9.

Insurer

10.

Food manufacturer

Yes CT and NY

No

Insurer conflict

11.

Warehouse work

No

No

Union contract issue

12.

Precision manufacturer

13.

Aerospace manufacturer

No

CT Pending

In review

14. Electronics manufacturer
(*) HITEC rejected

No

CT and MA

Pending

No

Location No(*) Yes Pending

CT and MA

No

Yes CT and NY

No* Restrictive policies
No* Travel Costs

In review

In review

Pending

MA and CT
No

Poor financial climate

Legal and financial client

Yes CT Pending

CT Pending

No

Status

In review

CT and NY

Pending

In review

In review

The situation is far from negative. The Connecticut DOT (Site 8) and Travelers itself (Site 9) are very interested in participation
but we have reserved them as defaults, because of an intent to diversify beyond two State agencies in the first case, and because of
conflict of interest and low injury rates in the case of Travelers office workers. If the pending manufacturing sites decline over the
next 2 months, we will engage either DOT or Travelers.
Department of Corrections
The program at the Connecticut DOC is underway at two sites. There was an extensive selection process which involved
clearances with all of the unions and the DOC administration. The MOU includes subsidization of time for participation in the
study and an a priori commitment from the State for ergonomic related changes. The selection process involved four elements.
1.
A review of worker's compensation, demographic, and facilities based records from all State facilities
2.
Repeated site visits to 9 facilities, including meetings with key personnel
3.
A management readiness survey was sent to 598 supervisors at 21 facilities, in order to identify most culturally similar
organizations.
4.
A DOC-wide steering committee was set-up involving central administration, wardens, union representatives and health
personnel to advise on final selection, implementation and system-wide dissemination.
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A summary of the two selected sites follows.
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Effect of Anastrozole on Bone Turnover Markers and Bone Mineral Density in Postmenopausal Women
with Primary Breast Cancer: A Pilot Study
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SUBPROJECT DESCRIPTION:

Aromatase Inhibitors (AI) are effective for secondary prevention of breast cancer and may soon replace tamoxifen as first-line
therapy in the treatment of hormone-sensitive breast cancer. However, because these medications produce a marked reduction
in serum estrogen levels, this is likely to result in an increased rate of bone loss and risk of developing osteoporosis and fractures
in postmenopausal women treated with these agents. Indeed, substantial bone loss has been reported in several large clinical
trials of AIs. Osteoporosis drugs are available that could prevent this loss, but they have frequent side effects and are expensive.
Thus, treating all women receiving AIs might not be the most appropriate and cost-effective approach. A better approach
might be to select women at highest risk of bone loss and only treat them with antiresorptive agents. We hypothesize that
women who demonstrate high bone turnover, as reflected by markers which can be measured in blood and urine samples in the
first 3 to 6-months on treatment, will have greater bone loss.
The proposed pilot study will evaluate women who receive anastrozole therapy, are receiving adequate amounts of calcium and
vitamin D and have baseline normal or moderately low bone mass in order to determine if early changes in bone turnover
markers correlate with bone loss at one year. If data from this pilot protocol support our hypothesis, then we would propose a
larger trial to confirm it. The ultimate aim is to predict which women are at higher risk of bone loss and therefore treat them
earlier with bone-sparing agents, while those with lower risk could be monitored on conservative therapy.
SUBPROJECT PROGRESS:

The study has been actively screening women over the past year and we currently have enrolled 10 women during the above time
frame. There is also 1 woman who is scheduled to start on 6/16/2008.
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Center on Aging
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INTERNAL MEDICINE

YALE UNIVERSITY, CT USA

KERSTETTER, JANE PHD

NUTRITION

UCONN - STORRS, CT USA

WEIGERT, JEAN MD

RADIOLOGY

WOMEN'S IMAGING, CT USA

SUBPROJECT DESCRIPTION:

Because increasing dietary protein increases urine calcium and metabolic acid load and because systemic acidosis favors bone loss,
it is thought that higher protein diets increase bone resorption and decrease Bone Mineral Density (BMD). However, most
cross-sectional, population-based studies with bone density, or rates of bone loss as the principal outcome, indicate that higher
dietary protein intakes are associated with higher (not lower) BMD and slower (not faster) rates of bone loss. Further,
increasing dietary protein in subjects consuming low-normal protein diets increases circulating levels of IGF-1 which is known to
be important for bone anabolism. Three recent diet-controlled isotopic calcium studies showed no net loss of calcium from bone
during high protein diets in humans (1-3). In 1 of these 3 studies, we (1) showed that a high protein diet increased urinary
calcium by increasing intestinal calcium absorption. Importantly, during the high protein diet, there was a significant reduction
in the fraction of urinary calcium of bone origin and a trend toward a reduction in the rate of bone turnover. None of the 3
isotopic studies found evidence for increased bone loss with increasing dietary protein. In fact, they all suggest the opposite;
higher protein diets actually improved calcium retention. These isotopic data lay the groundwork for a long-term protein
intervention trial with BMD as the principal outcome variable.
SUBPROJECT PROGRESS:

The study is underway and recruitment is beginning. Approximately 47 women have been recruited into the study and 6 women
have discontinued due to medical illness or not tolerating the inconvenience of taking the protein supplement. No unexpected
safety concerns have arisen. We are considering changes to the inclusion criteria to improve recruitment efforts. There have been
no publications from the study.
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Psychiatry
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Psychiatry

KRANZLER, HENRY MD

Psychiatry

LALANDE, MARC MD

Genetics & Develop Biology

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The purpose of this registry/repository is collect diagnostic data (psychiatric and medical diagnoses) and tissue specimens from
subjects and/or family members in order to build a Behavioral Gene Bank (BGB). The registry/repository aims to study: subjects
with known or suspected genetic or medical syndromes; families with high concentrations of psychiatric illnesses; and subjects
with dysmorphic features or other clinical characteristics suggestive of a genetic or chromosomal disorder. Relatives of
individuals with these features and healthy controls will also participate. Subjects will be invited to participate in further
behavioral studies in the future.
SUBPROJECT PROGRESS:

The purpose of this protocol is to establish a Behavioral Gene Bank, in which blood samples from patients with mental illness such
as bipolar disorder and schizophrenia are collected for genetics research. This protocol was initially approved by the IRB on
February 28, 2007 and was then IRB approved for annual continuation on 01/24/2008 (valid through 01/25/2009). A total of 32
subjects have been enrolled since July, 2007. An IRB approved recruitment brochure is posted on the GCRC website for the general
public in the "current research" section. There have been no unexpected safety concerns. There are no publications as of yet.
Proposed changes made to the protocol have been administrative only with no risk to participants.
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Taste and Colon Cancer
The Taste and Colon Cancer Collaboration Project
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DUFFY, VALERIE PHD

ALLIED HEALTH SCIENCES

UCONN, STORRS, CT USA

CONWAY, JUDITH ARNP

CANCER CENTER

LEVINE, JOEL MD

Medicine

SULLIVAN, BRIDGET MD

ALLIED HEALTH SCIENCES

UCONN - STORRS, CT USA

SUBPROJECT DESCRIPTION:

New colon cancer cases in the US have increased 38% from 1950 to 2001, reaching over 106,370 in 2004 (1) and resulting in
substantial morbidity and mortality. Colon cancer is an end result of a multiphase process. Aberrant Crypt Foci (ACF) appear
to be the earliest identifiable neoplastic lesions in the colon (2) through use of magnifying chromoendoscopy. ACF may be
detected in humans years before the appearance of neoplasms (2). Those that are dysplastic are most likely to progress to an
adenoma (3), which is a pedunculate polypoid structure that grows into the lumen of the colon. Number of adenomatous polyps
is considered the precursor of most large-bowel cancers. The genetics of colon cancer are very heterogeneous (4). Adenomas
can occur sporadically or in readily defined high-risk groups, including those with family history of colon cancer or
premalignant polyps. Although chemoprevention is being actively investigated (5-7), there is little at the present time to offer
high-risk patients other than an increased watchfulness for malignant transformation. Strong epidemiologic and experimental
data suggest that dietary factors play an important role in reducing the risk of colon cancer for genetically predisposed
individuals (8), with as many as 7 in 10 cancers being preventable through diet and lifestyle changes (9). Diets that promote
excess energy intakes, not the source of energy per se (8), and adiposity increase colon cancer risk (10), especially in men (11).
Risk of colon cancer varies genetically, which may explain why individuals who have the same dietary behaviors, vary in
colon cancer risk. Polymorphisms in folate-metabolizing enzymes affect risk of colorectal neoplasia (22) with some genotypes
deriving more benefit from diets rich in vegetable-related nutrients (23). Associations between colorectal cancer risk and meat
consumption patterns and prepartion varies with genetic differences in metabolism of heterocyclic amines, particulary to
genetic variants in cytochrome p-450 and glutathione S-trasferase activity (24). Higher intakes of vegetables also appears to
decrease risk of spontaneous colon tumors, particularly in individuals who have mutations of the adenomatous polyposis colic
gene (25).
Preliminary data suggests that another genetic variation in colon cancer risk involves genetic variation in taste. In a sample of
251 men, those who tasted PROP as more bitter had a higher number of polyps, but only among those who were years of age
(26). Those who had polyps were most likely to be overweight/obese and, according to a subset of study sample, those who
tasted PROP as most bitter reported lowest intake of vegetables.
SUBPROJECT PROGRESS:

There were no subjects enrolled during the report period and since initiation of the study because of staffing changes in the Colon
Cancer Prevention Center. We are working to start data collection over the summer and to continue from that point.
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Dietary Soy
Metabolism and Bioavailability of Dietary Soy Isoflavones in Postmenopausal Women
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BRUNO, RICHARD PHD, RD

NUTRITIONAL SCIENCES

UCONN STORRS, CT USA

KENNY, ANNE MD

Center on Aging

KERSTETTER, JANE PHD

NUTRITION

UCONN - STORRS, CT USA

SUBPROJECT DESCRIPTION:

Postmenopausal women are at significantly higher risk for developing osteoporosis and cardiovascular disease. Hormone
replacement therapy was suggested as a risk lowering, health promoting strategy for these chronic diseases among this high-risk
female population. However, growing health concerns surrounding the use of hormone replacement therapy have resulted in the
increased consumption of soy foods as an alternative natural" therapy. Soy contains an abundant mixture of isoflavones, a class
of flavonoids, which have phyto-estrogenic activities. The growing knowledge in this area has prompted a 15-fold escalation in
soy food sales to $4 billion dollars annually in comparison to the early 1990's. Despite the continued marketing of soy foods
and their perceived health promoting benefits for postmenopausal women, there remains a lack of credible evidence that the
consumption of these products will protect against the development of osteoporosis and/or cardiovascular disease. Moreover,
the current paradigm regarding soy has shifted such that the intestinal metabolism of soy isoflavones to bioactive metabolites
may dictate its benefits. Thus, in the absence of more thoroughly understanding the benefits of soy consumption and its
metabolism in humans, useful dietary recommendations will not be possible. The long-term goal of our research program is to
develop and evaluate dietary strategies that will
be effective in preventing and/or ameliorating oxidative stress-mediated processes implicated in the pathogenesis of chronic
disease. The objective of this Donaghue Medical Research Foundation application is to define the mechanisms by which dietary
soy consumption, as a complementary and alternative medical therapy, can favorably improve inflammatory and metabolic
processes involved in bone and cardiovascular health in postmenopausal women. Our central hypothesis is that the metabolism
profile of soy isoflavones will dictate an individual's response to specific biomarkers of bone and cardiovascular health. Our
hypothesis is supported by our preliminary data indicating that 12-mo of daily soy consumption in postmenopausal women
resulted in highly variable within-group responses with respect to bone mineral density and plasma lipoproteins. The lack of a
uniform metabolic response suggests that other physiological factors, such as the variable metabolism of isoflavones by
intestinal microflora, could potentially explain why select postmenopausal women had favorable biological responses whereas
other did not. Our multi-disciplinary team is ideally positioned to undertake this important human health problem. Dr. R. Bruno
(Principal Investigator) has been actively involved in studying the mechanisms by which phytonutrients contribute to human
health and has experience in the analytical measurements of flavonoids and antioxidants from biological samples. In addition,
Drs. J. Kerstetter (Consultant), K Prestwood and A Kenny are authorities in bone health and have already successfully conducted
the 12-mo soy intervention trial in postmenopausal women from which our hypothesis has been formulated.
SUBPROJECT PROGRESS:

The underlying objectives of this project were to enable our critical understanding of the bioavailability of soy isoflavones on bone
health and cardiovascular disease and to assess the potential protective effects of equol, a soy isoflavone metabolite, on these
parameters. Indeed, a considerable body of epidemiological literature suggests a protective effect of soy consumption in
post-menopausal women which has lead to the hypothesis that soy isoflavones, the purported bioactive constituents of soy, exhibit
estrogenic effects that protect against bone and cardiovascular disorders. Thus, the scope of this project was to evaluate serum soy
isoflavones (daidzein and genistein) and a primary isoflavone metabolite (equol) in serum samples archived from a 12-mo
prospective clinical trial where post-menopausal women (n = 97). The participants were randomized to daily dietary
supplementation with A) control protein (20 g/d) + placebo, B) control protein (20 g/d) + 100 mg/d isoflavones, C) soy protein
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(20 g/d) + placebo, or D) soy protein (20 g/d) + 100 mg/d isoflavones.
During this reporting period, we did not enroll any additional participants and we did not use the services of the UCHC GCRC.
Thus, in the absence of any additional participant enrollment, there were no adverse events to report. Also, no procedural changes
were made to this project from the original submission of this application.
We successfully developed a high sensitivity HPLC binary gradient separation method coupled with Coularray electrochemical
detection (Figure 1) to obtain the necessary lower limits (~50 nmol/L) of detection required to assess serum isoflavones (daidzein,
genistein, and equol) from free living individuals. In brief, serum isoflavone conjugates were hydrolyzed with â-glucuronidase and
sulfatase, followed by sample protein precipitation with acetonitrile, delipidation with hexane. Subsequently, isoflavones were
extracted with with methyl-t-butyl-ether (MTBE), dried under nitrogen gas and then reconstituted in HPLC mobile phase prior to
HPLC injection. The procedure has a linear operating range of 0.5-500 pmol injected (R2 > 0.99) for each analyte and the within
day and between day CV of the assay was <8%.
This method was then utilized to examine serum concentrations of soy isoflavones from our study participants. Indeed, the use of
this method enabled our ability to 1) assess compliance of the participants to their respective treatment or placebo, 2) determine
serum isoflavone plasma responses, and 3) characterize the proportion of the study population who were equol (isoflavone
metabolite) producers.
Data analysis for this project is actively underway. However, we are pleased to report that >95% of participants were compliant to
the supplementation intervention regimen. We also established that ~40% of those assigned to the isoflavone supplements were
equol producers. This is of particular importance because experimental evidence suggests that equol exhibits greater estrogen
receptor binding activity than native soy isoflavones. Thus, we hypothesize that the equol producers in this study will have more
favorable changes on health outcomes. Our currently statistical approaches are exploring the relationship of serum isoflavone
concentrations and equol production with well established biomarkers of bone health, cardiovascular disease, and inflammation. We
expect that these analyses will be completed during the next 3-mo and that up to three manuscripts will be submitted for
publication in peer reviewed scientific journals during fall 2008.

6/27/2008 9:32:04AM

189

5M01RR006192-14
SPID:

REPORT PD: 04/01/2007-03/31/2008

0651

651

PROTOCOL:

TYPE: RESEARCH

SHORT TITLE:
LONG TITLE:

Secondary Syphilis
Adaptive Immunity in Secondary Syphilis
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SALAZAR, JUAN MD

Pediatrics

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

To examine aspects of the systemic adaptive cellular response to infection with Treponema pallidum in secondary syphilis
patients.
Specific Objectives: To determine by intracellular cytokine staining the T. pallidum antigen specificity of circulating T cells in
secondary syphilis patients. To determine if circulating T cells in secondary syphilis patients are undergoing apoptosis. To
determine if T regulatory cells are increased in the blood of secondary syphilis patients. Adaptive Immunity in Secondary
Syphilis. Secondary Objective: To compare the relative yield of T. pallidum genomic DNA (flaATAQMAN) by Real Time
Quantitative Polymer Chain Reaction (PCR) assay between whole blood, plasma, serum and PBMC samples obtained from
secondary syphilis patients.
SUBPROJECT PROGRESS:

(A) Specific Aims:
Specific Aim 1. To examine aspects of the local and systemic inflammatory response to infection with Treponema pallidum of
particular relevance to HIV transmission and dissemination. This Aim was divided in two components: (a) to study the expression
of HIV co-receptors in dermal inflammatory cells within syphilitic lesions and peripheral blood of patients with secondary syphilis
and (b) to study the ex vivo effect(s) of T. pallidum on surface expression of HIV co-receptors by T-cells, macrophages and
dendritic cells and how these changes influence HIV susceptibility and infectiousness.
Specific Aim 2. To establish the effect of early syphilis on viral load in patients with HIV co-infection. As previously agreed upon
and reported in the previous year's progress report, the second Aim was eliminated. Instead we have significantly expanded Aim 1.
(B) Studies and Results:
Specific Aim 1. Part (a): This component has been completed and the results published in the Journal of Infectious Diseases
(March 15, 2007). We demonstrated that dermal lesions from secondary syphilis patients contained a mixture of mononuclear
cells, including T cells, monocytes/macrophages, and DCs, but no B cells. Lesional monocytes were larger and more granular and
expressed high levels of CD14, indicating that these cells had differentiated into macrophages. Both CD11c+ monocytoid DCs
(mDCs) and CD11c- plasmacytoid DCs (pDCs) were present in dermal infiltrates and expressed the HIV chemokine co-receptor
CCR5, which is also associated with leukocyte trafficking into inflamed skin. Both subsets expressed DC-SIGN, a member of the
C-type lectin family which is linked with DC-T-Cell interactions and is a key HIV co-receptor. HLA-DR expression increases in
mDCs but not pDCs, point to the primary role of this subset has in T. pallidum internalization and antigen presentation. Dermal
infiltrates also had substantial numbers of memory and memory effector CD4+ and CD8+ T cells. Together these findings in skin
confirmed that innate and adaptive immune responses co-evolve in tissues during active syphilitic infection setting the stage for
local stimulation of T. pallidum-reactive lymphocytes. Our study also revealed the extent of immunophenotypic alterations of
immune cells obtained from peripheral blood. Firstly, secondary syphilis patients displayed marked immunophenotypic
modifications in circulating CD4+ T cell subsets, supporting the notion that neosensitized T cells differentiate into memory,
memory/effector, and effector subsets. These cells are probably trafficking from lymph nodes to sites of infection (i.e. skin) to
interact with their cognate treponemal antigens. Secondly, we showed that over a third of circulating mDCs and pDCs expressed
the HIV co-receptors, CCR5 and DC-SIGN. Circulating monocytes, similar to those in the dermis, also had increased CD14 MFI
levels. It is our contention that these immunophenotypic changes in circulating monocytes and DCs occur as a result of their
direct interaction with circulating spirochetes. Part (b): For this aim we have first examined the effects of spirochetes on
monocytes and dendritic cells on PBMCs and isolated monocytes using an ex vivo model. We have already shown that spirochetes
up regulate monocyte cell surface expression of the activation markers CD40 and CD83 and secretion of the proinflammatory
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cytokines, TNFá, IL-6, and IL-1â. We have also demonstrated that for these events to occur the spirochetes need to be
internalized and that in the case of T. pallidum internalization is critically dependent on the presence of human syphilitic sera.
Results from these studies were published in collaboration with Meagan Moore, a talented MD/PhD student in Dr. Radolf's
laboratory (see Infection and Immunity April, 2007). These have separate GCRC approval and the report has already been
submitted by Dr. Radolf.
(C) Significance: Our published findings provide strong evidence that in the course of secondary syphilis, T. pallidum induces a
potent innate and adaptive cellular immune response in both skin and peripheral blood. In accord with our underlying hypothesis,
while this inflammatory response promotes clearance of the spirochete and may ultimately lead to some degree of resistance; it
also provides an environment optimal for bidirectional transmission of HIV. The degree of innate and adaptive immune cell
activation in peripheral blood also serves as a potential explanation for why individuals co-infected with HIV have demonstrable
increases in HIV viral load. Finally, this research has also propelled the city of Cali's public health department to set up a campaign
to improve diagnosis, treatment and follow-up of venereal syphilis. In addition, the collaboration has already improved gestational
syphilis case ascertainment and a subsequent decrease in congenital syphilis cases.
There have been no safety concerns that would warrant changes in the protocol.
All clinical activities and enrollments take place at the study site in Cali, Colombia. However, the database for this study is still in
development at the GCRC in collaboration with the investigator.
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PeriDial
Periodontal Infection, Depressive symptoms and inflammation in renal patients
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IOANNIDOU, EFFIE DDS

Periodontology

DONGARI-BAGTZOGLOU, ANNA DDS,
PHD

Periodontology

KAPLAN, RICHARD PHD

Psychiatry

LITT, MARK PHD

Behavioral Sci & Comm Hlth

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Periodontal diseases are chronic gram-negative oral infections initiated in the gingiva and leading to alveolar bone destruction
and gradual loss of tooth supporting connective tissues. Cumulatively, these infections affect more than 70% of the general
population. Recent evidence indicates that chronic severe periodontal disease is associated with systemically elevated
inflammatory mediators. Chronic kidney disease (CKD) patients are also characterized by a chronic inflammatory state which
contributes to an extremely high rate of atherosclerotic complications. Recently, both serum interleukin-6 (IL-6) and
C-reactive protein (CRP) levels have been found to predict cardiovascular mortality in CKD patients on HD. We hypothesize
that periodontal infections are highly prevalent in the CKD population and that both periodontal infections and depressive
symptoms affect the systemic inflammatory status of HD and pre-dialysis CKD patients.
SUBPROJECT PROGRESS:

The overall aim of the study was to compare the periodontal status between the HD and control subjects and explore the
relationship between hemodialysis, periodontal variables and systemic inflammation. The aim of these studies was also to collect
preliminary data to support the K23 application and conduct appropriate power analyses. Participants received a complete clinical
periodontal examination that included clinical attachment loss (CAL), probing depth (PD), plaque score (PS), bleeding on probing
(BOP) and number of missing teeth. Venous blood was collected prior to clinical evaluation for quantification of serum IL-6 and
CRP levels. Within 2 hours of blood collection, sera were separated after clotting for 30 minutes at 4oC followed by centrifugation
at 3000xg for 15 minutes. Sera were analyzed in duplicate by enzyme-linked immunosorbent assay without knowledge of the
periodontal disease or dialysis status of the participants. The assay analytical sensitivity was 2.0 pg/ml and the variation in IL-6
protein values within runs was less than 1%. The medical records of the HD patients were reviewed and all relevant information
was collected using a standardized data extraction form.
So far we recruited 38 subjects. Overall, in the hemodialysis population, the mean age was 55.7 years, 46.2% were females, 33.3%
were diabetic. When comparing the mean PD values between the two groups, HD subjects had higher, with a trend to significance,
values than control subjects. Also, patients in the HD group
showed more sites with BOP (p=0.50) and higher PS (p=0.10), although these were not statistically significant. When comparing
the serum CRP levels between subjects with periodontitis vs. subjects without periodontitis, we found that the serum CRP levels
were elevated with a trend to significance (p=0.1) in the subjects with periodontitis. Moreover, the serum IL-6 levels in subjects
with periodontitis were more elevated compared to the subjects without periodontitis although they didn't reach statistical
significance (p=0.4).
Although supportive of the hypothesis to be further tested in the proposed work, accurate interpretation of these preliminary data
is prohibited by the small sample size, which does not permit examination of confounding factors such as diabetes, concurrent
NSAID use, dialysis vintage or other systemic factors that may influence CRP and IL-6 levels in this population. Therefore, we are
proposing to conduct a larger scale study to examine the periodontal status of HD and pre-dialysis CKD patients and take into
account all relevant comorbidities, so that we can accurately assess the influence of periodontal infections in their systemic
inflammatory status.
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Estradiol Therapy
Pilot study on the Effect of Short Term Estradiol Therapy on Osteoclastogenesis from Human Peripheral
Blood Mononuclear Cells in Postmenopausal Women
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MIRZA, FARYAL MD

Medicine

LORENZO, JOSEPH MD

Medicine

RAISZ, LAWRENCE G MD

Medicine/Endocrinology

TAXEL, PAMELA MD

Medicine

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The mechanism of increased bone resorption with estrogen is not fully understood, but there is good evidence for effects on
osteoclastic precursors of the hematopoietic lineage, and on the osteoblastic cells of mesenchymal lineage that interact with
hematopoietic cells to produce osteoclasts. Circulating osteoclast precursors have been clearly demonstrated in peripheral blood,
and there is some evidence for circulating osteoblast precursors as well 2. We have shown that short term estrogen treatment
can alter the expression of receptor activator of NFligand (RANKL) indicating an effect on the osteoblastic lineage, and the
response to macrophage colony stimulating factor (MCSF) and RANKL, indicating an effect on hematopoietic lineage. Initial
aim of this study will be to analyze osteoclastogenesis in peripheral blood before and after estrogen treatment, when MCSF,
RANKL and other direct stimulators of osteoclastogenesis are added, thus testing the effects on hematopoietic lineage. RANKL
expression will also be measured, and if changes are observed, then additional studies to isolate and analyze effects of estrogen
on cells of osteoblastic lineage can be carried out.
SUBPROJECT PROGRESS:

Peripheral blood osteoclastogenesis in being studied in postmenopausal and premenopausal women. We started out with
postmenopausal women and tested changes in multiple aspects of our protocol (including plating density, Ficoll preparation, type
of centrifugation, type of culture plate, duration of culture) until we were successful in making large numbers of osteoclasts in vitro.
A considerable variability was noted in the postmenopausal and in the premenopausal women for reproducibility of these assays,
although premenopausal women had more robust osteoclastogenesis.
Currently we are using various methods including flow cytometry and antibody labeled beads to better identify and isolate the CD14
monocytes that serve as precursors of the osteoclasts to minimize variability in these assays. We think that reproducible
differences between pre- and postmenopausal women would be useful preliminary data for applying for other grants.

6/27/2008 9:32:04AM

193

5M01RR006192-14
SPID:

REPORT PD: 04/01/2007-03/31/2008

0655

655

PROTOCOL:

TYPE: RESEARCH

SHORT TITLE:
LONG TITLE:

Otoacoustic Emissions
Rapid Method for Collection of Stimulus Frequency Otoacoustic Emissions
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PARHAM, KOUROSH MD

Surgery

DUCK, KIM PHD

Surgery

NON-HOST INSTITUTION: STATE,
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SUBPROJECT DESCRIPTION:

Otoacoustic emissions (OAEs) are sounds generated by the inner ear and their properties have been used to assess inner ear
function. There are a number of ways of eliciting and measuring OAEs, e.g., click-evoked OAEs or distortion product OAEs.
Both of these techniques are currently in use clinically, however, it is recognized that both have shortcomings (i.e., poor
frequency specificity in the case of click-evoked and as yet indeterminant site of DPOAE generation thus unclear correlation
with site of cochlear pathology in the case of DPOAEs). Stimulus frequency otoacoustic emissions (SFOAEs) offer the most
frequency specific method of assessing function along the cochlear partition. Up to now measurement of SFOAEs has been too
time consuming to allow use in clinical applications. We have developed a rapid method for recording stimulus frequency
otoacoustic emissions (SFOAEs). Here we propose to develop this technique into a useful clinical tool with potential to replace
CEOAES and DPOAEs, and obtain normative data and preliminary results from hearing impaired listeners.
SUBPROJECT PROGRESS:

We tested 8 subjects this year. All subjects underwent audiometric evaluation and fulfilled inclusion criteria. Additionally, all were
tested using the novel stimulus frequency otoacoustic emissions. No safety concerns were encountered. The preliminary results
demonstrating our technical capability was presented at the annual meeting of the Association for Research in Otolaryngology in
February 2008. Since February 2008 we have not collected any further data because of increased clinical demand on the Principal
Investigator (PI). Currently, data collection and analysis are on hold pending IRB continuation. If our data analysis suggests we
have gathered sufficient results from normal hearing ears to establish a baseline for our measures, we may propose to test some
hearing impaired subjects to assess sensitivity and specificity of our novel method as a diagnostic tool. We will, of course, apply
for IRB modification and GCRC approval prior to proceeding. We are not likely to take these steps until late July 2008 when the
clinical load on the PI is expected to decrease.
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SWEDE, HELEN PHD

Community Medicine

STEVENS, RICHARD G PHD

Community Medicine

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Excess body fat (i.e., adiposity) has been implicated as a primary risk factor for colorectal cancer (CRC), but the precise
physiological mechanisms underlying this relationship remain largely unknown. Adiposity frequently triggers the insulin
resistance syndrome, a hallmark of which is a dysregulated Insulin-like Growth Factor (IGF) system. IGFs are potent mitogens
that play a pivotal role in cellular renewal and apoptosis. A growing body of pre-clinical and epidemiologic evidence links
various IGF abnormalities with CRC risk. A few epidemiologic studies have examined the association between circulating IGF
abnormalities and colonic polyps, yet this relationship has not been fully explored. The specific aims of the proposed study
aims are to examine features of polyps (number, size, histology) in relation to: 1) Circulating markers of insulin resistance (i.e.,
fasting levels of: IGF-1, IGF-2, IGF binding protein 3, insulin and glucose; and, 2) Circulating proinflammatory cytokines (CRP,
tumor necrosis factor-alpha.) We will examine these relationships in a sample of 80 non-diabetic patients receiving
colonoscopy at UCHC. Should the impact of biochemical abnormalities related to insulin resistance be observed in early colonic
lesions, it would offer new insights into CRC etiology and strengthen the evidence base about CRC prevention related to excess
body fat.
SUBPROJECT PROGRESS:

A project initiation was held, and an Institutional Review Board (IRB) application was submitted but the study was closed out in
early 2008 due to delays in starting patient recruitment as a result of a medical leave by the study gastroenterologist as well as
other staffing gaps. Subsequently, the project was subsumed into GCRC # 674 (Swede, PI) due to common research aims.

6/27/2008 9:32:04AM

195

5M01RR006192-14
SPID:

REPORT PD: 04/01/2007-03/31/2008

0657

657

PROTOCOL:

TYPE: RESEARCH

SHORT TITLE:
LONG TITLE:

Expressive Writing
Pilot Study of the Effects of Expressive Writing on Endothelial Function
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N

START DATE:

Final
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WAGNER, JULIE PHD

Behavioral Sci & Comm Hlth

TENNEN, HOWARD PHD

Community Medicine

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Our group has been investigating associations between history of depression and mental stress on the one hand, and endothelial
function on the other hand, in postmenopausal women. To date we have found that relative to their never depressed
counterparts, women with a history of depression show impaired resting endothelial function. The association between history
of depression and resting endothelial dysfunction is especially strong in women with type 2 diabetes. Preliminary data from our
group also suggest that women with a history of depression may show more endothelial dysfunction in response to an acute
stressor than their never depressed counterparts. Our group is now interested in testing interventions to improve resting
endothelial function, and endothelial stress reactivity, in women at risk for endothelial dysfunction. Expressive writing
interventions have shown benefits for a variety of health and mental health outcomes in healthy, medical, and psychiatric
samples. This pilot and feasibility study will explore the effects of an expressive writing intervention on endothelial function in
women with diabetes. Twenty women will participate, who will be recruited as part of GCRC study #453. History of depression
and current depressive symptoms will be assessed at baseline. Resting endothelial function and endothelial stress reactivity will be
assessed at baseline using brachial artery flow-mediated dilation (FMD). Participants will then be randomized to either an
expressive writing condition, or a control writing condition. Women in the expressive writing condition will write about the
facts and emotions related to a personal trauma or upsetting event. Women in the control writing condition will write about
assigned topics devoid of emotional content (e.g., fashion, daily tasks, shopping lists). All participants will complete
twice-weekly writing sessions for 4 weeks. Participants writing exercises will be mailed to the investigator so that the postmark
can verify compliance with the writing schedule. One month after the last writing exercise, participants will return for follow-up
resting FMD and FMD stress reactivity assessments. We hypothesize that relative to the women in the control writing
condition, women in the expressive writing condition will show improvement in resting FMD and FMD stress reactivity. We
further hypothesize that depression history will modify the effect of the intervention such that women with a history of
depression will benefit more from the intervention than their never depressed counterparts. We recognize that we will be
underpowered to detect significance; the goal of this pilot is to detect trends in the hypothesized directions. The specific aims
are to: 1) estimate an effect size to be used in a power analysis for a subsequent external grant proposal; 2) address the
acceptability of the protocol for this population; 3) gather participant feedback to be used to modify the intervention for future
proposals.
SUBPROJECT PROGRESS:

From 4/1/2007 until 3/31/2008 (and since initiation of the study), 3 women enrolled. One withdrew from the study citing time
commitments, one is currently participating, and one has completed. No modifications were made to this pilot study. There were
no expected safety concerns for this study. The study began enrolling in February of 2008, and there are no publications at this
time.
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AICD (Activation Induced Cell Death)
Rescuing CTL from Activation Induced Death
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MUKHERJI, BIJAY MD

Medicine

CLARK, ROBERT MD

Immunology

DORSKY, DAVID MD

Infectious Disease

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

This project is designed to examine the molecular mechanism underlying suicidal death in tumor antigen specific cytolytic T
lumphocytes (CTL) when they re-encounter antigen and to examine how such deaths in the CTL can be prevented so as to
orchestrate a robust and long-lived CTL response during cancer immunotherapy. The studies will be done in ex-vivo laboratory
experiments and in animals bearing grafts of human melanoma cells.
SUBPROJECT PROGRESS:

Number of subjects entered - 15
There has been no change in the recruitment plan
There has been no unexpected safety concern
Experiments and Data analysis are continuing
No change in the protocol
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HIV on Hepatitis C
Impact of HIV on Hepatitis C Infection in Hemophilia
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BONA, ROBERT MD

Medicine/Hem-Onc

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

This study is being done at hemophilia centers throughout the United States. The purpose of this study is to collect medical
information, blood samples and liver tissue samples from study subjects with hemophilia and hepatitis C (HCV). The major aim
of the study is to find how frequently individuals with hemophilia develop cirrhosis (liver scarring) from chronic hepatitis C
infection, and whether co-infection with human immunodeficiency virus (HIV) may worsen liver disease outcome due to their
hepatitis C.
SUBPROJECT PROGRESS:

One subject was enrolled into this study during the reporting period and since initiation of the study. There are no recruitment
plans as the study has been closed. The IRB closed this study effective as of 11/26/07. Our study subject did not experience any
adverse events during the time of his study participation. The study site has not given us any interim data or outcomes for this
study.
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Effects of Tabacco
The Effects of Tobacco on Brain Structure and Function are Amplified by Genotype

AIDS:

N

START DATE:

TOTALS

5/17/2007

Total # pts expected for entire study:

100

Inpatient

A
0

B
0

D
0

Scatter Bed

0

0

0

Outpatient

19

0

0

Scatter RN Hours

0

0

0

Offsite Visits

0

0

0

RESEARCH BIONUTRITION

N

MULTICENTER STUDY

N

INFORMATICS CORE

Y

CLINICAL TRIAL

N

BIOSTATISTICIAN

N

CORE LAB

Y

ANCILLARIES ONLY

N

INVESTIGATOR

DEPARTMENT

BAUER, LANCE PHD

Psychiatry

COVAULT, JONATHAN MD, PHD

Psychiatry

PEARLSON, GODFREY MD

PSYCHIATRY

NON-HOST INSTITUTION: STATE,
COUNTRY

INSTITUTE OF LIVING, CT USA

SUBPROJECT DESCRIPTION:

Red peppers (Capsicum frutescens) have been used for several thousand years as food additives and for a broad variety of medical
applications in Indian, Native American, African and Chinese medical traditions. CP is the pungent component of red peppers.
Chemically, it is a derivative of vanillyl amide, 8-methyl-N-vanillyl-6-noneamide and has a molecular weight of 305.42. The
receptor for CP is vanilloid receptor 1 (VR1). VR1 has been shown to be highly expressed in nociceptive neurons of dorsal root
and trigeminal ganglia. CP binds to VR1 on sensory neurons to convey the sensation of pain. Apart from its neurological
functions CP has also been shown
to be active immunologically, in generating more antibody-producing cells compared to untreated controls. Dietary CP in
BALB/c mice has been shown to enhance lymphocyte proliferation and serum immunoglobulin levels. Inhalation of CP
has been shown to interfere with neural responses involved in inflammation in the lungs of Lewis rats and such interference
modulates immunity to inhaled antigens. We and others have observed that mouse and human dendritic cells (DCs), a key cell
type in immune responses, have the receptor for CP, and engagement of this receptor has powerful immune consequences. Our
recent data suggest that intra-lesional administration of CP into a preexisting murine tumor results in retarded progression of
the injected tumor regardless of whether the tumor is at its early or late stage. Further, it leads to significant inhibition of
growth of other, un-injected tumors in the same animal. We have shown that only tumor cells but not normal cells undergo
apoptosis in response to CP but CP elicited anti-tumor immunity is T cell mediated and tumor-specific.
CP has been used previously in clinical studies. Intradermal and topical application of CP has been used to study mechanisms of
allodynia and hyperalgesia and the efficacy of drugs in relieving the symptoms. The dose of CP varied
from 20 to 250ƒn£gg. Pain intensity and vital signs were monitored after CP administration. We have used intra lesional CP in
mouse tumor model with MTD at a dose of 200 £gg. The common toxicity noticed was scar at the injection site. Based upon
our observations in the laboratory, we have hypothesized intra lesional use of CP in patients with melanoma may have
immunological relevance in this disease.
SUBPROJECT PROGRESS:

The general goal of the activity is to provide data regarding structural and functional brain abnormalities in middle-aged adults at
increased genetic and environmental risk for cerebrovascular disease. The activity is a clinical research project to be completed
within a one year period. The list of objectives includes the recruitment of 100 adults varying in risk as defined by the presence
versus absence of a history of heavy tobacco use. Each of these groups will be further stratified by ApoE-e4, Factor XIII
Val34Leu, and Paraoxonase-1 Gln192Arg genotypes in separate analyses. High resolution structural magnetic resonance images
will be collected of the whole brain. In addition, evoked electroencephalographic responses and cognitive test performance will be
recorded to determine whether the MRI abnormalities are physiologically significant. The primary analyses will examine the
independent and interactive effects of smoking and genotype."
As of this date (with 4 quarters of funding remaining), we have enrolled and tested 24 study participants. With the initial delays
associated with hiring study personnel and receiving approvals from 3 separate IRB/human subjects committees (at Universtiy of
Connecticut Health Center (UCHC), Institute of Living/Hartford Hospital (IOL/HH), and the Connecticut Department of Public
Health (CT DPH)) now passed, we foresee no barriers in meeting future enrollment targets. We are recruiting participants from
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multiple sources. Of course, at this early stage of data collection, we have no findings to report.
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FMSclerostin
Comparison of Serum Levels of Sclerostin in Premenopausal and Postmenopausal Women

AIDS:

N

START DATE:
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MIRZA, FARYAL MD

Medicine

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Osteocytes inhibit bone formation by secreting sclerostin, a peptide which is a product of the SOST gene and a negative
regulator of osteoblasts (1, 2). Once secreted, sclerostin is transported to the osteoblasts on the bone surface, where it regulates
their function. Sclerostin has been shown to inhibit osteoblast development in vitro by inhibiting proliferation, as well as early
and late stages of osteoblast differentiation, in both mouse and human osteogenic cells. Sclerostin also stimulates osteoblast
apoptosis (3). In sclerosteosis, the inhibitory effect of sclerostin is absent due to mutations in the SOST gene, which results in
an increase in bone mass as a result of increased bone formation.
SUBPROJECT PROGRESS:

Number of premenopausal women enrolled during report period is 9.
Number of premenopausal women enrolled since beginning of study is 12, of those 3 are presently active. There are 2 more
scheduled to start in May of 08.
Number of postmenopausal women enrolled since beginning of the study is 25. Of those 3 were found to be not eligible, 2 were lost
to follow-up. 20 completed the study.
We are doing well with recruitment. 25 postmenopausal women have been recruited for the study, of which 20 completed the
study. 12 premenopausal women have been enrolled in the study so far and we anticipate that we may complete enrollment by the
end of June, 2008.
No safety concerns have been reported to date. There are no publications as yet.
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Pharmacogenetics of Warfarin
Pharmacogenetic Testing for Warfarin Therapy
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FANG, MIN MD, PHD

Genetics & Dev. Biology

BONA, ROBERT MD

Medicine/Hem-Onc

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Pharmacogenetics is a new and rapidly evolving discipline. The goal is to enhance efficacy and safety by applying genetic
information to clinical administration of medications. Warfarin, an anticoagulant, is one of the most common prescription
medications worldwide. As much as it is a life-saver, warfarin can also pose high risk of morbidity and mortality. Major
bleeding episodes happen in ~7% of patients. Current dosing algorithms do not account for genetic factors. Recent studies have
shown strong evidence that individuals with certain genetic variants require lower doses. The Federal Drug Administration
(FDA) has proposed drug label changes for warfarin. And the National Academy of Clinical Biochemistry (NACB) has drafted
guidelines and recommendations for pharmacogenetic testing in general. Currently, the Department of Health & Human
Services (HHS) posted a draft report of the Secretarys Advisory Committee on Genetics, Health, and Society for public
comments until June 1, 2007. This report recommended that the FDA work with professionals to develop dosing guidelines,
encourage clinical trials exploring the relationships between diagnostics and drug response, and to translate the findings from
prospective studies into treatment guidelines. We have successfully employed the Invader technology to develop a genotyping
assay for patients under warfarin treatment. To determine the clinical performance characteristics of this test, we propose this
protocol to retrospectively genotype patients under warfarin therapy. New algorithms of warfarin dosing determination will be
evaluated. This study will pave the way for clinical implementation of randomized prospective clinical research on warfarin
dosing accuracy, cost effectiveness, and patient burden reduction.
SUBPROJECT PROGRESS:

- Number of subjects enrolling during the report period and since
initiation of the study: 150
- Any changes in recruitment plans that might be needed : No
- Unexpected safety concerns and their resolution : No
- Interim data and outcomes if appropriate: We found that pharmacogenetics information is helpful for warfarin dose prediction.
However, the published algorithm from the UK group needs minor adjustment when applied to our population, especially regarding
the parameter of height. Data analysis is underway.
- Any proposed changes made or anticipated in the protocol: No.
- Publications: manuscript in preparation. Will cite GCRC funding number
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Bone Health
Bone Health in Women with Breast Cancer on Aromatase Inhibitors
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TAXEL, PAMELA MD

Medicine

MIRZA, FARYAL MD

Medicine

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Aromatase Inhibitors (AIs) are a class of compounds that inhibit the synthesis of estrogens from androgens by blocking the
Cytochrome P-450 Enzyme Aromatase which catalyzes the conversion of androgens to estrogens in the peripheral tissue
(adipose tissue, bone, vascular endothelium, brain and breast tumors). They will effectively reduce the amount of circulating
estrogens and therefore play a powerful role in treatment of estrogen and progesterone- receptor sensitive breast cancer
patients. Because they cause a marked reduction in serum estrogen level, women treated with such agents are at an increased risk
of developing osteoporosis and bone fractures, as many clinical trials have reported. In the Bone Health Service of the Cancer
Center at University of Connecticut Health Center, we have been evaluating women who will receive AI's for breast cancer. In
preparation for a randomized controlled trial, we propose to evaluate parameters of bone health in this population.
SUBPROJECT PROGRESS:

This project is currently completing data entry and analysis with the assistance of the General Clinical Research Center (GCRC)
statistician.
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3RS
Behavioral and Physiological Responses to Race-Related Stress in Diabetic Women
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WAGNER, JULIE PHD

Behavioral Sci & Comm Hlth

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

The broad goal of this project is to establish evidence that race-related stress is associated with physiological and behavioral
processes that may contribute to the disproportionate rates of diabetes complications among African American women. We
propose studying the effects of racial stress on blood pressure, glycemia, insulin sensitivity, and diabetes self-care important
factors which underlie most, if not all, complications. We propose investigating experimentally induced racial stress and
day-to-day, self-reported racial stress.
SUBPROJECT PROGRESS:

During this period, equipment was ordered and staff was trained to administer the components of this study. Enrollment for the
study began in February, 2008. From initiation to 3/31/2008, 5 women enrolled and completed the study. An additional 30
participants have been screened and scheduled for enrollment after 4/1/2008. Several modifications to the project approved by
IRB this year include:
There are no unexpected safety concerns. There are no publications at this time.

6/27/2008 9:32:04AM

204

5M01RR006192-14
SPID:

REPORT PD: 04/01/2007-03/31/2008

0665

665

PROTOCOL:

TYPE: RESEARCH

SHORT TITLE:
LONG TITLE:

Topiramate Treatment
Topiramate Treatment of Problem Drinkers
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KRANZLER, HENRY MD

Psychiatry

ARMELI, STEPHEN PHD

NON-HOST INSTITUTION: STATE,
COUNTRY

PACE UNIVERSITY, NY USA

ONCKEN, CHERYL MD

Medicine

TENNEN, HOWARD PHD

Community Medicine

SUBPROJECT DESCRIPTION:

The proposed study is a 12-week trial comparing topiramate (TOP), at a dosage of 200 mg/day, with an inactive placebo. We
will randomly assign 160 problem drinkers (i.e., heavy drinkers without evidence of physical dependence on alcohol) who want
to reduce their drinking. It is estimated that 30% of the general population are problem drinkers (NIAAA 2007). Despite its
high prevalence, problem drinkers are understudied, particularly with respect to medications that may help them to reduce their
drinking to safe levels. The study will extend to this patient population findings from a trial of TOP, which showed the drug to
be well tolerated and efficacious in moderately-severe alcohol-dependent patients (Johnson et al. 2003). The aims of the
present study are to examine: 1) TOPs safety and efficacy in reducing drinking and heavy drinking, 2) the relations among
medication, daily mood, expectancies, and drinking behavior, and 3) the durability of TOP's effects during a six-month
post-treatment follow-up period. A fourth, exploratory aim, is to estimate the effect size of variation in genes encoding GABA
and glutamate receptors as moderators of both the therapeutic and adverse effects of TOP. A fifth aim is to to examine allelic
and haplotypic association to alcohol use disorders and related behavioral and psychiatric phenotypes by examining variants in
genes that have been implicated in the pathophysiology or risk of these behaviors or disorders. The study will use interactive
voice response technology to collect daily measures of drinking, mood, and medication usage. Biological measures of alcohol
consumption (i.e., GGTP and CDT) will be used to validate self-reports. Hierarchical linear modeling will be used to examine
effects at the between-person and within-person levels of analysis. Careful evaluation of the study's hypotheses will provide
important information on the efficacy and mechanism of effects of TOP as a treatment for problem drinkers.
SUBPROJECT PROGRESS:

Subject enrollment began in March 2008. A total of 3 subjects were enrolled during the report period (a total of 3 since initiation
of the study). No changes in recruitment plans are needed at this time. There have been no unexpected safety concerns associated
with this study. Interim data are not available since data collection is ongoing. This study uses interactive voice response
technology (IVR) for daily data collection, with support from the General Clinical Research Center (GCRC). Since this study was
originally approved we made the following changes in the protocol (all changes IRB-approved): 1) the Medical Management
counseling session manual was finalized and underwent IRB review (including a new subject handout used during the counseling
sessions: Quick Reference Medication Grid); 2) the Research and Development (RAND) 36-Item Health Survey replaced the Short
Form (SF)-36 in the battery of study questionnaires; 3) the up-titration medication schedule was modified to state (where
applicable) that instead of two 25 mg capsules, one 50mg capsule will be used. This will help reduce medication costs, and use of a
50 mg dosage in this manner has been well tolerated in other clinical trials of topiramate; 4) we updated the description of the
counseling session monitoring and feedback plan; 5) we added information to the protocol regarding topiramate's potential effects
on hormonal birth control (i.e., that topiramate may make some types of hormonal contraceptive methods less effective; and,
that women should report any changes in their bleeding patterns to the study clinician); 6) we added a statement to the consent
form asking participants to allow us to audiotape the counseling sessions and we added information regarding topiramate's potential
effects on hormonal birth control; 7) As per UConn Health Center (UCHC) Institutional Review Board (IRB) guidance, the HIPAA
Authorization was revised with the new UCHC template; 8) the IVR Script and Wallet Card were modified to update language
describing the collection of drinking, smoking, and medication data.; 8) addition of a co-investigator (Carolyn Drazinic); 9) edits to
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IVR script (during preliminary testing of the IVR telephone script, we found some areas of the script needing small edits in order to
improve the flow of questioning. The content of the information being collected has not changed and no new questions were added
to what was previously IRB-approved. Due to the edits we made to the script, the following subject handouts and forms were
modified so that they are consistent with the IVR script to be used during the conduct of the study: IVR Follow-Along Sheet IVR
Wallet Card, and IVR Information Form); 10) We updated some study questionnaires to add the visit number to the heading (in
order to facilitate data entry) and study documents used with the Pharmacy to add the study abbreviation ("Top/Alc"), which will
help identify the study for Pharmacy staff; 11) we modified the parameters to be used to randomize subjects into groups for
assignment to placebo vs. topiramate: we removed the variable "drinking days" and added the variables "drinks per drinking day"
and "number of DSM-IV alcohol dependence symptoms". The variable "heavy drinking days" was changed to "percent heavy
drinking days". All data were already being collected under IRB-approved protocol, so no changes are necessary to the information
being collected from subjects. We updated the protocol and URN form to reflect these changes.
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LALLA, RAJESH BDS, PHD

Oral Diagnosis

PETERSON, DOUGLAS DMD, PHD

Oral Diagnostics

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Head and neck cancer accounts for 5 to 40% of all malignancies, depending on geographical location in the world. Most head
and neck cancer patients are treated with radiation therapy (RT) in combination with surgery and/or chemotherapy. Almost
100% of patients treated for head and neck cancer, with radiation therapy to fields involving the oral cavity, develop
erythematous, erosive and ulcerative lesions of the oral mucosa referred to as oral mucositis. These lesions are extremely
painful, compromise nutrition and quality of life and may necessitate interruptions in RT, thus adversely affecting cancer
therapy outcomes 1, 2. Thus, the literature defines oral mucositis as the major dose-limiting toxicity of RT to the head and
neck region. Significant evidence implicates inflammatory responses to RT in the pathogenesis of oral mucositis 3. Evidence
available to date supports the investigation of anti-inflammatory agents in this condition. More specifically, evidence supports
the testing of a corticosteroid mouthrinse to reduce the severity of radiation-induced oral mucositis. However, with the
exception of one small uncontrolled study 4 which indicated impressive efficacy, topical corticosteroids have not been formally
evaluated for this condition. This constitutes an important gap in knowledge because oral mucositis is the single most
debilitating complication of radiation therapy for head and neck cancer. Our long-term goal is to identify effective therapeutic
interventions to reduce mucosal injury and pain in radiation-induced oral mucositis. The objective of this application is to
conduct a Phase I study that will provide information necessary to design an extramurally-funded, randomized,
placebo-controlled trial testing the effects of a topical corticosteroid mouthrinse on radiation-induced oral mucositis.
SUBPROJECT PROGRESS:

This study received initial IRB approval on 01/22/2008. There were no subjects enrolled on this study for the period 4/1/073/31/08. There are no changes in recruitment plans for this study.
There have been no unexpected safety concerns identified since the initiation of this study. There has been no data collected
through 3/31/08.
There are no planned modifications to the protocol at this time.
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CONNECTICUT CHILDREN'S MEDICAL,
CT USA

SUBPROJECT DESCRIPTION:

Bronchiolitis is a significant cause of morbidity and hospitalization in children, accounting for approximately 125,000
hospitalizations per year in the U.S. Of these hospitalized children, 8% will require ICU admission and 67% of these children
will require mechanical ventilation. Mortality in previously healthy children is generally low, however, in children with
high-risk medical conditions such as prematurity or congenital heart disease, mortality can be as high as 3%. In addition,
bronchiolitis infections are associated with long term respiratory problems including development of recurrent wheezing, airway
hyper-reactivity, and asthma. Despite four decades of clinical trials, there are no therapies demonstrated to be effective in
shortening either hospitalization or length of intensive care stay in children with bronchiolitis. Treatment for this disease is
largely supportive. Current controversies involve the utility of bronchodilators, steroids, antiviral therapies, and
immunoprophylaxis. Other attempted therapies include nebulized hypertonic saline, atrovent, nebulized deoxyribonuclease I
(pulmozyme), and inhaled nitric oxide. Although a mixture of these therapies are used in children with bronchiolitis based on
individual provider preference, none have been definitively shown to improve outcomes in children with bronchiolitis.
Recently, investigators have shown that genetic factors have important influences on a patientresponsiveness to ¥â2-adrenergic
receptor (¥â2-AR) agonists (such as albuterol). A single nucleotide polymorphism (SNP) at amino acid position 16 of the
©¬2-AR gene is the most common polymorphism and has been shown to be the most functionally relevant. A change at base
46 from adenine to guanine results in the amino acid sequence of the ©¬2-AR containing a glycine (Gly), rather than an
arginine (Arg), at amino acid position 16. Patients homozygous for Gly at this position (Gly/Gly) have been shown to have
improved responsivness to ©¬2-AR agonist therapy when compared to children homozygous for Arginine (Arg/Arg) or
heterozygous (Arg/Gly). Previous work has shown that bronchodilator responses in bronchiolitis range from marked
improvement to actual deterioration of lung function. One reason for the inconsistency of these findings is the lack of
sufficiently sensitive methods for evaluation of lung function in infants. In addition, grouped mean responses can fail to show
individual variation in responsiveness. For example, a recent study demonstrated that post-albuterol bronchodilator
measurements did not differ significantly from baseline measurements in an entire group of infants aged 2-18 months with
bronchiolitis; however, 11 of the 41 patients (27%) showed significant increases in lung function following inhalation of 200
mcg albuterol via metered dose inhaler. We believe that genetic factors influence responsiveness to albuterol therapy in
children with bronchiolitis. Specifically, we believe that ¥â2-AR polymorphisms at amino acid position 16 affect
responsiveness to acute ¥â2-AR agonist therapy in children with bronchiolitis. In support of this concept, Moore et al recently
demonstrated that RSV infection did not influence isoproterenol-induced cAMP formation in tracheal smooth muscle cells
obtained from 2 donors homozygous for the Gly16 haplotype, but it significantly decreased isoproterenol-induced cAMP
formation in cells from 2 individuals homozygous for the Arg16 haplotype. Thus, our hypothesis is that: children with
bronchiolitis who are homozygous for glycine at amino acid position 16 (Gly/Gly) will have improved responses to albuterol
therapy. We propose to investigate this research question in a prospective observational trial. Children admitted to the ICU
with bronchiolitis, who are intubated and mechanically ventilated with a cuffed endotracheal tube and who are receiving albuterol
will be included. Measurement of pulmonary function will be recorded before and after the albuterol from values routinely
determined by the Servo-I ventilator in use in the Pediatric ICU at CCMC. Genotyping of the ©¬2-AR gene will be performed
at the General Clinical Research Center at the University of Connecticut Health Center. Genotyping will be performed from
whole blood that is added onto routine blood sampling. Children will be stratified based on their genotype and outcomes
compared. Providers will be blinded to genotype at the time of treatment.

6/27/2008 9:32:04AM

208

5M01RR006192-14

REPORT PD: 04/01/2007-03/31/2008

Final

SUBPROJECT PROGRESS:

Bronchiolitis is a significant cause of morbidity and hospitalization in children, accounting for approximately 125,000
hospitalizations per year in the U.S. Recently, genetic variations of the â2-adrenergic receptor (â2-AR) have been shown to
influence responsiveness to â2-AR agonist therapy in children with asthma. We suspect that genetic variations of the â2-AR also
affect response to â2-AR agonist therapy in children with bronchiolitis. Our hypothesis is that mechanically ventilated children
with bronchiolitis who are homozygous for glycine at amino acid position 16 (Gly/Gly) will have improved pulmonary resistance
following â2-AR agonist therapy than children who are homozygous for arginine or heterozygous at amino acid position 16.
This project was approved on December 3, 2007 and began enrollement in December 15, 2007. Since that time, we have enrolled
15 of a planned 50 children in this trial. Genotyping of the ß2-AR gene was performed by the core laboratory of the GCRC. The
core laboratory was able to genotype all samples provided. However, due to the small numbers of patients enrolled, interim
data/statistical analysis has not been performed at this time.
There have been no safety concerns with this study. Nor are there any proposed changes or anticipated changes in the protocol or
in the recruitment plans. There have been no publications or abstracts submitted for this study.
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SUBPROJECT DESCRIPTION:

Cigarette smoking, the most common source of preventable morbidity and mortality in the United States, is more prevalent and
has more serious adverse health consequences in substance abusers compared to the general population. Contingency
management (CM), in which tangible incentives are provided contingent on a target behavior like abstinence, is highly
efficacious in improving substance abuse treatment outcomes and may be a useful smoking cessation tool in this difficult
population. We have preliminary data suggesting the efficacy of CM for smoking abstinence. In this application, we propose a
larger study to more rigorously evaluate a prize-based CM procedure for initiating smoking abstinence in residential substance
abuse treatment patients who want to quit smoking. Patients (N=102) who meet diagnostic criteria for alcohol, cocaine,
marijuana, or opiate abuse or dependence will meet with research staff on two days for quit preparation sessions (2 per day).
These sessions include testing a breath sample for evidence of smoking twice each day (separated by at least 5 hours), counseling
based on Public Health Service (PHS) guidelines for quitting smoking during the second session each day, and setting a quit date.
After these sessions, participants will be randomly assigned to: (a) standard care or (b) standard care plus prize CM for smoking
abstinence with the opportunity to win prizes ($1-$100 in value) for submitting samples that meet smoking abstinence criteria
(e.g., CO ¡Ü 6ppm; cotinine ¡Ü 30ng/mL). Nicotine withdrawal, urges to smoke, depressive symptoms, and other (non-nicotine)
substance use will be assessed weekly. In addition, self-efficacy, motivation to change, substance use, psychosocial problems, and
depressive symptoms will be assessed at intake and 1, 2, 3 and 6 months following the quit date. Primary outcomes will be
smoking abstinence based on CO and cotinine test results. Mediation effects of self-efficacy and motivation to change on
outcomes will be tested. Participant characteristics that may be associated with improved outcomes within and across conditions
will also be assessed. It is hypothesized that smoking abstinence rates will be higher in the CM condition compared to the
standard care condition.
SUBPROJECT PROGRESS:

Total Enrollment: 0
Past Year Enrollment: 0
No changes in recruitment plans are needed.
No unexpected safety concerns have occurred.
Interim data and outcomes are not available.
Changes to protocol: 1) Added the following sentence to the Informed Consent Form (ICF), "You will receive a $1 gift certificate
each time samples are submitted at Quit Preparations sessions and study sessions during weeks 1-4 for a total of up to $44" as
stated in the Compensation section (page 5) in order to introduce the concept earlier in the document. 2) Revised the order of the
sentence on page 3, first paragraph of the ICF under Treatment B to enhance comprehension. 3) Deleted the mention of
McDonald's gift certificates in the ICF as McDonald's $1 gift certificates may not be available for our purchase in the near future.
4) Clarified on page 9 of the protocol that the Mini-Mental State Exam is administered at intake as deemed necessary by the
research assistant. 5) Revised the Patient Information Form, by removing questions related to cigarette smoking. The Patient
Information Form will continue to be administered at baseline only. The cigarette smoking questions have been incorporated into a
more extensive questionnaire called the Cigarette Smoking History Questionnaire that we administer at baseline and each follow-up
interview. 6) Revised the Addiction Severity Index (ASI) adding questions regarding HIV status and previous/current treatment
history questions. 7) Clarified in the protocol that questions related to gender, ethnicity and other demographic information is
incorporated into the ASI. 8) Replaced the Beck Depression Inventory-II (BDI-II) with the Center for Epidemiological Studies-
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Depressed Mood scale. 9) Added the Ways of Coping Checklist-Revised
Results not yet published as study is ongoing.
Do you wish to continue to receive GCRC resources for the period April 1, 2008 through March 31, 2009? Yes
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KRANZLER, HENRY MD

Psychiatry

NON-HOST INSTITUTION: STATE,
COUNTRY

SUBPROJECT DESCRIPTION:

Thirty percent of female smokers are postmenopausal, and this proportion is expected to grow as the population ages. Based on
the elevated risk of osteoporosis in postmenopausal smokers, together with the high prevalence of depression history and
considerable weight gain we observed in previous studies, we have chosen to examine the potential utility of exercise as an
adjunct treatment for smoking cessation in postmenopausal women. The specific research aims of this study are to: 1)to
evaluate wheter adding an established moderate resistance/aerobic exercise program for postmenopausal women 50 years of age
and older to a standard smoking cessation treatment program improves short and long term smoking outcomes; 2)to examine
the main and interactive effects of history of depression and exercise on smoking cessation treatment; 3)to use interactive
voice recording (IVR) technology to examine the mechanisms by which exercise may improve smoking treatment outcomes in
postmenopausal women; 4)to examine whether adding a moderate exercise program to a standard smoking cessation treatment
program for postmenopausal women improves health outcomes such as, weight gain, bone mineral density, and quality of life
measurements. Study sites will include The University of Connecticut Health Center and the Unviersity of Minnesota. Subjects
(N=364) must be postmenopausal, at least 50 years of age, and smoke at least 10 cigarettes per day. All subjects will receive
smoking treatment (behavioral counseling and varenicline) and will be randomly assigned to either 1)a supervised exercise
program or 2)a supervised relaxation control condition. We hypothesize that 1)postmenopausal women randomized to the
exercise condition will have greater end of treatment abstinence rates and end of year abstinence rates than will those women
assigned to an attention control condition. 2a)women with a history of depression will have reduced short and long-term
smoking abstinence rates. b)ameliorative effects of exercise on smoking cessation and depression will exist such that women
with a history of depression will abstain from smoking at a rate equivalent to those with no such history; 3)exercise may
improve smoking cessation by reducing nicotine withdrawal symptoms and negative affect, and by increasing self-efficacy for
smoking cessation; 4)women randomized to the exercise condition will have increased bone mineral dinsity at the hip, and
improved quality of life compared to women in the control condition. An effective exercise program added to smoking
cessation for postmenopausal women has the potential to address many health problems in this at-risk population, and
markedly improve quality of life.
SUBPROJECT PROGRESS:

7 subject s were enrolled (signed consent), 6 randomized to RX.
1 subject dropped out after screening. Time limitations too much
1 subject dropped out after 1 class due to a number of reasons (didn't like group setting, interfered with work, unable to tolerate
any meds for smoking cessation)
1 subject dropped out after 2nd session declining to participate further
1 subject moved
3 subjects remain in treatment (10 out of 12 weeks). All have remained abstinent.
Our revised proposal is only a 12 week study. We are planning on submitting for approval for longer term follow-up on pilot
subjects.
We are applying for funding, will only enroll a limited number of subjects to obtain feasibility data. We are considering one more
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group session to enroll a few more participants.
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SUBPROJECT DESCRIPTION:

Contingency management (CM) interventions are highly efficacious in improving substance abuse treatment outcomes, but few
studies have implemented this approach with alcohol use disorder patients. Further, no known studies have experimentally
evaluated how duration of CM affects outcomes. This issue appears to be of central importance for impacting long-term
behavior change, given the well-established association between length of treatment engagement and outcomes. In this
application, we propose to evaluate the efficacy of prize-based CM when administered according to a usual duration of 12 weeks
versus an extended duration of 24 weeks. We will also investigate how probabilities of reinforcement may impact the
relationships between CM duration and outcomes. Alcohol abusing or dependent patients (N=310) beginning intensive
outpatient day treatment at community based clinics will be randomly assigned to one of four conditions: (a) standard treatment
as usual (ST) at the clinic without CM; (b) ST with CM for 12 weeks with a 0.5 probability of winning prizes for each negative
sample submitted and an expected average maximum earnings of $300 in prizes; (c) ST with CM for 24 weeks with a 0.34
probability of winning prizes for each negative sample submitted and an expected average maximum earnings of $300 in prizes;
or (d) ST with CM for 24 weeks with a 0.5 probability of winning prizes for each negative sample submitted and an expected
average maximum earnings of $500 in prizes. During weeks 1-12, two breath samples per week will be collected from all
patients, and those in the CM conditions will have the opportunity to win prizes for submission of negative samples. Those
assigned to the longer duration CM conditions will continue to receive reinforcement for negative samples provided weekly
during weeks 13-24. In group d, probabilities of reinforcement will be identical to those used in group b, but they will remain
available for an additional 12 weeks. In group c, the probabilities of winning prizes will be lower so that the magnitude of overall
reinforcement is consistent with group b. Alcohol use, other drug use, psychosocial problems, and HIV risk behaviors will be
measured at baseline, during and post treatment, and throughout an 18-month follow-up period. We expect that CM will
decrease alcohol use to a greater extent than non-CM treatment, and that availability of CM for 24 weeks may result in longer
term benefits than 12 week exposure to CM. This study will be the first to evaluate the effects of probability of winning prizes
on response to CM. We will also assess patient characteristics that may be associated with improved outcomes within and across
treatments
SUBPROJECT PROGRESS:

Total Enrollment: 2
Past Year Enrollment: 2
No changes in recruitment plans are needed.
•
No unexpected safety concerns have occurred.
•
Interim data and outcomes are not available.
•
Changes to protocol: 1) Added Danielle Barry as Study Coordinator and removed Sheila Alessi as Study Coordinator. 2)
Clarified that the Demos referred to in the Assessment table in protocol are included in the ASI questionnaire. 3) Replaced the
University of Rhode Island Change Assessment (URICA) with the Readiness to Change Questionnaire (RTCQ). 4) Added two new
questionnaires: Alcohol Abstinence Self-Efficacy (AASE) scale to assess self-efficacy and the Coping Strategies Scale (CSS) to
evaluate coping skills. 5) Clarified that the urine tests for stimulants, opiates, and marijuana will be performed using cups rather
than sticks. 6) Expanded the description of the payment for urine samples submitted to include other small items up to $2 in value
(e.g., toiletries, snacks, bus tokens, etc.) in addition to gift certificates. 7) Specified in both the ICF and protocol that the random
breath testing may be administered as needed one or more times during the 24-week treatment phase. 8) Corrected several
typographical errors discovered in the protocol and ICF. 9) Removed two items from our 10-item Consent Quiz in order to match
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the description of the 8-item Quiz in the protocol. 10) Updated HIPAA form to the IRB template. 11) Added questions to the
Addiction Severity Index (ASI) regarding HIV status and previous and current treatment. 12) Clarified in the protocol that the
DSM Checklist for stimulants includes cocaine, amphetamine and methamphetamine. 13) Clarified in the protocol amphetamine
and methamphetamine, in addition to cocaine, will be recorded in the Timeline Follow-back (TLFB). 14) Revised version of the
Cigarette Smoking History questionnaire and to clarify that it will be administered at intake and at each follow-up. 15) Added the
following sentence to the ICF, "The breath sample will test for alcohol" in order to introduce the concept of testing breath samples
for alcohol earlier in the document. 16) Added the name of one of the co-investigators, Danielle Barry to the audiotaping portion
of the consent on page 6 of the ICF. 17) Revised Consent Quiz for enhanced comprehension.
•
Results not yet published as study is ongoing.
Do you wish to continue to receive GCRC resources for the period April 1, 2008 through
March 31, 2009? Yes
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RESOURCE SUMMARY: SUBPROJECTS
The following only includes information associated with subprojects.
Pilot
(CReFF)

Research

Core Inf.

Total

0
0
0
0

151
199
56
6

0
0
0
0

151
199
56
6

Number of Subprojects
Number of Investigators
Number of Published
Number of In Press
Subprojects Using

A

B

D

Inpatient Days

0

0

0

Scatter Bed Days

0

0

0

Outpatient Visits

5,992

284

0

0

0

0

4,410

0

0

Scatter RN Hours
Offsite Research Visits
Subprojects Using
Patient Days/Visits
Research Bionutrition
Informatics Core

Total SPID Count

82
0
151

Biostatistician

9

Ancillaries Only

0

Multicenter

40

Clinical Trial

26

Core Lab

62

6/27/2008 9:32:04AM
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RESOURCE SUMMARY: ADMINISTRATIVE
GCRC Personnel Function

Program Direction

0.410

Administration

1.600

Nutrition and dietary support

0.000

Bioinformatics, computer systems managers

1.400

Biostatistician

0.530

Nursing

7.600

Research Subproject Advocacy

1.200

Core lab staff

3.850

Other

0.900
17.490

Total FTEs:

On Subprojects

INVESTIGATORS

Clinical Investigators

Not On Subprojects

199

11

GEOGRAPHICAL USAGE BY INVESTIGATORS AT NON-HOST INSTITUTIONS
Subproject Investigators by Country

1

CANADA

1

USA Subproject Investigators by State

53

CT
DC
IL
MA
MI
NC
NY

39
4
2
4
1
1
2

CLINICAL INVESTIGATORS BY DEGREE

PHD Only

68

PHD and MD

8

PHD and Dental

1

PHD and Other Doctoral

0

MD Only
MD and Other Doctoral
Dental Only

111
0
11

Educator Only

0

Other Doctoral Only

1

NON-Doctoral ONLY
NO DEGREE

6/27/2008 9:32:04AM
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RESOURCE SUMMARY: PUBLICATION/SUPPORT
PUBLICATIONS

Journals

Published
Total
Cited
68
49

Cited
1

In Press

Total
6

INVESTIGATOR SUPPORT
NON-FEDERAL

FOUNDATION

$397,508

INDUSTRY

$46,994

OTHER

$2,813,449

PVAS

$67,646

SCC

$538,605

NON-FEDERAL

3,864,202

FEDERAL
PHS

AA

$5,627,871

AG

$586,274

AI

$1,044,820

AR

$442,729

CA

$564,426

CDC

$179,450

DA

$3,766,892

DC

$702,703

DE

$1,290,391

DK

$621,793

EY

$832,917

HD

$107,488

HL

$662,013

MH

$175,694

TW

$39,380
PHS

TOTAL SUPPORT

6/27/2008 9:32:04AM

16,644,841

$20,509,043
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CENSUS DATA (for A, B, C, and D Patients)
Age Census Inpatient

ADMISSIONS
Age Group

A

INPATIENT DAYS

B

D

A

B

D

a. less than 1 year

0

0

0

0

0

0

b. 1 thru 12 years

0

0

0

0

0

0

c. 13 thru 21 years

0

0

0

0

0

0

d. 22 thru 65 years

0

0

0

0

0

0

e. 66 and over

0

0

0

0

0

0

Total

0

0

0

0

0

0

Age Census Scatter Bed

ADMISSIONS
Age Group

A

INPATIENT DAYS

B

D

A

B

D

a. less than 1 year

0

0

0

0

0

0

b. 1 thru 12 years

0

0

0

0

0

0

c. 13 thru 21 years

0

0

0

0

0

0

d. 22 thru 65 years

0

0

0

0

0

0

e. 66 and over

0

0

0

0

0

0

Total

0

0

0

0

0

0

Age Census Outpatient

OUTPATIENT VISITS
Age Group

A

B

D

a. less than 1 year

22

1

0

b. 1 thru 12 years

166

7

0

c. 13 thru 21 years

472

0

0

d. 22 thru 65 years

3,719

227

0

e. 66 and over

1,613

49

0

Total

5,992

284

0

Age Census Offsite

OFFSITE RESEARCH VISITS
Age Group

A

B

a. less than 1 year

1

0

b. 1 thru 12 years

210

0

c. 13 thru 21 years

217

0

d. 22 thru 65 years

3,969

0

13

0

4,410

0

e. 66 and over
Total

6/27/2008 9:32:04AM
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0
0

0

6/27/2008 9:32:04AM
0
0
0

0
0
0
0

476
20
0
0
496

313
0
313

0
0

0
0
0
0

5,992
284
0
0

6,276

4,410
0

4,410

0

0

0

0

0

294

0
427

0

427

597

0

0

432

0

432

443

0

0

6

437

0

0

0

495

0

495

569

0

0

5

564

0

0

0

0

0

0

0

0

0

30

NOV-07

48

0

48

750

0

0

9

741

0

0

0

0

0

0

0

0

0

31

OCT-07

381

0

381

389

0

0

13

376

0

0

0

0

0

0

0

0

0

30

SEP-07

343

0

343

491

0

0

29

462

0

0

0

0

0

0

0

0

0

31

AUG-07

309

0

309

557

0

0

75

482

0

0

0

0

0

0

0

0

0

31

JUL-07

351

0

351

603

0

0

65

538

0

0

0

0

0

0

0

0

0

30

JUN-07

485

0

485

413

0

0

19

394

0

0

0

0

0

0

0

0

0

31

MAY-07

C

B

A

D

C

B

A

TOT

D

B

A

TOT

532

0

TOT

B

532 A

495 TOT

0

0

13

482

0

0

0

0

0

0 D

0

0

0

30 Days Open

APR-07 Month

OUTPATIENT VISITS

294

473

0

0

15

582

0

0

0

0

0

0

0

0

0

31

DEC-07

SCATTER BED DAYS

15

458

0

0

0

0

0

0

0

0

0

31

JAN-08

INPATIENT DAYS

0

0

0

29

31

366

FEB-08

MAR-08

Total
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Utilization Table

INPATIENT
Funding Category

Awarded

SCATTER BED

OUTPATIENT

Used

Awarded

Used

Awarded

Used

A

0

0

0

0

0

5,992

B

0

0

0

0

0

284

C

0

0

0

0

0

0

D

0

0

0

0

0

0

Outpatient

OUTPATIENT VISITS
Length of Stay (hrs)

OFFSITE VISITS

A

B

C

D

A

B

5,221

276

0

0

4,410

0

b. >= 1 and <= 3

542

3

0

0

0

0

c. > 3 and <= 6

98

5

0

0

0

0

d. > 6 and <= 10

65

0

0

0

0

0

e. > 10 hours

66

0

0

0

0

0

5,992

284

0

0

4,410

0

a. < 1 hour

Total

GCRC Capacity

Number

Total Inpatient Beds

0

Inpatient Beds Used for Outpatients

0

Outpatient Rooms

8

6/27/2008 9:32:04AM
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(Figures to be rounded to nearest dollar)

RATE 1
INPATIENT
1.

If proposed rate is used, show date filed with HHS:

2.

If rate has been published by HHS, show date of agreement:

3.
4.A.

Period applicable rate:

4.B.

Per Diem Method:

0

Category A days x $

790.04

=

0

4.C.

Scatter Beds:

0

Category A days x $

790.04

=

0

4/1/2007

8/3/2006
6/30/2007

through

0

Routine Cost (or Space Cost for Per Diem Method):

$0

Total (4A and4B and 4C)
5.

Service Patient Credit (routine method):
0

Category B days x $

0.00

=

0

0

Category C days x $

0.00

=

0

0

Category D days x $

0.00

=

0

5.A.

Total Service Patient Credits

0

5.B.

All Other Inpatient Credits (specify: grants, contracts, other
sources)

0
$0

Total Credits (5A and 5B)
6.

7.

Inpatient Ancilliaries Required Solely for Research Purposes, Adjusted to Cost (Schedule 1)
0

Category A days x $

0.00

=

0.00

0

0.00

=

0

Category B days x $
Scatter Bed A days x $

0.00

0

Scatter Bed B days x $

0.00

=
=

0.00
0.00
0.00

Total Inpatient Ancillaries

$0

Other Costs (Specify: Drugs, raw food, special diets, outside laboratories, etc. provide Justification)

$0

8.
Total Inpatient Charges (Lines 4, 6 and 7, less 5)
OUTPATIENT

$0

9.

Space Charge

$0

10.

Outpatient Ancill
1,414
97

Category A Visits x $
Category B Visits x $

3.24
0.00

=
=

4,575.95
0.00
$4,576

Total Outpatient Ancillaries
11.

Other Costs (Specify: drugs, raw food, special diets, outside laboratories, facility fees, etc. Provide
justification)

12.

Outpatient Credits:
97

Category B Visits x $

1.00

=

97

0

Category C Visits x $

0.00

=

0

0

Category D Visits x $

0.00

=

$29,373

0
$97

12.A.

Total Outpatient Credits

12.B.

All Other Outpatient Credits (specify: grants, contracts, other sources)

13.

Total Credits (12A and 12B)
Total Outpatient Charges (Lines 9, 10, and 11, less line 12)

14.

Total Ancillary Costs Connected with Ancillary-Only Projects

$0

15.

Total Ancillary Costs Connected with Offsite Research Visits

$0

TOTAL PATIENT CARE CHARGES (Lines 8 + 13 + 14)

6/27/2008 9:32:04AM

$0
($97)
$33,852

$33,852
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RATE 2
INPATIENT
1.

If proposed rate is used, show date filed with HHS:

2.

If rate has been published by HHS, show date of agreement:

3.
4.A.

Period applicable rate:

4.B.

Per Diem Method:

0

Category A days x $

924.99

=

0

4.C.

Scatter Beds:

0

Category A days x $

924.99

=

0

7/1/2007

3/6/2007
3/31/2008

through

0

Routine Cost (or Space Cost for Per Diem Method):

$0

Total (4A and4B and 4C)
5.

Service Patient Credit (routine method):
0

Category B days x $

0.00

=

0

0

Category C days x $

0.00

=

0

0

Category D days x $

0.00

=

0

5.A.

Total Service Patient Credits

0

5.B.

All Other Inpatient Credits (specify: grants, contracts, other
sources)

0
$0

Total Credits (5A and 5B)
6.

7.

Inpatient Ancilliaries Required Solely for Research Purposes, Adjusted to Cost (Schedule 1)
0

Category A days x $

0.00

=

0.00

0

Category B days x $
Scatter Bed A days x $

0.00

=

0

0.00

0.00
0.00

0

Scatter Bed B days x $

0.00

=
=

0.00

Total Inpatient Ancillaries

$0

Other Costs (Specify: Drugs, raw food, special diets, outside laboratories, etc. provide Justification)

$0

8.
Total Inpatient Charges (Lines 4, 6 and 7, less 5)
OUTPATIENT

$0

9.

Space Charge

$0

10.

Outpatient Ancill
4,578
187

Category A Visits x $
Category B Visits x $

10.46
0.00

=
=

47,888.30
0.00

Total Outpatient Ancillaries

$47,888

11.

Other Costs (Specify: drugs, raw food, special diets, outside laboratories, facility fees, etc. Provide
justification)

$80,228

12.

Outpatient Credits:
187

Category B Visits x $

1.00

=

187

0

Category C Visits x $

0.00

=

0

0

Category D Visits x $

0.00

=

0
$187

12.A.

Total Outpatient Credits

12.B.

All Other Outpatient Credits (specify: grants, contracts, other sources)

13.

Total Credits (12A and 12B)
Total Outpatient Charges (Lines 9, 10, and 11, less line 12)

14.

Total Ancillary Costs Connected with Ancillary-Only Projects

$0

15.

Total Ancillary Costs Connected with Offsite Research Visits

$0

TOTAL PATIENT CARE CHARGES (Lines 8 + 13 + 14)
4/1/2007

$0
($187)
$127,930

$127,930

6/30/2007

6/27/2008 9:32:04AM
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OTHER COSTS DURING YEAR

Itemized costs. These totals appear on line 7 (Inpatient Other Costs) and on line 11 (Outpatient Other Costs) of the Patient
Care Computation sheet.
DRUGS, RAW FOOD, SPECIAL DIETS, LABS, ETC.

INPATIENT
0.00

OUTPATIENT

Outside Labs

0.00

16,099.83

Patient Nutrition

0.00

408.01

Research Pharmacy

0.00

3,807.45

0.00

29,373.24

Medica/Dental Supplies

Grand Total:

9,057.95

7/1/2007
3/31/2008
OTHER COSTS DURING YEAR

Itemized costs. These totals appear on line 7 (Inpatient Other Costs) and on line 11 (Outpatient Other Costs) of the Patient
Care Computation sheet.
DRUGS, RAW FOOD, SPECIAL DIETS, LABS, ETC.

INPATIENT
0.00

OUTPATIENT

Outside Labs

0.00

43,974.17

Patient Nutrition

0.00

1,114.43

Research Pharmacy

0.00

10,399.46

0.00

80,228.43

Medical/Dental Supplies

Grand Total:

24,740.37

INPATIENT
1.

If proposed rate is used, show date filed with HHS:

2.

If rate has been published by HHS, show date of agreement:

3.

Period applicable rate:

04/01/2007

8/3/2006
through

06/30/2007
0

4.A.

Routine Cost (or Space Cost for Per Diem Method):

4.B.

Per Diem Method:

0

Category A days

0

4.C.

Scatter Beds:

0

Category A days

0
$0

Total (4A and4B and 4C)
5.

Service Patient Credit (routine method):

5.A.

Total Service Patient Credits

0

5.B.

All Other Inpatient Credits (specify: grants, contracts,
other sources)
Total Credits (5A and 5B)
Inpatient Ancilliaries Required Solely for Research Purposes, Adjusted to Cost (Schedule
0
Category A days
0
Category B days
Scatter Bed A days
0

0

6.

0

Scatter Bed B days

$0
0
0
0
0

Total Inpatient Ancillaries
Other Costs (Specify: Drugs, raw food, special diets, outside laboratories, etc. provide
Justification)
8.
Total Inpatient Charges (Lines 4, 6 and 7, less 5
OUTPATIENT
7.

9.

Space Charge

10.

Outpatient Ancillaries Required Solely for Research Purposes, Adjusted to Cost (Schedule 2)
5,992
52,464
Category A Visits
284
0
Category B Visits

Total Outpatient Ancillaries
6/27/2008 9:32:04AM

$0
$0
$0
$0

$52,464
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11.

Other Costs (Specify: drugs, raw food, special diets, outside laboratories, facility fees, etc. Provide
justification)

12.

Outpatient Credits:
284
0
0

12.A.
12.B.
13.

Category B Visits
Category C Visits
Category D Visits

Total Outpatient Credits
All Other Outpatient Credits (specify: grants, contracts, other sources)
Total Credits (12A and 12B)
Total Outpatient Charges (Lines 9, 10, and 11, less line 12)

14.

Total Ancillary Costs Connected with Ancillary-Only Projects

15.

Total Ancillary Costs Connected with Outpatient Research Visits
TOTAL PATIENT CARE CHARGES (Lines 8 + 13 + 14)

6/27/2008 9:32:04AM

Final

$109,602

284
0
0
$284
$0
$(284)
$161,782
0
0
$161,782
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ANCILLARY CHARGES REQUIRED FOR RESEARCH PURPOSES
Department/ Cost Center

INPATIENT
Gross Charges

A

Adjustment
Factor (%)
B

Net Charges

A

B

TOTAL

Department/ Cost Center

OUTPATIENT
Gross Charges

Rate Period: 4/1/2007-6/30/2007
Clinical Lab

A
12,851.00

B
0.00

296.00

0.00

TOTAL

13,147.00

0.00

Rate Period: 7/1/2007-3/31/2008
Clinical Lab

A
64,568.49

B
0.00

11,092.00
9,000.00

Nuclear Medicine

DXA
Pathology
Professional Fees
Radiation Therapy
TOTAL

6/27/2008 9:32:04AM

Adjustment
Factor (%)

Net Charges

34.00%

A
4,369.34

B
0.00

69.80%

206.61

0.00

4,575.95

0.00

38.40%

A
24,794.30

B
0.00

0.00

100.00%

11,092.00

0.00

0.00

100.00%

9,000.00

0.00
0.00

565.00

0.00

80.00%

452.00

2,550.00

0.00

100.00%

2,550.00

0.00

87,775.49

0.00

47,888.30

0.00
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CORE LABORATORY

Test Name

25-OH Vitamin D

261

3

SPIDS
0609, 0624, 0614

Bone Specific Alkaline Phosphatase

135

1

0624

Cortisol

149

2

0590, 0497

78

1

0413

DNA Extraction

3,371

28

Endothelin 1-21

Creatinine

# of Tests

# of
SPIDS

108

1

0602, 0637, 0665, 0646, 0628,
0630, 0582, 0657, 0660, 0611,
0612, 0619, 0599, 0340, 0357,
0471, 0478, 0495, 0492, 0494,
0413, 0518, 0461, 0231, 0453,
0531, 0466, 0468
0591

E-Selectin

27

1

0568

Estradiol

175

2

0624, 0542

Estrone

40

1

0542

Estrone Sulfate

40

1

0542

FACS Analysis

228

1

0624

33,397

9

89

3

0602, 0630, 0560, 0612, 0619,
0549, 0495, 0492, 0466
0641, 0653, 0591

102

2

0568, 0497

IL-10

75

1

0497

IL-2

75

1

0497

IL-4

75

1

0497

IL-6

137

3

0641, 0653, 0497

intact PTH

199

2

0624, 0614

Lyme Screening

260

1

0496

Nitric Oxide

108

1

0591

N-telopeptide Collagen Crosslinks

213

2

0624, 0413

Osteocalcin

135

1

0624

PBMC Isolation

296

2

0646, 0624

12,056

35

Genotyping
hsCRP
IL-1 beta

73

3

0637, 0601, 0638, 0641, 0644,
0645, 0624, 0661, 0628, 0664,
0562, 0653, 0582, 0591, 0659,
0660, 0611, 0619, 0599, 0365,
0487, 0496, 0497, 0413, 0426,
0461, 0051, 0442, 0528, 0268,
0529, 0453, 0535, 0466, 0542
0637, 0646, 0461

RT-PCR

513

2

0600, 0530

Sequencing

248

6

SHBG

175

2

0637, 0625, 0612, 0549, 0492,
0530
0624, 0542

Testosterone

79

1

0542

Thrombin/Anti-thrombin III complex

27

1

0568

Processing

RNA Extraction

Tissue Factor
TNF alpha
VEGF

6/27/2008 9:32:04AM

27

1

0568

108

3

0568, 0581, 0497

27

1

0568
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MINORITY/CLINICAL ASSOCIATE PHYSICIAN PROGRAM SUMMARY
Current Status of CAPS whose appointments terminated in the last 5 years.

Teaching

Clinical
Research

Basic
Research

Clinical
Practice

Other

Current Appoint:
Current Address:
Phone Number:

6/27/2008 9:32:04AM
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MEDICAL STUDENTS
The University of Connecticut School of Medicine has a Medical Student Summer Fellowship Program through the Office
of Medical Student Affairs. The students formally apply to that program. Applications are reviewed by the Program
Director and the Associate Dean for Medical or Dental Affairs and selection is based on available faculty sponsorship. All
applicants with clinical projects meet with the GCRC Program Director. The Program Director presents all potential
applicants' projects to the Scientific Advisory Committee. The SAC selects the applicants with the most relevant GCRC
projects and ensures that a clinical investigator is available as a mentor. All applicants are required to attend an present at
a weekly seminar series with the GCRC Associate Program Director for Education and Planning. All applicants are
required to present their work at a Medical Student Research Day at the end of the summer.

Students and their Mentors.
DOUGLAS, KARA R
Degree Sought

BS, BS

Mentor Name

KRANZLER, HENRY

Period
Funds Received

06/01/2007 - 08/31/2007
3,200 *

Project Title

Effects of Aripiprazole on Subjective Responses to Alcohol

SPIDS

0536, 0536

Project Summary

I assisted data cleaning and analysis for the following study and co-authored a manuscript,
which is nearing readiness to be submitted for publication: Aripiprazole is of interest as a
potential pharmacologic intervention for the treatment of alcoholism. This study included
18 healthy subjects who were assigned to receive a high, low, or no-med dosage of
aripiprazole in a randomized, double-blind, within-subjects design. The subjects then
completed an alcohol challenge lab during which vital signs were monitored and self-report
surveys were used to measure subjective alcohol effects. It was found that the high dosage of
aripiprazole significantly reduced the pleasurable and euphoric effects of alcohol
consumption, while increasing feelings of sedation.

GRILLE, MICHAEL
Degree Sought

MD, BS

Mentor Name

PROTIVA, PETR

Period
Funds Received

06/01/2007 - 08/31/2007
3,200 *

Project Title

The Effect of Acute Aerobic Exercise on the Colorectal Mucosa

SPIDS
Project Summary

An investigation of the possible mechanisms responsible for the observed risk reduction in
colon cancer associated with aerobic exercise. The study focuses on several pathways with
effects on apoptosis and cell cycle progression including IGF receptor-mediated signaling,
PGE, and changes in gene expression.

KAPTUCH, JUSTIN
Degree Sought

MD, BS

Mentor Name

ONYIUKE, HILARY

Period

06/01/2007 - 08/31/2007
3,200 *

Funds Received
Project Title

A retrospective review of cervical corpectomy in instrumented and
non-instrumented fusions: indications, radiological features,
complications, and outcomes

SPIDS
Project Summary

This study examines the indications and outcomes of a surgery, cervical corpectomy,
commonly performed to alleviate cervical spinal cord compression or cervical myelopathy.

KOZLAK, SCOTT
Degree Sought

DMD, BS

Mentor Name

LALLA, RAJESH

Period
Funds Received

06/01/2007 - 08/31/2007
3,200 *

Project Title

Vitamin Levels in Patients with RAS

6/27/2008 9:32:04AM

236

5M01RR006192-14

REPORT PD: 04/01/2007-03/31/2008

SPIDS

0592, 0592

Project Summary

Vitamin levels in patients with recurrent aphthous stomatitis (RAS) are measured using a diet
history questionnaire and accompanying Diet-Calc software from the National Cancer
Institute. These levels are compared to the levels found in a normal population to look for
differences between the RAS cohort and the normal population.

Final

MADEJ, OLGA
Degree Sought

BA, MD

Mentor Name

MENZOIAN, JAMES

Period

06/01/2007 - 08/31/2007
3,200 *

Funds Received
Project Title

Incidence and Risk Factors for Transient Hypotension Following
Carotid Endarterectomy and Carotid Angioplasty with Stenting.

SPIDS
Project Summary

I worked on a retrospective review of 500+ charts from 3 hospitals: John Demspey, St.
Francis, and Hartford. I collected demographic and pertinent medical history data from
patients that underwent carotid surgery for the treatment of carotid artery occlusive disease.
The purpose was to determine the incidence of transient hypotension after the procedures
(at the 3 hospitals), and what, if any, risk factors exist.

ROPER, NITIN
Degree Sought

MD, BS

Mentor Name

FANG, MIN

Period
Funds Received

06/01/2007 - 08/31/2007
3,200 *

Project Title

Pharmacogenetics of Warfarin Therapy

SPIDS

0662, 0662

Project Summary

Coumadin (warfarin) is a blood thinner to help prevent serious and even fatal blood clots.
However, it is not easy to determine the correct dose. If a patient does not take enough
Coumadin, blood clots can form and if the dose given is too high, a person can have
bleeding, which can be fatal. Some of the differences in individual dose needed to achieve
therapeutic effect may be caused by the enzymes in an individual that break down the drug.
Current dosing schedules, however, do not account for these genetic factors. Recent studies
have shown strong evidence that individuals with certain genetic makeup require lower doses
of Coumadin.
The purpose of this research study is to identify patient genetic factors that may allow for a
lower dose of Coumadin to be used and to find a better way to determine the correct dose for
every patient.

WALSH, KEVIN
Degree Sought

BA, MD

Mentor Name

MAYER, BRUCE

Period

06/01/2007 - 08/31/2007
3,200 *

Funds Received
Project Title

Determining the Role of Nck in Cellular Protrusion and Motility
Stimulated by PDGF

SPIDS
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Membrane protrusion plays an important role in cell motility. Altered membrane
protrusion and cell motility have been linked with many diseases including atherosclerosis,
diabetic retinopathy, and cancer. The Nck1 and Nck2 adaptor proteins link tyrosine
phosphorylation with cytoskeletal dynamics, however, the role Nck plays in controlling
membrane protrusion downstream of the activated PDGFR has not been elucidated. In this
study the cellular levels of the Nck1 or Nck2 adapter proteins in NIH3T3 cells were down
regulated using siRNA, and the cells were imaged using DIC microscopy. The cells were
imaged for 10 minutes under starvation conditions, and imaged for another 10 minutes
following PDGF stimulation. The protrusion patterns were then examined using kymograph
analysis. The average protrusion velocity was similar for control and Nck1 knockdown cells
under starvation (0.0387 um/s). PDGF stimulation resulted in increased protrusion velocity
by 56% in control cells, and 7% in Nck1 knockdown cells. The average protrusion distance
was also similar for control and Nck1 knockdown cells under starvation (1.36 um). PDGF
stimulation resulted in increased protrusion distance by 83% in control cells, and 26% in
Nck1 knockdown cells. These results suggest Nck plays an important role in mediating
cellular protrusion downstream of the activated PDGFR.

ZAKKO, LIAM
Degree Sought

MD, BA

Mentor Name

SMILOWITZ, HENRY

Period

06/01/2007 - 08/31/2007
3,200 *

Funds Received
Project Title

Cellular Basis for the Efficacy of Uric Acid-Enhanced
Immunotherapy for F-98 Rat Glioma

SPIDS
Project Summary

Experimental results have shown that the lifespan of Fischer 344 rats with intracranial
implantation of F-98 malignant glioma was improved when followed by T regulatory cell
depletion and weekly injections of Granulocyte Macrophage Stimulating Factor (GM-CSF)
transfected and then irradiated F-98 cells (GVax). The improvement was even more marked
when the weekly GVax injections were accompanied with a dose of uric acid. An attempt
was therefore made to determine the cellular mechanism for the difference in outcomes
between these treatment methods by looking for the differences in immune cell responses to
F-98 tumor cells in vitro. Flow cytometry data indicated that lymphocytes from the rats
with uric acid injections produced 3 fold more Interferon gamma (IFN- g) than untreated rats
and about 40% more IFN- g than rats treated with GVax without uric acid. Interestingly,
however, about 30% of the IFN- g produced did not come from T-cells, but from other
lymphocytes.
The research this summer attempted to discover what other cells were producing IFN- g. It
was hypothesized that perhaps Natural Killer (NK) cells or Natural Killer like T (NKT) cells
were responsible. To test this theory a number of Fischer 344 Rats were treated with Gvax
and uric acid. Five days after treatment the rats' spleens were collected and lymphocytes
were isolated. Fluorescent labeling of the lymphocytes after this extraction, followed by
flow cytometry, revealed a number of cell populations: some cells were áâTCR+ indicating
they were T-cells; other cells were CD161+ indicating they were NK cells; still other cells
were áâTCR+ and CD 161+ indicating they were NKT cells. Performing the same
experiment except incubating the lymphocytes overnight in cell growth medium revealed
the same populations. Repeating the experiment, however, with the lymphocytes incubated
overnight in the presence of F-98 cells appeared to cause the loss of CD 161+ cell
populations. Experiments showed that the loss of these populations occurred over the
course of a couple hours, suggesting that the markers for the cells were being down-regulated,
or blocked, rather than the cells being degraded. Also a further experiment in which
lymphocytes were incubated in a 50/50 mix of normal medium and medium that was
conditioned over F-98 cells showed the same loss of CD 161+ population. From this result
it was concluded that a secretion from the F-98 cells was responsible for the CD 161+
population loss. Attempts were made to determine the nature of this secretion and its
affect, but this remains an area where further study is necessary. These results also
prevented a conclusion from being reached on the nature of the cells producing IFN- g.

No Reported Students.
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CLINICAL RESEARCH FEASIBILITY FUND (CReFF)
Specialty
Mentor Name
Funds Received
Period
Project Title
Attachment(s)
Project Summary
No CReFF Participants Reported.
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SCIENTIFIC HIGHLIGHTS
Addictions Research

SPID(s):

0051, 0468, 0470, 0536, 0560, 0598

KEYWORDS:

PAST SPID(s):0220,0295,0605

ALCOHOL, DRUGABUSE, NICOTINESMOKING

Studies in addictive behaviors, including problem drinking, dependence on alcohol, drugs and tobacco, and
compulsive gambling, are major areas of National Institutes of Health (NIH) funded research carried out by
investigators at the University of Connecticut Health Center (UCHC). Many of these studies are conducted in the
General Clinical Research Center (GCRC) and/or utilize GCRC resources, including the biostatistics, informatics,
clinical, and laboratory cores.
Dr. Henry Kranzler, Professor of Psychiatry, Program Director of the GCRC, and Associate Scientific Director of
the UCHC Alcohol Research Center (ARC), which is funded by the National Institute on Alcohol Abuse and
Alcoholism (NIAAA), and Dr. Jonathan Covault, Associate Professor of Psychiatry, Director of the GCRC Core
Laboratory and Director of the Molecular Genetics Laboratory of the ARC, have continued to examine candidate
genes in the GABA system in relation to alcohol dependence. Together with Dr. Lance Bauer, they found that
allelic variation in GABRA2, which maps to chromosome 4p, encodes the alpha-2 subunit of the GABA-A
receptor, and has been shown in multiple studies to be associated to alcohol dependence, predicts the drinking
behavior over time of individuals being treated with psychotherapy for alcohol dependence. In that study, they
also found preliminary evidence of an allele X treatment interaction, representing a potential opportunity for
individualized psychosocial treatment of alcohol dependence. Together with Drs. Howard Tennen and Tamlin
Conner, Drs. Covault and Kranzler examined the effects of GXE on drinking and drug use in a sample of college
students. They found that the short promoter allele of the serotonin transporter gene (SLC6A4) was associated
with more frequent drinking and drug use among individuals who had experienced stressful events during the year
preceding study enrollment. Together with Dr. Carlos Hernandez-Avila, Drs. Kranzler and Covault examined the
pharmacogenetics of naloxone stimulation of plasma cortisol, which despite its inclusion of a putatively functional
polymorphism in OPRM1, the gene encoding the mu-opioid receptor, differed as a function of European vs. Asian
ancestry, suggesting the presence of a balancing polymorphism in Asians. Drs. Kranzler and Covault have also
collaborated actively with Dr. Joel Gelernter of Yale University on studies of the genetics of alcohol and drug
dependence.
Dr. Victor Hesselbrock, Chair of the GCRC Advisory Committee (GAC) and Principal Investigator of the
NIH-funded ARC at UCHC, is a major collaborator in the multi-center Collaborative Study on the Genetics of
Alcoholism (COGA). Dr. Hesselbrock provides a vital connection between COGA, which continues to lead the field
of alcohol research in relation to the elucidation of the alcohol dependence phenotype and the genetic basis of the
disorder, and the UConn ARC and GCRC.
Dr. Cheryl Oncken, Associate Professor of Medicine and Associate Program Director of the GCRC, completed a
study of nicotine replacement in pregnant women, including a genetic substudy that was a major component of the
last GCRC competitive renewal. Together with Drs. Naveed Hussain and Winfried Krueger, she completed a study
of the effects of smoking on RNA expression in the umbilical cords of children born to mothers participating in the
clinical trial.
Dr. Nancy Petry, Professor of Psychiatry, directs a highly productive program studying alcohol and drug
dependence and compulsive gambling. The GCRC supported a number of studies of Dr. Petry, all of which continue
to recruit actively. All studies are conducted at community-based treatment programs throughout New England. Dr.
Lance Bauer has continued analysis of an NIH-funded project in the examination of cognitive control among
patients with HIV/AIDS. In addition, he has developed an active program of research in relation to
electrophysiologic and genetic predictors of the longitudinal course of alcohol and drug use among individuals with
dependence on these substances.
Publications:

Chen ACH, Tang Y, Rangaswamy M, Wang J, Almasy L, Foroud T, Edenberg HJ, Hesselbrock V, Nurnberger Jr. JI, Kuperman S,
O'Conner SJ, Schuckit MA, Bauer LO, Tischfield J, Rice JP, Bierut LJ, Goate A, Projesz B Association of Single Nucleotide
Polymorphisms in a Glutamate Receptor Gene (GRM8) with Theta Power of Event-Related Oscillations and Alcohol Dependence
Neuropsychiatric Genetics
Grucza RA, Wang JC, Stitzel JA, Hinrichs AL, Saccone SF, Saccone NL, Bucholz KK, Cloninger CR, Neuman RJ, Buddle JP, Fox L,
Bertelsen S, Kramer J, Hesselbrock V, Tischfield J, Nurnberger Jr JI, Almasy L, Poresz B, Kuperman K, Schuckit MA, Edenberg HJ,
Rice JP, Goate AM, Bierut LJ A Risk Allele for Nicotine Dependence in CHRNA5 is a Protective Allele for Cocaine Dependence
Biological Psychiatry
Luo X, Kranzler HR, Zuo L, Lappalainen J, Yang BZ, Gelernter J ADH4 gene variation is associated with alcohol dependence and drug
dependence in European Americans: results from HWD tests and case-control association studies. Neuropsychopharmacology 31
1085-95 2006
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Wang JC, Grucza R, Cruchaga C, Hinrichs AL, Bertelsen S, Budde J, Fox L, Goldstein E, Reyes O, Kuperman S, Nurnberger Jr JI,
Schuckit MA, Tischfield J, Hesselbrock V, Porjesz B, Edenberg H, Bierut LJ, Goate AM Genetic Variation in the CHRN5 Gene Affects
mRNA Levels and is Associated with Risk for Alcohol Dependence Molecular Psychiatry
Luo X, Kranzler HR, Zuo L, Wang S, Schork NJ, Gelernter J Diplotype trend regression analysis of the ADH gene cluster and the
ALDH2 gene: multiple significant associations with alcohol dependence. Am J Hum Genet 78 973-87 2006
Covault J, Tennen H, Armeli S, Conner TS, Herman AI, Cillessen AH, Kranzler HR Interactive effects of the serotonin transporter
5-HTTLPR polymorphism and stressful life events on college student drinking and drug use. Biol Psychiatry 61 609-16 2007
Zuo L, Kranzler HR, Luo X, Covault J, Gelernter J. CNR1 variation modulates risk for drug and alcohol dependence.Biol Psychiatry.
2007 Sep 15;62(6):616-26. Epub 2007 May 23.
Petry NM Concurrent and predictive validity of the Addiction Severity Index in pathological gamblers. Am J Addict 16 272-82 2007
Barta WD, Kiene SM, Tennen H, Abu-Hasaballah KS, Ferrer R The idiographic study of inconsistent condom use behavior of persons
living with HIV. AIDS Care 19 1058-64 2007
Barta WD, Portnoy DB, Kiene SM, Tennen H, Abu-Hasaballah KS, Ferrer R A Daily Process Investigation of Alcohol-involved Sexual
Risk Behavior Among Economically Disadvantaged Problem Drinkers Living with HIV/AIDS. AIDS Behav 2007
Bauer LO The effects of HIV on P300 are moderated by familial risk for substance dependence: implications for a theory of brain
reserve. Drug Alcohol Depend 94 92-100 2008
Hernandez-Avila CA, Covault J, Wand G, Zhang H, Gelernter J, Kranzler HR. Population-specific effects of the Asn40Asp
polymorphism at the mu-opioidreceptor gene (OPRM1) on HPA-axis activation.Pharmacogenet Genomics. 2007 Dec;17(12):1031-8.
Ittiwut C, Listman J, Mutirangura A, Malison R, Covault J, Kranzler HR, Sughondhabirom A, Thavichachart N, Gelernter J
Interpopulation linkage disequilibrium patterns of GABRA2 and GABRG1 genes at the GABA cluster locus on human chromosome 4.
Genomics 91 61-9 2008
Ittiwut C, Listman J, Mutirangura A, Malison R, Covault J, Kranzler HR, Sughondhabirom A, Thavichachart N, Gelernter J
Interpopulation linkage disequilibrium patterns of GABRA2 and GABRG1 genes at the GABA cluster locus on human chromosome 4.
Genomics 91 61-9 2008
Bauer LO, Covault J, Harel O, Das S, Gelernter J, Anton R, Kranzler HR. Variation in GABRA2 predicts drinking behavior in project
MATCH subjects.Alcohol Clin Exp Res. 2007 Nov;31(11):1780-7.
Agrawal A, Hinrichs AL, Dunn G, Bertelsen S, Dick DM, Saccone SF, Saccone NL, Grucza RA, Wang JC, Cloninger CR, Edenberg HJ,
Foroud T, Hesselbrock V, Kramer J, Bucholz KK, Kuperman S, Nurnberger JI, Porjesz B, Schuckit MA, Goate AM, Bierut LJ Linkage
scan for quantitative traits identifies new regions of interest for substance dependence in the Collaborative Study on the Genetics of
Alcoholism (COGA) sample. Drug Alcohol Depend 93 12-20 2008
Hirunsatit R, IlomÃ¤ki R, Malison R, RÃ¤sÃ¤nen P, IlomÃ¤ki E, Kranzler HR,Kosten T, Sughondhabirom A, Thavichachart N,
Tangwongchai S, Listman J,Mutirangura A, Gelernter J, Lappalainen J. Sequence variation and linkage disequilibrium in the GABA
transporter-1 gene(SLC6A1) in five populations: implications for pharmacogenetic research.BMC Genet. 2007 Oct 17;8:71.
Luo X, Kranzler HR, Zuo L, Zhang H, Wang S, Gelernter J. ADH7 variation modulates extraversion and conscientiousness
insubstance-dependent subjects.Am J Med Genet B Neuropsychiatr Genet. 2008 Mar 5;147B(2):179-86.
Hussain N, Krueger W, Covault J, Walsh S, Kranzler HR, Oncken C Effects of Prenatal Tobacco Exposure on Gene Expression
Profiling in Umbilical Cord Tissue. Pediatr Res 2008
Wang JC, Grucza R, Cruchaga C, Hinrichs AL, Bertelsen S, Budde JP, Fox L, Goldstein E, Reyes O, Saccone N, Saccone S, Xuei X,
Bucholz K, Kuperman S, Nurnberger J, Rice JP, Schuckit M, Tischfield J, Hesselbrock V, Porjesz B, Edenberg HJ, Bierut LJ, Goate AM
Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol Psychiatry 2008
Dick DM, Aliev F, Wang JC, Grucza RA, Schuckit M, Kuperman S, Kramer J, Hinrichs A, Bertelsen S, Budde JP, Hesselbrock V, Porjesz
B, Edenberg HJ, Bierut LJ, Goate A Using dimensional models of externalizing psychopathology to aid in gene identification. Arch Gen
Psychiatry 65 310-8 2008
Schuckit MA, Smith TL, Hesselbrock V, Bucholz KK, Bierut L, Edenberg H, Kramer J, Longacre E, Fukukura T, Kalmijn J, Danko GP,
Trim R Clinical implications of tolerance to alcohol in nondependent young drinkers. Am J Drug Alcohol Abuse 34 133-49 2008
Kranzler HR, Covault J, Pierucci-Lagha A, Chan G, Douglas K, Arias AJ,Oncken C. Effects of aripiprazole on subjective and
physiological responses to alcohol.Alcohol Clin Exp Res. 2008 Apr;32(4):573-9. Epub 2008 Feb 8.
Bauer LO A family history of psychopathology modifies the decrement in cognitive control among patients with HIV/AIDS. Brain
Cogn 67 103-14 2008
Luo X, Zuo L, Kranzler H, Zhang H, Wang S, Gelernter J Multiple OPR genes influence personality traits in substance dependent and
healthy subjects in two American populations. Am J Med Genet B Neuropsychiatr Genet 2008
Dick DM, Aliev F, Wang JC, Saccone S, Hinrichs A, Bertelsen S, Budde J, Saccone N, Foroud T, Nurnberger J, Xuei X, Conneally PM,
Schuckit M, Almasy L, Crowe R, Kuperman S, Kramer J, Tischfield JA, Hesselbrock V, Edenberg HJ, Porjesz B, Rice JP, Bierut L,
Goate A A Systematic single nucleotide polymorphism screen to fine-map alcohol dependence genes on chromosome 7 identifies
association with a novel susceptibility gene ACN9. Biol Psychiatry 63 1047-53 2008
Edenberg HJ, Xuei X, Wetherill LF, Bierut L, Bucholz K, Dick DM, Hesselbrock V, Kuperman S, Porjesz B, Schuckit MA, Tischfield
JA, Almasy LA, Nurnberger JI, Foroud T Association of NFKB1, which encodes a subunit of the transcription factor NF-kappaB, with
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alcohol dependence. Hum Mol Genet 17 963-70 2008
Schuckit MA, Danko GP, Smith TL, Bierut LJ, Bucholz KK, Edenberg HJ, Hesselbrock V, Kramer J, Nurnberger JI, Trim R, Allen R,
Kreikebaum S, Hinga B The prognostic implications of DSM-IV abuse criteria in drinking adolescents. Drug Alcohol Depend 2008
Ghosh S, Bierut LJ, Porjesz B, Edenberg HJ, Dick D, Goate A, Hesselbrock V, Nurnberger J, Foroud T, Kramer J, Rice J, Begleiter H A
novel non-parametric regression reveals linkage on chromosome 4 for the number of externalizing symptoms in sib-pairs. Am J Med
Genet B Neuropsychiatr Genet 2008
Yang BZ, Kranzler HR, Zhao H, Gruen JR, Luo X, Gelernter J. Association of haplotypic variants in DRD2, ANKK1, TTC12 and
NCAM1 to alcoholdependence in independent case control and family samples.Hum Mol Genet. 2007 Dec 1;16(23):2844-53. Epub
2007 Aug 30.
Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation
modulates substance dependence risk. Mol Psychiatry 13 531-43 2008
Wang JC, Hinrichs AL, Bertelsen S, Stock H, Budde JP, Dick DM, Bucholz KK, Rice J, Saccone N, Edenberg HJ, Hesselbrock V,
Kuperman S, Schuckit MA, Bierut LJ, Goate AM Functional variants in TAS2R38 and TAS2R16 influence alcohol consumption in
high-risk families of African-American origin. Alcohol Clin Exp Res 31 209-15 2007
Herman AI, Kranzler HR, Cubells JF, Gelernter J, Covault J Association study of the CNR1 gene exon 3 alternative promoter region
polymorphisms and substance dependence. Am J Med Genet B Neuropsychiatr Genet 141B 499-503 2006
Gacek, P., Conner, T.S., Tennen, H., Kranzler, H.R., Covault, J. Tryptophan Hydroxylase 2 Gene and Alcohol Use among College
Students. Addiction Biology
Bone, Endocrine and Aging

SPID(s):

0410, 0413, 0448, 0461, 0523, 0542, 0557, 0588, 0624,
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KEYWORDS:
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PAST SPID(s):0433,0597

Drs. Pamela Taxel, Joseph Lorenzo, Carol Pilbeam and Lawrence Raisz have been working to expand studies of
estrogen and osteoclastogenesis that they have successfully completed using bone marrow cells to a much larger
study population through the use of peripheral blood cells, which are much easier to obtain than are bone marrow
cells. The laboratory techniques for culturing osteoclasts from peripheral blood mononuclear cells (PBMCs) have
been developed and this group is working on studies in which they will correlate PBMC and bone marrow
osteoclastogenesis with bone turnover rates in older postmenopausal women who are estrogen deficient.
In addition, several clinical trials are underway to assess the effects of hormones on bone density or bone turnover
in aging adults. Dr. Anne Kenny, Associate Professor of Medicine and Associate Program Director (APD) of the
GCRC, is completing a 2-year randomized trial of testosterone replacement in older men with osteoporosis and
frailty, assessing the impact on bone mineral density, bone turnover, and physical performance/fall risk. She is also
completing a 6-month, randomized, controlled trial of dehydroepiandosterone and/or exercise in older
postmenopausal women with osteopenia and frailty, which is also using bone turnover, physical function, and
balance as outcome measures. The results from these studies will be analyzed later in 2008. She has two ongoing
trials that include: a) omega-3 fatty acid supplementation in older, frail postmenopausal women that assesses bone,
physical performance, and immune function and b) an 18-month intervention trial of protein supplement to assess
bone and muscle effects (collaboration with Drs Karl Insogna (Yale) and Jane Kerstetter (University of
Connecticut-Storrs). Dr. Taxel is conducting clinical trials assessing the impact of alendronate and/or estrogen on
bone density and markers of bone turnover in men with prostate cancer undergoing suppressive therapy with
leutinizing hormone releasing hormone and women with breast cancer receiving anti-estrogen therapy. Dr. Faryal
Mirza has completed a pilot study on the effect of estrogen deprivation with aromatase inhibitors on blood pressure
in post-menopausal women which shows that 24 ambulatory blood pressure increases with estrogen deficiency,
largely due to a rise in nocturnal systolic pressure. This study was presented at the annual Meeting of the Endocrine
Society in June 2008.
Publications:

Taxel P, Kaneko H, Lee SK, Aguila HL, Raisz LG, Lorenzo JA Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in
bone marrow cultures in postmenopausal women: a pilot study. Osteoporos Int 19 193-9 2008
DENTAL
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Investigators from the UConn School of Dental Medicine are also active in the GCRC and often collaborate with
research groups in the School of Medicine. Dr. Mark Litt, Professor of Oral Health and Diagnostic Sciences,
continues to collaborate with Drs. Oncken and Kranzler in a study of topiramate for smoking cessation, which uses
daily interactive voice response (IVR) technology (supported by the GCRC) to obtain multiple within-day
assessments of mood and other variables that may enhance our understanding of the mechanism of effects on risk
of smoking. He also conducts research on contingency management for drinking and cannabis abuse, and on
short-term interventions for temporomandibular disorder (TMD). Interventions with TMD patients involve
focused instruction in changing self-efficacy and decreasing "catastrophizing" with measurement outcomes including
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real time" assessments of pain ratings, mood and coping (using computerized IVR) and changes in pro- and
anti-inflammatory cytokines.
Dr. Robert Aseltine, Associate Professor of Oral Health and Diagnostic Sciences, has been active in screening, brief
intervention, and referral efforts to reduce drinking among patients admitted to emergency departments in urban
settings. He has been supported by the GCRC particularly through the use of interactive voice response (IVR)
technology to obtain data longitudinally from individuals participating in these studies.
Dr. Julie Wagner, Assistant Professor of Oral Health and Diagnostic Sciences, demonstrated a clear dose-response
relationship between depressive episodes and endothelial function measured by brachial artery flow-mediated
dilation. These analyses control for a number of potential confounds, including current sub-clinical depressive
episodes, ethnicity, hormone replacement therapy, and metabolic syndrome. She has also reported that among
diabetic women, those with a history of fully remitted depression have higher HbA1c, more diabetes symptoms, and
worse emotional functioning than their never depressed counterparts even after controlling for numerous
confounds.
Dr. Anna Dongari-Bagtzoglou, Associate Professor of Oral Health and Diagnostic Sciences is investigating potential
systemic effects of oral inflammatory processes, including oral candidiasis in kidney and heart transplant recipients
and how periodontal infections and depressive symptoms affect the systemic inflammatory status of hemodialysis
and pre-dialysis chronic kindney disease patients. Recent findings indicate that periodontal attachment loss
emerged as a significant predictor of glomerular filtration rate (renal function deterioration in allograft transplant
patients) after adjusting for cofounders. In addition, kidney and heart transplant recipients are infected with
Candida in higher percentages, have higher titers and higher frequency of asymtomatic colonization than healthy
controls.
Dr. Martin Freilich, Professor of Reconstructive Sciences, has begun a major observational study of bone health,
especially osteoporosis, as a risk factor in bone augmentation and dental implant placement. This R01-funded
project is expected to generate numerous hypotheses for further investigation.
Dr. Rajesh V. Lalla, Assistant Professor of Oral Health and Diagnostic Sciences, received a Mentored
Patient-Oriented Research Career Development Award (K23) from the National Institute of Dental and
Craniofacial Research (NIDCR). As part of his K23 training, he is currently conducting two clinical research studies
with GCRC support: (1) "Prevention of Recurrent Aphthous Stomatitis Using Vitamins," which will help to
determine the role of vitamin deficiencies in the pathogenesis of Recurrent Aphthous Stomatitis, which is the most
common ulcerative oral mucosal disease affecting humans. Conduct of this study is progressing well, with 100
subjects been enrolled to date. (2) "COX-2 Inhibition in Radiation-induced Oral Mucositis" will help elucidate the
pathogenesis of this debilitating condition and may identify a new therapeutic approach. Oral Mucositis is very
painful and negatively impacts nutritional intake and quality of life.
Publications:

Academic ED SBIRT Research Collaborative The impact of screening, brief intervention, and referral for treatment on emergency
department patients' alcohol use. Ann Emerg Med 50 699-710, 710.e1-6 2007
Bernstein E, Bernstein J, Feldman J, Fernandez W, Hagan M, Mitchell P, Safi C, Woolard R, Mello M, Baird J, Lee C, Bazargan-Hejazi
S, Broderick K, Laperrier KA, Kellermann A, Wald MM, Taylor RE, Walton K, Grant-Ervin M, Rollinson D, Edwards D, Chan T,
Davis D, Buchanan Marshall J, Aseltine R, James A, Schilling E, Abu-Hasaballah K, Baumann BM, Boudreaux ED, Maio RF,
Cunningham RM, Murrell T, Doezema D, Anglin D, Eliassen A, Martin M, Pines J, Buchanan L, Turner J, D'Onofrio G, Degutis LC,
Owens P An evidence based alcohol screening, brief intervention and referral to treatment (SBIRT) curriculum for emergency
department (ED) providers improves skills and utilization. Subst Abus 28 79-92 2007
Litt MD, Kadden RM, Kabela-Cormier E, Petry NM Coping skills training and contingency management treatments for marijuana
dependence: exploring mechanisms of behavior change. Addiction 103 638-48 2008
Herbst S, Pietrzak RH, Wagner J, White WB, Petry NM. Lifetime major depression is associated with coronary heart disease in
olderadults: results from the National Epidemiologic Survey on Alcohol and RelatedConditions.Psychosom Med. 2007
Nov;69(8):729-34. Epub 2007 Oct 17.
Wagner J, Tennen H, Mansoor G, Abbott G Endothelial dysfunction and history of recurrent depression in postmenopausal women
with Type 2 diabetes: a case-control study. J Diabetes Complications 2008
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The project by Drs. Peter Krause, Professor of Pediatrics, and Stephen Wikel, Professor of Immunology, entitled
"Health Burden of Deer-Associated Zoonoses," is primarily focused on the immunologic response to deer tick bites
in humans, with the long-term goal of developing a vaccine to prevent tick-borne infection in people. Current
work includes a histopathologic study of dermatologic reactions to deer tick bite in mice and humans and a review
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of the clinical manifestations and immunopathogenesis of local and systemic reactions to deer tick bite in people.
Recent findings on the histopathologic response to tick bite in mice and humans have been submitted for
publication. They suggest that human cutaneous hypersensitivity to tick bite may alter pathogen transmission.
Studies also focus on determining the underlying mechanisms of heightened resistance to tick-borne pathogen
transmission and identification of tick saliva molecules responsible for inducing and eliciting protective responses.
A secondary objective of the project is to investigate the health burden of human babesiosis.
Drs. Krause, Wikel, and colleagues are actively investigating the epidemiology and immunology of babesiosis in a
highly endemic area. These studies include genetic determinants of resistance to human babesiosis in relation to
aging.
Publications:

Hsieh YF, Liu HW, Hsu TC, Wei JC, Shih CM, Krause PJ, Tsay GJ Serum reactivity against Borrelia burgdorferi OspA in patients with
rheumatoid arthritis. Clin Vaccine Immunol 14 1437-41 2007
Feder HM, Johnson BJ, O'Connell S, Shapiro ED, Steere AC, Wormser GP, Ad Hoc International Lyme Disease Group, Agger WA,
Artsob H, Auwaerter P, Dumler JS, Bakken JS, Bockenstedt LK, Green J, Dattwyler RJ, Munoz J, Nadelman RB, Schwartz I, Draper T,
McSweegan E, Halperin JJ, Klempner MS, Krause PJ, Mead P, Morshed M, Porwancher R, Radolf JD, Smith RP, Sood S, Weinstein A,
Wong SJ, Zemel L A critical appraisal of "chronic Lyme disease". N Engl J Med 357 1422-30 2007
Krause PJ, Daily J, Telford SR, Vannier E, Lantos P, Spielman A Shared features in the pathobiology of babesiosis and malaria. Trends
Parasitol 23 605-10 2007
Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL,
Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, Christianson D, Dardick K,
Coleman M, Girotto JE, Spielman A Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 46 370-6
2008
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ADMINISTRATIVE NARRATIVES
ADMINISTRATION

The General Clinical Research Center (GCRC) significantly restructured contract arrangements
with Connecticut Children's Medical Center (CCMC). This was done to support pediatrics
investigators better while making the most cost-effective use of funds. It entailed meetings
over several months with research finance and administration managers at both entities, and
pediatric investigators and study coordinators. Contract arrangements now include an
umbrella memorandum of understanding between the GCRC and CCMC, and individual
contracts for specific GCRC Advisory Committee (GAC) approved, GCRC-sponsored projects.
Where clinical laboratory services are approved by GAC, additional associated contracts are
established with Clinical Lab Partners (CLP), a wholly owned subsidiary of Hartford Hospital.
As CCMC is on the same physical campus as Hartford Hospital, this allows investigators to
use local resources, rather than working through the logistics of transporting samples for
testing at UCHC with possible compromise of the samples.
The success of our prior year's data entry services "proof of concept" pilot encouraged fuller
roll-out. This support service was expanded from double-data entry to include study-specific
consultations on data management strategies, case report form design and SPSS database
development, and data quality procedures and documentation. Staffing continues to be from
the Informatics Core supervising student assistants. Funding for this activity continues to
come from the School of Medicine.
This is the third year of administering a grant-making program funded by the Donaghue
Foundation. The $110,000 annual program is focused on bio-nutrition research of a practical
benefit to Connecticut residents. It is open to investigators at the University of Connecticut
(UConn) Storrs and Farmington campuses as well as local area hospitals and
community-based organizations, who hold UConn academic appointments. Based on the
Request for Proposal and scientific review processes, 5 projects were approved and funded.
Three projects were approved the Institutional Review Board (IRB) and initiated during this
reporting period.
Several deferred internal administrative projects were undertaken to organize and archive
GCRC administrative and financial records. This included reviewing records retention
requirements, working with investigators on inventorying, returning and purging research
records and files, and relabeling research records to be consistent with study informed
consent forms. We also began converting paper transaction detail to electronic images, and
consolidating and documenting off-site storage holdings.
In preparation for the eventual transition from a GCRC to a clinical and translational science
institute (CTSI), work began on developing fee-for-service operational centers for Core
Laboratory, Informatics, Biostatistics, and Clinical (medical and dental) research services
("service centers"). The Service Centers were established as financial entities with published
fee schedules. Services have been advertised to investigators on a limited basis and will be
more broadly communicated in the future. Manual cost-tracking and billing functions have
been developed but are being refined as UConn plans for CTSI governance and technical
infrastructure.
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BIOSTATISTICIAN

The Biostatistics Core worked with established and potential GCRC investigators in the
development and design of new research projects. It also performed analysis of data from
GCRC protocols and guided GCRC investigators and staff members in conducting their own
data analyses. Core staff included the director (Dr. Stephen Walsh, 30% annual effort) and a
master's-level statistician (Ms. Deborah Dauser-Forrest, 25% annual effort). Dr. Walsh
provided consultations to GCRC investigators and also served as a member of the Executive
Committee and of the GAC. His role on the GAC was to review the statistical integrity of every
new protocol submitted to the GCRC. He also presented a lecture on sample size and power in
the Clinical Research Coordinator's Course sponsored by the Clinical Core and a session on
study design in the program for summer research scholars. Ms. Dauser-Forrest conducted
data analysis for GCRC projects under the direction of Dr. Walsh and monitored subject
recruitment to GCRC protocols to document each protocol's progress in achieving recruitment
objectives.
CORE LAB

During the April 2007 - March 2008 year 14 grant period, the Core Laboratory reported 41,050
assay results, an increase of 34% compared with year 13. These included 2,924 hormone or
protein analyte results, 33,397 genotype results, 248 DNA sequence analysis of PCR
amplicons, isolation of DNA or RNA from 3,444 samples, and analysis of 228 blood samples by
FACS.
During this past year we used institutional funds to replace a -80°C freezer and purchase a
384-well PCR thermocycler to support higher volumes of genotyping assays. Migration of our
sample data base to the FreezerWorks software system purchased in year 13 has been
completed. All archived as well as new samples are now included in our FreezerWorks sample
storage and tracking database. This has significantly improved our ability to manage
thousands of archived samples for more efficient staff time use.
The largest growth area for assay requests is in the area of genetics and gene expression.
When possible, to avoid duplication of equipment, we continue to make use of resources in
other UCHC labs to support this need. The Core Lab has developed partnerships in the past
year with the Translational Genomics Core at UCHC to provide microarray services for GCRC
protocols including gene expression and DNA methylation arrays. One such project used
gene expression array coupled with qPCR in the Core Lab to identify smoking-related changes
in umbilical cord gene expression. These results were recently accepted for publication in
Pediatric Research. Due to the increased requests for examination of epigenetic DNA
methylation levels by investigators, Core Lab staff have recently been trained in use of a
shared instrument (Biotage Pyrosequence Work Station) for quantitative CpG methylation
assays to respond to investigator needs. The instrumentation would also allow the Core Lab
to provide quantitative single nucleotide polymorphism (SNP) allele frequency from pooled
case-control studies. Finally, we have partnered with two other laboratories to maintain and
use a robotic liquid handling work station to more efficiently prepare 384-well sample plates for
genotyping.
The Core Laboratory continues to be licensed by the State of Connecticut Department of
Public Health with a CLIA certification. In our most recent 2-year inspection in August 2006,
no deficiencies were identified.
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INFORMATICS CORE

The Informatics Core continues to manage and develop a variety of platforms and functions
that are key to the research and administrative functions of the GCRC.
Interactive Voice Response (IVR). The IVR system, which was acquired in the Fall of 2002,
continues to grow. The system, used to host and administer phone-based interviews, has
been expanded to include 90 telephone lines that are made available to administer
questionnaires. Since inception, the system has supported 21 studies with 15 studies being
active in Year 14. In addition to supporting investigators at UConn, IVRS has hosted studies
for investigators from other institutions, including Yale University, the University of
Michigan, the University of Chicago, and Arizona State University. In the past year, the
system administered over 15,000 calls to 576 study participants, lasting approximately 1,000
hours. This effort has thereby substantially reduced study staff time required to collect data
from participants and has eliminated the time required for double entry of these data
(increasing the accuracy of the data as well). The IVR System represents one of the great
successes of the Informatics Core, but as such has required substantial time and effort from
Dr. Abu-Hasaballah, Informatics Core Director, and his staff.
Data Entry. The GCRC has expanded the data entry service it offers investigators. We have a
well-trained team of three undergraduate students who enter data for studies approved to use
this service, using the SPSS Data Builder/Workstation modules. Once the data have been
double entered and verified, they are made available for checking and analysis, and
subsequent export to other applications and formats. Currently the data entry team has 11
approved studies being developed or in active entry. Several more studies are pending IRB
approval to be initiated.
Fileshare. The GCRC has provided investigators disk space on a high capacity, high
availability file server to store study data and other protocol related files. Access to the
fileshare is based on a role-based access permission schema that allows investigators and
their staff to access their protocol folder and data only. In addition, the file server contains
group and personal folders for GCRC staff.
Research Portal. The Informatics Core is leading efforts at UConn to develop a web-based
research portal. The first phase of the portal is the creation of a recruitment registry, where
interested members of the public visit the portal, learn about clinical research, search for
clinical studies, and self-enter their information in the registry. Investigators will be able to
search the registry for potential volunteers. We anticipate this registry would serve as an
invaluable tool in recruitment efforts in clinical research at UConn. The initial design and
development work was completed, with roll-out of the new recruitment registry expected in
July 2008. The second phase of the portal is the development of a registry of investigators
and their area of research interest/expertise. We hope this investigatory registry will serve as a
matchmaking vehicle to help promote interdisciplinary research.
Administrative Software. The Informatics Core provides technical support to several internal
applications. Our Integrated Information System (IIS), a web-based application developed
in-house for electronic submission and management of GCRC resource utilization, staff task
reporting, and study participant visit tracking, is in its third year of production. A number of
reports and features continue to be added to the system to enhance data quality and increase
the system's utility in the ongoing operation of the GCRC as well as supporting NIH reporting.
Additionally, several commercial software packages are used: Freezerworks (to track
specimens in storage freezers), Grant Manager (to manage GCRC finances), and Personnel
Manager (to project and track payroll expenses and time and effort).
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NURSING

The Clinical Core continues to use a combination of clinical research nurses and clinical
research assistants (CRAs) to meet current and anticipated research study needs. Currently,
the Clinical Core consists of 5 nurses who are research facilitators (RFs) (4 full-time, 1
part-time), 1 clinical research nurse (CRN), 3 clinical research assistants (CRAs), and 2 dental
assistants (DA, 1 part time and 1 full time), each of whom coordinates 4-9 clinical research
protocols. Of 8 staff eligible for certification by the Society of Clinical Research Associates
(SoCRA), 7 are currently certified.
Personnel Changes - In the last year, changes in the Clinical Core included the departure of an
APRN, Michelle Kelly and the hiring of a CRA, Paul Appleton. Paul was hired to replace
veteran CRA, Laura Glynn, who graduated from nursing school in May 2007 and took a
position in an acute care facility. Paul Appleton, MD, comes to the GCRC with little research
experience, but with greater than 10 years experience in anatomical and clinical pathology. He
is funded by the GCRC grant at 50% time, coordinating 2 trials, and he receives 50% salary
support on an NIDDK grant to one of the GCRC investigators. Dr. Appleton is in the process
of applying for medical credentialing though the University's Medical Staffing Office. This will
enable him to assist investigators by conducting physical examinations and minor medical
procedures.
Thomas Kiely, RNC, Nurse Manager, continues to review currently active GCRC clinical
studies to identify the clinical staff expertise and time and effort needed. Over the last year the
clinical research teams, generally consisting of an RF and a CRA, have proved to be a valuable
combination that can share the coordinating efforts for several protocols. In these situations,
the RF (a registered nurse) usually serves as the team leader. This approach has three
strengths: it provides for staff cross-coverage, it helps to ensure that all aspects of a study are
adequately addressed, and it allows staff to complement one another in terms of their skills, so
that each team has the clinical skills necessary to complete all phases of the clinical contact.
For the sixth year, the Clinical Core sponsored a two-day Clinical Research Coordinators
Course. The course provides participants with 12 Connecticut Nurses' Association
continuing education units (CEUs), which are approved by the American Nurses Credentialing
Center's Commission on Accreditation. The course serves to introduce to CRAs, technicians,
nurses, and others interested in study coordination the principles of clinical research. It
consists of didactic presentations and the identification of relevant resources by experienced
research personnel. The course goal is to promote a conceptual awareness of what
distinguishes clinical research from clinical practice. There are12 hours of sessions led by
staff from the GCRC, Clinical Trials Unit, Human Subjects Protection Office, and the
Investigational Pharmacy Service. The course covers the research process, with an emphasis
on the many facets of study coordination that are necessary for safe and effective clinical
research. Specific topics covered include subject recruitment, compliance, IRB review,
industry-sponsored studies, the drug development process, adverse event reporting,
informatics, and fiscal compliance. Participant evaluations indicate that the course, which
draws students from throughout the Greater Hartford region, is very highly valued.
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OTHER

Other - Dental
NCRR approved both interim and final relocation plans for the Dental Clinical Research Center
(DCRC). Architect drawings are nearly complete for the renovation of a new facility being
accomplished with $300,000 in UConn support and $50,000 of industry in-kind gifts. This
clinic will be a state-of-the-art, attractive facility containing three operatories, a patient waiting
room, a business office, dirty and clean preparation rooms and a small dental laboratory.
Dental faculty were engaged in 8 active studies (approximately $3,000,000 in direct costs
during this fiscal year) most of which will continue into fiscal year '08- '09. In the past year the
DCRC accommodated one new R01 and a GCRC-funded pilot project. Staffing remained stable
during the year with our 1.6 FTE dental assistants functioning well together in study
coordination and research patient contact functions.

Other - Education and Training
This was an important year for our activities in education and training. Under the leadership
of Dr. Anne Kenny, a Master of Science in Clinical and Translational Research (MSCTR) was
developed, approved by the University and the Connecticut Board of Higher Education and
accredited. The first class began in September 2007 with 5 students and was the major formal
didactic offering in clinical research. The program graduated its first student in May 2008.
The GCRC course "Principles of Clinical Research" was quite successful during the past few
years under the leadership of Dr. Howard Tennen. The course was suspended during the past
year, to make it possible to initiate the MSCTR. The course is being transitioned to an on-line
offering with plans for 22 video lectures, related readings and monthly face-to-face meetings
with course leaders. The transition to the on-line course is nearly complete and the new
course will be offered beginning in the fall 2008. Plans are for the course to be offered three
times annually in the fall, spring, and summer sessions.
This was another stellar year for GCRC-sponsored seminars. From September 2007 through
June 2008, a total of 19 seminars were held, with an average attendance of 35 people at each
seminar.
We had eight summer fellows sponsored by the GCRC in the summer of 2007, two college
students, five medical school students and a dental school student. The summer student
seminars on clinical research, which ran for eight weeks, were open to all summer students at
the Health Center and were attended by 11 students each week.
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PROGRAM DIRECTION

Bruce Koeppen, MD, PhD, Dean of Academic Affairs and Principal Investigator. for the GCRC,
continues to meet monthly with the GCRC Executive Committee. These meetings provide a
forum to plan for the GCRC and to coordinate GCRC activities with other research activities at
UCHC.
Henry Kranzler, M.D., Professor of Psychiatry, continues in the role of Program Director. Dr.
Kranzler is an NIH-funded clinical investigator with a research program that focuses on the
pharmacological treatment of alcohol dependence (one of the top 10 priority goals of the NIH)
and on the genetics and pharmacogenetics of alcohol and drug dependence.
The leadership of the GCRC continues to include three Associate Program Directors. Anne
Kenny, M.D., Associate Professor of Medicine, Cheryl Oncken, M.D, M.PH., Associate
Professor of Medicine, and Lawrence Raisz, M.D., Professor of Medicine, share this role. This
arrangement has served the GCRC very well, and we expect to continue it for the foreseeable
future. Institutional support is provided to augment M01 support for these individuals, so
that the total support for the Associate Program Directors from the GCRC grant is 0.30 FTE.
Lesley Mancini, M.B.A. continues as the Administrative Director and Thomas Kiely, R.N.C. is
the Nurse Manager and Director of the Clinical Services Core. The directors of the other cores
remain unchanged. Jonathan Covault, M.D, PhD. continues as Director of the Core
Laboratory; Khamis Abu-Hasaballah, Ph.D. continues as Director of the Informatics Core; J.
Robert Kelly, D.D.S., Ph.D. continues as Director of the Dental Clinical Research Core; and
Stephen Walsh, Sc.D. continues as Director of the Biostatistics Core. Kathleen Salomone,
A.P.R.N., M.S.W., continues in the role of Research Subject Advocate (RSA), a 70% position.
Ms. Salomone's position also includes 30% time with the UCHC Human Subjects Protection
Office (which oversees the functions of the UCHC Institutional Review Boards), supported by
institutional funds. Ms. Rene Bumbera has replaced Ms. Theresa George in assisting Ms.
Salomone in discharging the duties of the RSA.
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RES SUBJECT ADVOCACY

Kathleen Salomone, MSW, APRN continued in her role as Research Subject Advocate (RSA)
for the GCRC, reporting to Dr. Bruce Koeppen and working closely with Dr. Henry Kranzler
(GCRC Program Director), Dr. Victor Hesselbrock (Chair of the GAC), GCRC staff and
investigators and the Human Subjects Protection Office (HSPO) of UConn Health Center.
Ms. Salomone reviewed all protocols submitted to SAC requesting GCRC resources at the time
of initial application and annual continuation . She ensured that every protocol reviewed by
GAC had a Data and Safety Monitoring Plan/ Board commensurate with the study risk. At the
time of annual continuation she also reviewed protocol deviations and adverse events and
communicated any concerns to GAC.
Ms. Salomone works closely with new investigators assisting them with the IRB application
process and helping them develop Data and Safety Monitoring Plans appropriate to their
protocol. She kept pertinent GCRC staff informed regarding lapses in IRB approval for GCRC
supported protocols.
Ms. Salomone conducted random audits of protocols supported by GCRC resources. The
audits are a quality management tool providing a systematic internal process to oversee
subject safety, ensure that monitoring is being conducted in accordance with the
IRB-approved DSMP/B and increase compliance with federal, state and institutional
requirements. Within the GCRC, she participated in the GAC, Executive Committee and Project
Review and Initiation Team (PRIT). Additionally, she attended quarterly meetings of the
UConn Office of Audit, Compliance and Ethics and acts as a GCRC liaison with that office.
Ms. Salomone worked closely with the Human Subjects Protection Office (HSPO) in providing
appropriate monitoring of GCRC supported studies, overseeing implementation of HSPO
policy changes within the GCRC and for all GCRC supported protocols. She represented
GCRC concerns to the UCHC IRB chairs and to the IRB chairs at collaborating institutions.
Ms. Salomone served on the HSPO Executive Council, which acts as an advisory board to the
Director of the Human Subjects Protection Office on matters of policy, regulations and issues
related to human subject protections.
Ms. Salomone also worked with research staff at the Connecticut Children's Medical Center
(CCMC), a UCHC collaborating institution, and the UConn Storrs campus. She assisted
investigators with properly invoking the IRB Cooperative Agreements between UCHC and
their respective institutions.
Finally, Ms. Salomone served on the Research Adverse Events Committee, a sub-committee of
the HSPO. This committee is charged with reviewing research-related serious adverse events
(SAEs) with the mission of protection of research subjects. She served as one of three primary
reviewers of SAEs submitted via the mandatory UCHC on-line reporting system.
RESEARCH BIONUTRITION

Not applicable.
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